 
ACTIV- 2/A5401  
 
 
Adaptive Platform Treatment Trial for Outpatients with COVID -19 
(Adapt Out COVID)  
 
 
A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)  
 
 
Sponsored by: 
National Institute of Allergy 
and Infectious Diseases 
 
 
Industry Support Provided by: 
 
CBER IND #27230  
SAB Biotherapeutics 
 
CDER IND #151193 
AstraZeneca 
Brii Biosciences 
Bristol Myers Squibb  
Lilly Research Laboratories, Eli Lilly and Company 
Regeneron Pharmaceuticals 
Sagent Pharmaceuticals 
Synairgen 
 
 
 Protocol Co-Chair s:      Kara Chew, MD, MS  
David (Davey) Smith, MD , MAS 
  Protocol Vice Chairs:      Eric Daar, MD  
     David Wohl, MD  
 DAIDS Clinical Representative:     Arzhang Cyrus Javan, MD, MPH, DTM&H   
 Clinical Trials Specialist s:     Lara A. Hosey, MA, CCRP  
     Jhoanna C. Roa, MD  
  
FINAL  Version 8 .0 
25 February 2022
  ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 ACTIV -2/A5401 
 
Adaptive Platform Treatment Trial for Outpatients with COVID -19 (Adapt Out COVID)  
 
SIGNATURE PAGE  
 
I will conduct the study in accordance with the provisions of this protocol and all applicable protocol -related documents. I agree to conduct this study in compliance with United States (US) 
Health and Human Service regulations (45 CFR 46); applicable US  Food and Drug 
Administration regulations; standards of the International Conference on Harmonization Guideline for Good Clinical Practice (E6); Institutional Review Board/Ethics Committee determinations; all applicable in-country, state, and local laws and regulations; and other applicable requirements ( e.g., US National Institutes of Health, Division of AIDS) and 
institutional policies.  
 The following study agents are included in this version of the protocol. Sites are expected to participate in all available study agents unless  other arrangements are approved by the 
Sponsor . 
 Initial each agent below to confirm site participation. If not participating in an agent, mark that 
agent with an N/A.  ____BAMLANIVIMAB INTRAVENOUS ADMINISTRATION  
 ____BRII -196 and BRII-198 INTRAVENOUS ADMINISTRATION  
 ____AZD7442 INTRAVENOUS ADMINISTRATION  
 ____AZD7442 INTRAMUSCULAR ADMINISTRATION  
 ____SNG001 INHALATION ADMINISTRATION  
 ____CAMOSTAT ORAL ADMINISTRATION  
 ____SAB-185 INTRAVENOUS  ADMINISTRATION  
 
____BMS -986414 (C135-LS) and BMS -986413 (C144-LS) SUBCUTANEOUS 
ADMINISTRATION  
 
____CASIRIVIMAB + IMDEVIMAB (REGN10933+REGN10987, REGN -COV2)  
 Principal Investigator: _______________________________________________ 
Print/Type  
 
Signed: ___________________________________ Date: _____________ 
 Name/Title 
ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 TABLE OF CONTENTS  
  Page 
SIGNATURE PAGE  ...................................................................................................................... 2 
SITES PARTICIPATING IN THE  STUDY  ..................................................................................... 6 
PROTOCOL TEAM ROSTER  ....................................................................................................... 7 
STUDY MANAGEMENT  ............................................................................................................. 13 
GLOSSARY OF PROTOCOL -SPECIFIC TERMS  ...................................................................... 14 
SCHEMA  ..................................................................................................................................... 15 
1.0 STUDY OBJECTIVES  ..................................................................................................... 18 
1.1 Co-Primary Objectives  ........................................................................................ 18 
1.2 Secondary Objectives  ......................................................................................... 18 
1.3 Exploratory Objectives  ........................................................................................ 19 
2.0 INTRODUCTION  ............................................................................................................. 20 
2.1 Background  ......................................................................................................... 20 
2.2 Rationale ............................................................................................................. 23 
3.0 STUDY DESIGN  ............................................................................................................. 25 
3.1 Overview of Study Design ................................................................................... 25 
3.2 Overview of Study Design for Graduation from Phase II to Phase III  .................. 27 
3.3 Considerations Regarding the Sharing of Comparator Group for Evaluating 
Multiple Investigational Agents  ............................................................................ 29 
4.0 SELECTION AND ENROLL MENT OF PARTICIPANTS  ................................................. 31 
4.1 General Eligibility Criteria .................................................................................... 31 
4.2 Study Enrollment Procedures  .............................................................................. 33 
4.3 Co-enrollment Guidelines  .................................................................................... 34 
5.0 INVESTIGATIONAL AGENT  ........................................................................................... 35 
5.1 Regimen, Administration, and Duration ............................................................... 35 
5.2 Formulation, Storage, and Preparation ............................................................... 35 
5.3 Supply, Distribution, and Accountability  .............................................................. 35 
5.4 Concomitant Medications  .................................................................................... 35 
6.0 CLINICAL AND LAB ORATORY EVALUATIONS ............................................................ 37 
6.1 Schedule of Evaluations ...................................................................................... 37 
6.2 Timing of Evaluations  .......................................................................................... 43 
6.3 Instructions for Evaluations  ................................................................................. 44 
7.0 ADVERSE EVENTS AND STUDY MONITORING.......................................................... 52 
7.1 Definitions of Adverse Events  ............................................................................. 52 
7.2 Eliciting and Documenting Adverse Events  ......................................................... 53 
7.3 Recording Adverse Events  .................................................................................. 54 
7.4 Follow -up of Participants Reporting Adverse Events  .......................................... 57 
7.5 Study Monitoring ................................................................................................. 57 
8.0 CLINICAL MANAGEMENT ISSUES ............................................................................... 57 
8.1 Toxicity  ................................................................................................................ 57 
ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 CONTENTS (Cont’d) Page 
 
 8.2 Management of Side Effects  ............................................................................... 58 
8.3 Pregnancy  ........................................................................................................... 59 
8.4 Breastfeeding ...................................................................................................... 59 
9.0 CRITERIA FOR DISCONTINUATION............................................................................. 59 
9.1 Permanent and Premature Treatment Discontinuation ....................................... 59 
9.2 Premature Study Discontinuation  ........................................................................ 60 
10.0 STATISTICAL CONSIDERATIONS  ................................................................................ 60 
10.1 General Design Issues  ........................................................................................ 60 
10.2 Outcome Measures  ............................................................................................. 61 
10.3 Randomization and Stratification  ......................................................................... 65 
10.4 Sample Size ........................................................................................................ 66 
10.5 10.5 Data and Safety Monitoring  ......................................................................... 71 
10.6 Analyses  .............................................................................................................. 73 
10.7 Unblinding  ........................................................................................................... 76 
11.0 PHARMACOLOGY PLAN  ............................................................................................... 76 
12.0 DATA COLLECTION AND MONITORING  ...................................................................... 76 
12.1 Data Quality Assurance  ....................................................................................... 76 
12.2 Records to Be Kept ............................................................................................. 77 
12.3 Role of Data Management .................................................................................. 77 
12.4 Clinical Site Monitoring and Record Availability .................................................. 77 
13.0 PARTICIPANTS  .............................................................................................................. 78 
13.1 Institutional Review Board (IRB) Review and Informed Consent ........................ 78 
13.2 Ethical Conduct of Study  ..................................................................................... 78 
13.3 Participant Information and Consent ................................................................... 78 
13.4  P
articipant Confidentiality  .................................................................................... 79 
13.5 Study Discontinuation  .......................................................................................... 79 
14.0 PUBLICATION OF RESEARCH FINDINGS  ................................................................... 79 
15.0 BIOHAZARD CONTAINMENT  ........................................................................................ 79 
16.0 REFERENCES ................................................................................................................ 81 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II, MAIN PROTOCOL  ..................... 83 
APPEND IX II: SAMPLE INFORMED CONSENT – PHASE III, MAIN PROTOCOL  ................... 97 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB ................................................ 112 
APPENDIX IV:  SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB  ...... 134 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 ........................................ 142 
APPENDIX VI: SAMPLE INFORMED CONSENT FOR STUDY DRUGS BRII -196 AND 
BRII-198 ........................................................................................................................ 174 
APPENDIX VII: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS 
ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 CONTENTS (Cont’d) Page 
 
 ADMINISTRATION  ....................................................................................................... 180 
APPENDIX VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED VIA INTRAVENOUS INFUSION  ....................................................... 197 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR 
ADMINISTRATION  ....................................................................................................... 203 
APPENDIX X: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED AS AN INTRAMUSCULAR INJECTION  ........................................... 222 
APPENDIX XI: INVESTIGATIONAL AGENT INHALED INTERFERON -β1a (SNG001) .......... 227 
APPENDIX XII: SAMPLE INFORMED CONSENT FOR STUDY DRUG SNG001  ................... 257 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT ..................................................... 261 
APPENDIX XIV:  SAMPLE INFORMED CONSENT FOR STUDY DRUG CAMOSTAT  .......... 280 
APPENDIX XV: SAB-185 ANTI-SARS-COV-2 HUMAN IMMUNOGLOBULIN 
INTRAVENOUS (TC BOVINE -DERIVED)  .................................................................... 284 
APPENDIX XVI: SAMPLE INFORMED CONSENT FOR STUDY DRUG SAB-185 ................. 316 
APPENDIX XVII: INVESTIGATIONAL AGENT BMS-986414 (C135-LS) and BMS-
986413 (C144-LS) ......................................................................................................... 321 
APPENDIX XVIII: SAMPLE INFORMED CONSENT FOR STUDY DRUGS  BMS -986414 
(C135-LS) and BMS -986413 (C144-LS) ....................................................................... 344 
APPENDIX XIX: SIGNATURE PAGE – STUDY DRUGS  ......................................................... 349 
 
 6 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 SITES  PARTICIPATING  IN THE STUDY  
 
ACTIV -2/A5401 is a multicenter study open to select US - and non-US-based clinical research 
sites.  
  
 7 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 PROTOCOL TEAM ROSTER  
 
Co-Chair s 
Kara Chew, MD, MS  
Clinical AIDS Research and Education 
University of California, Los Angeles  
911 Broxton Avenue, Suite 2 00 
Los Angeles, CA 90024 
Phone: 310-825-0796 Fax: 310-477 -7657 
E-mail: kchew@mednet.ucla.edu  
 David (Davey) Smith, MD, MAS  
Antiviral Research Center  
University of California, San Diego 
220 Dickinson Street 
San Diego, CA 92103 Phone: 619-543-7449 Fax: 619-298 -0177 
E-mail: d13smith@health.ucsd.edu  
 
Vice Chairs  
Eric Daar, MD  
Harbor University of California Los Angeles Center CRS, CDCRC Building 205 
1124 West Carson Street 
Torrance, CA 90502 
Phone: 424-201-3000 Fax: 310-533 -0447 
E-mail: e daar@lundquist.org  
 David Wohl, MD  
Chapel Hill CRS,  
Suite 2100, Bioinformatics Building  
130 Mason Farm Road  
Chapel Hill, NC 27514  
Phone: 919-843-2723 
Fax: 919-966 -8928 
E-mail: wohl@med.unc.eduDAIDS Clinical Representative  
Arzhang Javan, MD, MPH, DTM&H  
TRP, DAIDS, NIAID, NIH  
5601 Fishers Lane  
Room 9E41 , MSC 9830  
Rockville, MD 20852 
Phone: 301-761-7710 Mobile: 240-475-6683 
E-mail: arzhang.javan@nih.gov 
 
Clinical Trials Specialists  
Lara Hosey, MA  
ACTG Network Coordinating Center  
Social & Scientific Systems, Inc.,   a DLH Holdings Company  
8757 Georgia Avenue, 12th Floor  
Silver Spring, MD 20910 Phone: 301-628-3395 Fax: 301-628 -3302 
E-mail: lara.hosey@dlhcorp.com 
 Jhoanna C. Roa, MD  
ACTG Network Coordinating Center  
Social & Scientifi c Systems, Inc.,  
  a DLH Holdings Company  
8757 Georgia Avenue, 12th Floor  
Silver Spring, MD  20910-3714 Phone: 301-628-3196 Fax: 301-628 -3302 
E-mail: jhoanna.roa@dlhcorp.com  
 
Statisticians  
Mark Giganti, PhD  
Center for Biostatistics in AIDS Research Harvard T.H. Chan School of Public Health 
FXB Building, Room 603 
Boston, MA 02115 Phone: 617-432-3233 Fax: 617-432 -3163 
E-mail: mgiganti@sdac.harvard.edu
 8 ACTIV -2/A5401 
FINAL Version 8.0 
 TEAM ROSTER (Cont'd) 25Feb2022 
 
 Statisticians (Cont’d) 
Michael Hughes, PhD  
Statistical and Data Analysis Center  
Harvard T.H. Chan School of Public Health  
Building 2, Room 439A, 655 Huntington Avenue 
Boston, MA 02115-6017 Phone: 617-432-3161 Fax: 617-432 -2832 
E-mail: mhughes@sdac.harvard.edu 
 
Carlee Moser, PhD  
Center for Biostatistics in AIDS Research 
Harvard T.H. Chan School of Public Health 
FXB Building, Room 513 
Boston, MA 02115 
Phone: 617-432-2526 Fax: 617-432 -2829 
E-mail: cmoser@sdac.harvard.edu  
 
Justin Ritz, MS  
Center for Biostatistics in AIDS Research 
Harvard T.H. Chan School of Public Health FXB Building, Room 51 0 
Boston, MA 02115 Phone: 617-432-3034 
Fax: 617-432 -3163 
E-mail: jritz@sdac.harvard.edu 
 
DAIDS Pharmacists  
Kelly Colsh, PharmD  
Pharmaceutical Affairs Branch DAIDS, OCSO, PAB  
5601 Fishers Lane, 9E15 
Rockville, MD 20852 Phone: 240-669-5721 E-mail: kelly. colsh@nih.gov  
 
Justine Beck, Pharm D 
NIAID/NIH/DHHS/PAB  
5601 Fishers Lane  
Room 9D39  
Rockville, MD 20852 
Phone: 301-761-5288 
Fax: 240-627 -3112 
E-mail: justine.beck@nih.gov Immunologist 
Scott Sieg, PhD  
Case Western Reserve University  
Biomedical Research Building  
Room 1020  
2109 Adelbert Road Cleveland, OH 44106-4984 Phone: 216-368-6594 Fax: 216-368 -5415 
E-mail: sfs2@case.edu  
 
Virologist  
Jonathan Li, MD, MMSc  
Brigham and Women's Hospital 
Therapeutics (BWHT) CRS  
Harvard Medical School  
Department of Infectious Diseases  
65 Landsdowne Street, Room 421  
Boston, MA 02139 
Phone: 617-768-8476 
Fax: 617-768 -8738 
E-mail: jli@bwh.harvard.edu 
 
Pharmacologist  
Courtney Fletcher, PharmD  
University of Nebraska Medical Center  
College of Pharmacy  
986000 Nebraska Medical Center  
Omaha, NE 68198-6000 
Phone: 402-559-4333 
E-mail: cfletcher@unmc.edu 
 
Critical Care Specialist  
William Fischer, MD  
Division of Pulmonary and Critical Care Medicine University of NC School of Medicine  
Chapel Hi ll, NC 27516  
Phone: 410-908-7779 
E-mail: WFischer@med.unc.edu  
 
 9 ACTIV -2/A5401 
FINAL Version 8.0 
 TEAM ROSTER (Cont'd) 25Feb2022 
 
 Investigators  
Sandra Cardoso, MD, PhD 
Instituto de Pesquisa Clinica Evandro Chagas CRS 
Oswaldo Cruz Foundation 
Avenida Brasil 4365  
Manguinhos  
Rio de Janeiro, 21045--900 BRAZIL 
Phone: 55-21-38659623 
Fax: 55-21- 25644933 
E-mail: dra.wagner@gmail.com 
 Katya Corado, MD  
Harbor University of California Los Angeles Center CRS  
CDCRC Building  
1124 West Carson Street Torrance, CA 90502 
Phone: 424-201-3000 Ext. 7316  
E-mail: Katya.Corado@lundquist.org 
  Judith Currier, MD, MSc  
Clinical AIDS Research and Education (CARE) Center CRS  
911 Broxton Avenue, Suite 200  
Los Angeles, CA 90024 Phone: 310-825-9283 Fax: 310-477 -7657 
E-mail: jscurrier@mednet.ucla.edu  
 
Joseph Eron, MD  
University of North Carolina Global HIV 
Prevention and Treatment CTU  
Bioinformatics Building  
130 Mason Farm Road, Suite 210  
Chapel Hill, NC 27599-7215 
Phone: 919-843-2722 Fax: 919-966 -6714 
E-mail: jeron@med.unc.edu 
  
 
   Investigators (Cont’d)  
Teresa Evering, MD, MS  
Weill Cornell Medicine  
Uptown CRS  
1300 York Avenue  
New York, NY 10065 E-mail: evering@med.cornell.edu  
 
Rachel Bender Ignacio, MD, MPH  
University of Washington AIDS Clinical Trials Unit CRS  
325 9th Ave  
Harborview Medical Center  
P.O. Box 359929 
Seattle, WA 98104 
Phone: 206-940-5522 E-mail: rbi13@uw.edu 
 Prasanna Jagannathan, MD  
Division of Infectious Diseases and 
Geographic Medicine 
Stanford University   
240 Pasteur Drive Biomedical Innovations Building 3
rd Floor, Room 3456 
Palo Alto, CA 94304 Phone: 650-724-5343
 
E-mail: prasj@stanford.edu 
 Nikolaus Jilg, MD, PhD  
Massachusetts General Hospital/  
Harvard Medical School  
55 Fruit Street Boston, MA 02114  Phone: 617-416-7955  Fax: 617-726 -7653  
E-mail: njilg@partners.org  
     
 
   
 10 ACTIV -2/A5401 
FINAL Version 8.0 
 TEAM ROSTER (Cont'd) 25Feb2022 
 
 Investigators (Cont’d)  
Alan Perelson, PhD 
Los Alamos National Laboratory  
Theoretical Biology/Biophysics 
MS-K710,T10 
Drop Point TA3/480/01U  
Los Alamos, NM 87545  
Phone: 505-667-6829 
Fax: 505-665 -3493 
E-mail: asp@lanl.gov  
 
Sandy Pillay, MB, CHB  
Durban International CRS  
Enhancing Care Foundation 
306 African Palms  
9 Palm Boulevard 
Umhlanga Ridge Durban, KZN 4319 SOUTH AFRICA  
Phone: 27-31-5663933 
Fax: 27-86- 7251896 
E-mail: sandy@ecarefoundation.com  
 
Cynthia Riviere, MD  
Les Centres Gheskio (Gheskio-INLR) CRS  
Cite de L'exposition  
33 Boulevard Harry Truman  
Port-au-Prince, HT-6110 
HAITI  
Phone: 50929401431 Fax: 509-2239044 
E-mail: criviere@gheskio.org 
 
Upinder Singh, MD  
Departments of Internal  Medicine and 
Microbiology  and Immunology  
Stanford University School of Medicine 
Lane Building, Suite 134, Rm  121 
300 Pasteur Drive Stanford, CA  94305-5107 
Phone: 650-723-4045 
Fax: 650-724 -3892 
E-mail:  usingh@stanford.edu 
   Investigators (Cont’d)  
Babafemi Taiwo, MBBS, MD  
Northwestern University CRS  
Feinberg School of Medi cine 
Division of Infectious Diseases  
645 North Michigan Avenue, Suite 900 Chicago, IL 60611 Phone: 312-695-4994 Fax: 312-695 -5088 
E-mail: b-taiwo@northwestern.edu  
 
Field Representatives  
Joan Gottesman, BSN, RN, CCRP  
Vanderbilt Therapeutics (VT) CRS  
One Hundred Oaks  
719 Thompson Lane, Suite 47183 Nashville, TN 37204 Phone: 615-936-7143 Fax: 615-936 -2644 
E-mail: joan.gottesman@vumc.org 
 
Matthew Newell, BSN, RN, CCRN  
Chapel Hill CRS  
Campus Box 7215  
Bioinformatics Suite 2100 
130 Mason Farm Road  
Chapel Hill, NC 27599-7215 
Phone: 919-843-6929 Fax: 919-966 -8928 
E-mail: matthew_newell@med.unc.edu 
 
Laboratory Technologists  
Brian Greenfelder, BA  
Ohio State University CRS  
Division of Infectious Diseases  
Department of Internal Medicine  
Starling Loving B002 320 West 10th Avenue Columbus, OH 43210  
Phone: 614-293-8938 Fax: 614-293 -5810 
E-mail: brian.greenfelder@osumc.edu
 
 
   
 11 ACTIV -2/A5401 
FINAL Version 8.0 
 TEAM ROSTER (Cont'd) 25Feb2022 
 
 Laboratory Technologists (Cont’d)  
Cheryl Jennings, BS 
Northwestern University CRS  
Clinical Retrovirology Research Laboratory  
1181 Jelke Building  
1750 West Harrison Street Chicago, IL 60612 Phone: 312-942-5954 Fax: 312-942 -6787 
E-mail: cheryl_jennings@rush.edu 
 
Community Scientific Subcommittee (CSS) 
Representative  
Jan Kosmyna, MIS, RN, CCRP  
Case CRS, 10041 Brookside Circle  
North Royalton, OH 44133 E-mail: jankosmyna@gmail.com 
 
International Site Specialist  
Akbar Shahkolahi, PhD  
ACTG Network Coordinating Center  
Social & Scientific Systems, Inc.,  
  a DLH Holdings Company  
8757 Georgia Avenue, 12th Floor  
Silver Spring, MD 20910 
Phone: 301-628-3318 
Fax: 301-628 -3302 
E-mail: akbar.shahkolahi@dlhcorp.com  
 
Industry Representative s 
Robert A  Gasser, Jr ., MD  
Kelly Services , a Service Provider  
  to AstraZeneca One MedImmune Way  
Gaithersburg, MD 20878 
Phone 703-242-6259 
E-mail: robert.gasserjr@astrazeneca.com 
 David Margolis, MD, MPH  
Brii Biosciences  
WeWork One City Center  
110 Corcoran Street 
Durham, NC 27701 
Phone: 303-520-1579 
E-mail: david.margolis@briibio.com  
 Industry Representatives (Cont’d)  
Edgar Charles, MD  
Bristol Myers Squibb  
Route 206 & Province Line Road 
Lawrenceville, NJ 08543 
Phone: 609-252-3759 
E-mail: Edgar.Charles@bms.com  
 Paul Klekotka, MD, PhD  
Lilly Research Laboratories Lilly Biotechnology Center  
10290 Campus Point Drive  
San Diego, CA 92121 Phone: 619-346-8191 
E-mail: klekotka_paul@lilly.com 
 Veronica Mas Casullo, MD  
Internal Medicine/Infectious Diseases  
Regeneron 
777 Old Saw Mill River Road 
Tarrytown, NY 10591 
Phone: 914 847 8261 
E-mail: veronica.mascasullo@regeneron.com  
 Rick Finnegan 
SAB Biotherapeutics  
245 First Street, Suite 1836 
Cambridge, MA 02142  
Phone: 978-500-3354 
E-mail: rfinnegan@sabbiotherapeutics.com  
 
Jake Miles, MBA  
SAB Biotherapeutics  
2301 E 60th Street N 
Sioux Falls, SD 57104 Phone: 605-679-6988 
E-mail: jmiles@sabbiotherapeutics.com  
 
Bob Szurgot   
Sagent Pharmaceuticals  
1901 N. Roselle Rd, Suite 450 
Schaumburg, IL  60195  
Phone: 847-908-1616  
E-mail: bszurgot@SagentPharma.com  
 
 12 ACTIV -2/A5401 
FINAL Version 8.0 
 TEAM ROSTER (Cont'd) 25Feb2022 
 
 Industry Representatives (Cont’d)  
Mark J. Main, PhD  
Synairgen Research Ltd  
Mailpoint 810, Level F  
South Block  
Southampton General Hospital  
Tremona Road 
Southampton SO16 6YD  
UK 
Phone: +44 7768 415004 
E-mail: Mark.Main@synairgen.com 
 
Laboratory Specialist  
William A. Murtaugh, MPH   
ACTG Laboratory Center  
University of California Los Angeles  
11075 Santa Monica Boulevard, Suite #200 Los Angeles, CA 90025 Phone: 310-794-9894 
E-mail:  wmurtaugh@milabcentral.org 
  
 13 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 STUDY MANAGEMENT  
 
All general questions concerning this protocol and safety and risk management inquiries must be submitted through the electronic Protocol Inquiry Platform (ePIP) system. For urgent ePIPs, following entry into ePIP, contact the following PPD 24/7 global cov erage hotline:  
 
24-Hour Study Protocol Queries and Pharmacovigilance  Hotline  Telephone Number  
North America  1 888 483 7729  
Latin America  55 11 4504 4801  
Europe, Middle East, and Africa (EMEA) and Asia Pacific (APAC)  44 122 337 4240  
 
Protocol E-mail Group  
This protocol will have an email group to allow the study team to communicate directly with staff 
at participating sites.  
 
Each site must identify the staff members who need to receive study -related information, 
including announcement of conference calls, and ensure that they are added to the protocol 
email group, as soon as possible by contacting FSTRF User Support at 
actg.user.support@fstrf.org.   
 
Please note that there is no limit to the number of individuals who can be included in this group. At a minimum, we recommend that the following staff members be included: CRS Leader, Investigator of Record, CRS Coordinator, Pharmacist, Data Manager, and laboratory staff members.  
 
Protocol -Specific Web Page 
Additional information about management of the protocol can be found on the protocol -specific 
web page (PSWP). 
 14 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 GLOSSARY OF PROTOCOL -SPECIFIC TERMS  
 
ACTIV  Accelerating COVID-19 Therapeutic Interventions and Vaccines  
AE  adverse event  
AESI adverse event of special i nterest  
AUC  area under the curve  
BMI body mass index 
CDMS  Clinical Data Management System  
CLIA  Clinical Laboratory Improvement Amendments  
COVID -19 coronavirus disease 2019 
CoVs  c oronaviruses 
CRS  clinical research site  
DAIDS PRO  Division of AIDS Protocol Registration Office 
DSMB  Data and Safety Monitoring Board 
EC Ethics Committee 
EUA  Emergency Use Authorization 
EUL Emergency Use Listing 
FDA US Food and Drug Administration  
ICF informed consent form  
ICU intensive care unit 
IRT Interactive Response Technology  
LLoQ  lower limit of quantification 
LPC lab processing chart  
mAb monoclonal antibody  
MOPS  manual of procedures 
NI non-inferiority 
NP nasopharyngeal  
PBMC peripheral blood mononuclear cells   
PCI percutaneous coronary intervention 
RE regulatory entity 
RSC  Regulatory Support Center  
SAE  s erious adverse event  
SAP   statistical analysis plan   
SARS- CoV Severe Acute Respiratory Syndrome coronavirus  
SARS- CoV-2  Severe Acute Respiratory Syndrome coronavirus 2  
SOC  standard of care 
SOE  Schedule of E valuations  
SUSAR Suspected Unexpected Serious Adverse Reaction 
TOC  Trial Oversight Committee 
VOC  variants of concern 
WHO  World Health Organization 
 
 15 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 SCHEMA  
 
ACTIV -2 / A 5401 
 
Adaptive Platform Treatment Trial for Outpatients with COVID -19  
(Adapt Out COVID)  
 
DESIGN Adapt Out COVID is a master protocol to evaluate the safety and 
efficacy of investigational agents for the treatment of non-hospitalized 
adults with COVID -19.  
 
The trial is a randomized controlled platform that allows agents to be added and dropped during the course of the study for efficient phase II and phase III testing of new agents within the same trial infrastructure. 
 
Version 8 of the protocol provides for blinded phase II evaluation of an 
investigational agent for superiority  to placebo among participants at 
lower risk of progression to hospitalization or death. Agents in  phase 
III evaluation after initiation of this protocol version will be evaluated 
in persons at higher risk for progression to hospitalization or death for 
superiority to placebo, allowing for standard of care COVID -19 
treatment to be received any time after entry. When two or more 
agents are being evaluated in the same phase of the study, the trial 
design includes sharing of the control group for efficient evaluation of each agent. 
 
REGIMEN  Investigational agents will be approved by the Trial Oversight 
Committee (TOC ) for phase II evaluation based on the presence of in 
vitro data demonstrating promise as anti -SARS- CoV-2 therapeutics in 
pre-clinical testing and for which there are suitable pharmacokinetics and safety data from phase I testing or through clinical or research 
testing for a different indication, and agent availability. Investigational 
agents will be included in phase III evaluation based on agent entry criteria for phase III as outlined in the protocol (or by TOC approval based on data available outside of ACTIV -2). 
 
DURATION  Investigational agent bamlanivimab: 28 days of intensive follow -up, 
followed by limited follow -up through 24 weeks  in phase II and in 
phase III.  
 
All other investigational agents: 28 days of intensive follow -up, 
followed by limited follow -up through 72 weeks in phase II and phase 
III.  
 
Additional study visits may be required, depending on the agent. Details are listed in the agent-specific protocol appendix and 
 16 ACTIV -2/A5401 
FINAL Version 8.0 
 SCHEMA (Cont'd) 25Feb2022 
 
 consents.  
 
STRATIFICATION  Randomization in phase II will be stratified by time from symptom 
onset (≤5 days versus >5 days) . Randomization in phase III will be 
stratified by country of enrollment. 
 
POPULATION  O utpatient adults (≥18 years) with a documented positive SARS -CoV -2 
molecular (nucleic acid) or antigen test from a sample collected ≤240 
hours (10 days) prior to study entry and with ≤ 7 days of symptoms of 
COVID -19 at study entry, plus the presence of select symptoms within 
24 hours prior to study entry.  
 
For phase III, participants must meet protocol-specified criteria for being at “higher” risk of progression to hospitalization or 
death , as defined below, based on age, co-morbidities, and 
COVID -19 vaccination status.  
 
The following participants are considered at “higher” risk of progression to hospitalization or death if  they have NOT completed 
the primary series (meaning all of the doses required before a 
booster dose)  of an effective COVID -19 vaccine (see Manual of 
Procedures [MOP S] for list of vaccines considered to be 
effective): 
• ≥65 years of age 
• ≥55 years of age and satisfying at least one of the following : 
o Cardiovascular disease defined as history of any of the 
following: myocardial infarction, stroke, transient ischemic 
attack, heart failure, angina with prescribed nitroglycerin, coronary artery bypass grafts, percutaneous coronary 
intervention (PCI), carotid endarterectomy, and aortic bypass  
o Hypertension, with at least one medication recommended or 
prescribed  
o Chronic obstructive pulmonary disease or other chronic respiratory disease requiring daily prescribed therapy  
• ≥18 years of age and satisfying at least one of the following:  
o Body mass index (BMI) ≥35 kg/m
2 
NOTE: BMI is rounded to the nearest whole number, for 
example, 34.5 is rounded to 35 
o Chronic kidney disease requiring hemodialysis or peritoneal 
dialysis  
o Type 1 or type 2 diabetes  
o Exogenous or endogenous immunosuppression defined as 
any of the following:  
 HIV infection with CD4 count <200 cells/mm3 
 17 ACTIV -2/A5401 
FINAL Version 8.0 
 SCHEMA (Cont'd) 25Feb2022 
 
  receiving corticosteroids equivalent to prednisone ≥20 
mg daily for at least 14 consecutive days within 30 days prior to study entry  
 treatment with bi ologics (e.g., infliximab, abalizumab, 
ustekinumab, etc.), immunomodulators (e.g., methotrexate, 6MP, azathioprine, etc.), or cancer chemotherapy within 90 days prior to study entry 
 
The following participants age ≥18 years are considered at 
“higher” risk of progression to hospitalization or death REGARDLESS of whether  they have received any doses of a 
COVID -19 vaccine:  
• Receiving active therapy for cancer  
• Hematologic malignancies 
• Being within one year from receiving a hematopoietic stem 
cell or solid organ transplant  
• Untreated HIV infection with CD4 T lymphocyte count <200  
• Combined primary immunodeficiency disorder  
• Taking immunosuppressive medications (e.g., drugs to 
suppress rejection of transplanted organs or to treat 
rheumatologic conditions such as mycophenolate and 
rituximab, receipt of prednisone >20mg/day for more than 14 
days) 
 
SAMPLE SIZE The phase II evaluation will enroll approximately 110 participants 
per investigational agent (and 110 on placebo) (this includes all partici pants enrolled under previous protocol versions, irrespective 
of risk of progression to hospitalization or death). The phase III evaluation under this protocol version will enroll approximately 
600 participants on investigational agent and 600 on placebo.  
 
OUTCOME MEASURES  The primary outcome measures in the phase II evaluation will be 
duration of symptoms, SARS -CoV -2 RNA below lower limit of 
quantification by nasopharyngeal (NP) swabs, and safety.  
 
The primary outcome measures in the phase III evaluation will be 
the composite of hospitalization due to any cause or death due to 
any cause, and safety.  
 
 18 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 1.0 STUDY OBJECTIVES  
 
1.1 Co-Primary Objectives  
 
1.1.1 Phases II and III: To evaluate safety of the investigational agent.  
1.1.2 Phase II: To determine efficacy of the investigational agent to reduce the duration 
of COVID -19 symptoms through study day 28.  
 
1.1.3 Phase II: To determine the efficacy of the investigational agent to increase the proportion of participants with nasopharyngeal (NP) SARS -CoV-2 RNA below the 
lower limit of quantification (LLoQ) at study days 3, 7, and 14 . 
 
1.1.4 Phase III: To determine if the investigational agent will prevent the composite 
endpoint of hospitalization due to any cause or death due to any cause through 
study day 28. Hospitalization is defined as ≥24 hours of acute care, in a hospital 
or similar acute care facility, including Emergency Rooms or temporary facilities 
instituted to address medical needs of those with severe COVID -19 during the 
COVID -19 pandemic.  
 
1.2 Secondary Objectives  
 
1.2.1 Phases II and III: To determine whether the investigational agent reduces a 
COVID -19 Severity Ranking scale based on COVID -19-associated symptom 
burden (severity and duration), hospitalization, and death, through study day 28. 
 
1.2.2 Phase II and III: To determine whether the investigational agent reduces the 
progression of COVID -19-associated symptoms. 
 
1.2.3 Phase II and III: To determine if the investigational agent reduces levels of SARS- CoV-2 RNA in NP swabs. 
 
1.2.4 Phase III: To determine the efficacy of the investigational agent to increase the proportion of participants with NP  SARS-CoV-2 RNA below the LLoQ  at study 
day 3.  
 
1.2.5 Phase II: To determine the pharmacokinetics of the investigational agent. 
 
1.2.6 Phase II and III: To determine efficacy  of the investigational agent to obtain pulse 
oximetry  measurement of ≥96%  through day 28. 
 
 19 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 1.2.7 Phase III: To determine if the investigational agent will prevent the composite 
endpoint of hospitalization due to any cause or death due to any  cause through 
study week 72.  
 
1.2.8 Phase III: To evaluate if the investigational agent reduces the time to sustained symptom resolution through study d ay 28.  
 
1.2.9 Phase III: To determine if the investigational agent will prevent the composite endpoint of hospitalization or death through study day 28, 
excluding hospitalizations that are determined to be unrelated to COVID -19.  
 
1.3 Exploratory  Objectives  
 
1.3.1 Phases II and III: To explore the impact of the investigational agent on 
participant-reported rates of SARS -CoV-2 positivity of household contacts.  
 
1.3.2 Phases II and III: To explore if baseline and follow-up hematology, chemistry, coagulation, viral, and inflammatory biomarkers are associated with clinical and virologic outcomes in relation to investigational agent use.  
 
1.3.3 Phases II and III: To explore possible predictors of outcomes and differences between investigational agent and control across the study population, notably sex, time from symptom onset to start of investigational agent, and race/ethnicity.  
 
1.3.4 Phase II and III: To explore if the investigational agent changes the hospital 
course in those hospitalized. 
 
1.3.5 Phases II and III: To explore and develop a model for the interrelationships between virologic outcomes, clinical symptoms  and, in Phase III, hospitalization, 
and death in each study group.   
1.3.6 Phases II and III: To explore the relationship between exposure to the investigational agent and SARS -CoV-2 innate, humoral or cellular response, 
including anti -drug antibodies, as appropriate per investigational agent. 
 
1.3.7 Phases II and III: To explore baseline and emergent viral resistance to the 
investigational agent.  
 
1.3.8 Phases II and III: To explore the association between viral genotypes  and 
phenotypes,  and clinical  outcomes  and response  to agents.  
 
1.3.9 Phases II and III: To explore the association between host genetics  and clinical  
outcomes  and response  to agents.  
 
1.3.10 Phases II and III: To explore relationships between dose and concentration of 
investigational agent with virology, symptoms, and oxygenation. 
 20 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
1.3.11 Phases II and III: To explore the prevalence, severity and types of persistent 
symptoms and clinical sequelae in participants through end of study follow -up.  
 
1.3.12 Phases II and III: To explore measures of psychological health, functional health, 
and health-related quality of life in participants through end of study follow -up. 
 2.0 INTRODUCTION  
 
2.1 Background  
 
Virology  
Coronaviruses (CoVs) are positive- sense, single -stranded, enveloped RNA viruses, 
many of which are commonly found in humans and cause mild symptoms. Over the past two decades, emerging pathogenic CoVs capable of causing life-threatening disease in 
humans and animals have been identified, namely, severe acute respiratory syndrome  
coronavirus ( SARS- CoV) in 2002-2003 and Middle East Respiratory Syndrome 
coronavirus (MERS -CoV) in 2012 [1 ]. 
 
New Threat  
A novel pneumonia caused by a previously unknown betacoronavirus emerged in 
Wuhan, China, in December 2019. The virus is closely related to SARS- CoV-1, which 
caused an outbreak in 2003, and has been named SARS -CoV-2. The human disease 
caused by SARS-CoV -2 is called COVID -19.  
 
During the current SARS-CoV -2 outbreak, the incidence of known cases has rapidly 
increased such that, on January 5, 2020, there were 59 confirmed cases, 278 cases on 
January 20, 2118 cases on January 26, and more than 80,000 cases and 2700 deaths as of February 25, 2020, according to various international health reporting agencies. As a result, on January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO) declared the COVID -19 outbreak a 
Public Health Emergency of International Concern. On January 31, 2020, the US Department of Health and Human Services declared a public health emergency in the 
United States. Despite quarantine measures, SARS -CoV -2 has spread to over 188 
countries, infecting millions worldwide and killing hundreds of thousands [2]. As of January 5, 2022, there have been >290 million confirmed cases of COVID -19 and 
>5.5 million deaths attributed to COVID -19 globally [3 ]. Global efforts to evaluate 
novel antivirals and therapeutic interventions to treat COVID- 19 have intensified.  
 
Disease Course 
Once infection occurs, the clinical course is variable. Initial data suggested that fewer 
than 2.5% of infected per sons will show symptoms within 2.2 days (CI, 1.8 to 2.9 days) 
of exposure, and symptom onset will occur within 11.5 days (CI, 8.2 to 15.6 days)  for 
97.5% of infected persons  [4]. In most (~80%) cases, COVID -19 presents as a mild- to-
moderately severe, self- limited acute respiratory illness with fever, cough, and shortness 
of breath. During the period of  Omicron variant predominance, COVID -19 disease 
 21 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 severity has appeared to be lower than in the pre-Omicron period [5].  It remains 
unclear exactly what the rate of progression of COVID-19 is and what the predictors are 
for complications, including pneumonia, acute respiratory distress syndrome (ARDS), 
kidney failure, and death. It is clear that older age, male sex, and comorbidities including 
diabetes mellitus and hypertension increase the risk for worse outcomes  [6, 7]. In a 
recent meta-analysis, the main clinical symptoms were fever (88.5%), cough (68.6%), 
myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%). Minor 
symptoms included headache or dizziness (12.1%), diarrhea (4.8%), and nausea and vomiting (3.9%) [8 ]. Laboratory examinations showed that lymphocytopenia (64.5%), 
increase of C-reactive protein (CRP) (44.3%), increase of lactate dehydrogenase (LDH) 
(28.3%), and leukocytopenia (29.4%) were more common in those with COVID -19 [6, 9]. 
 
 
Figure 2.1-1: Timeline of COVID -19 Disease Progression. Onset refers to 
onset of symptoms.  
 
Shedding 
Viral infections jump from host to host through a variety of pathways. Coronaviruses do 
this through respiratory droplets. Understanding this shedding is important to 
understanding epidemic spread and how shedding relates to disease progression. Best 
evidence available now suggests that viral shedding, especially in upper respiratory 
secre tions, is detectable around 2 days before symptoms develop and continues 
throughout the symptomatic phase. This shedding can be quite high during active 
disease and can continue at low leve ls for many months in some persons [8 ]. 
 
Variants 
While circulating in human populations, SARS -CoV -2 has evolved with adaptation 
to evade human immune responses and to become more infectious [10]. Further, 
some variants, like Omicron, have become less pathogenic especially in the 

 22 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 setting of full vaccination and after booster  vaccination [5]. This viral evolution 
has created some variants that have circulated widely, and in some instances has 
replaced the original viral strain and variants. Such variants of SARS -CoV -2 have 
been termed “ variants of concern” (VOC) [11 ]. Some of these VOC have been 
shown in lab tests to have reduced susceptibility to some antibody-based 
therapies, including agents that have received emergency use authorization ( EUA) 
by the FDA [ 12], as described further below . As SARS -CoV-2 mutates and forms  
variants that spread across populations, it is clear  that some circulating variants 
are less susceptible to monoclonal antibodies (mAbs). The Omicron  variant has 
rapidly become the predominant SARS -CoV-2 variant in circulation on 
surveillance, which has led to the revocation of authorization or intermittently 
paused distribution or  limited authorization for several monoclonal antibodies, 
including bamlanivimab, bamlanivimab plus etesevimab, and, most  recently, 
casirivimab plus imdevimab, as these mAbs  have little to no activity against 
Omicron variant in in vitro pseudovirus and live virus neutralization assays [13, 
14, 15]. 
 
Biomedical Interventions  
Multiple monoclonal antibody therapies have received FDA emergency use 
authorization (EUA) for treatment of COVID -19 in the outpatient setting for persons at 
higher  risk for progression to hospitalization or death, based on the consistent 
demonstration across multiple mAb therapies of ~ 70-85% relative reduction in 
COVID -19-re lated hospitalizations and all-cause deaths in the pre-Delta, pre-
Omicron variant period of the pandemic [14, 15, 16]. As described above, the 
emergence of VOCs and the O micron variant in particular has rendered several of 
these agents significantly less inhibitory in in vitro assays, and they are thus not 
expected to be clinically effective. Emerging variants will continue to threaten 
COVID -19 therapeutics that target a single or limited number of Spike epitopes 
and may also threaten non-Spike targeting therapeutics.  The adenosine analog, 
remdesivir, has shown clinical benefit for COVID- 19 in non-hospitalized patients [17]. 
It was recently approved for use in non-hospitalized patients [ 18]. Remdesivir must 
be given intravenously once daily for three days, requiring resources that make it 
often difficult to deliver to a large population and limits uptake by health systems.  
 
New agents continue to be developed that may be useful for the treatment of non-
hospitalized persons with COVID -19, including polyclonal anti-SARS-CoV -2 antibodies, 
viral enzyme inhibitors, small interfering RNAs, immune modulators, and other small 
molecules [ 19]. Before these potential treatments can be clinically deployed, they will 
need to be evaluated quickly in ambulatory persons in a rigorous clinical trial, as will be 
achieved through ACTIV -2/A5401, the Adapt Out COVID Trial. The susceptibility of 
emergency use authorized mAbs to emerging VOCs and the challenges to delivery 
of currently available therapeutics highlight the need for continued investigation 
of therapeutics that are more likely to retain activity in the face of current and 
future SARS-CoV -2 variants.  
 
 23 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Placebo Comparator  for Phase III Evaluations  
Under protocol version 7, the study was designed to compare investigational 
agents to the monoclonal antibody cocktail casirivimab plus imdevimab 
(REGN10933+REGN10987, or REG EN-COV) as an active control in phase III 
evaluations. With the lack of activity of casirivimab plus imdevimab against the Omicron variant, continuing a non-inferiority (NI) design with casirivimab plus 
imdevimab as a con trol arm is no longer feasible. In this version of ACTIV -2/A5401, 
we pivot  to a superiority design and placebo comparator  for phase III evaluation, 
allowing all participants to receive standard of care (SOC) therapies for COVID- 19 
post-entry if they can access them  outside the trial. The intention is to recognize 
that there are effective therapies with emergency use or equivalent authorization 
and approval, but their supply and access are limited globally and potentially even 
regionally within a given country. This confluence of circumstances provides rationale for such a design where effective therapies are not prohibited but 
evaluation of investigational agents against placebo remains both scientifically and 
operationally feasible, as we expect only a small percentage of participants will be 
able to receive SOC therapy in addition to study intervention due to limited 
availability of these therapies. Participants enrolled under protocol Version 7 (randomized to SAB -185 or casirivimab plus imdevimab) will be included in the 
efficacy analyses of SAB-185 as described in the SAB -185 appendix.  
 2.2 Rationale 
 
There is an urgent need for a platform  to rapidly  evaluate therapies  in the outpatient 
setting, to prevent disease progression, and reduce serious  complications  of COVID -19 
and transmission [ 20]. ACTIV -2/A5401 is a randomized, controlled platform trial to 
efficiently evaluate agents in both phase II and phase III for the treatment of non-hospitalized persons with COVID -19. This will allow:  
• Comparison of multiple therapies with a common control group, when feasible, thus 
potentially requiring fewer participants than in independently conducted randomized controlled trials,  
• Continuous introduction of new promising agents as they become available, and 
• Minimized downtime, with rapid movement of promising agents into phase III 
evaluation.  
 
Additionally, the trial will facilitate the exploration of virologic endpoints as possible future 
primary endpoints in COVID-19 trials by assessing the correlation between changes in 
viral shedding and clinical outcomes. 
 
Outcome Measures  
Phase II evaluates the potential effect of an investigational agent on COVID -19-associated 
symptoms and on viral shedding. Although recent data from monoclonal antibody treatments 
have documented associations between higher baseline levels of viral shedding in NP 
swabs and higher rates of hospitalization and all -cause death [21] , it is unknown a priori  if an 
investigational agent that  is effective in reducing symptom duration and/or viral shedding will 
have meaningful impact on the clinical outcome of hospitalization or death. Therefore, an 
 24 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 investigational agent that has shown preliminary evidence of effects on viral shedding, 
clinical  symptoms, and/or hospitalization/ death compared to placebo, and has an acceptable 
safety profile in phase II evaluation will be considered by the TOC f or graduation to phase III 
evaluation. The TOC is comprised of protocol, ACTG, and NIH Accelerating COVID- 19 
Therapeutic Interventions and Vaccines (ACTIV) group leadership. 
 The primary symptom outcome measure in phase II and secondary outcome measure in 
phase III relies on targeted symptoms  that have been associated with COVID-19, and 
which are expected to be dynamic and improve with effective anti -SARS-CoV -2 therapy.  
 The phase III evaluation focuses on the primary efficacy outcome of hospitalization due 
to any  cause or death due to any cause. 
 
Investigational Agents 
See appendices  for rationale for each investigational agent. 
 
Multi -Site Design  
In any multi -site study, outcomes can potentially differ due to variation in site 
populations, stage of epidemic spread, diagnostic capability , and clinical management. It 
is expected that any differences between sites will be balanced between arms through 
randomization.  
 
Rationale for Placebo Control Design for Version 8 
Version 8 of the ACTIV -2/A5401 protocol will evaluate investigational agents 
against a blinded placebo control as casirivimab plus imdevimab is no longer an 
acceptable active comparator (discussed above). It is further challenging at this 
time to design a non-inf eriority trial with an alternative active control given the 
uncertainties around clinical efficacy and hospitalization/death event rates, as the 
data supporting the efficacy of alternative therapies with authorization or approval 
were collected during the pre -Omicron period. Recognizing that these other 
therapies (such as remdesivir, sotrovimab, and nirmatrelvir/ritonavir) are still used 
in routine care and expected to have retained activity against the predominant 
circulating variant at this time, participants will be required to have sought such 
available therapies prior to enrolling in the trial. O nce enrolled, participants will be 
allowed to continue to seek and receive standard of care therapies outside the 
trial if they become available to them . Use of these therapies outside the trial will 
be documented in the analysis of the study. 
  
The inclusion of a placebo group, rather than an untreated open-label control 
group, is considered important for the integrity of the study to reduce the possibility of differential retention of participants randomized to an investigational agent versus to the control group, as well as to minimize subjective bias in 
completion of symptom diaries by participants. The use of placebo is justified 
based on the following key aspects:  
• It is not feasible at this time to continue evaluation of new investigational 
agents against an active-control arm based of the evolution of  COVID -19 and 
 25 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 its variants. It is not known which active comparator  would remain effective, or 
how effective (estimates necessary to design a NI trial), as variants emerge  
(i.e., the “constancy”  assumption which underpins a NI trial may be violated).  
Use of placebo allows for continued evaluation of promising therapies in the 
interim, as available data are analyzed.  
• There is overall limited availability  of effective treatments globally.  
• Where available, SOC  therapy is allowed after randomization. Therefore, all 
participants (both active and placebo-assigned)  will have the opportunity to 
receive an authorized or approved treatment during their  participation in the 
trial and will not  be prohibited from  receiving SOC  therapies.  
• The challenges to delivery associated with some of the currently available 
therapeutics for outpatient treatment and variable activity of the available 
therapies with new and evolving variants further  highlight  the need for 
continued investigation of potential treatments. 
 
3.0 STUDY DESIGN  
 
3.1 Overview of Study Design 
 
ACTIV -2/A5401 is a master protocol to evaluate the safety and efficacy of investigational 
agents for the treatment of non-hospitalized adults with COVID -19. The trial is a 
randomized controlled platform that allows agents to be added and dropped during the course of the study for efficient phase II and phase III testing of new agents within the 
same trial infrastructure [ 20]. This protocol will be amended to include information about 
each new agent to be evaluated, as well as the handling of any design issues in the 
context of the platform design and changes in laboratory and survey measures. 
 
Enrollment of new study participants under this version of the protocol is to a platform 
trial with separate phase II and phase III evaluations of investigational agents. The 
phase II component is evaluating investigational agents in a superiority  comparison to a 
placebo control among participants at lower risk of progression to hospitalization or 
death (note though that for some agents, enrollment of higher risk participants was also 
allowed under earlier versions of the protocol). The phase III component is evaluating 
investigational agents in a superiority comparison to placebo among participants at 
higher risk of progression to hospitalization or death (allowing the use of SOC 
treatments in both arms if available) . The two components are linked in that 
investigational  agents showing evidence of antiviral effects and/or effects on symptoms 
of COVID -19 in the phase II component may then be evaluated further  in the phase III 
component, as it is expected that agents that demonstrate antiviral efficacy and/or 
symptom improvement in people who are at lower risk  will have clinical impact on 
hospitalization and death in higher risk persons . Statistical considerations for each of the 
phase II and phase III components are described in section 10.0. 
 
This version of the protocol provides for continued follow -up of participants enrolled into 
the active-controlled phase III trial evaluating the polyclonal antibody product 
SAB-185 against casirivimab plus imdevimab and a placebo-controlled phase III trial 
 26 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 evaluating the combination monoclonal antibody agent BRII-196 + BRII-198, as 
described in Appendix XV and Appendix  V, respectively.  
 
This version of the protocol also provides for continued follow -up of participants enrolled 
into a placebo-controlled phase II trial of the monoclonal antibody agent AZD7442 
delivered by IV infusion and delivered intramuscularly , the inhaled interferon-beta 
agent SNG001, the host serine protease inhibitor camostat, SAB-185 at two doses, 
and the mAb combination BMS-986414 (C135-LS) and BMS -986413 (C144-LS).  
These components of the study are in Appendices VII, IX, XI, XIII, XV, and XVII. 
 
Figure 3.1 -1 provides a simplified overview of the evaluations of investigational agents in 
phase II and phase III. The sample size of 110 participants receiving a given 
investigational agent (and 110 participants concurrently randomized to receive placebo) was chosen to provide high power to show a reduction in the proportion of participants 
with SARS- CoV-2 RNA below the LLoQ of the assay (the primary virologic outcome 
measure; see section 10.4
 for details).  
 
 
Figure 3.1 -1: Platform trial showing the phase II evaluation of investigational agents 
followed by phase III evaluation for an agent that graduates. Comparison of a given 
investigational agent in phase II is with concurrently randomized participants receiving placebo who could have been randomized to receive the agent. Phase III is a larger clinical outcome study comparing investigational agent to placebo (with background locally available SOC treatment in both arms).  
 

 27 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Selection of Investigational Agents  
The trial will rapidly assess various investigational agents that have shown substantial 
promise as anti -SARS- CoV-2 therapeutics in pre-clinical testing and for which there are 
suitable pharmacokinetics and safety data from phase I testing or through clinical or 
research testing for a different indication and agent availability. The TOC will choose 
which agents are evaluated by the trial and when a SOC  agent will replace a placebo for 
phase II evaluations [22]. The TOC will consider a variety of factors in their decisions 
including feasibility of implementing the agent. Up to two dose levels of the same agent 
may be assessed in phase II.  
 
Phase II Period of Evaluation 
In phase II, an investigational agent will be evaluated for safety, as well as for activity in 
reducing the duration of COVID -19 symptoms over 28 days and SARS -CoV-2 RNA 
shedding in NP swabs as compared to a placebo control. We will also monitor for the 
presence of baseline and emerging drug resistance.   
 
Phase II Early Termination 
During the phase II evaluation, the Data and Safety Monitoring Board (DSMB ) will 
review interim safety results on a monthly basis (or as otherwise recommended by the 
DSMB). The DSMB may recommend early termination of randomization to a particular 
investigational agent if there are safety concerns.  
 
Phase III Period of Evaluation 
In phase III, an investigational agent will be evaluated for safety, as well as for activity in reducing hospitalizations due to any cause or  deaths due to any cause as compared to a  
placebo control. The main period of evaluation is the 28 days from study entry and start 
of study treatment. There is less intensive follow-up through to 72 weeks to eval uate 
long-term safety and efficacy outcomes . We will also monitor for the presence of 
baseline and emerging drug resistance.  
Phase III Early Termination  
During the phase III evaluation, there will be reviews of both interim safety and efficacy results by an independent DSMB. The DSMB may recommend early termination of randomization to a particular investigational agent if there are safety concerns, or if efficacy of the agent versus placebo has been established, or if there is evidence that the agent has limited efficacy versus placebo (see section 10.5
 for more 
details).  
 
3.2 Overview of Study Design for Graduation from Phase II to Phase III  
 The following sections apply to investigational agents that have not been assessed for graduation to phase III in prior versions of the protocol.  
 28 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
Each investigational agent that is being considered for evaluation in phase III will be evaluated for safety, for activity in reducing COVID -19 symptoms and 
hospitalization/death, and for activity in reducing SARS -CoV-2 RNA shedding. An 
analysis to determine if an agent should graduate from phase II, and enter phase III, will be conducted when 220 participants assigned to the agent or concurrent placebo in phase II evaluation have completed their Day 7 evaluations and have the required data available in the database.   
The DSMB will review unblinded data and make recommendations to NIAID (as trial 
sponsor) and to the TOC, indicating whether graduation criteria have been met (see below for criteria). The recommendation for an agent to enter phase III evaluation will be made by the TOC in discussion with the company. The collaborating company that is responsible for the agent will decide whether to adopt the recommendation. The TOC 
and collaborating company will also consider which dose to recommend for evaluation in 
phase III, for investigational agents with more than one dose under evaluation in phase II. NIAID/DAIDS, as the sponsor of the study, will make the final determination regarding graduation of the study product.  
 The TOC may recommend an agent move directly into phase III, without evaluation in 
phase II in ACTIV -2, if there is sufficient safety and efficacy data supporting phase III 
evaluation available from outside of the trial. These agents will not undergo graduation 
analyses.  
 
Criteria for Graduation of an Agent from Phase II to Phase III 
Graduation of an investigational agent from phase II to phase III evaluation will be based 
on there being a desired level of evidence of an effect of an investigational agent versus placebo on one or more virologic and clinical outcome measures, as well as safety, as described below. The level of evidence required for the virology and clinical measures for agents evaluated in phase II of this protocol will be expressed in terms of Bayesian probability statements of the following form: 
 
Probability (agent is better than placebo by at least X) is greater than 0.6 where X is defined below for each outcome measure. The choice of 0.6 for this probability indicates that there is a 3 to 2 odds of the agent being better than placebo for that parameter. As there is considerable uncertainty about the association between phase II outcomes and 
the phase III outcome of hospitalization or death, graduation will be considered if this 
probability statement is met for any one of the virology and symptom /clinical  outcome 
measures listed below (i.e., it does not need to be met for all outcome measures listed).  Virology: The virology -based graduation guideline for an investigational agent to be 
eligible for phase III evaluation will be evidence of any one of the following:  
1. Higher absolute proportion of participants with SARS -CoV -2 below the assay LLoQ 
in NP swabs by at least 20% at one or more of the scheduled in-person 
measurement times (e.g., 60% for placebo and 80% for investigational agent at day 
 29 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 7) as compared to placebo (i.e., X in the probability statement above is an absolute 
20% increase for this outcome); or  
2. A decrease in median SARS-CoV -2 RNA levels in NP swabs of at least 0.5 log 10 
copies/mL at one or more of the scheduled in-person measurement times as 
compared to placebo (i.e., X in the probability statement above is 0.5  log 10 
copies/mL) (measurements after day 7 are not considered as a majority of 
participants are expected to be undetectable after day 7); or  
3. A relative reduction in median area under the curve measure (AUC) of SARS -CoV -2 
RNA levels in NP swabs through study day 7 of at least 20%, as compared to 
placebo (i.e., X in the probability statement above is a relative 20% reduction) . 
 
The absolute difference of 20% in (1) and the 0.5 log 10 copies/mL difference in (2) were 
surpassed in a comparison of monoclonal antibody treatments in trials for persons with 
COVID -19 [21, 23, 24]. The threshold used in (3) also seems achievable based on the 
same studies, although the AUC outcome was not formally evaluated in those tr ials. 
 Clinical: The clinical/symptom -based graduation guideline for an investigational agent to 
be eligible for phase III evaluation will be a relative reduction of at least 40% in the proportion of participants with either moderate or severe symptoms reported at day 7 (of the targeted symptoms in the participant diary) or have been hospitalized or died on or 
before Day 7 (i.e., X in the probability statement is a relative 40% reduction).  
 
Safety: Graduation to phase III will also depend on an acceptable safety profile, as 
determined by the DSMB. This decision will largely be based on differences in the frequency of Grade 3 and Grade 4 AEs between participants receiving the 
investigational agent and those receiving placebo. 
 
Phase III Entry 
Once an investigational agent has met criteria for entry into phase III, the agent may enter phase III. Data from phase II will NOT contribute to phase III outcomes.   
See appendices for additional details on graduation procedures relevant for each 
investigational agent.  
 
3.3 Considerations Regarding the Sharing of Comparator Group for Evaluating Multiple Investigational Agents  
 
To speed evaluation of multiple investigational agents, the study uses a comparator group that includes participants who received placebo in phase II, or the active comparator in 
phase III (under protocol Version 7) or placebo in phase III under the current 
protocol version. The selection of participants in the comparator group for evaluating a specific agent follows two key principles: (1) they must have been eligible to receive the 
specific agent of interest; and (2) they must have been concurrently randomized with the 
group of participants who received the specific agent of interest in the same phase (II or III) of evaluation. The randomization system  is complex, but has been designed to fulfill 
these principles and, in doing so, also allows for a comparator group that will have 
 30 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 approximately the same sample size and characteristics (including by the randomization 
stratification factor) as the group of participants receiving a specific agent.  
 
 Figure 3.3-1 provides  an illustration of how the randomization system  works  for the 
situation in which  there are five agents  in phase  II evaluation. The figure shows  how the 
randomization might occur  for 300 lower risk participants.  The choice of 300 participants  
for this illustration is arbitrary. The system  uses  two randomizations. The first 
randomization is to an “agent group”  and is not blinded because it is not practical  to blind 
mode of administration of an agent. The second randomization is within each agent 
group and is to active agent or associated placebo and is double-blind. Of note, the ratio 
of the second randomization to active agent or placebo depends  on the number of 
agents  in the same  phase of evaluation that a participant was eligible  to receive. The 
choice of this ratio provides  the mechanism  for achieving similar  sample sizes for the 
pooled placebo control  and active agent for a given agent group. A similar  process  is 
used for randomization in phase III, with enrollment restricted to those at higher  risk for 
progression to hospitalization or death.  
 
The platform design also needs to be flexible with regard to potential differences in study popul ati
on eligible for randomization to different agents, for example due to safety or 
polypharmacy issues. As an example, if some participants are eligible to receive Agent A 
but not Agent B, then the randomization is structured to allow randomization of these 
participants to Agent A or control  only. In this case, these participants would not be 
considered as part of the control group for evaluating Agent B since their inclusion in this 
comparison could introduce bias.  
 
The combining of placebo groups to construct the control placebo group for a given 
agent has the caveat that placebo effects might vary among the placebos  for different 
investigational agents, for example, related to mode of administration. The study team 

 31 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 considers that the risk of differential placebo effects on objective outcome measures 
such as the virologic outcome measures or hospitalizations (driven primarily by hypoxia) and deaths is likely very low. It is recognized that participants might possibly score symptoms of COVID -19 (in participant symptom diaries) differentially according to 
mode of administration of an agent, but the study team believes the risk is low.  
 
Isolation Procedures  
Given that SARS -CoV -2 is spread through respiratory secretions, each site must 
develop procedures to protect study staff and participants in other trials from infectious 
exposure. Each site will have a plan for appropriate protection by providing PPE, setting 
up isolation rooms, and providing special access points or contact with study participants, including the possibility for home or other non-clinic in -person visits. Each 
site will develop their own set of procedures for such participant contact. Guidance for the sites can be found in the Manual of Procedures (MOP S). 
 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS 
 4.1 General Eligibility Criteria 
 
4.1.1 Inclusion Criteria 
 
4.1.1.1 Ability and willingness of participant (or legally authorized representative) to provide informed consent prior to ini tiation of any 
study procedures . 
 
4.1.1.2 Individuals ≥18 years of age.  
4.1.1.3 Documentation of l aboratory -confirmed SARS- CoV-2 infection, as 
determined by a molecular (nucleic acid) or antigen test from any 
respiratory tract specimen (e.g., oropharyngeal, NP, or nasal swab, or 
saliva) collected ≤240 hours  prior to study entry.  Laboratory-confirmed 
SARS-CoV-2 infection outside the US must be conducted at a 
DAIDS -approved laboratory. 
 
4.1.1.4 Participants must be expected to begin study treatment no more than 7 days from self-reported onset of COVID-19-related symptoms  or 
measured fever, where the first day of symptoms is considered symptom day 0 and defined by the self-reported date of first reported 
sign/symptom  from the following list:  
• Subjective fever or feeling feverish  
• C ough 
• Shortness of breath or difficulty breathing at rest or with activity  
• Sore throat 
• Body pain or muscle pain/aches  
• F atigue  
 32 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 • H eadache 
• C hills 
• N asal obstruction or congestion  
• N asal discharge 
• L oss of taste or smell  
• N ausea or vomiting 
• D iarrhea 
• D ocumented temperature > 38°C  
 
4.1.1.5 O ne or more of the following signs/symptoms present within 24 hours 
prior to study entry : 
• Subjective fever or feeling feverish  
• C ough 
• Shortness of breath or difficulty breathing at rest or with activity    
• Sore throat 
• Body pain or muscle pain/aches  
• F atigue  
• H eadache 
• C hills 
• N asal obstruction or congestion  
• N asal discharge 
• N ausea or vomiting 
• D iarrhea 
• D ocumented temperature >38°C  
 
4.1.1.6 The participant has attempted to obtain SARS -CoV -2 treatment 
with an FDA or equivalent authorized or approved therapy (such as 
nirmatrelvir/ritonavir, remdesivir, anti-SARS -CoV-2 monoclonal 
antibodies, or molnupiravir) for the current SARS -CoV -2 infection 
and has not been able to receive it or , after being offered a 
treatment, has declined it for a clear reason as provided by the 
participant (such as refusal to receive a three-day IV course, concern about side effects, or distance required to travel for 
treatment).  
 
4.1.1.7 Agrees to not participate in another clinical trial for the treatment of 
COVID -19 or SARS- CoV-2 during the study period until reaching 
hospitalization or 28 days  post-entry , whichever is earliest. 
 
4.1.1.8 Additional inclusion criteria as appropriate for the investigational agent (see relevant appendix/appendic es). 
 
 33 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 4.1.2 Exclusion Criteria  
 
4.1.2.1 History of or current hospitalization for COVID-19. 
 
4.1.2.2 For the current SARS -CoV -2 infection, a ny positive SARS -CoV -2 nucleic 
acid or antigen tests from any respiratory tract specimen (e.g., 
oropharyngeal, NP, or nasal swab, or saliva) collected ˃240 hours prior 
to study entry . 
 
4.1.2.3 Current need for hospitalization or immediate medical attention in the clinical o pinion of the site investigator .  
 
4.1.2.4 Use of any inhaled steroids for the purpose of COVID-19 treatment (new or increased dose from chronic baseline) within 7  days prior to 
study entry.  
 
4.1.2.5 Resting oxygen saturation <92% (adjusted as needed for altitude, see guidance in the protocol MOP S) as measured by study staff 
within 24 hours prior to study entry. For a potential participant who regularly receives chronic supplementary oxygen for an 
underlying lung condition their oxygen saturation should be 
measured while on their standard home oxygen supplementation level.  
 
4.1.2.6 Receipt of SARS -CoV-2 treatments ( investigational, authorized, or 
approved, such as nirmatrelvir/ritonavir, remdesivir, fluvoxamine, or 
molnupiravir)  for SARS -CoV -2 within 7 days prior to study entry or 
receipt of any antibody-based SARS -CoV -2 treatment or prophylactic 
therapy within 90 days prior to study entry.  
 
4.1.2.7 Known allergy/sensitivity or any hypersensitivity to components of the 
investigational agent or placebo. See relevant appendix.  
 
4.1.2.8 Any co -morbidity requiring surgery within 7 days prior to study entry, or 
that is considered life threatening in the opinion of the site investigator 
within 30 days prior to study entry.  
 
4.1.2.9 Additional exclusion criteria as appropriate for the investigational agent (see relevant appendix/appendices).  
 4.2 Study Enrollment Procedures  
 
All sites will be registered through the DAIDS Protocol Registration Office (DAIDS PRO) 
at the Regulatory Support Center (RSC)
 by PPD.  
 
Prior to implementation of this protocol, and any subsequent full version amendments, 
 34 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 each site must have the protocol and the protocol consent form(s) approved, as 
appropriate, by the institutional review board (IRB)/ethics committee (EC) and any other applicable regulatory entity (RE) responsible for oversight of the study.  
 
Upon receiving final approval, PPD on the site’s behalf will submit all required protocol 
registration documents to the DAIDS PRO at the RSC. The DAIDS PRO will review the  submitted protocol registration packet to ensure that all of the required documents have been received.   
Site-specific informed consent forms (ICFs) will be reviewed and approved by the DAIDS 
PRO, and sites and PPD will receive an Initial Registration Notification from the DAIDS PRO. A copy of the Initial Registration Notification should be retained in the site's regulatory files.  
For amendments, sites will receive a notification letter from PPD with instructions to sites 
prior to implementation. Upon receiving final IRB/EC and any other applicable RE 
approvals for an amendment, sites should provide the necessary approvals to PPD.   PPD will submit amendment registration packets to the DAIDS PRO at the RSC on behalf of the sites. The DAIDS PRO will review the submitted protocol registration packet to 
ensure that all required documents have been received. For  full version protocol 
amendments , sites must receive the initial registration notification for the amendment from 
the DAIDS PRO  prior to implementing the amendment.
 Site-specific ICF(s) will be reviewed 
by the DAIDS PRO if the s ite ICF was not submitted as part of the prior registration.  
 
Sites and PPD will receive an Amendment Registration Notification when the DAIDS 
PRO receive s a complete registration packet. The first notification will be based on 
receipt of minimal document requirement, which allows sites to start the implementation of the amendment. A final notification will be sent to sites and PPD once the entire registration packet review has been completed. A copy of the Amendment Registration Notification should be retained in the site's regulatory files.  
 For additional information on the protocol registration process and specific documents required for initial and amendment registrations, refer to the current version of the DAIDS Protocol Registration Manual.   
4.2.1 Protocol Activation  
 
PPD will be responsible for site activation for both ACTG and non-ACTG sites.  
 
4.2.2 Randomization 
 
Participants  who meet the enrollment criteria will be randomized to the study 
through the IRT (Interactive Response Technology) system.  
 
4.3 Co-enrollment Guidelines   
 35 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
Co-enrollment in an observational study or the ACTG REPRIEVE study (ACTG 5332) is 
allowed and does not require permission from the A5401 protocol chairs, as long as 
ACTG network blood collection limits are not exceeded, that is , 450 mL over 8 weeks . 
 
Co-enrollment in an interventional study following hospitalization for COVID-19 or after 28 days 
post-entry (Day 29 onward) for the treatment of COVID -19 or its complications is allowed. 
 For specific questions and approval  for co-enrollment in other studies, sites should follow 
the directions  described i n the Study Management section
. 
 5.0 INVESTIGATIONAL AGENT  
 
For Phase II, study  treatment is defined as any active investigational agent and an 
appropriate placebo identified by the TOC for use in this study.  For Phase III, study  treatment is defined as any active investigational agent and placebo 
for the investigational agent . 
 
5.1 Regimen, Administration, and Duration 
 
See relevant appendix/appendices for details of investigational agents  and placebo 
comparators in phases  II and III.  
 5.2 Formulation, Storage, and Preparation 
 
See relevant appendix/appendices for details of investigational agents  and placebo 
comparators in phases  II and III.  
 5.3 Supply, Distribution, and Accountability  
 
See relevant appendix/appendices for details of investigational agents  and placebo 
comparators in phases  II and III.  
 5.4 Concomitant Medications  
 
Whenever a concomitant medication or investigational  agent is initiated or  a dose 
changed, investigators must review the concomitant medications and the relevant protocol appendix/appendices , as well as the most recent package insert, Investigator’s  
Broch ure, or updated information from DAIDS to obtain the most current information on 
drug interactions, contraindications, and precautions.   
All medications given as treatment for COVID -19 must be recorded on an eCRF.   
 
Additional drug information may be found on the ACTG Precautionary and Prohibited 
Medications Database located at http://tprc.pharm.buffalo.edu/home/di_search/. 
 36 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
5.4.1 Prohibited Medications  
 
See relevant appendix/appendices  for prohibited medications, if applicable. 
 
5.4.2 Precautionary Medications  
 
See relevant appendix/appendices  for precautionary medications, if applicable.  
 37 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
See appendix/appendices for additions  to the following clinical and laboratory evaluations. Specific evaluations, including 
physical assessments, laboratory tests or stored samples, may no longer be required (as determined by the protocol team), 
provided that they are not clinically relevant to the primary evaluation of safety and efficacy of the agents under investigation. 
 
6.1 Schedule of Evaluations  
 
Table 6.1-1: Schedule of Evaluations Phase II 
 Note that participants are followed through 72 weeks for all agents except bamlanivimab, for which participants are  
followed through 24 weeks . 
 
 
Phase II Evaluation  
Screening  
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Documentation of  
SARS -CoV-2 Infection  X             
COVID -19 Symptom Screen X X            
Medical/Medication History  X X            
Smoking Status   X            
Weight   X             
 38 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Phase II Evaluation  
Screening  
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Physical Exam   X            
Targeted Physical Exam    X X X X  X    X X 
Concomitant Medications    X X X X X X X X X X X 
Assessment for Adverse Events   X X X X X X X X X X X X 
Collect/Update Secondary Contacts   X X X X X X       
Vital Status Check   If Participant Cannot be Reached per section 6.3.8    
Investigational Agent  Administered   Per Appendix for Investigational Agent       
Study Kit Dispensed   X            
Participant -Completed Study Diary   Every Day through Day 28         
Study Diary Reminder   Days 1 - 28        
Staff Review of Study Diary   X X X X X      X  
Retrieval of Study Diary       X      X  
Post-Acute COVID -19 Assessment        X X X X X  X 
Household Infection and Linkage 
Report   X    X      X  
Staff-Collected N asopharygeal  Swab  X X X X       X  
 39 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Phase II Evaluation  
Screening  
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Hematology   Per Appendix for Investigational Agent  
Chemistry   Per Appendix for Investigational Agent  
Pregnancy Testing  Per Appendix for Investigational Agent  
Pharmacokinetics   Per Appendix for Investigational Agent  
Stored Plasma  X  X  X  X    X X 
Stored Serum   X  X  X  X    X X 
Stored PBMCs (Selected Sites)   X  X  X  X    X X 
 
  
 40 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Table 6.1-2 : Schedule of Evaluations Phase III  
 
Note that participants are followed through 72 weeks for all agents except bamlanivimab, for which participants are followed through 24 weeks.  
 
Participants who received casirivimab plus imdevimab under protocol Version 7 will follow this SOE  through end of 
study.  
 
Phase III Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C 
(Before Day 28)  
Premature Study D/C 
(After Day 28)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Documentation of  
SARS -CoV-2 Infection  X             
COVID -19 Symptom Screen X X            
Medical/Medication History  X X            
Smoking Status   X            
Weight  X             
Physical Exam   X            
Targeted Physical Exam    X   X  X    X X 
Concomitant Medications    X X X X X X X X X X X 
Assessment for Adverse Events  X X X X X X X X X X X X X 
 41 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Phase III Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C 
(Before Day 28)  
Premature Study D/C 
(After Day 28)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Collect/Update Secondary Contacts   X X X X X X       
Vital Status Check   If Participant Cannot be Reached per section 6.3.8    
Investigational Agent /Comparator 
Administered   Per Appendix for 
Investigational Agent          
Study Kit Dispensed   X            
Participant -Completed Study Diary   Every Day through Day 28         
Study Diary Reminder   Days 1 - 28        
Staff Review of Study Diary   X X X X X      X  
Retrieval of Study Diary       X      X  
Post-Acute COVID -19 Assessment        X X X X X  X 
Household Infection and Linkage 
Report   X    X      X  
Staff Collected Nasopharyngeal 
Swab   X X           
Hematology   X X   X      X  
Chemistry   X X   X      X  
Pregnancy Testing  X Whenever Pregnancy Suspected    
 42 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Phase III Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C 
(Before Day 28)  
Premature Study D/C 
(After Day 28)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Pharmacokinetics   Per Appendix for Investigational Agent  
Stored Plasma  X X   X  X    X X 
Stored Serum   X X   X  X    X X 
 43 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 6.2 Timing of Evaluations  
 
6.2.1 Screening Evaluations  
 
Screening evaluations must occur prior to the participant starting any study 
medications, treatments, or interventions. 
 
Screening and study entry visit evaluations may be combined unless not allowed per the relevant appendix/appendices. If feasible , screening evaluations may 
occur remotely.  
 Study entry visit evaluations must be done prior to administration of study agent.   
6.2.2 Entry Evaluations  
 
Entry evaluations must occur ≤48 hours after screening evaluations unless otherwise specified.  
 Participants must be expected to begin study treatment no more than 7 days 
from self-reported onset of COVID-19 related symptoms or measured fever  as 
noted in section 4.1.1.4
. 
 
6.2.3 Post-Entry Evaluations  
 
On-Treatment/Post-Treatment Evaluations   
Evaluations should occur in the visit windows described in Tables 6.1-1  and 6.1-2 . 
 
Study Completion Evaluations   
Week 72 evaluations will serve as the study completion evaluations (except for bamlanivimab, where Week 24 evaluations will serve as the study completion evaluations).  
 
6.2.4 Event-Driven Evaluations  
 
See relevant appendix/appendices for details of any event-dr iven evaluations. 
 
6.2.5 Discontinuation Evaluations  
 
Evaluations for Randomized Participants Who Do Not Start Investigational 
Agent/ Comparator  
All eCRFs must be keyed for the period up to and including the entry visit . 
Participants who were randomized but do not start investigational agent or 
comparator will be prematurely discontinued from the study and will not be 
followed. 
 
 44 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Premature Treatment Discontinuation Evaluation s  
Participants  who discontinue investigational agent or comparator early should 
remain on study and all evaluations should be performed as outlined in Tables 
6.1-1  and 6.1-2. 
 
Premature Study Discontinuation Evaluations  
Participants who discontinue study participation should have premature study 
discontinuation evaluations, as outlined in Tables 6.1-1  and 6.1-2 and the 
relevant appendi x/appendices, prior to  being taken off the study, unless the 
reason for premature study discontinuation was that they did not start investigational agent or comparator . 
 
6.3 Instructions for Evaluations  
 
Sites must follow PPD source document guidelines.  
 
All evaluations below are for both Phase II and III unless otherwise noted.  All stated evaluations are to be recorded on the eCRF unless otherwise specified. Refer to section 7.0
 for information on reporting of adverse events . 
 
In the event of hospitalization, targeted physical examination, study diary entry and 
review, and specimen collection do not need to be completed during hospitalization but 
should be restarted after discharge. Other evaluations should be performed as feasible, including ascertainment of interventions, including medications received, and outcomes of interest/study endpoints.  
 
Location of Study Visits  
Sites should, in discussion with participants, determine the most appropriate place to conduct study visits, whether in-person or remote.   In person visits will take place at the clinic, at the participant’s home, or at another non-
clinic location if the site is able to accomplish all of the scheduled study visit evaluations. 
 Remote visits can take place over the phone or via telemedicine systems approved for use at the site.  
 
6.3.1 Documentation of SARS-CoV -2 Infection  
 Section 4.1.1.3 
specifies assay requirements for SARS -CoV-2 infection 
documentation. SARS-CoV -2 infection documentation is recorded on the eCRF. 
If a viral load level is available, it should be recorded as well. 
 See the MOP S for further guidance.  
 
 45 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 6.3.2 COVID -19 Symptoms   
 
COVID -19 Symptom Screen 
Participants will be asked about their first symptoms related to COVID -19 and 
their current s ymptoms.  
 
The date of symptom onset and time from symptom onset at anticipated study entry (in days, including ≤5 days versus >5 days in phase II) should be recorded.  
6.3.3 M edical History  
 At Screening and updated at Study Entry , a complete medical history for the 
preceding 120 days should be recorded. Additionally,
 the following diagnoses 
should be recorded regardless of when the diagnosis was made, except where 
noted:  
• Autoimmune disease  
• Pulmonary embolus  
• Deep venous thrombosis  
• HIV infection 
• Cancer (exclusive of basal/squamous cell skin cancer)  
• Acute viral respiratory infection (influenza, parainfluenza, respiratory syncytial 
virus, rhinovirus) within the previous 14 days (if known by participant)  
• Chronic lung disease  
• Asthma requiring daily  inhaled medication  
• Obesity (body mass index [BMI] >35; may be based on self -report of height 
and weight)  
• Hypertension 
• Cardiovascular disease  
• Diabetes  
• Chronic kidney disease  
• History of cirrhosis   
• Exogenous or endogenous immunosuppression  
 
The participant’s risk category for progression to hospitalization or death (“high er” 
vs. “low er” risk) should be recorded. If participant meets the criteria for “higher ” 
risk, all higher risk criteria that are met should be recorded.  
 
Any allergies to any medications and their formulations must also be documented.  
 
See appendix/appendices for additional elements of the medical history that should be recorded.  
 
 46 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 6.3.4 Medication History  
 
A medication history must be present, including start and stop dates. The table 
below lists the medications that must be included in the history at screening and 
updated at entry.  
 
Table 6.3.4-1: Medication History  
Medication/Category  Timeframe  
All prescription drugs  Last 7 days  
Corticosteroids, a nabolic steroids  Last 30 days  
Prescription drugs for high blood pressure  Last 3 months  
Prescription drugs for diabetes and pre -diabetes  Last 3 months  
Prescription drugs for lung disease  Last 3 months  
Prescription drugs for heart disease  Last 3 months  
Prescription drugs for autoimmune disease  Last 3 months  
Cancer chemotherapy  Last 3 months  
Antiretroviral therapy  Last 3 months  
Immune -based therapy  Last 3 months  
Blinded investigational agent  Last 12 months  
CoV-related vaccines or treatments  Complete history  
Hydroxychloroquine  Complete history  
Antibiotics  Last 3 months  
Anti-parasitics  Last 3 months  
Alternative therapies  Last 3 months  
Dietary supplements  
(including zinc and vitamins C and D) Last 3 months  
 
6.3.5 Smoking Status  
 
A Smoking Status questionnaire will be completed as part of medical history and recorded on the eCRF.   
6.3.6 Clinical Assessments  
 
Weight 
Weight is measured per the SOE .  
 
Physical Exam  
Perform physical exam, including cardiac exam, pulmonary exam, and vital signs 
(temperature, pulse, blood pressure, and resting peripheral oxygen saturation). 
 
Targeted Physical Exam  
Perform a targeted physical examination per the SOE and at other visits  not 
listed here if required for specific agents (see appendix/appendices).  
 47 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
A targeted physical examination includes vital signs (temperature, pulse, blood 
pressure, and resting peripheral oxygen saturation) and examinations  driven by 
any previously identified or new adverse event/targeted condition that the 
participant has experienced.  
 
Supplemental oxygen use will be recorded at each visit at which vital signs are 
recorded.  
 
At study entry, if peripheral oxygen saturation is <92% on usual supplemental 
oxygen requirements, and if indicated based on the investigator’s clinical 
assessment, the participant should be referred for emergency department 
evaluation and should not initiate investigational product.   
Post-entry , peripheral oxygenation saturation measures < 96% should be reviewed by an 
investigator and referral for medical attention made at the discretion of the investigator. 
 
See appendix/appendices for  any additional elements needed for the targeted exam. 
 
Post entry, see section 8.3
 for collection requirements for pregnancy.  
 
Concomitant Medications  
Post entry, the following new and discontinued concomitant medications must be recorded:  
• High blood pressure medications  
• Steroids or other immunosuppressive or immunomodulatory medication 
• Non-steroidal anti -inflammatory drugs (NSAIDS) 
• Chemotherapy  
• Antibiotics, antifungals, antiparasitics , and antivirals (including antiretrovirals)  
• Anticoagulants  
• Antiplatelets  
• Any approved or investigational agent felt to have potential COVID -19 activity 
(including remdesivir, sotrovimab and other  anti-SARS -CoV-2 monoclonal 
antibodies, convalescent plasma, fluvoxamine, nirmatrelvir/ritonavir, 
molnupiravir, hydroxychloroquine, chloroquine, ivermectin, HIV protease 
inhibitors , and SARS- CoV-2 vaccines ) 
• Inhalers  
• Medications for symptoms of COVID -19, including aspirin, ibuprofen, 
acetaminophen, zinc, dietary supplements, herbal remedies, decongestants, 
cough suppressants, and antihistamines.  
 
Assessment for Adverse E vents  
Beginning at  entry, participants will be assessed at every visit  (remote or in-
person) for any new signs or symptoms and the relationship to study treatment. 
 
 48 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 6.3.7 Collec t/Update Secondary Contacts  
 
Sites will capture contact information for at least two individuals that the site can contact if the participant cannot be reached ( e.g., spouse, friend, neighbor). Sites 
will also request health care provider contact information and hospital (s) that the 
participant is likely to go to if they get sick.  
 Contact information for secondary contacts or health care provider will not be recorded on any eCRF. 
 
At study entry only, sites will record the participant’s home address in site records (it will not be reported on an eCRF).  
 
6.3.8 Vital Status Check  
 
If a participant cannot be reached after two attempts 24 hours apart, then their listed secondary contact person(s) or health care provider will be contacted for a check of the participant’s vital status  and study endpoints. In addition, for 
participants who prematurely discontinue for reasons other than withdrawal of consent or non-initiation of investigational product, or at any time the site 
becomes aware of a potential hospitalization or death after the participant 
discontinued study, site personnel should attempt to obtain information on the vital status of the participant and study endpoints as outlined in the MOP S. 
 Vital status contacts and other reported information should be recorded on the 
eCRFs.  
 
6.3.9 Investigational Agent Administered 
 
See relevant appendix /appendices  for dispensing/administration details.  
 Post entry, record any initial dose of treatment, modification to treatment, 
treatment interruption, and permanent discontinuation of treatment, and the reason for the modification, interruption, or discontinuation. 
 
6.3.10 Study Kit Dispensed  
 The kit will include:  
• Copy of informed consent 
• Information about the study  
• Instructions on study procedures  
• Pocket/wallet card with site staff contact information 
 49 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 • Instructions on what to do if participants  have worsening symptoms/become 
hospitalized  
• Study diary (see below)  
 
6.3.11 Study Diary  
 
Participant- Completed Study Diary  
Participants will be asked to keep a log of symptoms, medications they are taking 
for COVID -19 symptoms, and major events such as urgent visit to an emergency 
room or clinic and hospitalization in their study diary. This log will be completed on paper or e lectronically if appropriate electronic systems are available.  
 At study entry, participants will complete the study diary with site staff prior to 
initiating investigational agent/placebo. Participants will be asked to complete 
subsequent entries per the SOE . The diary should be completed at 
approximately the same time every day .  
 If the day 28 visit occurs on study day 28, then the day 28 study diary may be 
completed with the site staff during the day  28 visit, otherwise it should be 
completed by the participant on study day 28.  
 
Study Diary Reminder and Staff Review of Study Diary  
Participant will be contacted every day on days 1-28 and reminded to complete 
their study diary. This reminder may be by telephone, text message, email, or 
other method for which the participant provides permission. A direct response 
from the participant is not required.  
 The study  diary will be reviewed by study staff in person or remotely with each 
participant according to the schedule in Tables 6.1-1  and 6.1-2
. If an appropriate 
electronic system is available, the participant’s diary entries will automatically be captured in the eCRF. If such a system is not available, the study staff will record 
the participant’s answers on the study diary eCRF. If the participant uses a paper 
diary and it is feasible, prior to or during the remote study visits, sites will ask the participant to send images of each of their study diary entries to be reviewed at the next study contact. See MOPS for requirements for timely eCRF entry of 
diary data.  
 Participants who report worsening symptoms  from any cause during the trial may 
be referred to their health care provider or closest emergency room. Such  instances will be recorded at the time of the notification, and during follow -up to 
assess study endpoints, i.e., hospitalization or death. 
 
Retrieval of Study Diary  
If the participant uses a paper diary , the study diary should be collected following 
the current Diary Completion Guidelines  on the A5401 PSWP. See MOPS for 
additional instructions on retrieval of Study Diary.  
 50 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
6.3.12 Post-Acute COVID -19 Assessment  
 
If a diary in appropriate language is available, participants will be asked about 
potential COVID -19-related symptoms and diagnoses experienced after day 28 
using standardized questionnaires (the Participant Study Diary - Long Term 
Follow Up and EQ -5D-5L and SF-36v2 instruments). 
 
6.3.13 Household Infection and Linkage Report 
 
At Study Entry/Day 0, participants will be asked if anyone who resides in their 
household, defined as sharing indoor living space or housekeeping space (i.e., kitchen, dining area, or bathroom) has been diagnosed with SARS -CoV-2 
infection or are also enrolled in the study , and the response recorded on the 
eCRF. If a household member is enrolled in the study, the participant ID for the first household member enrolled into the study  will be recorded.  
 Post entry, participants will be asked if any new househ old members have been 
diagnosed with SARS -CoV-2 infection, and the response recorded on the eCRF.  
 
6.3.14 Virologic Studies  
  
NP swabs will be collected by site staff. NP swabs can be collected outside of a 
clinic setting (e.g., home). At study entry, the swab sample should be collected prior to the first dose of investigational agent/comparator . NP swabs  will be 
collected for quantitative SARS- CoV-2 RNA, performed in near real -time , and 
other virology performed later .  
 
Additional information can be found in the MOP S and the LPC.  
 
6.3.15 Laboratory Evaluations  
 The following laboratory evaluations are for all investigational agents. If additional measures are needed, these are detailed in the relevant investigational agent appendix.  
 
Refer to the LPC for details of collection, processing, and shipping.  
At screening, entry, and post-entry , all laboratory values must be recorded unless 
otherwise specified in the relevant appendix/appendices.  
  
At study entry, blood samples should be collected prior to initiation of the 
investigational agent. 
 
Blood can be collected outside of a clinic setting (e.g., home). 
 
 
 51 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Hematology  
Participants will have blood drawn for complete blood cell count (CBC) with 
automated differential and platelet count.   
At Entry/Day 0, blood should be drawn before study drug administration.  
 
Chemistry  
Participants wil l have blood drawn for liver function tests (ALT, ALP, AST, total 
bilirubin, direct bilirubin, and total protein), and renal function tests (albumin, 
BUN, creatinine, potassium, glucose, and sodium).  
 
At Entry/Day 0, blood should be drawn before study drug administration.  
 
Pregnancy Testing  
For participants of reproductive potential: Serum or urine β-HCG. (Urine test 
must have a sensitivity of ≤25 mIU/mL.) 
 
Post-screening, pregnancy testing should be done any time pregnancy is 
suspected.  
 In the event of pregnancy occurring during the study, record pregnancy on an eCRF and record pregnancy outcome per section 8.3
. 
 
6.3.16 Pharmacokinetics  
 Pharmacokinetic sampling will be performed per the relevant appendix/appendices.  
 
6.3.17 Stored Samples  
 
Collected plasma, sera, or PBMC will be used to assess SARS -CoV -2 virologic 
and immune responses. All Entry/Day 0 samples should be collected prior to the 
first dose of investigational agent/placebo. Additional samples will be collected for agent-specific evaluations per the relevant appendix/appendices.  
 
Stored Plasma  
Blood plasma will be collected and stored for future testing, including: 
• Immunologic studies including markers linked to systemic inflammation (IL-6, 
TNF-a), inflammasome activation (IL- 1beta, IL-18), interferon pathways (IP -
10, type I interferon), neutrophil activation (MPO), monocyte activation 
(sCD14), as well as markers associated with coagulation or endothelial cell dysfunction (VWF, P -selectin, tissue factor) 
• SARS- CoV-2 sero conversion and antibody titers (among seroconverter s) 
• Quantitative SARS -CoV-2 RNA  
 52 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 • Full viral genome sequencing will be performed from select samples that are 
detectable for SARS- CoV-2 RNA to assess for signs of viral evolution and 
resistance to the investigational agent or immune responses. If sequence 
analysis suggests viral escape from the investigational agent (e.g., mutations in 
putative binding regions or epitopes), then phenotypic analyses may be pursued.  
 
Stored Serum  
Blood sera will be collected and stored for future testing, including:  
• Total and neutralizing antibody assays  
 
Stored Peripheral Blood Mononuclear Cells (PBMCs)  
PBMCs will be collected only at select sites. PBMC processing must be done in an IQA -approved lab. PBMCs will be stored for future testing, which may include 
the following : 
• Cellular immune responses between treatment and control samples, 
including assessment of T-cell  responses  to SARS-CoV -2 protein  
• Cellular activation/exhaustion phenotypes among innate or adaptive immune cells  
• Host genetics  
 
7.0 ADVERSE EVENTS AND STUDY MONITORING 
 
See relevant appendix/appendices  for any modifications to recording of AEs and study 
monitoring.  
See the MOPS for further instructions on AE reporting.  
 
7.1 Definitions of Adverse Events  
 
Adverse Event 
An adverse event ( AE) is any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study  REGARDLESS of the attribution ( i.e., relationship of event to 
medical treatment/inv estigational agent/device or procedure/intervention) or clinical 
significance as determined by the site investigator . This includes any occurrence 
that is new in onset or aggravated in severity or frequency from the baseline condition. 
 
The scale used in the Study Diary for participant symptoms does NOT equate to the AE grading as found in the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017.  
Sites should grade participant symptoms according to the DAIDS AE Grading Table.  
 
Serious Adverse Events (SAEs)  
An SAE is defined as any untoward medical occurrence that results in any of the 
following outcomes: 
 53 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 • Results in death 
• Is life-threatening 
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect.  
• Is an important medical event that may not be immediately life threatening or result in 
death or hospitalization but may jeopardize the participant or may require 
intervention to prevent one of the other outcomes listed in the definition above). 
 
Adverse Events of Special Interest  
An adverse event of special interest ( AESI) (serious or nonserious) is defined as an AE 
or SAE of scientific and medical concern specific to the investigational agent, for which ongoing monitoring and rapid communication by the investigator to the sponsor could be appropriate.  
The following are AESIs for casirivimab plus imdevimab, although no further 
participants will be treated with casirivimab plus imdevimab:  
• Grade ≥2 infusion-related reactions  occurring within 12 hours of administration 
(deemed related to study product by the site investigator)  
• Grade ≥2 allergic/hypersensitivity  reactions  occurring within 12 hours of 
administration (deemed related to study product by the site investigator)
 
 
See appendix/appendices for AESIs related to specific investigational agents.  
 
Suspected Unexpected Adverse Events  
A Suspected Unexpected Serious Adverse Reaction ( SUSAR) is defined as a serious 
adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g. , Investigator ’s Brochure fo r an unapproved investigational 
product).  
 
7.2 Eliciting and Documenting Adverse Events  
 
Adverse events will be assessed beginning at Entry/Day 0 and through study completion 
or discontinuation. 
 
If the investigator learns of any SAE, including a death, at any time after a participant 
has been discharged from the study, and he/she considers the event to be reasonably related to the investigational agent or study participation, the investigator must promptly notify the sponsor.  Serious AEs that occur after study completion or discontinuation need not be reported 
unless the investigator considers them related to the investigational product.  
 At every study visit, participants will be asked a standard nonleading question to elicit any medically related changes in their well -being. They will also be asked if they have 
 54 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 been hospitalized, had any accidents, used any new medications, or changed 
concomitant medication regimens (both prescription and OTC medications).  Regardless of grade, AEs identified from any study data (e.g. , laboratory values, physical 
examination findings, or identified from review of other documents [e.g. , participant 
diaries ]) or reported by a participant that are relevant to participant safety , as 
determined by the site investigator , will be documented on the AE page in the eCRF. 
 7.2.1 Assessment of Severity  
 
The severity, or intensity, of an AE refers to the extent to which an AE affects the participant’s daily activities. 
 
All AEs that are reported must have their severity graded. To grade AEs, sites 
must refer to the Division of AIDS Table for Grading the Severity of Adult and 
Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can be found on the DAIDS RSC website at: https://rsc.niaid.nih.gov/clinical -research-sites/daids -adverse-event-grading-tables . 
 
7.2.2 Assessment of Causality  
 
If there is any doubt as to whether a clinical observation is an AE, the event should be reported.  The relationship or association of the investigational agent/placebo in causing or 
contributing to the AE will be characterized using the following classification and criteria:  
• Unrelated: There is no association between the investigational agent/placebo and the reported event.  
• Related: A causal relationship exists between administration of the investigational agent/placebo and the AE, and other conditions (concurrent illness, progression/expression of disease state, or concurrent medication reaction) do not appear to explain the event.  
 
7.3 Recording Adverse Events  
 Post entry, the following must be recorded on the eCRFs within 72 hours:   
• Grade 1 non-laboratory AEs through week 24 
• All G rade ≥2 AEs including laboratory AEs through week 72 (through week 24 for 
bamlanivimab)  
• AEs that led to a change in study treatment/intervention regardless of grade 
• AEs that are relevant to participant safety as determined by the site 
investigator, regardless of grade. 
 
 55 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Post entry, the following must be recorded on the eCRFs within 24 hours:  
• AEs meeting SAE definition  
• AESIs  
 
Information to be collected includes the following: • Study product group (investigational agent/comparator ) 
• Route of administration  
• Dose 
• Event term  
• Time of onset (if known)  
• Investigator- specified assessment of severity and relationship to the investigational 
product  
• Time of resolution of the event  
• Seriousness  
• Any required treatment or evaluations  
• Outcome  
 
Adverse events resulting from concurrent illnesses, reactions to concurrent illnesses, 
reactions to concurrent medications, or progression of disease states must also be reported. 
All AEs will be followed to adequate resolution. The MedDRA will be used to code all  AEs. 
 
Any medical condition that is present at the time that the participant is screened but does not deteriorate should not be reported as an AE. However, if it deteriorates at any time during the study, it should be recorded as an AE  with a descriptive modifier (e.g., 
“Exacerbation of,” “Worsening of,” “ Deterioration of”) the event. 
 
7.3.1 Reporting Serious Adverse Events  
 
Any AE that meets SAE criteria must be reported to PPD, Inc., immediately (i.e., within 24 hours of the time that the site personnel first learn about the event) by indicating on the Adverse Event eCRF within the Electronic Data Capture (EDC) system that s eriousness criteria is met and providing initial relatedness/causality.  
 
In the event the EDC electronic submission is not possible, a completed 
SAE/AESI report form along with written description of the serious  adverse 
experience must be sent to PPD PVG by facsimile within 1 business day after awareness of the event (see regional Fax numbers below). Please note, the 
event must be entered into EDC once access has been corrected.  
PPD Safety Reporting  Fax Number  
NA: +1 888 529 3580  
LA: +55 11 4504 4802  
EMEA/APAC: +44 (0)1223 374102  
  
 56 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 The following contact information is to be used for inquiries to determine if an 
event is reportable as an SAE:  
 
PPD Safety Hotline Phone Number  
NA (RTP): +1 888 483 7729 
LA: +55 11 4504 4801  
EMEA/APAC: +44 (0)1223 374240 
 
The sponsor has a legal responsibility to notify the US FDA and other regulatory agencies about the safety of an investigational product under clinical 
investigation. The sponsor will comply with country -specific regulatory 
requirements relating to safety reporting to the regulatory authority, institutional 
review board/independent ethics committee ( IRB/IEC ), and investigators. 
 An investigator who receives an investigator safety report or memorandum describing an SAE or other specific safety information from the sponsor will 
review and then file it as appropriate and will notify the IRB/IEC and local 
regulatory agencies, if appropriate according to local requirements. 
 
7.3.2 Reporting Adverse Events of Special Interest  
 
Any AE that meets AESI criteria (section 7.1)
 must be reported immediately (i.e., 
within 24 hours of the time that the site personnel first learn about the event) by 
indicating on the Adverse Event eCRF that AESI criteria are met. If electronic 
submission is not possible it can be submitted in the same manner as the back -
up manual SAE/AESI reporting process (section 7.3.1 ). 
 
Contact the PPD Safety Hotline Phone Number with any questions on 
reportability.  
 
7.3.3 Reporting Suspected Unexpected Serious Adverse Reactions  
 
The sponsor will promptly evaluate all S USARs  and nonserious AEs of special 
interest (defined in section 7.1 ) against cumulative product experience to identify 
and expeditiously communicate possible new safety findings to investigators, IRBs/IECs, and applicable health authorities based on applicable legislation. 
To determine reporting requirements for single AE cases, the sponsor will assess 
the expectedness of these events using the investigational agent Investigator ’s 
Brochure. 
 The sponsor will compare the severity of each SUSAR and the cumulative event frequency reported for the study with the severity and frequency reported in the applicable reference document. 
 57 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
Reporting requirements will also be based on the investigator's assessment of causality and seriousness, with allowance for upgrading by the sponsor as needed. 
 
7.4 Follow -up of Participants Reporting Adverse Events  
 
All AEs must be reported in detail on the appropriate page in the eCRF and followed to 
satisfactory resolution, until the investigator deems the event to be chronic or not 
clinically significant, the event is considered to be stable, or the participant is lost to 
follow -up. If an AE is ongoing at completion of participation in the study, only those that 
are investigational agent-related SAEs need continued follow -up to resolution or stability  
until 30 days past the last study visit . 
 
7.5 Study Monitoring 
 
The protocol team will monitor the conduct and safety of the study via regular summaries 
of accrual, study discontinuation, data completeness, and adverse events.  The DAIDS Clinical Representative will review and assess select AE reports for potential 
impact on the study participant safety and protocol conduct as per DAIDS policies, 
guidance documents, and SOPs as applicable.  
 
The DSMB will conduct interim reviews for safety. Enrollment will pause and the DSMB will review any death that occurs on study that is deemed related to study product as 
determined by the site investigator. A pause in enrollment for that study product group 
(investigational agent/placebo) will also occur and the DSMB will review  if two 
participants  experience a Grade  4 AE that is deemed related  to study  product as 
determined  by the site investigator. 
 See section 10.0
 for statistical and other considerations related to interim monitoring. 
 
Detailed plans for study monitoring are outlined in a Safety Management Plan.  See relevant appendix/appendices  for additional monitoring procedures.  
 
8.0 CLINICAL MANAGEMENT ISSUES 
 
The following guidance pertains to all investigational agents and casirivimab plus 
imdevimab; however, additional guidance for particular agents are included in the appendix relevant for each investigational agent. 
 8.1 Toxicity  
 
Criteria for participant management, dose adjustments and discontinuation, or changes in treatment will be described only for toxicities attributable to the investigational agent s, 
when applicable, and are included in the appendix/appendices.  
 58 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
The grading system for drug toxicities is located in the Division of AIDS Table for 
Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), 
corrected Version 2.1, July 2017, which can be found on the DAIDS RSC website at 
https://rsc.niaid.nih.gov/clinical -research-sites/daids -adverse-event-grading-tables. 
 
NOTE: The protocol team  must be notified within 72 hours regarding toxicities that result 
in a change in study regimen (follow the directions described in the Study Management 
section ). 
 For all agents evaluated in this trial, including casirivimab plus  imdevimab, if a participant 
develops a Grade 3 AE that is related  to the study product as determined by the site 
investigator, no further doses of the study treatment should be administered.  
 
It is possible that some participants will experience transient or prolonged AEs during the study. As some of the visits will be conducted remotely, AEs will often be assessed remotely and unplanned study visits scheduled if deemed necessary by the site investigator. For any concerning AEs that are felt to require clinical intervention, 
participants should be instructed to contact their health care provider or seek urgent or emergent care, or 911 should be called, as appropriate.  
 
Treatment may be discontinued without contacting the protocol team in advance, but the protocol team  should be notified within 24 hours of parenteral and 72 hours of non-
parenteral treatment dis continuation  (follow the directions described in the 
Study 
Management section ). This includes an interruption in administration for single-dosed 
agents.  
 
8.2 Management of Side Effects  
 See relevant appendix/appendices for additional details on the management of side 
effects.  
 
8.2.1 Overdose 
 
An overdose is any dose of study treatment given to a participant or taken by a participant that exceeds the dose described in the protocol. 
 
Any overdose must be reported to the PPD Drug Safety Center  within 24 hours 
(follow the directions described in the Stu dy Management section
). The overdose 
itself is not to be reported as an AE. However, any AEs associated with the overdose are to be reported on relevant AE/SAE sections in the eCRF.  
In the event of an overdose, the site investigator should:  
1. Contact the protocol team  immediately (follow the directions described in the 
Study Management section ). 
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities.  
 59 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 3. Obtain a plasma sample for PK analysis within 3  days from the date of the last 
dose of investigational agent/placebo if requested by the medical monitor. 
4. Document the quantity of the excess dose as well as the duration of the 
overdose in the eCRF. 
 
Decisions regarding dose interruptions or modifications will be made by the site 
investigator in consultation with the medical monitor based on the clinical evaluation of the participant. 
 
8.3 Pregnancy  
 
If a participant becomes pregnant during the study (post-entry), the participant will 
remain on study through the end of the study and the pregnancy will be followed 
through completion. At the end of the pregnancy, outcome and adverse events for 
participant and infant will be recorded on the outcome eCRF . 
 The ability to continue or need to discontinue investigational agent in event of pregnancy 
is outlined in the relevant appendix/appendices .  
 8.4 Breastfeeding 
 
The use of investigational agent in breastfeeding participants will vary depending upon agent and is outlined in the relevant appendix/appendices.  
 For participants who received casirivimab plus imdevimab, per the EUA Fact Sheet 
for Health Care Providers for casirivimab and imdevimab [ 15], “There are no available 
data on the presence of casirivimab and/or imdevimab in human milk or animal milk, the effects on the breastfed infant, or the effects of the drug on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for REGEN -
COV (casirivimab and imdevimab) and any potential adverse effects on the breastfed 
child from REGEN -COV or from the underlying maternal condition. Breastfeeding 
individuals with COVID- 19 should follow practices according to clinical guidelines to 
avoid exposing the infant to COVID-19 .” [15]  
 
9.0 CRITERIA FOR DISCONTINUATION 
 
Participants may discontinue from the investigational product or withdraw from the study at any time and for any reason without prejudice to their future medical care by the investigator or at the study site. Every effort should be made to keep participants in the study. The reasons for participants discontinuing the investigational product and/or withdrawing from the study will be recorded on an eCRF. 
 
9.1 Permanent and Premature Treatment Discontinuation 
 
• Drug-related toxicity  mandating discontinuation (see appendix/appendices) . 
 60 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 • Participant experiencing an SAE that is considered related to investigational agent. 
• Requirement for prohibited concomitant medications (see section 5.4  and rel evant 
appendix/appendices ) if the reason the medications are prohibited is due to drug-
drug interactions or other concern for toxicity.  
• Request by participant to terminate treatment. 
NOTE: The reason for treatment discontinuation should be documented ( e.g., 
concern for AE, lack of efficacy, or other reason).  
• Clinical reasons believed life threatening by site clinical staff , even if not addressed 
in the Toxicity section  of the protocol. 
• Any additional indications are outlined in the relevant appendix/appendices. 
 
9.2 Premature Study Discontinuation  
 
• Failure to initiate investigational agent or comparator . 
• Request by the participant to withdraw consent.  
• Request of the health c are provider if they think  the study is no longer in the best 
interest of the participant. Need for or use of a prohibited medication does not 
require study discontinuation. 
• At the discretion of the IRB/EC, FDA, NIAID, ACTG, Office for Human Research 
Protections (OHRP), other government agencies as part of their duties, investigator, 
or industry supporter . 
• Any additional indications are outlined in the relevant appendix/appendices . 
 
In the event that a participant prematurely discontinues from the study, unless they have 
withdrawn consent or never initiated investigational agent/placebo, sites will attempt to 
obtain information regarding vital status (including date last seen alive, hospitalization, date of death, and primary cause of death) from other sources (e.g., family members, 
other designated secondary contacts, or clinic records). See the MOP S for further 
guidance.  
 10.0 STATISTICAL CONSIDERATIONS  
 10.1 General Design Issues  
 
Enrollment of new study participants under this version of the protocol is to a platform 
trial with a phase II evaluation and a separate phase III evaluation of investigational 
agents. The phase II component is evaluating investigational agents in a 
superiority  comparison to a placebo control among participants at low er risk of 
progression to hospitalization or death (note though that for some agents, enrollment of 
higher risk participants was also allowed under earlier versions of the protocol) . The 
phase III component is evaluating investigational agents in a superiority  comparison to 
a placebo control (with use of SOC treatments allowed in both arms, if available)  
among participants at protocol-defined higher risk of progression to hospitalization or 
death. The two components are linked in that investigational  agents showing evidence of 
antiviral effects and/or effects on symptoms of COVID -19 in the phase II component may 
 61 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 then be evaluated further  in the phase III component. Statistical considerations for eac h 
of the phase II and phase III components are described in this section (additional 
details of the analyses for the investigational agent SAB-185, for which 
participants were randomized, under protocol Version 7, to SAB-185 or active 
comparator casirivimab plus imdevimab, are  discussed in the SAB -185 appendix, 
Appendix XV ). 
     
The major benefit of the proposed platform trial design is that each of the phase II and phase III components allows for efficient evaluation of multiple investigational agents 
compared to concurrently randomized participants (who were eligible for a particular 
agent) in a combined control group. In both phase II and phase III evaluation, the intent is to focus on comparisons between each investigational agent and the control regimen, and not on comparisons among investigational agents. Control of type I error rate in each of the phase II and phase III components will be undertaken separately for each 
investigational agent rather than across all investigational agents (so not controlling the 
experiment-wise or family -wise error rate across investigational agents).  
 
10.2 Outcome Measures  
 
Primary and secondary outcome measures listed below will be addressed in the study’s 
primary Statistical Analysis Plan, which will define the content of the Primary Analysis 
Report of outcomes through day 28 of follow -up. A subsequent report of further 
outcomes through to end of study follow -up for each investigational agent will be 
generated at a later time. These reports  will form the basis for the main study 
manuscript(s) and results reporting to ClinicalTrials.gov.  
 
10.2.1 Phase II: Primary Outcome Measures  
 
10.2.1.1 Clinical (Symptom Duration): Duration of targeted COVID -19 
associated symptoms from start of investigational agent (day 0) 
based on self-assessment. Duration defined as the number of days 
from start of investigational treatment to the first of two consecutive days when all symptoms scored as moderate or severe at study 
entry (pre-treatment) are scored as  mild or absent, AND all 
symptoms scored as mild or absent at study entry (pre-treatment) are scored as absent. The targeted symptoms are feeling feverish, 
cough, shortness of breath or difficulty breathing, sore throat, body 
pain or muscle pain or aches, fatigue (low energy), headache, chills, nasal obstruction or congestion (stuffy nose), nasal discharge (runny nose), nausea, vomiting, and diarrhea. Each symptom is scored daily 
by the participant as absent (score 0), mild (1), moderate (2) and severe (3).  
 
10.2.1.2 Virologic : At each of days 3, 7, and 14 quantification (<LLoQ versus 
≥LLoQ) of SARS -CoV -2 RNA from staff-collected NP swabs. 
 
 62 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 10.2.1.3 Safety : New Grade 3 or higher AE through 28 days.  
 
10.2.2 Phase III: Primary Outcome Measures  
 
10.2.2.1 Efficacy : Death due to any cause or hospitalization due to any cause 
during the 28-day period from and including the day of the first dose 
of investigational agent or placebo. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to 
address medical needs of those with severe COVID -19 during the 
COVID -19 pandemic. 
 
10.2.2.2 Safety : New Grade 3 or higher AE through 28 days.  
 
10.2.3 Secondary Outcome Measures 
 
The clinical primary outcome measure in phase II (symptom duration) will also 
be assessed in phase III as a secondary outcome measure. The virologic primary outcome measure in phase II (quantification (<LLoQ versus ≥LLoQ) of SARS- CoV-2 RNA from staff-collected NP swabs) will also be assessed in 
phase III as a secondary outcome measure, except only at Day 3. 
 The primary outcome measure in phase III (death due to any  cause or 
hospitalization due to any cause through 28 days) will also be assessed in 
phase II as a secondary outcome measure.  
 
The following secondary outcome measures will also be assessed:  
 
10.2.3.1 Phase II and III: Level of SARS -CoV-2 RNA from staff-collected NP l 
swabs through day 14 in phase II and at day 3 in phase III.  
 
10.2.3.2 Phases II and III: Duration of targeted COVID -19 associated symptoms 
from start of investigational agent (day 0) based on self-assessment. Duration defined as the number of days from start of investigational treatment to the first of four consecutive days when all symptoms are 
scored as  absent. The targeted symptoms are feeling feverish, cough, 
shortness of breath or difficulty breathing, sore throat, body pain or muscle pain or aches, fatigue (low energy), headache, chills, nasal obstruction or congestion (stuffy nose), nasal discharge (runny nose), nausea, vomiting, and diarrhea. Each symptom is scored daily by the 
participant as absent (score 0), mild (1), moderate (2) , and severe (3). 
 
10.2.3.3 Phases II and III: COVID -19 severity ranking based on symptom 
severity scores over time during the 28-day period from and including the day of the first dose of investigational agent or placebo, hospitalization, and death. For participants who are alive at 28 days and 
 63 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 not previously hospitalized, the severity ranking will be based on their  
area under the curve AUC of the daily total symptom score associated 
with COVID- 19 over time (through 28 days counting day 0 as the first 
day) where the total symptom score on a given day is defined as the 
sum of scores for the targeted symptoms in the participant’s study diary (each individual symptom is scored from 0 to 3). Participants who are hospitalized or who die during follow -up through 28 days will be ranked 
as worse than those alive and never hospitalized as follows (in worsening rank order): alive and not hospitalized at 28 days; 
hospitalized but alive at 28 days; and died at or before 28 days. 
 
10.2.3.4 Phases II and III: Progression through day 28 of one or more COVID -
19-associated symptoms to a worse status than recorded in the study 
diary at study entry, prior to start of investigational agent or placebo.  
 
10.2.3.5 Phases II and III: Time to self-reported return to usual health, defined as the number of days from start o f investigational treatment until the first of two 
consecutive days that a participant reported return to usual (pre-COVID -19) 
health as recorded in a participant’s study diary through Day 28. 
 
10.2.3.6 Phases II and III: Death due to any cause or hospitalization d ue to 
any cause during the 24 -week period from and including the day of 
the first dose of investigational agent, and during the 72-week period from and including the day of the first dose of investigational agent. 
 
10.2.3.7 Phase II and Phase III: Oxygen saturation (i.e., pulse oximeter measures) as a quantitative measure and categorized as <96 versus ≥96% through day 28.  
 10.2.3.8 Phase II only: Area under the curve and above the assay lower limit of quantification of quantitative SARS-CoV -2 RNA over time from 
site-collected NP swabs at days 0, 3, 7 and 14.  
 
10.2.3.9 Phases II and III: Phases II and III: New Grade 2 or higher AE through 28 days, and through week 24. 
 
10.2.3.10 Phases II and III: New Grade 3 or higher AE through week 24.  
10.2.3.11 Phase II only: Pharmacokinetic measures will be defined in the agent-specific appendices. 
 
10.2.3.12 Phase II and III: Time to self-reported return to usual health, defined 
as the number of days from start of investigational treatment until the 
first of four consecutive days that a participant reported return to usual (pre-COVID -19) health as recorded in a participant’s study 
diary  through Day 28. 
 64 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
10.2.3.13 Efficacy: Death due to any cause or hospitalization due to any 
cause, but excluding hospitalizations that are deemed unrelated to COVID -19, during the 28-day period from and including the 
day of the first dose of investigational agent or placebo. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID -19 during the COVID -19 
pandemic. 
 
10.2.4 Other Outcome Measures  
 
10.2.4.1 Phases II and III: Worst clinical status assessed using ordinal scale 
among participants who become hospitalized. Ordinal scale defined as:  
• Death 
• Hospitalized, on invasive mechanical ventilation or ECMO  
• Hospitalized, on non-invasive ventilation or high flow oxygen 
devices  
• Hospitalized, requiring supplemental oxygen 
• Hospitalized, not requiring supplemental oxygen (COVID -19 
related or otherwise)  
 
10.2.4.2 Ph ases II and III: Duration of hospital stay among participants who 
become hospitalized.  
 
10.2.4.3 Phases II and III: ICU admission (yes versus no) among participants 
who become hospitalized. 
 
10.2.4.4 Phases II and III: Duration of ICU admission among participants who are admitted to the ICU.  
10.2.4.5 Phases II and III: New SARS-CoV -2 positivity among household 
contacts through to 28 days and through to 24 weeks from start of investigational agent or placebo.  
 
10.2.4.6 Phases II and III: Hematology and chemistry, coagulation, and inflammatory markers through 28 days from start of investigational agent. 
 
10.2.4.7 Phases II and III: Plasma markers of inflammation and antibody 
respons es to SARS- CoV-2 infections, measured in blood in all phase 
II participants and in a subset of phase III participants per relevant appendix.  
 
 65 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 10.2.4.8 Phase II and III: Viral resistance (to be defined at the time of 
laboratory analysis).  
 
10.2.4.9  Phase II only: Immune cell phenotypes and T and B cell responses 
to SARS-CoV-2 measured in PBMCs (to be defined at the time of laboratory analysis).  
 
10.2.4.10 Phase II and III: Persistent clinical symptoms and sequelae through end of study follow-up. 
 
10.2.4.11 Phase II and III: Psychological health, functional health, and health-related quality of life measures through end of study follow -up. 
 10.3 Randomization and Stratification  
 The phase II trial and the phase III trial involve different populations and will have separate randomizations. However, the structure of the randomization system will be the 
same for each of the two trials, as described in the following.  
 In each trial, at any time that enrollment is ongoing, eligible participants will be 
randomized in two steps with the ultimate intent of having approximately equal numbers 
of concurrently randomized participants on a given investigational agent and in the comparator group for that agent (i.e., combining participants who were eligible to receive the agent but who were randomized to any of the available placebos in the same phase of evaluation). Participants at higher risk of progression to hospitalization or death will 
be randomized to agents that are in phase III evaluation, and participants who are not at 
higher risk of progression will be randomized to agents that are in phase II evaluation.  The randomization in each trial will be undertaken in two steps. First, participants at a site will be randomized in approximately equal numbers to groups corresponding to the investigational agents in the trial that they are eligible to receive which are under study at 
that site. For example, when enrollment is ongoing for Agents A, B, and C at a given 
site, participants will be randomized to Groups A, B, and C if they are eligible to receive any of Agents A, B, and C. Participants who are only eligible to receive two of the three agents (e.g., Agents A and B) would only be randomized to the two respective groups (e.g., Groups A and B). Participants who are only eligible for one agent (e.g., Agent A) 
would be assigned to the respective group (e.g., Group A). Note that the eligibility assessment takes account of whether a participant is at higher or lower risk of progression to hospitalization or death and hence the randomization of higher risk participants is  to agents in phase III evaluation and of low -risk participants is to agents in 
phase II evaluation.  
 
Immediately following the first randomization, participants will be randomized within their 
assigned group to receive the interventional agent or the appropriate comparator (the matching placebo for that agent). For example, in the phase II trial, in Group A, participants would be randomized to receive Agent A or the placebo for Agent A. In this 
 66 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 second randomization, the ratio of assignment to the interventional agent or the 
comparator agent will be r:1 where r is the number of agents in the same phase of evaluation that a given participant is eligible to receive.  
 
As an example, consider the situation in which randomization is ongoing to agents B and C in phase II evaluation, and consider participants at lower risk of progression to hospitalization or death who are eligible to receive either of agents B or C in the phase II trial. In the first randomization, a 1:1 ratio would be used to assign these lower risk participants to Agent Groups B and C. In the second randomization, participants in 
Agent Group B will be randomized in the ratio 2:1 to active Agent B and Plac ebo for B 
(as these participants were eligible to receive either of these two agents in phase II 
evaluation). Participants in Agent Group C will also be randomized in the ratio 2:1 to active Agent C and Placebo for C. Participants assigned to Placebo for B  or to Placebo 
for C will contribute to the placebo control group for evaluating both Agent B and Agent 
C in phase II.  
 This two-step randomization process will achieve approximately equal numbers being assigned to an investigational agent and its concurrent comparator group (comprised of all concurrently enrolled comparator arms combined, restricted to participants who were eligible to receive that agent).  
 
Both randomization steps will be stratified (using blocked randomization) by time from symptom ons et (≤ versus >5 days) in phase II, and by country in phase III.  
 
10.4 Sample Size 
 
10.4.1 Phase II 
 
The phase II evaluation of an investigational agent involves the comparison of two primary outcomes (SARS -CoV-2 RNA <LLoQ versus ≥LLoQ at days 3, 7 
and 14; and symptom duration) among participants randomized to that agent 
versus participants concurrently randomized to the placebo. This evaluation will 
involve approximately 110 participants randomized to the investigational agent and approximately 110 participants  concurrently randomized to the control 
group for that agent (combined across one or more concurrently randomized placebo arms). The choice of sample size has been chosen to give high power 
to identify an active agent based on the primary virologic outcome so we 
describe that first. The phase II study is not specifically designed to have a high 
level of power for the symptom duration outcome, but we illustrate the anticipated power to detect a range of reductions in median symptom duration. As this is the phase II component of the study and hence there will be further evaluation of an agent that graduates to phase III, no adjustment is made for 
the multiplicity of outcomes being assessed for a given investigational agent (or 
across investigational agents).  
 
 67 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Virologic Outcome 
The percentage of participants with quantifiable SARS -CoV -2 RNA in NP 
swabs will be compared between an investigational agent and placebo control 
at each of days 3, 7 and 14. It is uncertain what might be the percentage <LLoQ 
at each of these times in the population being studied, and this percentage is 
likely to depend on the time since onset of symptoms at which participants are enrolled. However, a 20% absolute increase in percentage of participants with SARS- CoV-2 RNA <LLoQ is thought to be relevant. For example, in a clinical 
trial comparing the combination of interferon beta-1b, ribavirin, 
lopinavir/ritonavir (n=86) to lopinavir/ritonavir alone (n=41) in hospitalized 
COVID -19 patients in China, there was both a difference in clinical outcomes 
and more than a 20% reduction in undetectable virus at about 7 days (with the caveat that this does not establish that a difference in virologic outcome is a surrogate for a difference in clinical outcome) [9 ]. The median time to 
undetectable virus was 7 versus 14 days in this trial (based on daily NP swabs obtainable in the hospitalized setting), indicating that 50% of participants were undetectable at 7 and 14 days in the two groups.  With a phase II sample size of 110 participants assigned to an investigational 
agent and a similar number concurrently assigned to placebo, we assume that 
about 100 participants in each group will have NP swabs available at a 
scheduled measurement time. Table 10.4.1-1 shows the power to detect a 20% 
absolute increase in percentage of participants with unquantifiable virus for a 
range of percentages with unquantifiable virus in the placebo arm. The power was calculated for the comparison of two proportions using a normal 
approximation to the binomial distribution and unpooled variance, with two-sided 
Type I error rate of 5%. A power of over 82% is achieved regardless of the percentage of participants with unquantifiable virus in the control group. A sample size of 100 per group with NP swabs would also provide reasonabl e 
precision in estimating the absolute difference between groups in percentage with unquantifiable virus: for example, the width of a two-sided 95% confidence 
interval would be no more than ±13.6% around the observed difference, and the 
width of a two-sided 90% confidence interval would be no more than ±11.4%. 
 
Table 10.4.1 -1: Power to Detect a 20% Absolute Increase in % with SARS-
CoV-2 RNA <LLoQ for Various Percentages Unquantifiable in Control Group 
(calculated in PASS15 software)  
Control 
Group: 
Number 
with NP 
Swabs  Investigational 
Group: 
Number with NP 
Swabs  Percentage 
Unquantifiable 
in 
Investigational 
Arm Percentage 
Unquantifiable 
in Placebo 
Arm Power 
(%) 
100 100 30 10 95.5 
100 100 40 20 88.5 
100 100 50 30 83.9 
 68 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 Control 
Group: 
Number 
with NP 
Swabs  Investigational 
Group: 
Number with NP 
Swabs  Percentage 
Unquantifiable 
in 
Investigational 
Arm Percentage 
Unquantifiable 
in Placebo 
Arm Power 
(%) 
100 100 60 40 82.3 
100 100 70 50 83.9 
100 100 80 60 88.5 
100 100 90 70 95.5 
 
The duration of symptoms from the start of investigational agent through 28 
days of follow -up will be compared between an investigational agent and 
placebo control.   
To evaluate power and precision for this comparison, an estimate of the 
variability in durations is needed. We use data from the placebo arm of a US study (n=60), in which the median duration of COVID-19 symptoms (defined as time to first day with symptoms absent) was 8 days and the inter -quartile range 
(IQR) was 4 to 15 days [ 8]. For the purposes of calculating sample size, we 
assume that the relative variability of durations among participants will be the 
same for this study’s symptom duration outcome measure as in this recent data 
(recognizing that this study is using a different definition for symptom duration, which does not require all symptoms to be absent but conversely requires two consecutive days of sufficient symptom improvement from day 0 scores). To proceed with an assessment of power, we make the simplifying assumption that 
the log
10-transformed symptom duration will be approximately normally 
distributed and use this normality assumption to infer a standard deviation 
based on the above IQR, specifically that the standard deviation equals 
[log10(15) – log10(4)]/1. 35= 0. 425. 
 
Division by 1.35 in this expression arises because the IQR for a normal 
distribution has width 1.35 times its standard deviation. For simplicity, we also 
ignore the fact that symptom durations will be measured in integer days rather than as continuous measurements  and assume that the symptom durations will 
be observed for all participants by day 28 (i.e., no censoring of symptom durations at 28 days).  
 
Assuming that 100 of the 110 participants in each of the investigational agent and placebo control groups will provide study diary data and continuing to 
assume a normal distribution for log
10 durations with standard deviation of 
0.425, then the phase II c omponent of the study will have about 81% power to 
show a one-third (33%) relative reduction in median duration of symptoms from the start of investigational agent (e.g., 12 days to 8 days). This calculation is based on using a Wilcoxon rank sum test to compare groups using a two-sided significance level of 0.05. The power to detect smaller relative reductions will be 
 69 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 lower: For example, it would be only 52% to detect a one-quarter (25%) relative 
reduction in median duration symptoms (e.g., 12 days to 9 day s).  
 
10.4.2 Phase III  
 
The Phase III trial is focused on a superiority comparison of the proportion of 
participants who are hospitalized or who die through to 28 days for an investigational agent versus placebo (with use of SOC treatment  in both 
arms , if available) . The primary analysis will focus on evaluating the ratio 
of proportions (investigational agent /placebo) or, equivalently, the relative 
reduction in risk of hospitalization/death for the  active investigational 
agent versus placebo. The sample size of 1200 participants, with 
approximately 600 randomized to an investigational agent and 600 to placebo, has been chosen to give good power (>90%) to detect relative 
risk reductions of 70% (as found for other antibody treatments) if the proportion hospitalized/dead in the placebo group is about 5% or higher, 
using a two-sided Type I error rate of 5% . There are multiple factors that 
will affect the power which are discussed below . To provide context for 
this discussion, the following table 10.4.2-1 shows the power of the study 
to detect relative risk reductions of between 50% and 70% for proportions 
hospitalized/dead in the placebo group of 3 % to 6%. The powers shown 
were obtained in PASS software (version 15.0.4) for testing two proportions using a z -test (so the normal approximation method) with 
unpooled variance. They are based on an effective sample size of 570 per arm, with the 5% reduction from 600 per arm built in to allow for loss to 
follow -up and interim monitoring using the O’Brien and Fleming stopping 
guideline. 
 
Table  10.4.2 -1: Power to detect various true effect sizes (relative 
reduction in risk of hospitalization/death) for selected true 
proportions hospitalized/dead on placebo between 3 % and 6%  
Proportion 
Hospitalized/Dead  Relative Risk 
Reduction for 
Active versus 
Placebo  Power  
Placebo  Active  
3% 
 0.9%  70% 73% 
1.2%  60% 56% 
1.5%  50% 40% 
4% 1.2% 70% 85% 
1.6% 60% 69% 
2.0% 50% 51% 
5% 1.5% 70% 92% 
2.0% 60% 79% 
2.5% 50% 61% 
6% 1.8% 70% 96% 
2.4% 60% 86% 
3.0% 50% 69% 
 70 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
  
Discussion of F actors Affecting the Power  of the Study 
a. Proportion hospitalized/dead in placebo control group: As can be seen 
in the table, the proportion hospitalized/dead in the placebo group has 
a reasonable effect on power with lower proportions leading to a 
reduction in power . For the placebo control group for evaluating the 
BRII agent in ACTIV -2, the proportion was 11%  [25]. However, the 
proportion in the phase 3 trial of sotrovimab was 6% [ 26]. There is also 
a possibility that the pr oportion may be lower for the O micron variant 
than previous variants.  
b. Use of SOC treatment by some participants: Higher use of SOC 
treatment will reduce the proportion hospitalized/dead in both 
randomized arms. For example the proportion hospitalized/dead in the 
placebo arm would change from 6% if none receive SOC treatment to 
5.58%, 4.74% and 3.90% if SOC treatment is used by a random sample 
of 10%, 30% and 50%, respectively, of participants in the placebo arm (i.e., SOC treatment use is not related to risk of hospitalization/death) 
and SOC treatment reduces risk of hospitalization/death by 70%. If SOC treatment use is not random, for example it is taken up by the 
highest risk participants, then the impact might be larger. As the trial 
excludes participants who have accessed SOC treatment prior to entry 
and there is a general lack of availability of such treatments globally, 
use in the trial is expected to be very low  (e.g., <10%) and so limit the 
impact. 
c. Differential effect of an investigational agent versus placebo according 
to use or not of SOC treatment: For a given proportion of participants 
hospitalized/dead in the placebo arm, the power shown in the above 
table is valid if the relative effect of SAB versus placebo is not affected 
by the use of SOC treatment. Power would be reduced from the values 
shown if the effect of SAB versus placebo is reduced in the presence 
versus absence of  background therapy. A related concern arises if use 
of SOC treatment is differential in the investigational agent arm versus the placebo arm. For example, accessing SOC treatment at a higher rate in the placebo arm because more participants have a deteriorating health status might diminish a tr ue difference in effect between arms 
and hence reduce power. As noted above, use of SOC treatment is 
expected to be low and so any reduction in power is expected to be 
limited even if this occurs.  
d. Failure to start randomized treatment and loss to follow -up: The 
impact of any loss to follow -up is expected to be minimal as there will 
be regular contact between research site staff and participants (or 
their secondary contacts) . Previous experience in the study and other 
trials has shown that the large majority of hospitalizations/deaths occur early in follow -up (first two weeks of follow -up) when loss to 
follow -up has also been minimal (approximately 1 to 1.5%) in this 
study. In addition, a very small proportion of participants who are 
 71 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 randomized will not start study treatment and so be excluded from the 
analysis of the primary outcome. Based on ACTIV -2 experience, 
allowance for 3-4% not starting treatment or being lost to follow -up 
before hospitalization is built into the above power table (with 
additional allowance of 1-2% for interim monitoring using the O’Brien 
and Fleming stopping guideline). 
 
Because of these uncertainties, the DSMB will be asked to monitor the potential impact of the above factors on the operational feasibility of the study.  
 
10.5 10.5 D ata and Safety Monitoring  
 
10.5.1 Phase II Trial  
 
Monitoring of safety during the time an investigational agent is in phase II evaluation is described in section 7.5
.  
 There will be interim analyses of safety data for review by a NIAID -appointed 
DSMB approximately each month (or on a schedule recommended by the DSMB) 
with the first review approximately six weeks after enrollment to an agent starts.  
 
10.5.2 Phase III Trial   
 
An NIAID -appointed DSMB will undertake reviews of interim data from the study 
to help ensure the safety of participants in the study, and to recommend 
changes to the study including termination or modification for safety reasons or 
if efficacy of the agent versus placebo has been established, or if it is 
unlikely that the agent has sufficient efficacy to warrant further  evaluation 
in this study. It is not intended, however, to terminate evaluation of an agent early for efficacy based on symptom outcome measures. The DSMB may also recommend termination or modification of the study if it appears futile on 
statistical or operational grounds to continue an investigational agent in the 
study as designed. The operation of the DSMB is governed by the NIAID DSMB 
Charter.  
 
Unless otherwise recommended by the DSMB, two  interim analyses for 
DSMB review are planned for each investigational agent, after approximately one-third (i.e., approximately 400 participants) and two-
thirds (i.e., approximately 800 participants) of the planned enrollment for 
an investigational agent has been completed and followed through to day 14 (the choice of day 14 is because the large majority of hospitalizations/deaths in ACTIV -2 have been observed to occur by day 
14).   At each interim review of an investigational agent, the DSMB will review summaries of data by randomized treatment arm for the primary outcome of 
 72 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 hospitalization/death, the secondary outcome of death, losses to follow -up, and 
adverse events (including early discontinuation of investigational agent).  
 
Decision Guideline for Efficacy  Favoring an Investigational Agent Versus 
Placebo 
The general approach for decision-making with respect to efficacy is 
based on evaluating a two-sided 95% confidence interval (adjusted for interim analyses—see further below) for the relative d ifference 
(investigational agent / placebo) in the proportion of participants 
hospitalized or dead by day 28. As a stopping guideline for greater 
efficacy of an investigational agent compared with placebo, the O’Brien 
and Fleming boundary will be used. The stopping guideline will be 
implemented using the Lan-DeMets spending function approach to allow 
for the possibility of changes in the timing of interim analyses and/or 
additional (or fewer) interim analyses if recommended by the DSMB . 
Information time for  the spending function will be based on the proportion 
of the planned enrollment (i.e., of the 1200 participants for comparing an 
investigational agent to placebo) who could have been followed through 
day 14 at the time of the data freeze for the interim analysis. The choice of 
day 14 here reflects the fact that the very large majority of hospitalizations 
and deaths in ACTIV -2 have occurred by 14 days of follow -up. As a 
guideline, if the two-sided 95% confidence interval (adjusted for interim 
analyses) excludes a risk ratio of one (equivalently a relative risk 
reduction of zero) favoring the investigational agent, then the DSMB may 
recommend closure of randomization to that agent; release of interim 
results may also be recommended.  
   
There is the possibility that differences between the treatment groups 
may be observed early in follow -up. However, the overall goal of the study 
is to prevent hospitalization and deaths regardless of the timing, and 
therefore the focus of the treatment group comparisons will be on the 
cumulative proportion hospitalized/dead at day 28. 
 
Stopping Randomization to an Investigational Agent Because of Limited 
Efficacy 
Because there are treatm ents available that may substantially reduce the 
risk of hospitalization/death, albeit with limited availability and the caveat 
that they have generally been evaluated among individuals infected with 
earlier variants of SARS -CoV -2, it is likely that a treatment which reduces 
the risk of hospitalization/death by less than 30% versus placebo will have limited utility in clinical practice. Therefore, as a non-binding guideline, the DSMB may recommend early termination of randomization to a 
specific investigational agent because of limited efficacy if the two -sided 
95% confidence interval (adjusted for interim analyses) for the risk ratio is entirely above 0.7 or, equivalently, the two-sided 95% confidence interval 
 73 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 (adjusted for interim analyses) for the relative risk reduction is entirely 
below 30%. 
 
Modifying or Stopping the Study for Operational Futility 
The DSMB will also monitor operational futility, in particular related to losses to 
follow up, low hospitalization/death rate in the placebo arm  (which, in part, 
may arise due to more extensive use of SOC treatment than anticipated). 
As most hospitalizations are expected to occur early in follow up (e.g., during the first 14 days), early losses to follow up would be most rel evant. As a 
benchmark, an overall loss to follow-up rate (excluding losses after a participant is hospitalized) of more than 5% would be cause for concern.  
 With regard to the hospitalization/death rate in the placebo arm, the power 
of the study is limited if this rate is below 3% (see power analysis table in 
section 10.4.2
). Therefore, as a benchmark, an observed rate of less than 
3% in the placebo arm  would be a cause for concern. If this arises, or 
temporal trends in hospitalization/death rate suggest it might, then any 
DSMB recommendation concerning this issue might incorporate information about factors that might be driving it (eg., increasing use of SOC treatment, evolving lower risk of participants enrolled, or lower risk 
with new variants). 
 
10.6 Analyses  
 
A Statistical Analysis Plan (SAP) will be developed that describes, in detail, the analyses 
to address the study’s primary and secondary objectives in both phase II and phase III. 
The following provides an outline of the methods for the main comparisons between randomized groups, particularly for the primary outcome measures in each of phase II and phase III.   A general principle in all analyses is that outcomes among participants randomized to 
receive a specific investigational agent will be compared to outcomes among participants 
who were eligible to have been randomized (in the two-step randomization process) to the investigational agent but who were randomized instead to receive placebo. This ensures 
that the comparison is restricted to concurrently randomized participants eligible to have taken the investigational agent of interest. All analyses involving randomized comparisons 
will, however, be restricted to randomized participants who started an investigational agent 
or placebo, according to a modified intention-to-treat approach. Additional details of 
the approach to be taken for analyses of SAB -185 vs casirivimab plus imdevimab 
and SAB-185 vs placebo are described in the SAB -185 appendix, Appendix XV
. 
 10.6.1 Primary Outcome Measures for Phase II  
 
Virologic Outcome: Unquantifiable SARS -CoV -2 RNA in NP Swabs  
Descriptive statistics will be used to describe the proportion of participants with RNA <LLoQ at each scheduled measurement time. Because of uncertainty 
 74 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 about whether hospitalization might be driven by immunologic factors rather 
than virologic factors, the main analysis will not impute virologic outcome if resul ts are not available because of hospitalization (though the sensitivity of this 
issue may be explored by considering an imputation of having quantifiable virus 
during hospitalization). For (frequentist) inference in presenting results, a 
repeated measures analysis will be undertaken across the scheduled measurement times using a binary regression model fitted using the generalized estimating equation approach with an independence working correlation structure, and two-sided 5% Type I error rate applied to a Wald -type 
test of the treatment by time interaction term (time included with indicator variables for each evaluation time). 
 
Clinical Outcome: Symptom Duration  
Symptom durations will be compared between study groups using a two- sided 
Wilcoxon test with a 5% Type I error rate taking account of censoring, with descriptive summaries of the distribution of symptoms durations among participants.  
 
Safety and Tolerability: Grade 3 or Higher AE  
Safety and tolerability will be evaluated by estimating the proportion of 
participants start ing study treatment with new Grade 3 or higher AE(s) by study 
day 28 and will be compared between groups using binary regression.  
 
10.6.2  Primary Outcome Measures for Phase III  
 
Hospitalization/Death   
The cumulative proportion of participants hospitalized or dying during the first 28 days of follow -up will be estimated for each randomized group 
using Kaplan-Meier methods to take account of losses to follow -up (and 
incomplete follow -up at interim analyses). Participants who prematurely 
discontinue the study, who are not able to be contacted by the site to 
ascertain outcomes after discontinuation, will have follow up censored at 
the date of last known status.  
 
The difference between randomized groups in the estimated log cumulative proportion will be calculated and the variance for this 
difference will be obtained using Greenwood’s formula. Two-sided 95% 
confidence intervals (adjusted for multiple interim analyses)  and 
associated p-value for the test of no difference between groups will then 
be obtained. To preserve confidence interval coverage (and type I error 
rate for assessing superiority) over multiple interim analyses, the confidence interval will be calculated using a “repeated” confidence 
interval approach with spending of error rate at each interim analysis 
using the Lan and DeMets approach with an O’Brien and Fleming 
spending function.  
 
 75 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 If there are zero hospitalizations/deaths in one arm, then the above 
analysis will not be possible. In addition, if the number of 
hospitalizations/deaths in either arm is very small, then the asymptotic statistical theory underpinning the validity of the above analysis (e.g., 
coverage of confidence intervals) may be questionable. Using a standard 
rule of thumb, if the number of hospitalizations/deaths in either arm is 
less than five, then the primary interpretation of results will use Fisher’s Exact Test.  
 
Safety and Tolerability: Grade 3 or Higher AE  
Safety and tolerability will be evaluated by estimating the proportion of participants starting study treatment with new Grade 3 or higher AE(s) by study day 28 and will be compared between groups using binary regression.  
 
10.6.3  Secondary Outcomes  
 
10.6.3.1  The cumulative proportion of participants dying during the first 28 days of follow -up, and through to 24 and 72 weeks,  and the cumulative 
proportion hospitalized/dying through to 24 weeks and through to 72 weeks will be analyzed in a similar manner to the phase III primary 
outcome.  
 
10.6.3.2  Analysis of the proportion of participants with new Grade 2 or higher AE(s) by day 28 and through week 24, and new Grade 3 or higher AE(s) through week 24, and the proportion with progression of symptoms, will 
be undertaken using the same approach as for the primary safety 
analysis.  
 
10.6.3.3  The duration of time to self- reported return to usual health will be 
analyzed using similar methods as  for the analysis  of symptom 
durations.  
 
10.6.3.4  The AUC virologic  outcome, COVID -19 severity ranking, will be 
compared between arms using a Wilcoxon test, with descriptive 
summaries of the distribution of these outcome measures among participants.  
 
10.6.3.5  Levels of SARS -CoV -2 RNA on days 3, 7 and 14 will be compared 
between arms using non- parametric Wilcoxon rank -sum tests and 
descriptive statistics, separately at each scheduled measurement time (considering RNA results below assay limit as the lowest rank).   
10.6.3.6  Descriptive summaries of clinical outcomes among those hospitalized will be provided by arm, recognizing that this would not be a randomized 
comparison, if restricted to participants who were hospitalized.  
 
 76 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 10.7 Unblinding  
 
Unblinding requests will follow PPD procedures.  
 
In general, participants who become hospitalized can have their individual study 
treatment unblinded if essential for their future treatment management or if necessary for 
enrollment into a COVID-19 treatment clinical trial. This determination should be made 
by the Investigator of Record at the trial site and documented on the eCRF. 
  
If treatment assignment is unblinded, this information should only be shared with the 
physicians responsible for the management of the participant on a need-to -know basis. 
Treatment assignment should not be shared with others. This includes not sharing 
treatment assignment with the study team.  
 
11.0 PHARMACOLOGY PLAN  
 
The phase II pharmacology objective is to determine the pharmacokinetics of the 
investigational agent. For phases II and III, the pharmacology objective is to  explore 
relationships between dose and concentration of investigational agent with virology, 
symptoms, and oxygenation. Samples for quantification of concentrations of the 
investigational agent will be obtained using a collection schedule appropriate for that 
agent and phase of evaluation, taking into consideration known pharmacokinetic 
characteristics (e.g., elimination half-life). Pharmacokinetic data analysis will use 
conventional and accepted approaches such as non-compartmental analysis, 
compartmental analysis , and population approaches . Usual parameters of interest are 
area under the concentration-time curve (AUC), total or apparent body clearance (CL), 
elimination half-life (T 1/2), and maximum and minimum concentrations (C max, Cmin). 
Exploration of relationships between dose and concentration of investigational agent 
with virology, symptoms, and oxygenation will be approached using conventional and 
accepted methods for pharmacokinetic /pharmacodynamic (PK/PD) data analyses . Such 
methods might include the E max or sigmoid E max model or structurally linked PK/PD 
models to explore exposure-response relationships . Exposure-response relationships 
will be performed in conjunction with the protocol statisticians .  
 
See relevant appendix/appendices for details of the agent-specific pharmacology plan.  
12.0 DATA COLLECTION AND MONITORING  
 12.1 Data Quality Assurance  
 
This study will be conducted according to the ICH E6(R2) risk and quality processes 
described in the applicable procedural documents. The quality management approach to 
be implemented in this study will be documented and will comply with the current ICH 
guidance on quality and risk management. The sponsor assumes accountability for 
actions delegated to other individuals (e.g., Contract Research Organizations).  
 
 77 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 12.2 Records to Be Kept 
 
Electronic case report form (eCRF) screens will be made available to sites for data entry. 
Participants must not be identified by name on any data submitted to the DMC. 
Participants will be identified by the subject number provided by the Clinical Data 
Management System (CDMS ) upon enrollment. 
 
12.3 Role of Data Manageme nt 
 
As part of the responsibilities assumed by participating in the study, the investigator 
agrees to maintain adequate case histories for the participants treated as part of the research under this protocol. The investigator agrees to maintain accurate eCRFs and source documentation as part of the case histories.  
 
All eCRF information is to be filled in. If an item is not available or is not applicable, this 
fact should be indicated. Blank spaces should not be present unless otherwise directed.   Investigativ e site personnel will enter participant data into CDMS. The analysis data sets 
will be a combination of these data and data from other sources (e.g., laboratory data). 
 
Clinical data management will be performed in accordance with applicable DAIDS and PPD standards and data cleaning procedures to ensure the integrity of the data, for example, removing errors and inconsistencies in the data. Adverse event terms will be coded using MedDRA, an internal validated medical dictionary, and concomitant medications will be coded using WHODRUG . 
 
12.4 Clinical Site Monitoring and Record Availability 
 
12.4.1 Site monitors under contract to the NIAID will visit participating clinical research sites to review the individual participant records, including consent forms, 
eCRFs, supporting data, laboratory specimen records, and medical records 
(physicians’ progress  notes, nurses’ notes, individuals’ hospital charts), to 
ensure protection of study participants, compliance with the protocol, and 
accuracy and completeness of records. The monitors also will inspect sites’ regulatory files to ensure that regulatory requirements are being followed and sites’ pharmacies to review product storage and management. 
 
Monitoring visits may be conducted on-site or remotely. Remote visits may include remote source document verification using methods specified for this purpose by NIAID. Remote monitoring visits may be performed in place of, or in addition to onsite visits to ensure the safety of study participants and data integrity [27]. The site will make available study documents for site monitors to 
review utilizing a secure platform that is HIPAA and 21 CFR Part 11 compliant. 
Potential platform options include: Veeva SiteVault, site- controlled SharePoint 
or cloud-based portal, direct access to Electronic Medical Record (EMR), and Medidata Rave Imaging Solutions . Other secure platforms that are 21 CFR Part 
 78 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 11 compliant may be utilized, as allowed by the DAIDS Office of Clinical Site 
Oversight (OCSO).  
 
12.4.2 The site investigator will make study documents ( e.g., consent forms, drug 
distribution forms, e CRFs) and pertinent hospital or clinic records readily 
available for inspection by the local IRB /IEC, the site monitors, the FDA , the 
NIAID, the ACTG, the OHRP, the industry supporter(s) or designee (as appropriate), other local, US, and international regulatory authorities/entities  for 
confirmation of the study data.  
 
13.0 PARTICIPANT S 
 13.1 Institutional Review Board (IRB) Review and Informed Consent 
 
Federal regulations and the ICH guidelines require that approval be obtained from an IRB/IEC before human subjects participate in research studies. Before study onset, the protocol, informed consent, advertisements to be used for the recruitment of study participants, and any other written information regarding this study to be provided to the participant or the participant’s legal guardian must be approved by the IRB/IEC. Documentation of all IRB/IEC approvals and of the IRB/IEC compliance with ICH 
harmonized tripartite guideline E6(R2). GCP will be maintained by the site and will be 
available for review by the sponsor or its designee. 
 All IRB/IEC approvals should be signed by the IRB/IEC chair  or designee and must 
identify the IRB/IEC name and address, the clinical protocol by title or protocol number 
or both, and the date approval or a favorable opinion was granted. 
 
The investigator is responsible for providing written summaries of the progress and 
status of the study at intervals not exceeding 1 year or otherwise specified by the 
IRB/IEC. The investigator must promptly supply the sponsor or its designee, the IRB/IEC, and, where applicable, the institution, with written reports on any changes 
significantly affecting the conduct of the study or increasing the risk to participants.  
 
13.2 Ethi cal Conduct of S tudy 
 
The study will be performed in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, ICH GCP, and all applicable regulations. 
 
13.3 Participant Information and Consent  
Informed consent in compliance with US Title 21 CFR Part 50 and US Title 45 CFR Part 
46 shall be obtained from each participant before entering the study or performing any 
unusual or nonroutine procedure that involves risk to the participant. An informed consent template may be provided by the sponsor to investigative sites. If any institution-specific modifications to study -related procedures are proposed or made by the site, the 
consent should be reviewed by the sponsor or its designee or both before IRB/IEC 
 79 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 submission. Once reviewed, the consent will be submitted by the investigator to his or 
her IRB/IEC for review and approval before the start of the study. If the consent for the 
phase and investigational agent a participant is enrolled in is revised during the course 
of the study, participants will be reconsented according to requirements of their IRB.  
 
Before recruitment and enrollment, each prospective participant or his or her legal guardian will be given a full explanation of the study, be allowed to read the approved ICF, and have any questions answered. Once the investigator is assured that the participant/legal guardian understands the implications of participating in the study, the 
participant/legal guardian will be asked to give consent to participate in the study. A 
witness may be used for the informed consent process if remote consent is performed and it is not possible to obtain a copy of the signed consent form from the participant (or legal guardian or person with power of attorney for participants who cannot consent for themselves). 
 13.4 Participant Confidentiality  
 
All laboratory specimens, evaluation forms, reports , and other records that leave the site 
will be identified by coded number only to maintain participant confidentiality. All records 
will be kept locked. All computer entry and networking programs will be done with coded 
numbers only. Clinical information will not be released without written permission of the 
participant, except as necessary for monitoring by the ACTG, IRB /EC, FDA, NIAID, 
OHRP,  other local, US, and international regulatory authorities/entities  as part of their 
duties, or the industry  supporter(s) or designee.   
 
13.5 Study Discontinuation  
 
The study may be discontinued at any time by the ACTG, IRB/EC, FDA, NIAID, OHRP, other country -specific government agencies as part of their duties to ensure that 
research participants are protected (as appropriate), or the industry supporter(s).  
14.0 PUBLICATION OF RESEARCH FINDINGS  
 Publication of the results of this trial will be governed by ACTG policies . Any 
presentation, abstract, or manuscript will be made available for review by the industry  
supporter (s) prior to submission.  
 
15.0 BIOHAZARD CONTAINMENT  
 As the transmission of SARS -CoV -2 and other pathogens can occur through contact 
with contaminated needles, respiratory secretions, blood, and blood products, appropriate blood and secretion precautions will be employed by all personnel in the 
drawing of blood and shipping and handling of all specimens for this study, as currently 
recommended by the CDC and the National Institutes of Health. 
 
 80 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 All dangerous goods and materials, including diagnostic specimens and infectious 
substances, must be transported using packaging mandated by CFR 42 Part 72. Please 
refer to instructions detailed in the International Air Transport Association (IATA) 
Dangerous Goods Regulations.   
 81 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 16.0 REFERENCES 
 
1. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID -19: immunity, 
inflammation and i ntervention. Nat Rev Immunol 2020;20: 363-74.  
2. C OVID -19 Dashboard by the Center for Systems Science and Engineering (CSSE) at 
Johns Hopkins University (JHU) [Educational]; 2020 [updated 2020/05/03/]. Available from: http://coronavirusstatistics.org/. 
3. WHO Coronavirus (COVID -19) Dashboard. World Health Organization. Available from: 
https://covid19.who.int/ 
4. Lauer SA, Grantz KH, Bi Q, et al. The incubation period of Coronavirus Disease 2019 (COVID -19) from publicly reported confirmed cases: estimation and 
application. Ann Intern Med 2020;172:577-82. PMID: 32150748. 
5. Danza P, Koo TH, Haddix M, et al. SARS -CoV-2 Infection and Hospitalization 
Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, 
California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep 2022;71:177-81. PMID: 35113851. 
6. Beigel JH, Tomashek KM, Dodd LE, et al.; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 -- final report. N Engl J Med 2020;383:1813 -26. 
7. Chang D, Mo G, Yuan X, et al. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med 2020;201:1150-2.  
8. Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID -19: a randomized placebo-controlled trial. Medixrv 
preprint posted November 23, 2020. https://doi.org/10.1101/2020.11.18.20234161. 
9. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir -
ritonav ir, and ribavirin in the treatment of patients admitted to hospital with COVID -19: an 
open-label, randomised, phase 2 trial. Lancet 2020;395(10238):P1695-P1704.  
10. Fall A, Eldesouki RE, Sachithanandham J, et al. A quick displacement of the SARS -CoV-2 variant Delta with Omicron: unprecedented spike in COVID-19 cases 
associated with fewer admissions and comparable upper respiratory viral loads. medRxiv 2022;Jan 28;2022.01.26.22269927. PMID: 35118480. 
11. CDC. COVID-19. Variants of the virus. Updated Aug. 11 , 2021. Available from: 
https://www.cdc.gov/coronavirus/2019-ncov/variants/index.html. 
12. Tada T, Zhou H, Dcosta BM, et al. Increased resistance of SARS- CoV-2 Omicron 
variant to neutralization by vaccine-elicited and therapeutic antibodies. bioRxiv 2021. Posted December 30, 2021. doi: https://doi.org/10.1101/2021.12.28.474369 . 
13. US FDA. Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of Bamlanivimab. Revised March 18, 2021. Available from: https://www.fda.gov/media/143603/download. 
14. US FDA. Fact Sheet For Health Care Providers. Emergency Use Authorization 
(EUA) of Bamlanivimab and Etesevimab. Revised January 24, 2022. Available 
from: https://www.fda.gov/media/145802/download. 
 82 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 15. US FDA. Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of 
Casirivimab and Imdevimab. Revised November 2020. Available from: https://www.fda.gov/media/143892/download. 
16. US FDA. Sotrovimab EUA Letter. December 16, 2021. Available from:  
https://www.fda.gov/media/149532/download.  
17. Gottlieb RL, Vaca CE, Paredes R, et al.; GS -US-540-9012 (PINETREE) 
Investigators. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022;386:305-15. PMID: 34937145. 
18. VECKLURY® (remdesivir) Package Insert. Reference ID 4690158. Issued 10/2020. 
Gilead, Foster City, CA. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf . 
19. Coronavirus Disease 2019 (COVID -19) Treatment Guidelines [Government]; 2020. 
Available from: https://www.covid19treatmentguidelines.nih.gov/introduction/.  
20. The Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov 2019;18:797-807. 
21. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients. MedRxiv preprint doi: 
https://doi.org/10.1101/2021.05.19.21257469. Posted May 21, 2021. Available from: 
https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v1.full.pdf. 
22. NIH. COVID -19 Treatment Guidelines. General Management of Nonhospitalized 
Patients with Acute COVID -19. Updated December  16, 2021. Available at: 
https://www.covid19treatmentguidelines.nih.gov/management/clinical -
management/nonhospitalized-patients --general -management/ or 
https://www.covid19treatmentguidelines.nih.gov/outpatient-management/. 
23. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN- COV2, a neutralizing antibody 
cocktail, in outpatients with Covid-19. N Engl J Med 2021;384:238-51. 
24. Chen P, Nirula A, Heller B, et al.; BLAZE -1 Investigators. SARS-CoV -2 neutralizing 
antibody LY -CoV555 in outpatients with Covid-19. N Engl J Med 2021;384:229-37. DOI: 
10.1056/NEJMoa2029849. 
25. Evering TH, Giganti M, Chew KW, et al. LB2. Safety and efficacy of combination SARS -CoV-2 monoclonal neutralizing antibodies (mAb) BRII-196 and BRII-198 in 
non-hospitalized COVID -19 patients. Open Forum Inf Dis 2021;8(Suppl 1):S807-
S808. https://doi.org/10.1093/ofid/ofab466.1643. 
26. Gupta A, Gonzalez -Rojas Y, Juarez E, et al. Effect of the neutralizing SARS -CoV-2 
antibody sotrovimab in preventing progression of COVID -19: a randomized 
clinical trial. medRxiv Posted November 08, 2021. https://doi.org/10.1101/2021.11.03.21265533. 
27. FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID -19 
Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards, March 2020, Updated on January 27, 2021. Accessed at: https://www.fda.gov/media/136238/download. 
 
 83 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  APPENDIX I: SAMPLE INFORMED CONSENT  – PHASE II, MAIN PROTOCOL  
 
DIVISION  OF AIDS  
AIDS  CLINICAL  TRIALS  GROUP  (ACTG)  SAMPLE INFORMED CONSENT  
FOR  PROTOCOL:  ACTIV -2 / A5401  
 
Adaptive Platform Treatment Trial for Outpatients with COVID -19, FINAL  Version 8.0 
 
SHORT  TITLE  FOR  THE STUDY: Adapt Out COVID  
 
SUMMARY  
 
PURPOSE  This is a research study and your participation in this study is voluntary. 
The purpose of this study is to evaluate the ability of various drugs to 
improve health outcomes for people with COVID -19. We also want to see 
if these drugs are safe, and if these drugs can stop the disease process 
and prevent hospitalization and death. This study is designed to quickly 
identify safe and effective drugs that can treat COVID -19. 
 STUDY  
DRUG
 Study drug will be either an active drug or a placebo. A placebo looks like 
a “real” drug, but it does not have any active medication in it.  
  As drugs are recommended for the treatment of COVID -19 symptoms, 
some of them will be selected for testing in this study. Therefore, there 
may be different drugs being used as part of the study at different times. 
You will receive information about specific drugs being tested at this time in a separate consent form. Regardless of how many study drugs are being tested, you will only receive one study drug (or placebo).  
  
If, during the course of the study, a standard treatment for COVID -19 is 
identified, that treatment will be substituted for placebo.  
 NUMBER OF  
PARTICIPANTS
 For each drug being tested, a minimum of 110 people will receive that drug and an equal or smaller number will receive placebo. If a drug 
appears to be safe and effective when 110 people have received it, then 
the drug will be tested in a larger trial.  
 
LENGTH  OF 
STUDY  Your participation in this study  will last for 72 weeks (18 months).  
 
 84 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  REQUIRED  
ACTIVITIES  If you are in this study, the following study procedures are required: 
• you will record your symptoms  
• you will provide blood samples  
• you will have nasopharyngeal swabs (also known as deep nasal 
swabs) collected by a study staff person 
• you will complete surveys about your symptoms  
 
RISKS There are some risks that are specific to the study drug that you might receive. We will tell you about those risks in the second part of this consent process.  
 
BENEFITS If you take part in this study, there may be a direct benefit to you, but no 
guarantee can be made. It is also possible that you will receive no benefit from being in this study. Information learned from this study may help others who have COVID-19. 
 
OTHER  CHOICES  Instead of being in this study, you have the option of: 
• treatment with prescription drugs available to you through your health 
care provider  
• treatment with other experimental drugs, if you qualify, including treatments available through emergency use authorizations (such as through the US Food and Drug Adminis tration) 
• no treatment 
 INTRODUCTION  
 You are being asked to take part in this research study because you have been diagnosed with 
SARS- CoV-2 and have symptoms of the disease it causes, which is commonly known as 
COVID -19. This study is sponsored by the National Institutes of Health (NIH). The doctor in 
charge of this study at this site is: (insert name of Principal Investigator). Before you decide if 
you want to be a part of this study, we want you to know about the study.  
 
This is a consent form. It gives you information about this study. The study staff will talk with you 
about this information. You are free to ask questions about this study at any time. If you agree to take part in this study, you will be asked to sign this consent form. You will get a copy to keep.  
  
 85 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  WHY  IS THIS  STUDY BEING  DONE?  
 
SARS- CoV-2 is a new virus that has caused a widespread outbreak of an illness called COVID - 
19. In most people, it causes a mild to moderate symptoms, like a “cold”. In others, this virus 
can cause a pneumonia (an inflammation of the lungs), which can be serious and life 
threatening. As of May 15, 2021, there have been >161 million confirmed cases of COVID -19 
and >3 million deaths attributed to COVID-19 globally.   For each drug that is tested in this study, there could be two study parts. In the first part, we will 
see if the drug is safe. We will also see if it can decrease how long people have COVID -19 
symptoms and if it can help get rid of SARS -CoV-2 virus more than the placebo. Drugs that 
appear to be safe and to work better than the placebo in the first part of the study (also known 
as Phase II) will be tested in a separate second part of the study  (also known as Phase III). You 
are currently being asked to participate in the first part of the study.  
 
Your assignment is random, like the flip of a coin. You will be told about all the study drugs you may be assigned to in this study. If only one study drug is available, you will have an equal chance of receiving the study drug or placebo. If two study drugs are available, you will have a 2:1 chance of receiving a study drug or placebo. If three study drugs are available, you will have a 3:1 chance of receiving a study drug or placebo, and so forth. You will be told about all the 
study drugs you may be assigned to in this study. You will not be able to choose your group 
(study drug), and neither you, your study doctor, nor the study staff at your site will know 
whether you are receiving the study drug or placebo.  The study is designed to rapidly evaluate new therapies for COVID -19. This could mean that the 
study finds that a drug that you were started on will not be studied further. If this happens, we will tell you. If you agree we would like you to continue to participate in the study and have all of the study visits, but this is your choice. We will not ask you to stay on the study drug if early results suggest that the study drug is not safe.  
  
WHAT  DO I HAVE TO DO IF I AM IN THIS  STUDY? 
 
Location of Study Visits  
Your study visits will take place in person or remotely. You and the staff at your site will discuss 
the location for each visit.  
• In-person visits will take place at the clinic, at your home, or at another non-clinic location.  
• Remote visits will take place over the phone or via telemedicine systems approved for use at 
your site.  
 
Information Collected at Screening 
There is some information that we collect on everyone who is screened for this study. As part of your screening visit, some demographic (for example, age, gender, race), clinical (for example, disease condition, diagnosis), and laboratory values will be collected from you.    
 86 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  We will collect this information even if you do not enroll in this study. This information is 
collected so that researchers may determine whether there are patterns and/or common reasons why people do not join a study.  
Blood Drawn 
The site staff can tell you how much blood will be collected at any particular visit. At most visits, 
the amount will be no more than XX mL (x tablespoons)  of blood collected. At a few visits, up to 
XX-XX mL (x -x tablespoons)  will be collected.  
 
Screening Vis it 
If you would like to be in this study, after you have read and signed this consent form, you will have a screening visit to make sure you meet the requirements for joining the study. This visit will take about 1 hour.  At this visit:  
• study  staff will review your history and confirm  that you have tested positive for SARS- CoV-2 
infection.  
• you will be asked  about  symptoms  you are
 experiencing.  
• study  staff will ask you about any health conditions  you have  and questions  about your 
health in general.  
• study staff will ask you about your medication history and any medications you are taking. 
• you may have a brief physical exam if your screening visit takes place in person.  
 
Entry Visit  
If you qualify for the study, you will have an entry visit. This visit might occur on the same day as 
your screening visit. At this visit, you will be randomly assigned (like flipping a coin or rolling 
dice) to a study group. You and the study staff will not be able to choose which treatment group you are in. You will not know whether you are receiving active drug or placebo. We will tell you more about the treatment groups that you might be in during the second part of this consent process.  
 Also at the Entry visit:  
• you will have a physical exam and answer questions about your medical history and any medications you are taking or have taken in the past.  
• you will be asked  about  symptoms  you are
 experiencing.  
• you will be asked about your smoking status and  history.  
• the study staff will ask if anyone else in your household has been diagnosed with SARS -
CoV-2 infection. 
• you will be asked  to provide your home  address. 
 87 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  • you will be asked  to provide contact information for people the study  staff could contact in 
case we cannot reach you for a study visit.  You will need to tell these people  that you are in 
the study,  and that they could receive a call  from study  staff.  If study  staff cannot reach you 
after two tries (separated by 24 hours), they will call one of the people you have identified.  
• you will be asked  to provide  your health care provider contact information, like your physician 
or commonly used clinic and hospital.  
• you will receive  a kit that includes  information about the study,  a diary in which you will 
record how you are feeling, instructions  on what to do if you have worsening symptoms , and 
contact  information for the study  staff.  
• you will complete your first entry in the study diary with the study staff to make sure that you 
understand how to complete the diary.  
• you will have blood drawn. This blood will be used for the following tests:  o for protocol -required testing 
• you will start study drug. Details of this are provided in the next part of the consent.  
• you will have a swab collected from your nose. This swab is used to detect viruses. For this swab, the site staff will insert a swab into your nostril.  The swab  will be placed deep towards  
to the back  of your throat. The swab  will be left in place for
 several  seconds  and then slowly  
removed.  This procedure is uncomfortable and it might make you gag or make your nose 
bleed.  
 
Daily on Days 1-28  
You will record your symptoms in your study diary at about the same time every day. If you are 
not feeling well, someone can help you by writing the responses down for you, but the 
responses should come from you.   You will receive a reminder every day on days 1- 28 to complete your study diary. This reminder 
may be by telephone, text message, email, or other method that you give permission for.   
Study Visits on Days 3, 7, 14, 28  
At these visits: 
• you will have a brief physical exam and answer questions about any medications you are 
taking  
• the study staff will ask you if there are any updates to the contact information for the people you have identified  
• you will review the entries in your study diary with study staff. On day 28, the study staff will 
collect your diary  
• the study staff will ask you if anyone else in your household has been diagnosed with SARS- CoV-2 infection. (Day 28) 
• you will have blood drawn (Day 7 and 28). This blood will be used for the following tests:   
o for protocol -required testing 
• the site staff will collect a deep nasal swab as described above (Days 3, 7, 14)  
 
 88 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  Study Visits at Weeks 12 and 24 
At these visits: 
• you will have a brief physical exam (week 24)  
• you will answer questions about any medications you are taking 
• at week 12, the study staff will ask you if there are any updates to the contact information for 
the people you have identified  
• you will answer questions about any potential COVID -19 related symptoms or conditions 
you have experi enced  
• at week 24, you will have blood drawn. This blood will be used for the following tests:   o for protocol -required testing 
 
Study Visits on Weeks 36, 48, and 72 
• You will be contacted by phone by the study team to assess whether you have had any new symptoms or clinical events since your last visit  
• You will be asked about any new medications you have taken or are taking  
• You will answer questions about any potential COVID -19 related symptoms or conditions 
you have experienced  
 
Additional Study Visits  
Study visits may be required in addition to the ones described here. This will depend on the 
study drug/placebo you received. Details are listed in the consent which discusses the study drug you might receive.  
 
Early Discontinuation  
If at any point in the study  you want to stop participating  in the study,  you must  contact the site 
immediately . The study doctor may ask you to continue to be part of the study and return for 
some study visits and procedures.  
 If you have not withdrawn consent but must discontinue participation in the study after starting study drug, the site will attempt to obtain information regarding vital status (whether you are 
living or have died) from other sources, such as family members, other secondary contacts  that 
you have provided, or clinical records. 
 If you choose to withdraw consent, no additional samples will be collected and no new information will be collected. Any samples that have not been analyzed prior to your withdrawal 
of consent will be destroyed, but any information from any samples already analyzed will still be 
used.  
 
Genetic Testing [sites remove this section if PBMCs are not collected at your site]  
Your body, like all living things, is made up of cells. Cells contain deoxyribonucleic acid, 
also known as “DNA”. DNA is like a string of information put together in a certain order. 
Parts of the string make up “genes”. Genes contain instructions on how to make your body 
work and fight disease. Differences or changes in DNA explain some of the physical 
differences among people. These differences partly explain why some people get diseases 
 89 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  like cancer or diabetes while others do not. Genetic testing looks at  the differences in 
people’s DNA. This testing also looks at how differences affect health and the body’s 
response to disease and treatment.   
If you agree, some of your blood that is collected will be used to study whether there are 
genetic differences in how sick people get when they are infected with SARS -CoV-2 or how 
they respond to study drugs. 
This genetic testing might include whole genome sequencing 
(WGS). “Sequencing” is looking at the order of a person’s genes to see how this order is 
different fr om the order of most people.  
 You do not have to agree to participate in this genetic testing. Even if you do not agree, you 
can still participate in the rest of the study.  
 
Please put your initials below to indicate your choice:  
 
________ (initials) I understand and I agree to this use of my samples  
 
OR 
 _________ (initials)  I understand but I do not agree to this use of my samples  
 If you agree now but choose to withdraw consent for genetic testing in the future, no additional 
samples will be collected for this purpose and no new information will be collected. Any samples that have not been analyzed prior to your withdrawal or consent will not be used for genetic 
testing in the future. However, any information from samples already analyzed will still be used.  
 
 WILL I RECEIVE THE RESULTS OF ANY TESTS?  
 
Some of the blood that is collected from you will be stored and tested later. Some of these tests 
may be done after you are done with the study, and other tests are not yet approved by the FDA and are still considered “research” tests. For these reasons, you will not receive the results of the tests to:  
• check how well your blood clots  
• check if your body developed antibodies to SARS -CoV -2 
• check levels of virus in your blood  
 You will be told of any new information learned during the course of the study that might cause you to change your mind about staying in the study. At the end of the study, you will be told when study results may be available and how to learn about them. As with all studies, if we find 
out important information that may affect your care, you will be provided with those results.  
 
 HOW  MANY  PEOPLE WILL TAKE PART IN THIS STUDY? 
 90 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL   
110 people will receive each study drug and a similar number of people will receive placebo.  
  
HOW  LONG  WILL I BE IN THIS  STUDY? 
 
You will be in this study  72 weeks (18 months). 
  
WHY  WOULD THE DOCTOR  TAKE ME OFF THIS  STUDY EARLY? 
 
The study  doctor  may need to take you off the study  early  without your permission if: 
• the study  is stopped or cancelled  
• your health care provider requests that you stop participating in the study  
• you do not receive the first dose of study drug when you start the study  
The study  doctor  may also need to take you off the study drug without  your permission if: 
• you are taking other medications  that should not be taken with the study drug 
• continuing the study drug may be harmful to you 
 If you must  stop taking the study drug before you are finished with the study, the study  doctor 
will ask
 you to continue  to be part of the study  and return for study  visits and procedures.  
  
WHAT  HAPPENS IF I DECIDE  TO PERMANENTLY STOP  TAKING STUDY- PROVIDED
 
MEDICATIONS?  
 
If you must  permanently  stop taking study drug before  your study  participation is over, the study  
staff will discuss  other options  that may be of benefit to you. 
  WHA
T HAPPENS WHEN I FINISH  THE STUDY ? 
 After  you have  completed your study  participation, the study  will not be able to continue to
 
provide you with the study drug you received on the study. If continuing  to take these  or similar  
drugs/agents  would be of benefit to you, the study  staff will discuss  how you may be able to 
obtain them. 
  
 91 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  WHAT  ARE THE RISKS OF THE STUDY?  
 
Risks of Study Drug 
There are risks to taking part in any research study.  We do not yet know if the study drugs will 
successfully treat COVID -19. One risk is that the study drug may not stop you from becoming 
sicker,  being  hospitalized, or dying from COVID -19.  
 
There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are 
taken with the study drug. For your safety, you must  tell the study  doctor or nurse about all 
medications  you are taking before you start the study.   
 There are some risks that are specific to the study drug that you might be assigned to. We will tell you 
about those risks in the second part of this consent process.  
 
Risks of Blood Draw  
Having blood drawn may cause some discomfort, bleeding, bruising, and/or swelling where the needle enters the body, and in rare cases it may result in fainting. There is a small risk of infection.  
 
Risks of Nose Swabs  
Nose swabs might make you gag or sneeze. They may also cause discomfort or cause your nose to bleed.   
Effect on Future Vaccination 
Vaccines against the virus that causes COVID -19 are becoming available. It is currently 
unknown how long people should wait to receive a COVID -19 vaccine after having COVID-19, 
since the body's own immune response may offer protection for several months. W e also do not 
know how your body’s immune response to COVID -19 vaccines may be affected by  the 
drugs  being evaluated in this study. If there are potential effects and recommendations for a 
given study drug, they will be reviewed with you.  
  
ARE THERE  RISK S RELATED TO PREGNANCY  AND BREASTFEEDING?
 
 
In the second part of the consent process, we will tell you about the specific drugs that you might receive and whether they have any risks related to pregnancy and breastfeeding.  
 
If at any point during the study you think you may be pregnant, you should let the staff at your site know so that a pregnancy test can be done.  
 If you become pregnant while on study, the study staff would like to obtain information from you about the outcome of the pregnancy (even if it is after your participation in the study ends).  
 
 ARE THERE  BENEFITS TO TAKING  PART  IN THIS  STUDY? 
 92 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL   
If you take part in this study, there may be a direct  benefit  to you, but no guarantee can be 
made. It is also possible  that you may receive no benefit from being in this study. Information 
learned from this study  may help others  who have COVID -19. 
  WHAT  OTHER  CHOICES  DO I HAVE  BESIDES THIS  STUDY? 
 Instead of being in this study  you have  the choice  of: 
• treatment with prescription drugs  available to you from your health care provider  
• treatment with other experimental  drugs if you qualify  
• supportive treatment, like bedrest  and over the counter pain, cough, and fever medication 
• no treatment  
• There may be a COVID treatment available to you through a United States Food and Drug Administration (US FDA) Emergency Use Authorization (EUA).
 Under an EUA, the FDA may 
allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent 
serious or life-threatening diseases or conditions. Your site will tell you about any COVID 
treatments that might be available to you through an EUA.  
 
Please talk to your doctor  about these and other choices  available to you. Your doctor  will 
explain the risks and benefits of these choices.  
  WHAT  ABOUT  CONFIDENTIALITY? 
 
For sites in the US  
We will do everything we can to protect your privacy. In addition to the efforts of the study staff to help keep your personal information private, we have gotten a Certificate of Confidentiality from the US Federal Government. This certificate means that researchers cannot be forced to tell people who are not connected with this study, such as the court system, about your participation. Any publication of this study will not use your name or identify you personally.  
 Your records may be reviewed by the US  FDA, the ACTG, the US Office for Human Research 
Protections (OHRP), or other local, US, and international regulatory entities as part of their duties, (insert name of site) institutional review board (IRB) (a committee that protects the rights and safety of participants in research), National Institutes of Health (NIH), study staff, study 
monitors, drug companies supporting this study, and their designees. Having a Certificate of 
Confidentiality does not prevent you from releasing information about yourself and your participation in the study.  Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse and/or neglect or a risk of harm to yourself or others, we will be required to tell the proper authorities.  
 
 93 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  A description of this clinical trial will be available on https//www.ClinicalTrials.gov , as required by 
US law. This website will not include information that can identify you. At most, the website will 
include a summary of the results. You can search this website at any time.  
 
For sites outside the US 
Efforts will be made to keep your personal information confidential. We cannot guarantee absolute confidentiality. Your personal information may be disclosed if required by law. Any publication of this study will not use your name or identify you personally. 
 
Your records may be reviewed by the US FDA, the ACTG, the US Department of Health and 
Human Services Office for Human Research Protections ( OHRP ), or other local, US, and 
international regulatory entities as part of their duties , (insert name of site) Institutional Review 
Board (IRB ) or Ethics Committee (a committee that protects the rights and safety of participants 
in research), NIH, study staff, study monitors, drug companies supporting this study, and their 
designees.  
 
A description of this clinical trial will be available on ClinicalTrials.gov , as required by US law. 
This website will not include information that can identify you. At most, the website will include a 
summary of the results. You can search this website at any time.  
 
For all sites : 
All information collected about you as part of the study will be sent securely to the ACTG 
statistical and data management center in the United States and to PPD, a company that is 
managing the data for this study. Your information will be combined with information from 
other study participants and statistical analysis of study results. Your name and other personal 
identifiers will not be sent. Your research site is responsible for sending your information in 
accordance with the laws, regulations and policies of your country and research site. 
 Your de-identified study records will be provided to the pharmaceutical companies that are supporting this study. ‘De-identified’, means that information such as your name or 
other information that can identify you (such as address, birth date, social security 
number, etc.) will be removed. These companies will use your de-identified personal information for legitimate business, research, or regulatory purposes such as for getting their drugs approved. 
 
 WHAT  IF THE SITE CAN NO LONGER  REACH ME DURING  THE STUDY?  
 If you cannot  be reached  after two attempts  to contact you (with 24 hours between attempts), 
study  staff may try to
 contact you through the family, friends , or acquaintances  you provided at 
screening and updated at each visit.  
 If you are still unable
 to be reached,  we will attempt  to obtain information about your status 
(whether you are living or have died) by  contacting your health care provider (if you agree) or by 
 94 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  accessing publicly available records (you do not have to give your permission for us to access 
these records).    
WHAT  ARE THE COSTS  TO ME? 
 
There will be no cost to you for study -related visits  or procedures. If you require medical  care as 
a result of taking study drug, it is possible that your insurance  company  will not pay for these 
costs because you
 are taking part in a research study. Costs  related to acute care/hospitalization 
will not be covered by the study.  
  WILL I RECEIVE ANY PAYMENT? 
 
[Insert site-specific  information  on compensation to study  participants.]  
 
 WHAT  HAPPENS  IF I AM INJURED?  
 If you are injured as a result of being  in this study, you will be given immediate treatment for
 your 
injuries.  The NIH does not have a mechanism to provide direct compensation for research 
related injury .  
 [Sites: Please modify (if necessary) and insert one of these two statements, as appropriate to your site. If your site is required to carry CTI, this must be indicated in the informed consent.  
• this site has clinical trials insurance. This insurance will allow the site to provide you with monetary compensation if you suffer harm as a result of participating in this research study.  
OR 
• the cost for this treatment will be charged to you or your insurance company. There is no program for compensation either through this institution or the NIH.] 
 The US federal government has a program that may provide compensation to you or your family if you experience serious physical injuries or death and these costs are not covered by other payors. To find out more about this “Countermeasures Injury Compensation Program” go to  https://www.hrsa.gov/cicp/about/index.html  
or call 1-855 -266-2427. 
 
Due to the coronavirus public health crisis, the US federal government has issued an order 
that may limit your right to sue and recover for losses if you are injured or harmed while 
participating in this COVID -19 clinical study. If the order applies, it limits your right to sue and 
recover for losses from the researchers, healthcare providers, any study sponsor or 
manufacturer or distributor involved with the study. However, the order does not limit your right to seek compensation for injuries that result from conduct or activities of the researchers, health care providers, study sponsors, manufacturers, and distributors that is unrelated to the study.  
 95 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL   
You will not be giving up any of your legal rights by signing this consent form.  
  
WHAT  ARE MY RIGHTS  AS A RESEARCH PARTICIPANT?  
 
Taking part in this study  is completely  voluntary.  You may choose not to take part in this study
 or 
leave this study  at any time. Your decision will not have any impact on your participation in other 
studies  and will not result in any penalty  or loss of benefits  to which  you are otherwise  entitled.  
 We will tell you about new information from this or other studies  that may affect your health,
 
welfare, or willingness  to stay in this study.  If you want the results  of the study,  let the study  staff 
know.   
 
WHAT  DO I DO IF I HAVE  QUESTIONS  OR PROBLEMS? 
 For questions about this study  or a research- related injury, contact: 
• name of the investigator  or other study  staff 
• telephone number  of above 
 For questions about your rights  as a research participant,  contact:  
• name or title of person on the IRB or other organization  appropriate for the site 
• telephone number  of above 
 
Contacting Your Health Care  Provider 
[Sites  modify  per local requirements  for obtaining health care records .] 
With your permission, for which  you would need to sign a waiver, study  staff may contact your 
health care provider  or hospital(s) where you might receive care to determine if you have been  
hospitalized or died while  in the study,  and the cause  of death.  You can still participate in this study 
even if you do not give us permission to contact your health care provider or hospital(s).  
 Will you allow  us to contact  your
 health care provider  or hospital(s) to obtain this information? 
 
________   YES   
________  NO   
________ Initials  
 If you said Yes, please  list the names  of your health care provider  and the hospitals  you would
 
likely  be admitted to, below: 
________________________________________________________________________________________________________________________________________________________
____________________________________________________________________________
____________________________________________________________________________ 
 96 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX I: SAMPLE INFORMED CONSENT – PHASE II,  MAIN PROTOCOL  SIGNATURE  PAGE  
 
If you have  read this consent  form (or had it explained to you),  all your questions  have been  
answered and you agree to take part in this study,  please sign your name below. 
   ______________________________________ ___________________________________ 
Participant’s  Name  (print)  Participant’s  Signature and Date 
    ______________________________________ ___________________________________ 
Participant’s  Legally  Authorized Representative  Legally  Authorized Representative (print) 
(As appropriate)      Signature and Date  
    
________________________________ ___________________________________ 
Study  Staff Conducting   Study  Staff’s  Signature and Date
 Consent 
Discussion  (print)  
  
  
 ___________________________________ _____________________________________ 
Witness’s  Name  (print)   Witness’s  Signature and Date
 (As appropriate)  
  
 97 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 APPENDIX II : SAMPLE INFORMED CONSENT – PHASE III, MAIN PROTOCOL  
 
DIVISION  OF AIDS  
AIDS  CLINICAL  TRIALS  GROUP  (ACTG)  SAMPLE INFORMED CONSENT  
FOR  PROTOCOL:  ACTIV -2 / A5401  
 
Adaptive Platform Treatment Trial for Outpatients with COVID -19, FINAL  Version 8.0 
 
SHORT  TITLE  FOR  THE STUDY: Adapt Out COVID  
 
SUMMARY  
 
PURPOSE  This is a research study and your participation in this study is voluntary. 
The purpose of this study is to evaluate the ability of various drugs to 
improve health outcomes for people with COVID -19. We also want to see 
if these drugs are safe, and if these drugs can stop the disease process 
and prevent hospitalization and death. This study is designed to quickly 
identify safe and effective drugs that can treat COVID -19. 
 STUDY  
DRUG
 Study drug will be either an active study drug or a placebo. A placebo 
looks like a “real” drug, but it does not have any active medication in it.  
  As drugs are recommended for the treatment of COVID -19 symptoms, 
some of them will be selected for testing in this study. Therefore, there may be different drugs being used as part of the study at different times. You will receive information about specific drugs being tested at this time in a separate consent form. Regardless of how many study drugs are being tested, you will only receive one study drug (active drug or placebo).  
  NUMBER OF  
PARTICIPANTS
 For each drug being tested in this part  of the study, approximately  600 
people will receive the study drug and an equal number will receive 
placebo.  
 
LENGTH  OF 
STUDY  Your participation in this study  will last 72 weeks (18 months). 
 REQUIRED  
ACTIVITIES  If you are in this study, the following study procedures are required: 
• you will record your symptoms  
• you will provide blood samples  
 98 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 • you will have nasopharyngeal swabs (also known as deep nasal 
swabs) collected by a study staff person 
• you will complete surveys about your symptoms  
  
RISKS There are some risks that are specific to the study drug that you might 
receive. We will tell you about those risks in the second part of this consent process.  
 
BENEFITS If you take part in this study, there may be a direct benefit to you, but no 
guarantee can be made. It is also possible that you will receive no benefit from being in this study. Information learned from this study may help others who have COVID-19. 
 
OTHER  CHOICES  Instead of being in this study, you have the option of: 
• a COVID -19 treatment available to you through a United States Food 
and Drug Administration (US FDA) Emergency Use Authorization 
(EUA) or equivalent authorization or approval. Under certain 
circumstances, the FDA or other similar regulatory agency may 
allow unapproved medical products to be used in an emergency to 
diagnose, treat, or prevent serious or life-threatening diseases or 
conditions. Your site will tell you about any authorized or approved 
COVID treatments that might be available to you. Since these 
treatments work very well at preventing hospitalizations from COVID -19, you should see if you can receive these authorized or 
approved treatments before participating in this study. If the treatments are not currently an option for you or you choose not 
to receive them, you may be be able to participate in this study, and if the treatments become an option for you later, you will be allowed to receive them. 
• treatment with other experimental drugs if you qualify 
• no treatment  
 
 INTRODUCTION  
 
You are being asked to take part in this research study because you have been diagnosed with 
SARS- CoV-2 and have symptoms of the disease it causes, which is commonly known as 
COVID -19. This study is sponsored by the National Institutes of Health (NIH). The doctor in 
charge of this study at this site is: (insert name of Principal Investigator). Before you decide if 
you want to be a part of this study, we want you to know about the study.  
 This is a consent form. It gives you information about this study. The study staff will talk with you about this information. You are free to ask questions about this study at any time. If you agree to take part in this study, you will be asked to sign this consent form. You will get a copy to keep.  
 99 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 WHY  IS THIS  STUDY BEING  DONE?  
 
SARS- CoV-2 is a new virus that has caused a widespread outbreak of an illness called COVID - 
19. In most people, it causes a mild to moderate symptoms, like a “cold”. In others, this virus 
can cause a pneumonia (an inflammation of the lungs), which can be serious and life 
threatening. As of January 5, 2022 , there have been >290 million confirmed c ases of COVID-
19 and >5.5 million deaths attributed to COVID-19 globally.  
 In this  part of the study, we will study drugs that looked safe and seemed to work better 
than placebo in an earlier part of the study. We will collect more information on how safe 
the study drug is. We will see if the study drug can reduce the number of people who have to go 
into the hospital or who die from COVID-19.  
 A previous version of this study compared the study drug to casirivimab plus imdevimab 
(also known as REGEN -COV ). Casirivimab plus imdevimab is a treatment given through 
an IV  (in a vein) that was shown before to be safe and lower  the chance of being 
hospitaliz ed or dying from COVID -19. There is now a new variant (type) of the SARS -CoV-
2 virus that has become very common around the world, the Omicron variant. A variant 
means that parts of the virus have changed. As a result of these changes, casirivimab 
plus imdevimab is not expected to work against the Omicron virus, and is no longer 
authorized by the FDA for treatment of COVID -19 in parts of the US where Omicron is 
common. As we cannot continue to give casirivimab plus imdevimab in the study, the 
study has been changed to compare the study drug to a placebo. For people newly 
learning about this study, you must check whether  there are other authorized or 
approved treatments for COVID -19 that are an option for you before you can join the 
study.  You will receive either a study drug or placebo for the study drug. Your assignment is 
random, like the flip of a coin. You will be told about all the study drugs you may be assigned to in this study. If only one study drug is available, you will have an equal chance of receiving the study drug or placebo. If two study drugs are available, you will have a 2:1 chance of receiving 
a study drug or placebo. You will be told about all the study drugs you may be assigned to in 
this study. You will not be able to choose your study drug. Neither you, your study doctor, nor 
the study staff at your site will know whether you are receiving the active study drug or placebo.  
The study is designed to rapidly evaluate new therapies for COVID -19. This could mean that the 
study finds that a drug that you were started on will not be studied further. If this happens, we 
will tell you. If you agree we would like you to continue to participate in the study and have all of the study visits, but this is your choice. We will not ask you to stay on the study drug if early results suggest that the study drug is not safe.  
 
 
WHAT  DO I HAVE TO DO IF I AM IN THIS  STUDY? 
 100 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
  
Location of Study Visits  
Your study visits will take place in person or remotely. You and the staff at your site will discuss 
the location for each visit.  
• In-person visits will take place at the clinic, at your home, or at another non-clinic location 
• Remote visits will take place over the phone or via telemedicine systems approved for use at 
your site  
 
Information Collected at Screening 
There is some information that we collect on everyone who is screened for this study. As part of 
your screening visit, some demographic (for example, age, gender, race), clinical (for example, disease condition, diagnosis), and laboratory values will be collected from you.    
We will collect this information even if you do not enroll in this study. This information is 
collected so that researchers may determine whether there are patterns and/or common reasons why people do not join a study.  
Blood Drawn  
The site staff can tell you how much blood will be collected at any particular visit. At most visits, the amount will be no more than XX mL (x tablespoons)  of blood collected. At a few visits, up to 
XX-XX mL (x -x tablespoons)  will be collected.  
 
Screening Visit  
If you would like to be in this study, after you have read and signed this consent form, you will 
have a screening visit to make sure you meet the requirements for joining the study. This visit 
will take about 1 hour.  At this visit:  
• study  staff will review your history and confirm  that you have tested positive for SARS- CoV-2 
infection  
• you will be asked  about  symptoms  you are
 experiencing  
• study  staff will ask you about any health conditions  you have  and questions  about your 
health in general 
• study staff will ask you about your medication history and any medications you are taking  
• If you can become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample for a pregnancy test  
• you may have a brief physical exam if your screening visit takes place in person 
 
Entry Visit  
If you qualify for the study, you will have an entry visit. This visit might occur on the same day as your screening visit. At this visit, you will be randomly assigned (like flipping a coin or rolling 
dice) to a study group. You and the study staff will not be able to choose which treatment group 
you are in. We will tell you more about the treatment groups that you might be in during the 
second part of this consent process.  
 
 101 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 Also at the Entry vi sit: 
• you will have a physical exam and answer questions about your medical history and any 
medications you are taking or have taken in the past 
• you will be asked  about  symptoms  you are  experiencing  
• you will be asked about your smoking status and history  
• the study staff will ask if anyone else in your household has been diagnosed with SARS -
CoV-2 infection 
• you will be asked  to provide your home  address  
• you will be asked  to provide contact information for people the study  staff could contact in 
case we cannot reach you for a study visit.  You will need to tell these people  that you are in 
the study,  and that they could receive a call  from study  staff.  If study  staff cannot reach you 
after two tries (separated by 24 hours), they will call one of the people you have identified.  
• you will be asked  to provide  your health care provider contact information, like your physician 
or commonly used clinic and hospital  
• you will receive  a kit that includes  information about the study,  a diary in which you will 
record how you are feeling, instructions  on what to do if you have worsening symptoms  and 
contact  information for the study  staff 
• you will complete your first entry in the study diary with the study staff to make sure that you understand how to complete the diary  
• a swab will be collected from your nose. This swab is used to detect viruses. For this swab, the site staff will insert a swab into your nostril. The swab  will be placed deep towards  to the 
back  of your throat. The swab  will be left in place  for
 several  seconds  and then slowly  
removed.  This procedure is uncomfortable,  and it might make you gag or make your nose 
bleed.  
• you will have blood drawn. This blood will be used for the following tests:  o for protocol -required testing 
o routine safety tests (liver and kidney tests and blood counts)  
• you will start study drug.  
 
Daily on Days 1-28  
You will record your symptoms in your study diary at about the same time every day. If you are not feeling well, someone can help you by writing the responses down for you, but the 
responses should come from you. 
 You will receive a reminder every day on days 1- 28 to complete your study diary. This reminder 
may be by telephone, text message, email, or other method that you give permission for.  
Study Visits on Days 3, 7, and 14 
At these visits: 
• you will answer questions about how you are feeling and any medications you are taking  
• you will have a brief physical exam (Day 3)  
• the study staff will ask you if there are any updates to the contact information for the people 
you have identified  
 102 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 • you will review the entries in your study diary with study staff  
• a nasal  swab will be collected from your nose as described above (Day 3)  
• you will have blood drawn (Day 3). This blood will be used for the following tests:  
o for protocol -required testing 
o routine safety tests (liver and kidney tests and blood counts)  
 
Study Visit on Day 28 
At this visit:  
• you will have a brief physical exam and answer questions about any medications you are 
taking  
• the study staff will ask you if there are any updates to the contact information for the people you have identified  
• you will review the entries in your study diary with study staff and the study staff will collect your diary  
• the study staff will ask you if anyone else in your household has been diagnosed with SARS- CoV-2 infection  
• you will have blood drawn. This blood will be used for the following tests:  o for protocol -required testing 
o routine safety tests (liver and kidney tests and blood counts)  
 
Study Visits at Weeks 12, 24, 36, 48, and 72 
At these visits: 
• you will have a brief physical exam (week 24)  
• you will answer questions about any medications you are taking 
• at week 12, the study staff will ask you if there are any updates to the contact information for 
the people you have identified  
• you will answer questions about any  potential COVID -19 related symptoms or conditions 
you have experienced. 
• at week 24, you will have blood drawn. This blood will be used for the following tests:   o for protocol -required testing  
 
Early Discontinuation  
If at any point in the study  you want to stop participating  in the study,  you must  contact the site 
immediately . The study doctor may ask you to continue to be part of the study and return for 
some study visits and procedures.  
 If you have not withdrawn consent but must discontinue participation in the study after starting study drug, the site will attempt to obtain information regarding vital status (whether you are living or have died) from other sources, such as family members, other secondary contacts that 
you have provided, or clinical records.  
 
If you choose to withdraw consent, no additional samples will be collected and no new information will be collected. Any samples that have not been analyzed prior to your withdrawal 
 103 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 of consent will be destroyed, but any information from any samples already analyzed will still be 
used.  
  
WILL I RECEIVE THE RESULTS OF ANY TESTS?  
 
Some of the blood that is collected from you will be stored and tested later. Some of these tests may be done after you are done with the study, and other tests are not yet approved by the FDA and are still considered “research” tests. For these reasons, you will not receive the results of 
the tests to:  
• check if your body developed antibodies to SARS -CoV -2 
• check levels of virus in your blood and nose  
 You will be told of any new information learned during the course of the study that might cause 
you to change your mind about staying in the study. At the end of the study, you will be told when study results may be available and how to learn about them. As with all studies, if we find out important information that may affect your care, you will be provided with those results.  
 
 
HOW  MANY  PEOPLE WILL TAKE PART IN THIS STUDY? 
 Approximately 600 people will receive the study drug, and an equal number will receive 
placebo for the study drug.   
 
HOW  LONG  WILL I BE IN THIS  STUDY? 
 You will be in this study  72 weeks (18 months). 
 
 
WHY  WOULD THE DOCTOR  TAKE ME OFF THIS  STUDY EARLY? 
 The study  doctor  may need to take you off the study  early  without your permission if: 
• the study  is stopped or cancelled  
• your health care provider requests that you stop participating in the study  
• you do not receive the first dose of study drug when you start the study  
The study  doctor  may also need to take you off the study drug without  your permission if: 
• you are taking other medications  that should not be taken with the study drug 
• continuing the study drug may be harmful to you 
 If you must  stop taking the study drug before you are finished with the study, the study  doctor 
will ask
 you to continue  to be part of the study  and return for study  visits and procedures.  
 
 104 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
  
WHAT  HAPPENS IF I DECIDE  TO PERMANENTLY STOP  TAKING STUDY- PROVIDED  
MEDICATIONS?  
 
If you must  permanently  stop taking study drug before  your study  participation is over, the study  
staff will discuss  other options  that may be of benefit to you. 
 
 WHAT  HAPPENS WHEN I FINISH  THE STUDY ? 
 After  you have  completed your study  participation, the study  will not be able to continue to
 
provide you with the study drug you received on the study. If continuing  to take these  or similar  
drugs/agents  would be of benefit to you, the study  staff will discuss  how you may be able to 
obtain them. 
  WHAT  ARE THE RISKS OF THE STUDY?  
 
Risks of Study Drug 
There are risks to taking part in any research study.  The effectiveness  of the study drug is  not 
known. One risk is that the study drug may  not stop you from becoming sicker,  being  
hospitalized,  or dying from COVID -19. We also do not know if the study drug will work against 
variants (types) of the virus that might appear  in the future.  
 If you are assigned to placebo, it will not stop you from becoming sicker, hospitalized, or dying 
from COVID -19. 
 
There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are
 
taken with the study drug. For your safety, you must  tell the study  doctor or nurse about all 
medications  you are taking before you start the study.   
 
There are some risks that are specific to the study drug that you might be assigned to. We will tell you 
about those risks in the second part of this consent process.  
 
Effect on Future Vaccination 
We do not know how receiving the study drugs in this study will affect your body’s immune response to COVID -19 vaccines if you receive a vaccine after you receive the 
study drug. If there are potential effects and recommendations for a given study drug, 
they will be reviewed with you.   
For participants who received casirivimab plus imdevimab in ACTIV -2, the US Centers for 
Disease Control and Prevention (CDC)  recently changed their guidance to say that 
people who have received antibody-based treatment (like casirivimab plus imdevimab) 
can receive a COVID -19 vaccine at any time, and do not have to wait for a period after 
 105 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 receiving the antibody treatment.  It is possible that the levels of antibodies generated by 
vaccination may be lower in people who received an antibody treatment before 
vaccination than in people who did not receive an antibody treatment before vaccination, 
but it is not known if this means you will not be as protected from future COVID -19, and 
the CDC still recommends proceeding with vaccination.  
 
Risks of Blood Draw  
Having blood drawn may cause some discomfort, bleeding, bruising, and/or swelling where the 
needle enters the body, and in rare cases it may result in fainting. There is a small risk of 
infection.  
 
Risks of Nose Swabs  
Nose swabs might make you gag or sneeze. They may also cause discomfort or cause your 
nose to bleed.  
  
ARE THERE  RISKS RELATED TO PREGNANCY  AND BREASTFEEDING?
 
 
In the second part of the consent process, we will tell you about the specific drugs that you might receive and whether they have any risks related to pregnancy and breastfeeding.  
 
If at any point during the study you think you may be pregnant, you should let the staff at your 
site know so that a pregnancy test can be done.  
 If you become pregnant while on study, the study staff would like to obtain information from you 
about the outcome of the pregnancy (even if it is after your participation in the study  ends).  
 
 ARE THERE  BENEFITS TO TAKING  PART  IN THIS  STUDY? 
 If you take part in this
 study, there may be a direct  benefit  to you, but no guarantee can be 
made. It is also possible  that you may receive no benefit from being in this study. Information 
learned from this study  may help others  who have COVID -19. 
  WHAT  OTHER  CHOICES  DO I HAVE  BESIDES THIS  STUDY? 
 Instead of being in this study  you have  the choice  of: 
• a COVID -19 treatment available to you through a United States FDA EUA or equivalent 
authorization or approval.  Under certain circumstances, the FDA  or other similar regulatory 
agency  may allow unapproved medical products to be used in an emergency to diagnose, 
treat, or prevent serious or life-threatening diseases or conditions. Your site will tell you about any authorized or approved COVID -19 treatments that might be available to you.
 
Examples of these treatments include a pill called nirmatrelvir/ritonavir (also known 
 106 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 as Paxlovid), a drug called remdesivir, which is given once a day for three days 
through the vein (“intravenously” or “IV”), a drug called sotrovimab and another 
called bebtelovimab, which are  given once IV, and molnupiravir, which is a pill.  
Several of these treatments have been shown to work very well at preventing 
hospitalizations from COVID -19, although these treatments may have been evaluated 
in people with an earlier variant (type) of COVID -19. Y ou must see if you can receive 
these treatments through your healthcare provider or clinics or other locations in your community before participating in this study. It is recommended that you receive these other treatments if possible, instead of being in this study. If the treatments are 
not currently an option for you or you choose not to receive them, you may be able to 
participate in this study, and if the treatments become an option for you later, you will be allowed to receive them. Due to availability, it is likely that not ever yone will have 
the option to receive these treatments in addit ion to the study drug. This study will 
not pay for these treatments that you may receive outside of the study.  
• treatment with other experimental  drugs if you qualify  
• no treatment 
 Please talk to your doctor  about these and other choices  available to you. Your doctor  will
 
explain the risks and benefits of these choices.  
  WHAT  ABOUT  CONFIDENTIALITY? 
 
For sites in the US  
We will do everything we can to protect your privacy. In addition to the efforts of the study staff to help keep your personal information private, we have gotten a Certificate of Confidentiality from the US Federal Government. This certificate means that researchers cannot be forced to tell people who are not connected with this study, such as the court system, about your participation. Any publication of this study will not use your name or identify you personally.  
 Your records may be reviewed by the US  FDA, the ACTG, the US Office for Human Research 
Protections (OHRP), or other local, US, and international regulatory entities as part of their duties, (insert name of site) institutional review board (IRB) (a committee that protects the rights and safety of participants in research), National Institutes of Health (NIH), study staff, study monitors, drug companies supporting this study, and their designees. Having a Certificate of 
Confidentiality does not prevent you from releasing information about yourself and your 
participation in the study.  Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse and/or neglect or a risk of harm to yourself or others, we will be required to tell the proper authorities.  
 
A description of this clinical trial will be available on https//www.ClinicalTrials.gov , as required by 
US law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.  
 107 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
  
For sites outside the US 
Efforts will be made to keep your personal information confidential. We cannot guarantee 
absolute confidentiality. Your personal information may be disclosed if required by law. Any 
publication of this study will not use your name or identify you personally. 
 Your records may be reviewed by the US FDA, the ACTG, the US Office for Human Research Protections (OHRP ), or other local, US, and international regulatory entities as part of their 
duties (insert name of site) institutional review board ( IRB) or Ethics Committee (a committee 
that protects  the rights and safety of participants in research), NIH, study staff, study monitors, 
drug companies supporting this study, and their designees.  
 
A description of this clinical trial will be available on ClinicalTrials.gov , as required by US law. 
This website will not include information that can identify you. At most, the website will include a 
summary of the results. You can search this website at any time.  
 
For all sites: 
All information collected about you as part of the study will be sent securely to the ACTG 
statistical and data management center in the United States and to PPD, a company that is 
managing the data for this study. Your information will be combined with  information from 
other study participants and statistical analysis of study results. Your name and other personal 
identifiers will not be sent. Your research site is responsible for sending your information in 
accordance with the laws, regulations and policies of your country and research site. 
 
Your de-i dentified study records will be provided to the pharmaceutical companies that 
are supporting this study. ‘De-identified’, means that information such as your name or other information that can identify you (such as address, birth date, social security number, etc.) will be removed. These companies will use your de-identified personal information for legitimate business, research, or regulatory purposes such as for getting their drugs approved.  
 
WHAT  IF THE SITE CAN NO LONGER  REACH ME DURING  THE STUDY?  
 If you cannot  be reached  after two attempts  to contact you (with 24 hours between attempts), 
study  staff may try to
 contact you through the family, friends , or acquaintances  you provided at 
screening and updated at each visit.  
 If you are still unable
 to be reached,  we will attempt  to obtain information about your status 
(whether you are living or have died) by  contacting your health care provider (if you agree) or by 
accessing publicly available records (you do not have to give your permission for us to access these records).  
 
 
 108 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 WHAT  ARE THE COSTS  TO ME? 
 
There will be no cost to you for study -related visits  or procedures. If you require medical  care as 
a result of taking study drug, it is possible that your insurance  company  will not pay for these 
costs because you are taking part in a research study. Costs  related to acute care/hospitalization 
will not be covered by the study.  
  WILL I RECEIVE ANY PAYMENT? 
 [Insert site-specific  information  on compensation to study  participants.]  
  WHAT  HAPPENS  IF I AM INJURED?  
 If you are injured as a result of being  in this study, you will be given immediate treatment for
 your 
injuries.  The NIH does not have a mechanism to provide direct compensation for research 
related injury .  
 [Sites: Please modify (if necessary) and insert one of these two statements, as appropriate to 
your site. If your site is required to carry CTI, this must be indicated in the informed consent.  
• this site has clinical trials insurance. This insurance will allow the site to provide you with 
monetary compensation if you suffer harm as a result of participating in this research study.  
OR 
• the cost for this treatment will be charged to you or your insurance company. There is no program for compensation either through this institution or the NIH.] 
 
The US federal government has a program that may provide compensation to you or your family if you experience serious physical injuries or death and these costs are not covered by 
other payors. To find out more about this “Countermeasures Injury Compensation Program” 
go to https://www.hrsa.gov/cicp/about/index.html or call 1-855 -266-2427. 
 
Due to the coronavirus public health crisis, the US federal government has issued an order 
that may limit your right to sue and recover for losses if you are injured or harmed while participating in this COVID -19 clinical study. If the order applies, it limits your right to sue and 
recover for losses from the researchers, healthcare providers, any study sponsor or manufacturer or distributor involved with the study. However, the order does not limit your right to seek compensation for injuries that result from conduct or activities of the researchers, health care providers, study sponsors, manufacturers, and distributors that is unrelated to the 
study.  
 You will not be giving up any of your legal rights by signing this consent form.  
  
 109 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 WHAT  ARE MY RIGHTS  AS A RESEARCH PARTICIPANT?  
 
Taking part in this study  is completely  voluntary.  You may choose not to take part in this study  or 
leave this study  at any time. Your decision will not have any impact on your participation in other 
studies  and will not result in any penalty  or loss of benefits  to which  you are otherwise  entitled.  
 We will tell you about new information from this or other studies  that may affect your health,
 
welfare, or willingness  to stay in this study.  If you want the results  of the study,  let the study  staff 
know.  
 
 WHAT  DO I DO IF I HAVE  QUESTIONS  OR PROBLEMS? 
 For questions about this study  or a research- related injury, contact: 
• name of the investigator  or other study  staff 
• telephone number  of above 
 For questions about your rights  as a research participant,  contact:  
• name or title of person on the IRB or other organization  appropriate for the site 
• telephone number  of above 
 
Contacting Your Health Care  Provider 
[Sites  modify  per local requirements  for obtaining health care records .] 
With your permission, for which  you would need to sign a waiver, study  staff may contact your 
health care provider  or hospital(s) where you might receive care to determine if you have been  
hospitalized or died while  in the study,  and the cause  of death.  You can still participate in this study 
even if you do not give us permission to contact your health care provider or hospital(s).  
 
Will you allow  us to contact  your health care provider  or hospital(s) to obtain this information? 
 
________   YES   
________  NO   
________ Initials  
 
If you said Yes, please  list the names  of your health care provider  and the hospitals  you would  
likely  be admitted to, below: 
____________________________________________________________________________
____________________________________________________________________________
________________________________________________________________________________________________________________________________________________________ 
 110 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 SIGNATURE  PAGE  
 
If you have  read this consent  form (or had it explained to you),  all your questions  have been  
answered and you agree to take part in this study,  please sign your name below. 
   ______________________________________ ___________________________________ 
Participant’s  Name  (print)  Participant’s  Signature and Date 
    ______________________________________ ___________________________________ 
Participant’s  Legally  Authorized Representative  Legally  Authorized Representative (print) 
(As appropriate)      Signature and Date  
    
________________________________ ___________________________________ 
Study  Staff Conducting   Study  Staff’s  Signature and Date
 Consent 
Discussion  (print)  
 
 
 
 ___________________________________ _____________________________________ 
Witness’s  Name  (print)   Witness’s  Signature and Date
 (As appropriate)  
  
 
  
 111 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX II: SAMPLE INFORMED CONSENT – PHASE III,  MAIN PROTOCOL  
 ATTACHMENT A: CONSENT FOR USE OF EXTRA SAMPLES  
 
When samples are no longer  needed  for this study,  the ACTG  may want  to use them  in other  
studies  and share them  with other  researchers.  These samples are called  “extra  samples.”  The 
ACTG  will only allow  your extra samples  to be used in other  studies  if you agree to this. If you 
have any questions, please ask. 
 
Identifiers  will be removed from your samples  and from any private information that has been  
collected  about  you. This means  that no one looking at the labels  or at other  information will be 
able to know  that the samples  or information came  from you. 
 Extra samples  are stored  in a secure central  place called a repository.  Your  samples  will be
 
stored  in the ACTG  repository  located in the United States.  
 
There is no limit on how long your extra samples  will be stored. [Site: Revise  the previous  
sentence to insert  limits  if your regulatory  authority  imposes  them.] 
 
When a researcher  wants  to use your samples  and information, the research plan must  be 
approved by the ACTG.  Also, the researcher’s  institutional  review  board (IRB) or ethics  
committee (EC) will review  the plan. [Site: If review  by your institution’s  IRB/EC/RE  is also 
required, insert a sentence stating this.] IRBs/ECs protect the rights  and well-being of people in 
research. If the research plan is approved,  the ACTG  will send your samples  to the researcher’s  
location. This means  that researchers who are not part of the protocol  team  may use your 
samples  without asking you again for your consent. 
 
You
 will not be paid for your samples. Also, a researcher  may make  a new scientific  discovery  or 
product based on the use of your samples.  If this happens,  there  is no plan to share any money  
with you. 
 
You may withdraw  your consent for research on your extra samples  at any time and the 
specimens  will be discarded.  However, any information from samples already analyzed will still 
be used.  
 Please choose the response that matches  what you want by putting your initials  in the space
 
provided. Please ask the staff any questions  that you have before you indicate your selection. 
 
Research without Human Genetic  Testing  
If you agree,  your extra  samples  may be stored (with usual  protection of your identity) and used  
for ACTG -approved research that does  not include human genetic  testing.  
________ (initials) I understand and I agree to this storage and possible use of my samples. 
OR 
________ (initials) I understand but I do not agree to this storage and possible use of my 
samples. 
 112 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB 
 
Information/evaluations noted in this agent-specific appendix are IN ADDITION to those presented in the master protocol. Section numbering aligns with the master protocol . 
 SCHEMA  
 DESIGN After enrollment of approximately 220 participants in the phase II bamlanivimab 700mg arm, the phase II arm will close and 
bamlanivimab will enter directly into a phase III open-label, single-arm 
evaluation, without a graduation analysis of the phase II data. The phase III arm of bamlanivimab will evaluate the safety of the 
investigational agent.
  
 
DURATION  24 weeks.  
 SAMPLE SIZE Approxi mately 220 participants in the phase II evaluation of 
bamlanivimab 700mg (110 receiving bamlanivimab and 110 receiving 
placebo). In phase III, enrollment will continue until another agent 
enters the study, at which point the phase III evaluation of 
bamlani vimab  700mg will close. At current enrollments rates, it is 
expected that the number of participants who will receive the investigational agent (including those enrolled in phase II) may be 300 or more.
 
 REGIMEN  Phase II: Bamlanivimab or placebo for bamlanivimab  700mg 
administered intravenously (IV) for one dose.  
  Phase III: Bamlanivimab 700mg IV administered IV for one dose.  
 
 
1.0 STUDY OBJECTIVES  
 1.1 Co-Primary Objectives
 
 
1.1.1 Phases II and III: To evaluate safety of the investigational agent. 
 
1.1.2 Phase II: To determine efficacy of the investigational agent to reduce the duration of COVID -19 symptoms through study day 28.  
 
1.1.3 Phase II: To determine the efficacy of the investigational agent to increase the 
proportion of participants with undetectable nasopharyngeal (NP) SARS -CoV -2 
RNA at study days 3, 7, 14, and 28.  
 
 113 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  1.2 Secondary Objectives  
 
1.2.1  Phase II: To determine whether the investigational agent reduces a COVID -19 
Severity Ranking scale based on COVID -19-associated symptom burden 
(severity and duration), hospitalization, and death, through study day 28.  
 
1.2.2 Phase II: To determine whether the investigational agent reduces the 
progression of COVID-19 -associated symptoms. 
 
1.2.3 Phase II: To determine if the investigational agent reduces SARS -CoV -2 
detection or levels of RNA in nasal swabs.  
1.2.4 Phase II: To determine the pharmacokinetics of the investigational agent. 
 
1.2.5 Phase II: To evaluate differences in SARS -CoV-2 RNA levels in NP swabs 
between the investigational agent versus placebo treatment groups and among subgroups of the population and risk groups defined by age and comorbidities.  
 
1.2.6 Phase II: To determine if the investigational agent reduces SARS -CoV -2 
detection or levels of RNA in saliva and nasal swabs. 
 
1.2.7 Phase II: To  determine efficacy  of the investigational  agent to obtain pulse 
oximetry  measurement of ≥96%  through day 28. 
 
1.2.8 Phase III: Among participants receiving the investigational agent, to describe SARS- CoV-2 RNA levels in nasal swabs, symptom duration and severity, and 
proportion of participants  hospitalized or dying through to day 28. 
 
1.2.9 Phase III: Among participants  receiving the investigational agent, to explore 
associations between SARS -CoV -2 RNA levels in nasal swabs, symptom 
duration and severity, and risk of hospitalization/death  
1.3 Exploratory Objectives
 
 
1.3.1 Phases II and III: To explore the impact of the investigational agent on 
participant-reported rates of SARS -CoV-2 positivity of household contacts.  
 
1.3.2 Phases II: To explore if baseline and follow -up hematology, chemistry, 
coagulation, viral, and inflammatory biomarkers are associated with clinical and virologic outcomes in relation to investigational agent use.  
 
1.3.3 Phases II and III: To explore possible predictors of outcomes across the study 
population, notably sex, time from symptom onset to start of investigational 
agent, race/ethnicity, and risk groups defined by age and comorbidities. 
 114 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  1.3.4 Phases II and III: To explore if the investigational agent changes the hospital 
course once a participant requires hospitalization.  
 
1.3.5 Phases II and III: To explore and develop a model for the interrelationships 
between virologic outcomes, clinical symptoms, hospitalization, and death in 
each study group.  
 
1.3.6 Phases II and III: To explore the relationship between exposure to the investigational agent and SARS -CoV-2 innate, humoral, or cellular response, 
including anti -drug antibodies.  
 
1.3.7 Phases II and III: To explore baseline and emergent viral resistance to the investigational agent.  
 
1.3.8 Phases II and III: To explore the association between viral genotypes  and 
phenotypes,  and clinical  outcomes  and, in phase  II, response  to agents.  
 
1.3.9 Phases II and III: To explore the association between host genetics  and clinical  
outcomes  and, in phase  II, response  to agents.  
 
1.3.10 Phases II and III: To explore relationships between dose and concentration of 
investigational agent with virology, symptoms, and oxygenation. 
 
1.3.11 Phases II and III: To explore the association between zinc and vitamin D levels 
and clinical outcomes and, in phase II, response to agents.  
 
1.3.12 Phase II: To explore the impact of investigational agents on SARS -CoV-2 
viremia, i.e., detection or level of SARS -CoV -2 RNA in the blood. 
 
1.3.13 Phase II: To explore if self-collected nasal swabs and saliva correlate with the frequency of detection and levels of SARS -CoV-2 RNA in site-collected NP 
swabs.  
 2.0 INTRODUCTION  
 2.2 Rationale
 
 
Monoclonal Antibodies (mAbs)  
Sera obtained from persons or animals who recovered from a particular infection has 
shown prophylactic and therapeutic potential for a variety of infections, and Emil von 
Behring won the Nobel Prize in 1893 for his work on use of immune serum from the 
blood of infected animals to provide immunity to diphtheria [1]. Currently, hyperimmune 
human sera immunoglobulin is still used to treat many viral infections including  
 115 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  cytomegalovirus (CMV), respiratory syncytial virus (RSV), hepatitis A virus (HAV), 
hepatitis B virus (HBV), and rabies [2].  
 
Unfortunately, heterologous sera was associated with a variety of complications 
including serum sickness and hypersensitivity, which significantly limited its usefulness 
clinically [3]. Given the long history of use of antibodies for infectious diseases, 
monoclonal antibodies were developed (mAbs). Improved purification techniques and 
the ability to engineer humanized mAbs allowed for the development of broadly reactive 
and potent mAbs, which helped reduce some of the issues that hampered the utility of 
heterologous sera [3, 4]. In fact, current technology allows mAbs to be produced  
requiring only tissue culture or microbial expression systems, thus the potential toxicity 
of humanized mAbs is comparable to antibiotics [2, 4]. 
 
Engineered humanized mAbs have shown considerable efficacy for viral infections. The 
first was p alivizumab in 1998, which is used for RSV [5 ]. Monoclonal antibodies have 
also been quickly developed for emerging infections such as Ebola [6 ]. As a part of the 
massive scientific effort to stop COVID -19, mAbs have been developed for treatment of 
COVID -19. These agents now need to be evaluated in rigorous randomized clinical 
trials.  
 
The limitations of mAbs continue to be cost and that these antibodies  are perishable, 
require refrigeration, and must be administered parenterally  [4]; however, their use may 
still be useful in the outpatient setting, as one dose often stays in the therapeutic range 
for months [5], potentially allowing an entire treatment course with a single 
administration. 
 
A number of viral infectious diseases have been successfully treated with mAbs, including RSV and HIV. Some of these mAbs were derived from persons who were infected with these viruses and mounted neutralizing humoral responses. The first investigational agent to be evaluated in this trial will be the mAb bamlanivimab made by 
Lilly Research Laboratories, Eli Lilly and Company, in partnership with AbCellera 
Biologics. B amlanivimab was derived from a person who was infected with and 
recovered from SARS-CoV -2.  
 
Investigational Agent  
Bamlanivimab is a neutralizing immunoglobulin G (IgG) -1 mAb directed to the spike (S) 
protein of SARS -CoV -2. It was developed as a potential treatment for COVID-19. This 
mAb blocks S protein attachment to human angiotensin-converting enzyme 2 (ACE2) 
receptors, thus preventing viral entry into human cells and its subsequent viral replication. This treatment is expected to result in a clinically important decrease of viral replication, mitigating the severity of COVID-19 in persons with the infection in whom ongoing viral replication is the primary driver of pathophysiology. The potential reduction 
in viral replication may also decrease a treated person’s extent and duration of viral 
shedding and transmission, thus potentially positively impacting public health. The first in-human clinical studies  of bamlanivimab started on May 28, 2020 
 116 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  ([STUDY_ID_REMOVED]) [7]. 
 
Nonclinical single -dose studies of IV administered bamlanivimab have been performed 
in rats and cynomolgus monkeys . In rats, the mean elimination half-life was 277 hours 
(11.5 days); in cynomolgus monkeys, the mean elimination half-life was 315 hours (13.1 days). These data informed predictions of clinical pharmacokinetic characteristics of a total body clearance of 0.26 L/day  and an elimination half-life of 19 days . Prelimi nary 
data available from a limited number of subjects who received a single dose of 700 mg indicate pharmacokinetic behavior consistent with predictions . [Bamlanivimab 
Investigator’s Brochure, June 26, 2020].   
Rationale for Dose of 700mg and Graduation Directly to Open-Label, Single-Arm, Phase 
III Study  
On September 16, 2020, preliminary results were reported from a dose-finding study of 
the monoclonal antibody LY -CoV555 (also referred to as bamlanivimab and 
bamlanivimab), BLAZE- 1, sponsored by Eli Lilly. Three doses (700mg, 2800mg, and 
7000mg) were evaluated in non-hospitalized persons with early COVID -19. This study 
reported that: 
• The primary endpoint of viral load change from baseline at day 11 was met for the 
2800mg dose, although all doses showed virologic response.  
• Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY -CoV555 versus 
6 percent (9/150) for placebo—a 72 percent risk reduction.  
• LY-CoV555 was well tolerated across all doses with no drug-related serious adverse 
events. Of 409 persons who received LY -CoV555 or placebo, eight people 
experienced possible reactions to the infusion (“infusion reactions”) that were mild or moderate, including itching, flushing, rash, and face swelling. All eight were able to 
complete the infusion and all symptoms resolved with or without an antihistamine. 
 
Pharmacokinetic analysis suggests that a dose of 700mg will have a sustained concentration above in vitro IC90 of viral cell -entry neutralization for at least 28 days in 
90% of the patient population. Selection of the 700mg dose allows lower exposure of 
investigational agent to participants, expanded availability of this dose to the public if 
found effective and potential re-formulation of the compound to subcutaneous delivery 
instead of an infusion, which could expand its utility in an outpatient setting.  On November 9, 2020, based on the available interim data from the BLAZE-1 trial, the FDA issued an Emergency Use Authorization (EUA) for bamlanivimab in the United 
States for mild to moderate COVID -19 illness in outpatients. Access to the antibody 
through the EUA process will take time to implement and data collection during the EUA 
process will only be via FDA MedWatch reporting of serious adverse events or medication errors (EUA factsheet). The only studies outside of ACTIV -2 that are 
currently recruiting that include bamlanivimab are a study of bamlanivimab as 
monotherapy in low -risk patients and a study of bamlanivimab in combination with a 
second antibody (LY38324279) ([STUDY_ID_REMOVED]). Clinical data for bamlanivimab remain 
limited and the safety profile of bamlanivimab monotherapy has not been established. 
Therefore, the current randomized comparison of bamlanivimab will be converted in 
 117 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  phase III to a single arm, open-label study to continue to capture more detailed safety 
data (primary objective) and to collect additional viral shedding, clinical symptom improvement, and hospitalization data (secondary objectives) using our phase III schedule of events. The intent is to continue this single arm study until another agent 
enters the study. This is likely to occur in November/December 2020. These data will 
enhance our understanding of the safety of this agent and provide correlative data between our phase II and phase III assessments.  
 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  
 
Participants must meet inclusion and exclusion criteria from the master protocol, as well 
as the appropriate inclusion and exclusion criteria for the investigational agent included below.  
 
4.1 General  Eligibility Criteria  
 
4.1.1 Inclusion Criteria  4.1.1.10 For participants who are of reproductive potential, negative serum or urine pregnancy test at within 48 hours prior to study entry  by any 
clinic or laboratory that has a CLIA certification or its equivalent, or by a point of care (POC)/CLIA -waived test.  
 
NOTE: Reproductive potential is defined as:  
• participant s who have reached menarche 
• participants who have not been post -menopausal for at least 12 
consecutive months with follicle-stimulating hormone (FSH) ≥40 IU/mL or 24 consecutive months  if an FSH is not available  
• participants who have not undergone surgical sterilization ( e.g., 
hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or 
bilateral salpingectomy)  
• participants with no other clinical conditions (such as anorexia nervosa) that could induce amenorrhea 
• participant s not taking medications such as oral contraceptives, 
hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs) or chemotherapy that could induce amenorrhea  
• For individuals with permanent infertility due to an alternate medical cause (e.g., Mullerian agenesis, androgen insensitivity), 
investigator discretion shoul d be applied to determining study 
entry . 
 
4.1.1.11 If participating in sexual activity that could lead to pregnancy, 
participants  who are of reproductive potential must agree to use two 
 118 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  forms of effective contraception, where at least one form is highly 
effective (less than 1% failure rate), for the entirety of the study and for 90 days after investigational agent is administered.  Highly effective methods of contraception (less than 1% failure rate) 
include, but are not limited to: 
• combi nation oral contraceptives  
• implanted contraceptives  
• intrauterine devices 
 
Effective methods  of contraception include, but are not limited to  
• diaphragms and cervical caps with spermicide 
• cervical sponges  
• condoms  with spermicide 
 
NOTE: Participants not of reproductive potential are eligible without 
requiring the use of a contraceptive method. Par ticipant-reported 
history is acceptable documentation of surgica l sterilization and 
menopause. 
 NOTE:  
• Use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these 
barrier methods are combined.  
• Barrier protection methods without concomitant use of a 
spermicide are not an effective or acceptable method of contraception.  
• Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception. 
 
4.1.1.12 Participants that engage in sexual activity that may lead to pregnancy 
in their partner must agree to either remain abstinent or use male or 
female condoms with spermicide as well as one additional form of 
effective contraception with non-pregnant sexual partners  of 
reproductive  potential, for the entirety of the study and for 90 days after 
investigational agent is administered. 
 
Additional forms  of effective contraception that may be used by the 
partner include:  
• hormone-based contraception (oral, patch, parenteral, implants, or 
vaginal ring)  
• intrauterine device (IUD)  
• diaphragms and cervical caps  with spermicide 
 119 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  • cervical sponge 
 
Participants with pregnant partners should use condoms during vaginal 
intercourse through 90 days after investigational agent administration.  
 
Participants should refrain from sperm donation through 90 days  after 
investigational agent administration.  
 
4.1.2 Exclusion Criterion  
 
4.1.2.10 Currently pregnant 
 
4.1.2.11 Currently breastfeeding  
 
5.0 INVESTIGATIONAL AGENT  
 
5.1 Regimen, Administration, and Duration  
 
5.1.1 Regimen and Duration 
 
Participants will be randomized to receive one of the following two regimens: 
 
Investigational Agent: Bamlanivimab, 700 mg, to be administered intravenously 
(IV) for one dose at study Entry/Day 0.  
 OR  
Placebo for bamlanivimab: 0.9% Sodium Chloride Injection, USP, to be 
administered IV for one dose at study Entry/Day 0.  
 NOTE: Phase III is an open-label, single-arm evaluation of bamlanivimab; participants will not be randomized to receive placebo in phase III.  
 
5.1.2. Administration 
 
Bamlanivimab/Placebo to be administered IV over approximately 60 minutes.   Prior to administration, attach an infusion set containing a 0.2 or 0.22 µm in-line  
polyethersulfone (PES) filter to the IV bag and prime the infusion set with the prepared investigational agent. (Note: an infusion set rated for at least 200 mL/hour flow rate should be used.) The entire contents of the IV bag must be infused to the participant. After the entire contents of the IV bag have been administered, flush the infusion line as per site requirements or with 
approximately 25 mL of 0.9% Sodium Chloride Injection, USP, and administer 
the flush volume to the participant to ensure delivery of the required dose.  
 120 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB   
Participants will be monitored for signs and symptoms of infusion reaction per 
section 6.3.9  and the infusion rate may be slowed, paused, or stopped,  
lengthening the duration of infusion as deemed necessary if an infusion reaction 
is observed (s ections 8.2.2 and 8.2.3 ). 
 
5.2 Formulation, Storage, and Preparation  
 
5.2.1 Formulation and Storage 
 
Bamlanivimab is supplied as a 700 mg/20 mL (35 mg/mL) aqueous solution in 20 
mL glass vials. The aqueous solution concentrate is  a clear to slightly opalescent 
and colorless to slightly yellow to slightly brown solution. Bamlanivimab vials 
must be stored between 2° to 8°C (refrigerated storage) until use. Bamlanivimab 
is described in further detail in the bamlanivimab Investigator’s Brochure. 
 
Placebo for bamlanivimab will be 0.9% Sodium Chloride Injection, USP. The 
product must be locally sourced and stored according to the manufacturer’s 
recommendation.  
 
5.2.2 Preparation 
 
Pharmacists must follow appropriate aseptic technique and consider sterile preparation procedures/guidance as outlined in USP  General Chapter  <797> 
Pharmaceutical Compounding – Sterile Preparations  Pharmacists must also 
follow the requirements  of their country, institution, and pharmacy regulatory 
authority regarding these procedures. The investigational agent and placebo 
should be prepared in a sterile environment, utilizing a biosafety cabinet/isolator. If a biosafety cabinet or isolator is not available, a laminar flow hood may be used. Local regulations and site institutional policies and procedures for use of 
personal protective equipment, such as gloves, gowns, face masks and safety 
glasses, must be followed.  
 Any unused portion of investigational agent must not be used for another participant. Any empty vials, unused portion of entered vials, or unused solution which contains investigational agent should be discarded in a biohazard 
containment bag and incinerated or autoclaved in accordance with institutional or 
pharmacy policy.  
 
 121 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  5.2.2.1 Bamlanivimab 
 
1. Remove one (1) vial of bamlanivimab from the refrigerator, an 
appropriately sized IV bag of 0.9% Sodium Chloride Injection, USP 
from storage, and an empty, sterile IV bag of appropriate size to 
contain 200 mL volume. Equilibrate the bamlanivimab vials to room 
temperature, not exceeding 30°C, for approximately 20 minutes  (or 
no longer cool to the touch). 
2. Gently invert the bamlanivimab vial by hand approximately 10 
times to ensure homogeneity of the contents. Do not shake or vigorously agitate the vial. Visually inspect the vial for the presence of any visible particulate matter. If visible particulate matter is observed, appropriately discard the vial, obtain a new vial, and 
restart the preparation. Using an appropriately sized syringe  fitted 
with 18-gauge (or larger gauge) needles, withdraw 180 mL of 0.9% Sodium Chloride Injection, USP from the bag obtained in Step 1 and inject into the empty, sterile IV bag. 
3. Using an appropriately sized syringe fitted with an 18-gauge (or 
larger gauge) needle, withdraw 20 mL of bamlanivimab solution 
from one (1)  vial. When the stopper of the vial is punctured to start 
preparation, record this time as the investigational agent preparation time. Assign a 7-hour beyond use date and time from the preparation time if stored at room temperature or a 24-hour 
beyond use date and time from the preparation time if stored refrigerated.  
4. Inject the contents of the syringe prepared in Step 3 into IV bag 
with Sodium Chloride Injection, USP prepared in Step 2 , such that 
the IV bag now contains a total volume of 200 mL (180 mL of 0.9% Sodium Chloride Injection, USP and 20 mL of bamlanivimab).  
5. Gently invert the prepared IV bag by hand approximately ten times to ensure homogeneity of the contents. Do not shake or vigorously 
agitate the prepared bag. Avoid foaming. Visually inspect the bag 
after preparation. The contents of the bag should be free of any visible particulate matter. Obtain a new bamlanivimab vial and re-
prepare the dose if visible particulate matter  is observed. Encase 
the IV bag in an opaque cover.  
 
Prepared investigational agent in an IV bag should be administered 
immediately . If immediate administration is not possible, the 
investigational agent may be held at refrigerated conditions for NOT MORE THAN 24 hours or at ambient light and room temperature conditions for NOT MORE THAN 7 hours. The hold time includes 
preparation + s olution hold + infusion + flush. Any solution which 
exceeds these time period requirements must be discarded and a  
 122 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  fresh solution must be prepared. (R efer to the assigned beyond use 
time in Step 3 above).  
 
5.2.2.2 Placebo for Bamlanivimab 
 
1. Remove an appropriately sized IV bag of 0.9% Sodium Chloride 
Injection, USP from storage and one empty, sterile IV bag of 
appropriate size to contain 200 mL volume of 0.9% Sodium Chloride Injection, USP. 
2. Using appropriately sized syringes, fitted with 18 -gauge (or larger 
gauge) needles, withdraw 200 mL of 0.9% Sodium Chloride Injection, USP from the IV bag obtained in Step 1and inject into the empty, sterile IV bag. When the IV bag of 0.9% Sodium Chloride 
Injection, USP is first punctured to start preparation, record this 
time as the placebo preparation time. Assign a 7-hour beyond use 
date and time from the preparation time if stored at room 
temperature or a 24-hour beyond use date and time from the 
preparation time if stored refrigerated. 
3. Visually inspect the bag after preparation. The contents of the bag 
should be free of any visible particulate matter. Obtain a new IV 
bag of 0.9% Sodium Chloride Injection, USP and re-prepare the 
dose if visible particulate matter is observed.  
4.  Encase the IV bag in an opaque cover.  
 
Prepared placebo in an IV bag should be administered immediately . If 
immediate administration is not possible, the placebo may be held at refrigerated conditions for NOT MORE THAN 24 hours or at ambient light and room temperature conditions for NOT MORE THAN 7 hours. The hold time includes preparation + solution hold + infusion + flush. Any solution which exceeds these time period requirements must be discarded and a fresh solution must be prepared (refer to the assigned 
beyond use time in Step 2 above). 
 
5.2.2.3 Labeling of Investigational Agent and Placebo  
 
Label the prepared IV bag with the following information: 
a. Participant identifier(s)  
b. Protocol number: ACTIV -2/A5401 
c. Investigational agent name: Bamlanivimab 700 mg or Placebo  
d. Total volume: 200 mL 
e. Route: IV  
f. Infusion rate/time: 200 mL/hour  over approximately 60 minutes  
g. Preparation date and time 
 123 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  h. Beyond use date and time: 7 hours at room temperature conditions 
or 24 hours at refrigerated conditions after preparation 
i. Any additional information required by jurisdiction  
 
5.3 Supply, Distribution, and Accountability  
 
5.3.1 Supply/Distribution  
 
Bamlanivimab will be provided by Eli Lilly and Company and will be available 
through the NIAID Clinical Research Products Management Center (CRPMC). 
The site pharmacist will receive ordering instructions for the bamlanivimab vials 
from the NIAID CRPMC.   0.9% Sodium C hloride Injection, USP, infusion sets, and any other ancillary 
supplies will be locally sourced by the site.  
 
5.3.2 Accountability  
 
The site pharmacist is required to maintain complete records of all investigational agents received from the NIAID CRPMC and subsequently dispensed. At US 
CRSs, all unused investigational agents must be returned to the NIAID CRPMC 
(or as otherwise directed by the sponsor) after the study is completed or 
terminated. At non-US CRSs , the site pharmacist must follow the instructions  
provided by the CRPMC  for the destruction of unused investigational agents.  
 
5.4 Concomitant Medications
 
 
Any pre -medications given will be documented as a concomitant medication. 
 
 124 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
 6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Evaluations  
 
Table 6.1-1: Schedule of Evaluations Phase II  
 
Phase II Evaluation  
Screening 
Entry / Day 0  
Day 3 
Day 7 
Day 14 Day 28 
Week 12  
Week 24  
Hypersensitivity Reaction  
(Three Sample Time Points)  
Premature Study D/C      
(Before Day 28)  
Premature Study D/C      
(After Day 28)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days     
Investigational Agent Administered   X          
Hematology   X X  X X   X X  
Chemistry   X X  X X   X X  
Pregnancy Testing  X Whenever pregnancy suspected  X    
PK Studies   X   X X X X  X X 
Antidrug Antibodies   X   X X X X  X X 
Blood Collected for Evaluation of 
Hypersensitivity Reaction          X   
Urine Collected for Evaluation of 
Hypersensitivity Reaction          X   
 125 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB   
Table 6.1-2: Schedule of Evaluations Phase III  
Phase III Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week 24  
Hypersensitivity Reaction  
(Three Sample Time Points)  
Premature Study D/C 
(Before Day 28)  
Premature Study D/C     
(After Day 28)  
Visit Window    +/-1 
day +/-2 days  +4 
days  -7/+14 days     
Investigational Agent Administered   X          
Hematology   X    X   X X  
Chemistry   X    X   X X  
Pregnancy Testing  X  Whenever pregnancy suspected  X    
PK Studies   X    X X X  X X 
Antidrug Antibodies   X    X X X  X X 
Blood Collected for Evaluation of 
Hypersensitivity Reaction          X   
Urine Collected for Evaluation of 
Hypersensitivity Reaction          X   
 126 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
 6.2 Timing of Evaluations  
 
6.2.1 Screening Evaluations  
 
Screening evaluations must occur prior to the participant starting any study 
medications, treatments, or interventions. 
 
Screening and study entry visit evaluations may be combined. 
 
6.2.4 Event Driven Evaluations  
 
Hypersensitivity Reactions  (see section 8.2.3 ) 
In the case of generalized urticaria or anaphylaxis occurring at any time following investigational agent administration through day 28, additional blood and urine 
samples should be collected at the following time points  following instructions in 
the LPC : 
• collect initial sample after the participant has been stabilized, and within 1 to 
2 hours of the event; however, samples may be obtained as late as 12 hours 
after the event as analytes can remain altered for an extended period of time. Record the time at which the sample was collected 
• obtain a follow -up sample at the next regularly scheduled visit or after 
approximately 4 weeks, whichever is later  
• obtain a third follow-up sample at 12 weeks after the event  
 6.3 Instructions for Evaluations
 
 
 6.3.9 Investigational Agent Administered 
 
Pre-Medication 
Pre-medication for infusions is not planned. However, if an infusion reaction occurs during administration or if the participant has a medical history suggesting 
a potential benefit from pre-medication, the study investigator(s) should 
determine the appropriate pre-medication. 
 
Any pre -medications given will be documented as a concomitant medication. 
 
If minor infusion reactions are observed, administration of acetaminophen, 500 mg to 1000 mg, antihistamines, and/or other appropriately indicated medications may be given prior to the start of infusions for subsequent participants.  
  
Before the Infusion  
Vital signs (temperature, heart rate, respiratory rate, blood pressure, and SpO2).  
 
 127 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
 During the Infusion  
Vital signs (temperature, heart rate, respiratory rate, blood pressure, and SpO2) 
will be measured every 15 minutes during the infusion.  
 
After Infusion 
Vital signs (temperature, heart rate, respiratory rate, blood pressure, and SpO2) 
will be measured every 30 minutes for one hour post infusion.  (This post-infusion 
observation period is consistent with the observation period required in the EUA 
for bamlanivimab) 
 
Only vital signs that meet AE reporting requirements will be recorded on an eCRF . 
 
6.3.15 Laboratory Evaluations 
 
Hematology  
Participants will have blood drawn for complete blood cell count (CBC) with automated differential and platelet count.   At Entry/Day 0, blood should be drawn before study drug administration.  
 
Chemistry  
Participants will have blood drawn for liver function tests (ALT, ALP, AST, total 
bilirubin, direct bilirubin, and total protein), and renal function tests (albumin, BUN, creatinine, potassium, glucose, and sodium).  
 At Entry/Day 0, blood should be drawn before study drug administration.  
 
Pregnancy Testing  
For participants of reproductive potential: Serum or urine β-HCG. (Urine test 
must have a sensitivity of ≤ 25 mIU/mL).  
 
Post-screening, pregnancy testing should be done any time pregnancy is suspected.  
 
In the event of pregnancy occurring during the study, record pregnancy and 
pregnancy outcome per section 8.3
. 
 
6.3.16 Pharmacokinetics  
 
Serum will be collected and used to measure investigational agent levels  unless 
the required Covance kits for these assays are not available.   At Entry/Day 0, serum should be collected before the dose of investigational 
 128 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
 agent/placebo and again 30 minutes after the flush to clear the line of any 
remaining investigational agent/placebo following the end of the infusion of the second investigational agent/placebo (post-end of infusion PK assessment). The 30-minute post-end of infusion PK draw should be collected from an opposite 
limb and not the IV line/same site as the infusion.  
 
Post-entry, serum should be collected as per the SOE. Date and time of collection should be recorded.   
Samples will be analyzed at a laboratory approved by the sponsor and stored at 
a facility designated by the sponsor. Concentrations of the investigational agent will be assayed using a validated bioanalytical method. Analyses of samples collected from placebo-treated subjects are not planned. Sampl es will be 
retained for up to 2-years after last patient visit. Remaining samples used for PK 
may be pooled and used for exploratory metabolism or bioanalytical method experiments as deemed appropriate.  
 
6.3.18 Anti-Drug A ntibodies  
 
Serum will be collected to measure anti -drug antibodies  unless the required 
Covance kits for these assays are not available. At Entry/Day 0, serum should be 
collected before the dose of investigational agent/placebo.  
 Post-entry, serum should be collected as per the SOE (at the same time as serum collection for PK analysis). Date and time of collection should be recorded.  
 Samples will be analyzed at a laboratory approved by the sponsor and stored at a facility designated by the sponsor.  
 7.0 ADVERSE EVENTS AND STUDY MONITORING 
 
7.1 Definitions of Adverse Events
 
 
Adverse Events of Special Interest  
The following are AESIs for the agent bamlanivimab or placebo for bamlanivimab:  
• ≥ Grade 1 infusion-related reactions   
• ≥ Grade 1 allergic/hypersensitivity  reactions  
 
8.0 CLINICAL MANAGEMENT ISSUES 
 8.2 Management of Side Effects 
 
 
8.2.1 Overdose 
 
 129 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
 There is no known antidote for bamlanivimab overdose. In the event this occurs, 
the participant should be closely monitored for AE/SAE and laboratory 
abnormalities, and supportive care provided as indicated.  
 
8.2.2 Infusion-Related Reactions  
 
All participants should be monitored closely, as there is a risk of infusion reaction (including anaphylaxis) with any biological agent .  
 
Symptoms and signs that may occur as part of an infusion reaction include, but 
are not limited to fever, chills, nausea, headache, bronchospasm, hypotension, 
angioedema, throat irritation, rash including urticaria, pruritus, myalgia, and dizziness.  
   
The severity of i nfusion-related reactions will be assessed and reported using the 
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can be found on the DAIDS RSC website at https://rsc.niaid.nih.gov/clinical -research-
sites/daids -adverse-event-grading-tables . 
 
The clinical site should have necessary equipment and medications for the 
management of any infusion reaction, which may include but is not limited to oxygen, IV fluid, epinephrine, acetaminophen, and antihistamine. 
 Investigators should determine the severity of the infusion reaction and manage 
infusion reactions based on standard of care and their clinical judgment. If an 
infusion reaction occurs, then supportive care should be provided in accordance 
with the signs and symptoms. 
 Dosin g can be modified, such as slowing infusion, for mild or moderate reactions 
(Grade 1 or Grade 2). 
 
8.2.3 Hypersensitivity  
 
Signs and symptoms of infusion-related immediate hypersensitivity reactions 
may include, but are not limited to anaphylaxis, angioedema, bronchospasm, 
chills, diarrhea, hypotension, itching, skin rash, shortness of breath, urticaria, 
tachycardia, and throat irritation or tightness [8].  
 Participants will be closely monitored for immediate hypersensitivity reactions.  
Sites should have appropriately trained medical staff and appropriate medical equipment available when study participants are receiving bamla nivimab. It is 
recommended that participants who experience a systemic hypersensitivity reaction be treated per the local standard of care.  
 130 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
  
Dosing can be modified, such as slowing infusion, for mild or moderate reactions (Grade 1 or Grade 2).  
8.3 Pregnancy
  
 
Since there are no data regarding the use of bamlanivimab in participants  who are 
pregnant, participants who are pregnant are not eligible for the study. Participants  of 
childbearing potential and participants  who may impre gnate their partners  are required 
to follow the instructions for prevention of pregnancy provided in the protocol.  
 If a participant becomes pregnant during the study (post-entry), study follo w up will 
continue for the duration of the study.  
 
At the end of the pregnancy, outcome and adverse events for participant and infant will 
be recorded on the outcome eCRF.  
 8.4 Breastfeeding
 
 
Since there are no data regarding the use of bamlanivimab in participants  who are 
breastfeeding, participants who are breastfeeding are not eligible for the study. 
 9.0  CRITERIA FOR DISCONTINUATION 
 9.1 Permanent and Premature Treatment Discontinuation
 
 
A participant will stop investigational agent/placebo with if a Grade ≥3 event occurs that 
is deemed  related  to the investigational agent/placebo.  
 10.0 STATISTICAL CONSIDERATIONS  
 
10.2 Outcome Measures
 
 
The outcomes in phase III will use the same definitions as the corresponding outcomes 
in phase II.  
 
10.3 Randomization and Stratification  
 
There is no randomization in phase III. All participants will receive the investigational 
agent (700mg dose).  
10.4 Sample Size  
 
The uncontrolled open-label study in phase III will be started after phase II is fully 
enrolled. The intent is to continue enrollment in phase III until the next investigational 
 131 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
 agent is opened to enrollment. This next agent is expected to start enrollment in 
December 2020. At current enrollments rates, it is expected that the number of 
participants who will receive the investigational agent (including those enrolled in phase 
II) may be 300 or more. As the intent of phase III is to provide additional safety  data for 
the investigational agent, and to describe further  SARS- CoV-2 RNA levels in nasal 
swabs, symptom duration and severity, and proportion of participants  hospitalized or 
dying through to Day 28 among participants receiving the investigational agent, no 
formal power considerations are provided.  
10.5 
Data and Safety Monitoring 
 
No formal review of phase III will be undertaken by the DSMB unless the criteria described in section 7.0
 for triggering a safety review are met, or unless  requested by 
the DSMB.  
 10.6 
Analyses  
 
The descriptive analysis of data on safety and efficacy outcomes will be undertaken using the same methods as for phase II. Any comparisons, if undertaken, of the overall 
population of participants receiving the investigational agent to the placebo arm  enrolled 
during phase II will be considered as exploratory (as such comparisons are not randomized and so are subject to potential bias due to changes in the population of 
participants enrolled). Among participants  receiving the investigational agent, analyses 
of associations between SARS- CoV-2 RNA levels in nasal swabs, symptom duration 
and severity, and risk of hospitalization/death will be ex ploratory. 
 11.0 PHARMACOLOGY PLAN  
 11.1 Pharmacology Objectives   
 
The phase II pharmacology objective is to determine the pharmacokinetics of 
bamlanivimab. For phases II and III, the pharmacology objective is to  explore 
relationships between dose and concentration of bamlanivimab with virology, symptoms, 
and oxygenation.  
 
11.2 Pharmacology Study Design Overview   
 
The Schedule of Evaluations shows the collection schedule for Phase II and for Phase 
III. Bamlanivimab has a long elimination in preclinical animal studies and is expected to 
be between 2-4 weeks in humans; the predicted elimination half-life based on the preclinical data is 19 days . Very limi ted data in participants who received a single dose 
of 700 mg indicated PK behavior  consistent with expectations. The PK sample 
schedules are based on the long-elimination half-life of bamlanivimab and are designed 
to meet the phase II objective of determination of bamlanivimab pharmacokinetics and 
 132 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
 the phase III objective to explore dose/concentration-response relationships . By design, 
the sample collection schedules are different, with the phase II schedule being more 
intense to determine PK behavior, and the phase III schedule more sparse to confirm PK 
behavior and support dose/concentration-response analyses .  
 
11.3 Pharmacology Data Analysis and Modeling  
 
Pharmacokinetic data analysis of phase II data will use conventional and accepted 
approaches such as non -compartmental analysis or compartmental analysis to 
determine the PK characteristics of bamlanivimab. Population pharmacokinetic 
approaches (e.g., nonlinear mix effects modeling such as implemented in NONMEM) 
may also be used. The usual parameters of interest are area under the concentration-
time curve (AUC), total body clearance (CL), elimination half-life (T 1/2), and maximum 
and minimum concentrations (C max, Cmin). Exploration of relationships between dose and 
concentration of bamlanivimab with virology, symptoms, and oxygenation will be 
approached using conventional and accepted methods for 
pharmacokinetic/pharmacodynamic (PK/PD) data analyses. Such methods will include 
the E max or sigmoid E max model or structurally linked PK/PD models (as could be 
performed within NONMEM) to explore exposure-response relationships. Exposure -
response relationships will be performed in conjunction with the protocol statisticians.  
 
  
 133 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX III: INVESTIGATIONAL AGENT BAMLANIVIMAB  
 16.0 REFERENCES 
 
1. Doherty M, Robertson MJ. Some early trends in immunology. Trends Immunol 2004;25:623 -31. 
2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004;2:695-703. 
3. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody -based therapies for 
microbial diseases. Vaccine 2009;27:G38-G46.  
4. Casadevall A. The case for pathogen-specific therapy. Expert Opin Pharmacother 2009;10:1699-703.  
5. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531-7.  
6. Fan P, Chi X, Liu L, et al. Potent neutralizing monoclonal antibodies against E bola 
virus isolated from vaccinated donors. MAbs 2020;12(1):1742457.  
7. ClinicalTrials.gov. A Study of LY3819253 ( LY3819253) in Participants Hospitalized 
for COVID -19. Study Registry ID: [REMOVED]. First posted June 2, 2020. 
8. Everds NE, Tarrant JM. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicol Pathol 2013;41:280-302.
 134 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IV: SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB APPENDIX IV:  SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB  
 
No participants will be enrolled in version 7 or later of this protocol for this investigational agent. 
Consents retained for recording purposes.  
 
If you are in the first part of this study, one of the study drugs that you might be assigned to is 
bamlanivimab or the placebo for bamlanivimab. If you are in the second part of this study, you 
might be assigned to receive bamlanivimab. No participants will receive the placebo for bamlanivimab in the second part of the study.  
 Bamlanivimab is a type of drug called a monoclonal antibody. Many antibodies are naturally 
made by your body and help fight diseases. Bamlanivimab is made in a laboratory. 
“Monoclonal” means that bamlanivimab is made up of many copies of just one antibody.  
 
Your assignment is random, like the flip of a coin. You will be told about all the study drugs you 
may be assigned to in this study. If only one study drug is available, you will have an equal chance of receiving the study drug or placebo. If two study drugs are available, you will have a 2:1 chance of receiving a study drug or placebo. You will not be able to choose your group, and neither you, your study doctor, nor the study staff at your site will know which group you are in.  
 
The United States Food and Drug Administration (FDA) has not approved bamlanivimab for 
general use by the public. However, we have told the FDA about this study and they have given us permission to conduct this study . On November 9, 2020 the FDA issued an emergency use 
authorization (EUA) for bamlanivimab for the treatment of mild-to-mo derate COVID -19 in 
patients who are 12 years of age and older and who are at high risk for progressing to severe 
COVID -19 and/or hospitalization. The issuance of an EUA is different from FDA approval. The 
data for bamlanivimab are still limited, but in deciding whether to issue an EUA, the FDA 
determined that the known and potential benefits of bamlanivimab outweigh the known and 
potential risks for use during an emergency. Even though there is now an EUA for 
bamlanivimab, we want to continue to study bamla nivimab so that we can collect more 
information about the safety of bamlanivimab and risk factors associated with COVID -19 
disease progression.  
  ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE BAMLANIVIMAB OR 
PLACEBO? 
 
Screening Visit  
• At your screening visit, if you can become pregnant, you will be asked to give blood (1 
teaspoon) or a urine sample for a pregnancy test. You cannot receive bamlanivimab or 
placebo if you are pregnant.  
 
Entry Visit  
• You will have blood drawn. This blood will be used for the following tests:  o routine safety tests (liver and kidney tests and blood counts)  
 135 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IV: SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB 
 o levels of antibodies to the drug (your body’s immune response to the drug)  
o for future protocol -required testing  
• You will have the infusion of bamlanivimab or placebo. The infusion will be given through a 
small plastic tube that will be placed into a vein in your arm. This is called an intravenous 
(IV) infusion. The infusion will take approximately 1 hour. You will be monitored in the clinic for one hour after the end of the infusion.  
• You will have blood drawn to check the levels of drug in your blood. The blood sample will 
be collected before the study infusion and 30 minutes after the study infusion in the opposite 
limb as the study  infusion. 
 
Study Visits  
After the Entry visit, your study visits and evaluations will be different depending on whether you are in the first part of the study or the second part of the study.  
 
 IF YOU ARE IN THE FIRST PART OF THE STUDY:  
 
Study Visits on Days 3, 14, and 28  
• You will have blood drawn. This blood will be used for the following tests:  o routine safety tests (liver and kidney tests and blood counts)  
o on days 14 and 28, levels of the drug and levels of antibodies to the drug (your body’s immune response to the drug)  
 
Study Visits on Week 12 and Week 24 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
o for future protocol -required testing  
• If you can become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample 
for a pregnancy test (week 24)  
 
Extra Visits  
If you have a bad reaction to the infusion of study drug, you may have to come back for two 
extra visits 4 weeks and 12 weeks after the reaction, unless there is another visit at this time. 
 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
o levels of inflammatory markers and cells in your blood 
• You will be asked to give a urine sample to check for markers of inflammation (week 4)   
  
 136 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IV: SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB 
 IF YOU ARE IN THE SECOND PART OF THE STUDY:  
 
Study Visit on Day 28 
• You will have blood drawn. This blood will be used for the following tests:  
o routine safety tests (liver and kidney tests and blood counts)  
o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
 
Study Visits on Week 12 and Week 24 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
 
Extra Visits  
If you have a bad reaction to the infusion of study drug, you may have to come back for two extra visits 4 weeks and 12 weeks after the reaction, unless there is another visit at this time. 
 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
o levels of inflammatory markers and cells in your blood 
• You will be asked to give a urine sample to check for markers of inflammation (week 4)   
  WHAT ARE THE RISKS OF BAMLANIVIMAB?  There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are
 
taken with the study drugs. For your safety, you must  tell the study  doctor  or nurse about all 
medications  you are taking before you start the study.   
 Another risk is that the study drug used in this
 study  may have side effects, some  of which  are 
listed below.  Additionally,  the study drug tested  in the study  may have unknown side effects  in 
persons  with SARS-CoV -2 infection.  In a research  study, all of the risks or side effects  may not 
be known before you start the study. You need to tell your doctor  or a member  of the study  team  
immediately  if you experience any side effects.  
 Please note that these lists do not include all the side effects  seen with this study drug.
 These 
lists include the more  serious  or common side effects  with a known or possible  relationship to the 
study drug. If you have questions  concerning the additional side effects,  please ask the medical  
staff at your site. 
 
 137 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IV: SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB 
 Risks A ssociated with Bamlanivimab 
Bamlanivimab is being administered for the first time to hospitalized and non-hospitalized 
persons with COVID -19 in a separate study . 
 
There is limited safety data on bamlanivimab since it has not been given to a lot of people. As of 
September 4, 2020, there have been no serious unwanted effects reported by people taking 
bamlanivimab or placebo to date. Most effects after taking bamlanivimab or placebo have been 
mild or moderate and have either all gone away or are getting better.  
 
Of 409 non-hospitalized persons who received bamlanivimab or placebo, eight people 
experienced possible reactions to the infusion (“infusion reactions”) that were mild or moderate, 
including itching, flushing, rash, and face swelling. All eight were able to complete the infusion 
and all symptoms resolved with or without an antihistamine.   
Among hospitalized persons, t hree people had difficulty breathing that was severe; all three 
people have either recovered or are getting better. One patient had chills that were mild and 
started a few hours after bamlanivimab injection; they lasted one hour and were thought to be 
related to bamlanivimab. Two people had a drop in white blood cell counts (below the normal 
range), which continued for a few days after bamlanivimab or placebo administration and 
returned to normal again soon after that.  
Administration of bamlanivimab may result in allergic reactions. Signs and symptoms of these 
reactions include:  
• chills  
• skin rash  
• itching  
• hives  
• flushing (reddening) of the skin  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
• loose stools  
 
Administration of bamlanivimab may induce release of chemicals called cytokines in the body. 
These chemicals may induce allergic reactions listed above as well as : 
• fever 
• muscle aches  
• nausea  
• vomiting 
 138 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IV: SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB 
 • headache  
• dizziness  
 
Some of these reactions may be serious or life-threatening including:  
• skin rash  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
 
You will be monitored closely during administration of study drug. Medical personnel, equipment, 
and medication will be available to manage these reactions appropriately if they occur.  
Administration of study drug may also cause the following risks and discomforts: 
• development of proteins (antibodies) against bamlanivimab. This may cause your body to 
get rid of bamlanivimab more quickly or change the effect of bamlanivimab on the body. 
Your blood will be tested to find out whether your body made antibodies to bamlanivimab. 
The anticipated risk of this is low because bamlanivimab is a fully human antibody. 
Therefore, it is less likely to be seen as “foreign” by your body’s immune system and your body is less likely to form antibodies against bamlanivimab. 
• mixture of antibody and other chemicals in the body that may be deposited in tissues such 
as blood vessels and kidneys.  
• unexpected increase in virus reproduction in your body. Although this has been observed 
with some viruses, this has not been observed with COVID -19 or with the use of serum -
containing antibodies given to people with COVID -19. This risk of increased viral growth is 
perhaps greater when there are l ower levels of antibodies in the blood in the presence of 
virus. To avoid this, bamlanivimab will be given at a dose that is felt to be high enough to 
keep this from occurring. 
• There is a risk that this study drug may blunt your body’s own immune response to the viral infection, like development of immunity. This might mean that you might get sick with COVID  
infection again in the future.  
 
Effect on Future Vaccination 
The US Centers for Disease Control and Prevention (CDC) currently recommends that people wait at least 90 days after receiving antibody treatment before receiving a COVID -19 vaccine. 
Bamlanivimab remains in the body for about 90 days, and there is a chance that these 
antibodies could interfere with how your body responds to the vaccine during those 90 days.  
  
 139 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IV: SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB 
 ARE THERE  RISKS RELATED TO PREGNANCY  AND BREASTFEEDING? 
 
Pregnancy  
Since there are no data regarding the use of this study drug in people who are pregnant, you 
are not eligible to receive this study drug if you are pregnant.  
 
The study drug may involve risks to you (or to the embryo or fetus, if you or your partner  become 
pregnant), which  are currently  unforeseen.  
 
If you are participating in sexual activity that could lead to you becoming pregnant, you must 
agree to use  two forms of effective contraception, where at least one form is highly effec tive, for 
the entirety of the study and for 90 days after you receive the study drug .  
 
Highly effective methods of contraception (less than 1% failure rate) include, but are not limited to: 
• combination oral contraceptives  
• implanted contraceptives  
• intrauterine devices 
 
Effective methods of contraception include, but are not limited to:  
• diaphragms with spermicide 
• cervical sponges  
 
If you engage in sexual activity that may lead to pregnancy in a partner, you must agree to either remain abstinent or use condoms with spermicide AND your partner must use one 
additional form of effective contraception, through 90 days after you receive the study drug.  
 
Additional forms of effective contraception your partner may use include:  
• hormone-based contraception (oral, patch, parenteral, implants, or vaginal ring)  
• intrauterine device (IUD)  
 
If applicable, if your partner is pregnant you must use condoms during vaginal intercourse 
through 90 days after you receive the study drug.  
If applicable, you must not donate sperm through 90 days  after you receive the study drug. 
 
If you think you may be pregnant, let the staff at your site know so that a pregnancy test can be done.   Let your doctor know  immediately  if you
 become  pregnant. If you become pregnant while  on the 
study, you will be asked to continue to have study visits and the study  staff would like to obtain 
information from you about the outcome of the pregnancy  (even if it is after your participation in 
the study  ends). 
 
 140 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IV: SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB 
 Breastfeeding 
It is not known if this study drug is safe to use in people who are breastfeeding. You are not 
eligible to receive this study drug if you are breastfeeding.
 141 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IV: SAMPLE INFORMED CONSENT FOR STUDY DRUG BAMLANIVIMAB SIGNATURE PAGE  
 
If you have read this consent form (or had it explained to you), all your questions have been 
answered and you agree to take part in this study, please sign your name below. 
 
 ______________________________________ ___________________________________ 
Participant’s Name (print)     Participant’s Signature and Date 
 
 
 ______________________________________ ___________________________________ 
Participant’s Legally Authorized Representative Legally Authorized Representative  
(print) (As appropriate)     Signature and Date 
   ______________________________________ ___________________________________ 
Study Staff Conducting     Study Staff’s Signature and Date 
Consent Discussion (print)   
  ___________________________________  __________________________________ 
Witness’s Name (print)    Witness’s Signature and Date  
(As appropriate)  
   
 142 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 
 
Information/evaluations noted in this agent-specific appendix are IN ADDITION to those presented in the master protocol. Section numbering aligns with the master  protocol  
 SCHEMA  
 DESIGN:  The current phase III evaluation will continue as a placebo-co ntrolled 
evaluation of BRII-196 plus BRII -198, which was previously approved for 
full phase III evaluation by the Trial Oversight Committee (TOC) and will 
continue to include only participants who are at higher risk of progression to hospitalization or death. 
 STRATIFICATION:  Randomization in phase III will be stratified by time from symptom onset 
(≤5 days versus >5 days). 
 
2.0 INTRODUCTION  
 2.2 Rationale
 
 
Monoclonal Antibodies (mAbs)  
Sera obtained from persons or animals who recovered from a particular infection has 
shown prophylactic and therapeutic potential for a variety of infections, and Emil von 
Behring won the Nobel Prize in 1893 for his work on use of immune serum from the 
blood of infected animals to provide immunity to diphtheria [1]. Currently, hyperimmune 
human sera immunoglobulin is still used to treat many viral infections including 
cytomegalovirus (CMV), respiratory syncytial virus (RSV), hepatitis A virus (HAV), 
hepatitis B virus (HBV), and rabies [2].  
 
Unfortunately, heterologous sera was associated with a variety of complications 
including serum sickness and hypersensitivity, which significantly limited its usefulness 
clinically [3]. Given the long history of use of antibodies for infectious diseases, 
monoclonal antibodies were developed (mAbs). Improved purification techniques and 
the ability to engineer humanized mAbs allowed for the development of broadly reactive 
and potent mAbs, which helped reduce some of the issues that hampered the utility of 
heterologous sera [3, 4]. In fact, current technology allows mAbs to be produced 
requiring only tissue culture or microbial expression systems, thus the potential toxicity 
of humanized mAbs is comparable to antibiotics [2, 4]. 
 
Engineered humanized mAbs have shown considerable efficacy for viral infections. The 
first was Palivizumab in 1998, which is used for RSV [5]. Monoclonal antibodies have 
also been quickly developed for emerging infections such as Ebola [6]. As a part of the 
massive scientific effort to stop COVID -19, mAbs have been developed for treatment of 
COVID -19. These agents now need to be evaluated in rigorous randomized clinical 
trials.  
 143 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 The limitations of mAbs continue to be cost and that these antibodies are perishable, 
require refrigeration, and must be administered parenterally [4]; however, their use may 
still be useful in the outpatient setting, as one dose often stays in the therapeutic range  
for months [5], potentially allowing an entire treatment course with a single 
administration. 
 
A number of viral infectious diseases have been successfully treated with mAbs, including RSV and HIV. Some of these mAbs were derived from persons who were 
infected with these viruses and mounted neutralizing humoral responses.  
 
Investigational Agent  
BRII-196 and BRII-198 are two fully human immunoglobulin G (IgG) -1 mAbs derived from 
antibodies P2C-1F11 and P2B -1G5, respectively, that were isolated directly from human B 
cells of a convalescent COVID -19 patient [7-9]. These mAbs target distinct epitopes in the 
SARS- CoV-2 receptor binding domain (RBD) in the coronavirus spike (S) glycoprotein that 
uses ACE2 to enter cells via interaction with the RBD [10]. The first investigational agent to 
be evaluated in this trial is the mAb bamlanivimab made by Lilly. Subsequent therapeutics 
to be evaluated in this trial will include the combination of BRII -196 with BRII-198, both 
potent in neutralizing SARS-CoV -2 viruses in pseudo-virus as well as live virus 
neutralization assays. The targeting of different epitopes in the viral antigen by the BRII-196 
and BRII-198 cocktail is a strategy to reduce the generation and selection of resistant virus 
as compared to a single  antibody. Further, the fragment crystallizable (Fc) region of BRII-
196 and BRII-198 are engineered with a triple-amino-acid (M252Y/S254T/T256E [YTE]) substitution to allow an extended half-life [11, 12]. The introduction of YTE also reduces the 
binding activity against Fc γ receptors by approximately 3-fold, thereby potentially 
minimizing the potential risk of Fc -mediated antibody -dependent enhancement (ADE). 
 
Brii Biosciences is evaluating the safety, tolerability, and pharmacokinetics (PK) of each 
antibody in two randomized, placebo-controlled, single-ascending-dose, phase I, first in 
human studies at three dose levels of BRII-196 (750 mg, 1500 mg, 3000 mg) in study 
BRII-196-001 ([STUDY_ID_REMOVED]) [13] and three dose levels of BRII-198 (750 mg, 1500 mg, 
3000 mg) in study BRII-198-001 (NCT 04479644) [14]. In each study of 16 healthy 
volunteers, the active formulation is injected into an IV bag of 0.9% sodium chloride before being administered intravenously. Subjects of each dose cohort, for each respective study, are randomized in a ratio of 3:1 to receive either the active formulation 
or placebo (0.9% sodium chloride). Subjects remain as inpatients at the clinical 
investigational site for sample collection and assessments for 7 days post- dose and 
thereafter return to the clinic at designated visit times for additional sample collection and assessments, with the last visit scheduled on Day 181. A Safety Review Committee (SRC) performs ongoing reviews of safety and tolerability based on data collected in pre-
planned cohorts to guide the progress of the study and ensure the safety of the subjects. 
Both studies completed enrollment of planned subjects and preliminary safety , 
tolerability, and PK data from these studies are supportive of the dose selected for use in this study. BRII -196 and BRII-198 are being administered for the first time to hospitalized 
persons with COVID -19 in a separate study.  
 144 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198  
Brii Bioscience’s BRII-196 and BRII-198 antibodies have preclinical data for viral 
neutralization. Live virus neutralization for BRII-196 had IC 50 of 0.024 μg/mL, and for 
BRII-198 IC 50 of 0.030 μg/mL. The IC 90 for live virus neutralization with BRII-196 is 
≤0.296 μg/mL and for BRII-198 ≤0.49 μg/mL. BRII-196 neutralizes SARS -CoV -2 by 
directly blocking the binding of receptor ACE2 to RBD for viral entry. The structural analysis of BRII-196 Fab complexed with the RBD protein provided insights into the neutralizatio n mechanism. It revealed a highly conserved conformational antigenic site 
comprised of 23 contact residues in RBD and 11 of them are used by ACE2 to bind 
SARS- CoV-2. Unlike BRII-196, BRII-198 demonstrated no or little competing capacity 
with ACE2, indicating two antibodies have distinct and non-overlapping epitopes, and 
neutralize virus through different mechanisms. As expected, when evaluated in the live virus microneutralization assay in combination, they displayed moderate additive effect. While the YTE modification improves the half-life of antibodies to provide prolonged 
duration of protection and extended therapeutic treatment window, it reduces binding 
activity to human Fc γ receptors, thereby minimizing the potential risk of Fc -mediated 
antibody -dependent enhancement. 
 
Brii Bioscience has submitted a general information update to pre-Investigational New 
Drug (IND ) on September 3, 2020 that includes clinical summary of Phase I study 
results. Of the data available as of August 24, 2020, BRII-196 and BRII-198 have 
exhibited favorable safety profile based in preliminary phase I data in healthy volunteers. 
Thus far, there have been no reports of infusion -related reaction, allergic reaction, or 
adjustment of infusion rate required due to AEs during administration. In addition, no 
Grade 3 or Grade 4 AEs, SAEs, deaths, or AEs leading to discontinuation have been 
reported from this interim reporting.  
Justification for D ose of BRII-196 and BRII 198 
The 1000 mg/1000 mg clinical doses of the BRII-196 and BRII-198 combination therapy in the phase II/III study is selected by considering the in vitro  and in vivo  pharmacology 
results, hypothesized in vivo  target coverage requirements, predicted human serum drug 
concentration profiles, available safety data, including nonclinical toxicology data and preliminary clinical safety, and tolerability results from the ongoing phase I studies in 
healthy adult parti cipants. 
 
Based on the potent and unique RBD binding properties and in vitro antiviral neutralization 
activity, BRII-196 can be used as the main clinical efficacy component of the combination 
therapy. BRII-198 which also demonstrated potent antiviral neutralizing activity in vitro, has a non-competitive RBD target binding epitope that is different from BRII- 196 and does not 
block the binding of ACE2 to the RBD region. These unique properties of BRII-198 make it a 
potentially important additional component as part of combination therapy in order to 
achieve a more effective treatment of COVID -19 patients infected with wild type and 
different mutations of SARS -CoV -2 viruses and to minimize potential viral escape. Similar to 
reported data from other anti -SARS- CoV-2 antibodies [15, 16], preliminary results indicated 
BRII-196 and BRII-198 combination therapy (1:1 ratio) treatment led to effective viral 
 145 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 clearance and less body weight loss in the in vivo hACE -2 mouse model. Based on the 
above considerations, it is believed that the equivalent dose strategy of the BRII-196 and 
BRII-198 combination therapy will efficiently utilize unique characteristics of both antibodies 
that will lead to anticipated clinical efficacy.  
 Based on previous experience with other antiviral  neutralizing mAbs [17-19], as well as 
preliminary in vivo  efficacy data in the hACE2 hamster model, it is hypothesized that drug 
coverage of 10-30 folds of in vitro IC
90 at the sites of infection, e.g., nasal cavity and lung, is 
needed for effective treatment of COVID -19 patients. Literature reported biodistribution 
coefficients of monoclonal antibodies in the nasal cavity and lung are about 3-4% [15] and 
10-15% [20] of the corresponding serum drug concentrations, respectively. Based on this assessment, the target minimal serum BRII-196 and BRII-198 concentrations are 100-300 folds of in vitro  IC
90 for at least 3-weeks, the target duration considered suitable for 
neutralizing antibody therapy [21,22,23 ]. 
 A population PK model was built for human monoclonal antibodies with YTE mutation and applied to predict human PK profiles of the BRII-196 and BRII-198. To support fixed 
dose strategy, body weight has been incorporated as a covariate in the population PK model, and the covariate analysis suggested minimal impact of body weight to the pharmacokinetics of BRII-196 and BRII-198. The model predicted terminal half-life is 
89.2 days (10
th-90th percentile: 65.2- 124 days) that is in the reported range of other YTE 
mAbs in human [5, 6]. Interim data from the ongoing BRII-196 and BRII-198 phase I 
studies in the healthy adult participants is consistent with the predicted concentration –
time profiles at dose levels of 750, 1500, and 3000 mg. The proposed dose of 1000 mg of each antibody is predicted to have sufficient target coverage individually over 
minimally 3 -week period.  
 
In addition, the nonclinical and preliminary clinical safety data also support the proposed 
dose of 1000 mg /1000 mg for BRII- 196 and BRII-198. BRII-196 and BRII-198 were well 
tolerated after two weekly doses of 100 or 300 mg/kg in the GLP 14-day toxicity studies with 56-day recovery. The “No-Observed Adverse Effect Level” (NOAEL) was 300 mg/kg 
for BRII-196 and BRII-198, the highest dose level tested in the studies. At the proposed 
dose of 1000 mg, the safety margins for BRII-196 were approximately 6.8-fold (human equivalent dose (HED)), 34-fold (C
max) and 23-fold (AUC). The corresponding safety 
margins for BRII-198 were approximately 6.8-fold (HED), 29 -fold (C max) and 23-fold 
(AUC). In addition, the combined dose of BRII-196 and BRII-198 was well tolerated in a 
single dose acute toxicity study in rats with the NOAEL at 300 mg/kg for each antibody. In the in vitro tissue cross reaction (TCR) study using representative human and cynomolgus monkey tissues, BRII-196 and BRII-198 had no cross reactivity with both human and cynomolgus tissues at concentrations up to 4-10 folds of the optimal positive  
staining concentrations. At the dose level of up to 3000 mg, both BRII-196 and BRII-198 were well tolerated in the ongoing phase I studies in the healthy adult participants.  
 Based on the PK and PK/PD assessment and the available nonclinical and clinical safety profile, the following doses of BRII-196 and BRII-198 were chosen for study in 
 146 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 ACTIV -2: 1000 mg and 1000 mg, respectively.  
 
This dose is selected to minimize potential concerns about underdosing and thus failing to detect an efficacy signal for an efficacious therapy. There are no significant safety  
concerns about using the 1000 mg dose of each of the antibodies, as side effects in antibody therapy are not generally dose dependent.  
4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  
 
Participants must meet inclusion and exclusion criteria from the master protocol, as well as the appropriate inclusion and exclusion criteria for the investigational agent included below.  
 4.1 General Eligibility Criteria
 
 
4.1.1 Inclusion Criteria 
 
4.1.1.9 Meet the protocol definition of being at “higher ” risk of progression to 
hospital ization or death (see SCHEMA, POPULATION ) 
 
4.1.1.10 For participants who are of reproductive potential, negative serum or 
urine pregnancy test at within 48 hours prior to study entry by any 
clinic or laboratory that has a CLIA certification or its equivalent, or by a point of care (POC)/CLIA -waived test.  
 
Reproductive potential is defined as: 
• participants who have reached menarche 
• participants who have not been post -menopausal for at least 12 
consecutive months with follicle-stimulating hormone (FSH) ≥40 
IU/mL or 24 consecutive months if an FSH is not available  
• participants who have not undergone surgical sterilization (e.g., 
hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy)  
• participants with no other clinical conditions (such as anorexia nervosa) that could induce amenorrhea 
• participants not taking medications such as oral contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs) or chemotherapy that could induce amenorrhea  
• For individuals with permanent infertility due to an alternate medical cause (e.g., Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study 
entry.  
 
 147 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 If participating in sexual activity that could lead to pregnancy, 
participants who are of reproductive potential must agree to use 
effective contraception for 24 weeks after investigational agent is administered. This would include oral contraceptives, implanted 
contraceptives, intrauterine devices, and barrier methods. 
 
NOTE: Participants not of reproductive potential are eligible without requiring the use of a contraceptive method. Participant-reported history is acceptable documentation of surgical sterilization and 
menopause. 
 
4.1.1.11 Participants that engage in sexual activity that may lead to pregnancy 
in their partner must agree to either remain abstinent or use male contraceptives. They are also stron gly advised to inform their non-
pregnant sexual partners of reproductive potential to use effective contraceptives for 24 weeks after inves tigational agent is 
administered. 
 
Participants with pregnant partners should use condoms during vaginal intercourse through 24 weeks after investigational agent 
administration. 
 Participants should refrain from sperm donation for 24 weeks after investigational agent administration.  
 
4.1.2 Exclusion Criterion  
 
4.1.2.10 Currently pregnant or breastfeeding  
 5.0 INVESTIGATIONAL AGENT  
 
5.1 Regimen, Administration, and Duration
 
 
5.1.1 Regimen and Duration 
 
Participants will be randomized to receive one of the following two regimens:  
Investigational Agent: BRII-196, 1000 mg, followed by BRII-198, 1000 mg, to be administered as two separate infusions as a one-time dose.   OR 
 
Placebo for BRII-196 followed by Placebo for BRII-198: 0.9% S odium Chloride 
Injection, USP to be administered as  two separate infusions as a one-time dose.  
 
 148 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 5.1.2 Administration 
 
Prior to administration, attach an infusion set and prime the infusion set per 
institutional procedures.  
 BRII-196/placebo is to be administered as an intravenous infusion over no less 
than 25 minutes, followed by BRII-198/placebo administered as an intravenous infusion over no less than 25 minutes.   
Flush the infusion line with a sufficient volume of 0.9% S odium Chloride Injection, 
USP to ensure full dose administration of BRII-196/Placebo, and a second line 
flush after the administration of BRII-198/Placebo. 
 
Administer investigational agents/placebo immediately after preparation. If 
immediate administration is not possible, the investigational agents/placebo 
should be used within 4 hours  if stored at room temperature and within 24 hours 
if stored under refrigerated conditions, including flush of line for both investigational agents /placebo. 
 5.2 Formulation, Storage, and Preparation
 
 
5.2.1 Formulation and Storage 
 
BRII-196 
BRII-196 is a sterile, clear solution packaged in 10R glass vials. BRII-196 must 
be stored between 2°C to 8°C (refrigerated storage) and protected from light.  
 Vials contain:  
• 100 mg of BRII-196 at a target concentration of 30 mg/mL with a fill volume of 
at least 3.33 mL. Ten vials are packaged in a carton.  OR 
• 250 mg of BRII-196 at a target concentration of 30 mg/mL with a fill volume of at least 8.33 mL. Four vials are packaged in a carton. OR 
• 500 mg of BRII-196 at a target concentration 50 mg/mL with a fill volume of at least 10 mL. Two vials are packaged in a carton.  
 
BRII-196 is described in further detail in the BRII -196 Investigator’s Brochure. 
 
BRII-198 
BRII-198 is a sterile, clear solution packaged in 10R glass vials. BRII-198 must 
be stored between 2° to 8°C (refrigerated storage) and protected from light.  
 
Vials contain:  
 149 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 • 100 mg of BRII-198 at a target concentration of 30 mg/mL with a fill volume of 
at least 3.33 mL. Ten vials are packaged in a carton.  
OR 
• 250 mg of BRII-198 at a target concentration of 30 mg/mL with a fill volume of at least 8.33 mL. Four vials are packaged in a carton. OR 
• 500 mg of BRII-198 at a target concentration 50 mg/mL with a fill volume of at least 10 mL. Two vials are packaged in a carton.  
 
BRII-198 is described in further detail in the BRII -198 Investigator’s Brochure. 
 
Placebo for BRII-196 and Placebo for BRII-198 
Placebo for BRII-196 and Placebo for BRII-198 will be 0.9% S odium Chloride 
Injection, USP. The product must be locally sourced and stored according to the manufacturer’s recommendation.  
 
5.2.2 Preparation 
 
Pharmacists must follow appropriate aseptic technique and consider sterile preparation procedures/guidance as  outlined in USP General Chapter <797> 
Pharmaceutical Compounding – Sterile Preparations. Pharmacists must also 
follow the requirements of their country, institution, and pharmacy regulatory authority regarding these procedures. The investigational agents and placebo should be prepared in a sterile environment, utilizing a pharmacy biosafety cabinet/isolator. If a biosafety cabinet or isolator is not available, a laminar flow hood may be used. Local regulations and site institutional policies and procedures  for use of personal protective equipment, such as gloves, gowns, 
face masks and safety glasses, must be followed.  Any unused portion of investigational agent must not be used for another participant. Any empty vials, unused portion of entered vials, or unused solution which contains investigational agent should be discarded in a biohazard 
containment bag and incinerated or autoclaved in accordance with institutional or 
pharmacy policy.  
 
5.2.2.1  Preparation of BRII-196, 1000 mg, using 100 mg/3.33 mL vials (30 
mg/mL)  
 
1. Remove ten (10) vials of BRII-196 from the refrigerator and a 100 mL IV bag of 0.9% Sodium Chloride Injection, USP from storage.  
2. Visually inspect the BRII-196 vials to ensure the vials are free from particulate matter and that there is no damage to the vials. Do not shake or vigorously agitate the vials. If the vials are identified to be 
 150 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 unusable, appropriately discard the vials and obtain new vials to 
restart the preparation.  
3. Using an appropriately sized syringe(s) fitted with ≤22-gauge needle, withdraw 33.3 mL volume from the IV bag of 0.9% Sodium 
Chloride Injection, USP.  
4. Using an appropriately sized syringe(s) fitted with ≤22-gauge 
needle, withdraw 33.3 mL of BRII-196 and inject into the IV bag of 0.9% Sodium Chloride Injection, USP prepared in Step 3. When the stopper of the first vial is punctured to start preparation, 
record this time as the investigational agent preparation time. 
Assign a 4-hour beyond use date and time from the preparation time if stored at room temperature, or a 24-hour beyond use date and time if stored under refrigerated conditions.  
5. Visually inspect the prepared IV bag to ensure the bag is free from 
particulate matter. Do not shake or vigorously agitate the prepared 
bag and avoid foaming. If particulate matter is observed, appropriately discard the IV bag, obtain new vials, and restart the preparation.  
6. Place a colored sleeve over the IV bag. The sleeve must be tinted, but translucent, so the volume of fluid and study label are visible 
through the sleeve.  
 
5.2.2.2 Preparation of BRII-196, 1000 mg, using 250 mg/8.33 mL vials (30 
mg/mL)  
 
1. Remove four (4) vials of BRII-196 from the refrigerator and a 100 
mL IV bag of 0.9% Sodium Chloride Injection, USP from  storage.  
2. Visually inspect the BRII-196 vials to ensure the vials are free from particulate matter and that there is no damage to the vials. Do not shake or vigorously agitate the vials. If the vials are identified to be unusable, appropriately discard the vials and obtain new vials to 
restart the preparation.  
3. Using an appropriately sized syringe(s) fitted with ≤22-gauge 
needle, withdraw 33.3 mL volume from the IV bag of 0.9% Sodium Chloride Injection, USP.  
4. Using an appropriately sized syringe(s) fitted with ≤22-gauge 
needle, withdraw 33.3 mL of BRII-196 and inject into the IV bag of 
0.9% Sodium Chloride Injection, USP prepared in Step 3.   When the stopper of the first vial is punctured to start preparation, record this time as the investigational agent preparation time. Assign a 4-hour beyond use date and time from the preparation 
time if stored at room temperature, or a 24-hour beyond use date 
and time if stored under refrigerated conditions.  
 151 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 5. Visually inspect the prepared IV bag to ensure the bag is free  from 
particulate matter. Do not shake or vigorously agitate the prepared 
bag and avoid foaming. If particulate matter is observed, appropriately discard the IV bag, obtain new vials, and restart the 
preparation.  
6. Place a colored sleeve over the IV bag. The sleeve must be tinted, 
but translucent, so the volume of fluid and study label are visible through the sleeve.  
 
5.2.2.3 Preparation of BRII-196, 1000 mg, using 500 mg/10 mL vials (50 mg/mL)  
 
1. Remove two (2) vials of BRII-196 from the refrigerator and a 100 mL IV bag of 0.9% Sodium Chloride Injection, USP from storage.  
2. Visually inspect the BRII-196 vials to ensure the vials are free from particulate matter and that there is no damage to the vials. Do not shake or vigorously agitate the vials. If the vials are identified to be unusable, appropriately discard the vials and obtain new vials to restart the preparation.  
3. Using an appropriately sized syringe(s) fitted with ≤22-gauge 
needle, withdraw 20 mL volume from the IV bag of 0.9% Sodium 
Chloride Injection, USP.  
4. Using an appropriately sized syringe(s) fitted with ≤22-gauge 
needle, withdraw 20 mL of BRII-196 and inject into the IV bag of 0.9% Sodium Chloride Injection, USP prepared in Step 3.  
 
When the stopper of the first vial is punctured to start preparation, record this time as the investigational agent preparation time. Assign a 4-hour beyond use date and time from the preparation time if stored at room temperature, or a 24-hour beyond use date and time if stored under refrigerated conditions.  
5. Visually inspect the prepared IV bag to ensure the bag is free from particulate matter. Do not shake or vigorously agitate the prepared bag and avoid foaming. If particulate matter is observed, appropriately discard the IV bag, obtain new vials, and restart the preparation.  
6. Place a colored sleeve over the IV bag. The sleeve must be tinted, but translucent, so the volume of fluid and study label are visible through the sleeve.  
 
5.2.2.4 Preparation of BRII -198, 1000 mg, using 100 mg/3.33 mL vials (30 
mg/mL)  
 
1. Remove ten (10) vials of BRII-198 from the refrigerator and a 100 mL IV bag of 0.9% Sodium Chloride Injection, USP from storage.  
 152 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 2. Visually inspect the BRII-198 vials to ensure the vials are free from 
particulate matter and that there is no damage to the vials. Do not shake or vigorously agitate the vials. If the vials are identified to be unusable, appropriately discard the vials and obtain new vials to 
restart the preparation.  
3. Using an appropriately sized syringe(s) fitted with ≤22-gauge 
needle, withdraw 33.3 mL volume from the IV bag of 0.9% Sodium Chloride Injection, USP.  
4. Using an appropriately sized syringe(s) fitted with ≤22-gauge 
needle, withdraw 33.3 mL of BRII-198 and inject into the IV bag of 
0.9% Sodium Chloride Injection, USP prepared in Step 3.   When the stopper of the first vial is punctured to start preparation, record this time as the investigational agent preparation time. 
Assign a 4-hour beyond use date and time from the preparation 
time if stored at room temperature, or a 24-hour beyond use date 
and time if stored under refrigerated conditions.  
5. Visually inspect the prepared IV bag to ensure the bag is free from particulate matter. Do not shake or vigorously agitate the prepared bag and avoid foaming. If particulate matter is observed, 
appropriately discard the IV bag, obtain new vials, and restart the 
preparation.  
6. Place a colored sleeve over the IV bag. The sleeve must be tinted, but translucent, so the volume of fluid and study label are visible through the sleeve.  
 
5.2.2.5 Preparation of BRII-198, 1000 mg, using 250 mg/8.33 mL vials (30 
mg/mL)  
 
1. Remove four (4) vials of BRII-198 from the refrigerator and a 100 mL IV bag of 0.9% Sodium Chloride Injection, USP from storage.  
2. Visually inspect the BRII-198 vials to ensure the vials are free from particulate matter and that there is no damage to the vials. Do not shake or vigorously agitate the vials. If the vials are identified to be unusable, appropriately discard the vials and obtain new vials to restart the preparation.  
3. Using an appropriately sized syringe(s) fitted with ≤22-gauge needle, wi thdraw 33.3 mL volume from the IV bag of 0.9% Sodium 
Chloride Injection, USP.  
4. Using an appropriately sized syringe(s) fitted with ≤22-gauge needle, withdraw 33.3 mL of BRII-198 and inject into the IV bag of 0.9% Sodium Chloride Injection, USP prepared in Step 3.  
 
When the stopper of the first vial is punctured to start preparation, record this time as the investigational agent preparation time. 
 153 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 Assign a 4-hour beyond use date and time from the preparation 
time if stored at room temperature, or a 24-hour beyond use date and time if stored under refrigerated conditions.  
5. Visually inspect the prepared IV bag to ensure the bag is free from 
particulate matter. Do not shake or vigorously agitate the prepared 
bag and avoid foaming. If particulate matter is observed, appropriately discard the IV bag, obtain new vials, and restart the preparation.  
6. Place a colored sleeve over the IV bag. The sleeve must be tinted, 
but translucent, so the volume of fluid and study label are visible 
through the sleeve.  
 
5.2.2.6 Preparation of BRII-198, 1000 mg, using 500 mg/10 mL vials (50 mg/mL)  
 
1. Remove two (2) vials of BRII-198 from the refrigerator and a 100 mL IV bag of 0.9% Sodium Chloride Injection, USP from storage.  
2. Visually inspect the BRII-198 vials to ensure the vials are free from particulate matter and that there is no damage to the vials. Do not shake or vigorously agitate the vials. If the vials are identified to be 
unusable, appropriately discard the vials and obtain new vials to 
restart the preparation.  
3. Using an appropriately sized syringe(s) fitted with ≤22-gauge needle, withdraw 20 mL volume from the IV bag of 0.9% Sodium Chloride Injection, USP.  
4. Using an appropriately sized syringe(s) fitted with ≤22-gauge needle, withdraw 20 mL of BRII-198 and inject into the IV bag of 0.9% Sodium Chloride Injection, USP prepared in Step 3.   When the stopper of the first vial is punctured to start preparation, record this time as the investigational agent preparation time. 
Assign a 4-hour beyond use date and time from the preparation time 
if stored at room temperature, or a 24-hour beyond use date and time if stored under refrigerated conditions.  
5. Visually inspect the prepared IV bag to ensure the bag is free from particulate matter. Do not shake or vigorously agitate the prepared 
bag and avoid foaming. If particulate matter is observed, 
appropriately discard the IV bag, obtain new vials, and restart the 
preparation.  
6. Place a colored sleeve over the IV bag. The sleeve must be tinted, but translucent, so the volume of fluid and study label are visible through the sleeve.  
 
 154 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 5.2.2.7 Placebo for BRII-196  
 
1. Remove one 100 mL IV bag of 0.9% Sodium Chloride Injection, 
USP from storage. 
2. Visually inspect the IV bag. The contents of the bag should be free of any visible particulate matter. Obtain a new IV bag of 0.9% Sodium Chloride Injection, USP if visible particulate matter is observed.  
3. Assign a 4-hour beyond use date and time from the time of 
removal from storage if stored at room temperature, or a 24-hour 
beyond use date and time if stored under refrigerated conditions. 
4. Place a colored sleeve over the IV bag. The sleeve must be tinted, but translucent, so the volume of fluid and study label are visible through the sleeve.  
 
5.2.2.8 Placebo for BRII-198  
 
1. Remove one 100 mL IV bag of 0.9% Sodium Chloride Injection, USP from storage. 
2. Visually inspect the IV bag. The contents of the bag should be free 
of any visible particulate matter. Obtain a new IV bag of 0.9% 
Sodium Chloride Injection, USP if visible particulate matter is observed.  
3. Assign a 4-hour beyond use date and time from the time of removal from storage if stored at room temperature, or a 24-hour 
beyond use date and time if stored under refrigerated conditions. 
4. Place a colored sleeve over the IV bag. The sleeve must be ti nted, 
but translucent, so the volume of fluid and study label are visible 
through the sleeve.  
 
5.2.2.9 Labeling of Investigational Agent and Placebo  
 
Label the prepared IV bags with the following information: a. Participant identifier(s)  
b. Protocol number: ACTI V-2/A5401 
c. Investigational agent name:  
i. BRII-196 1000 mg or placebo  
ii. BRII-198 1000 mg or placebo   
d. Describe sequential order of administration (Administer BRII -
196/placebo, first, followed by BRII-198/placebo)  
e. Total volume: 100 mL  
f. Route: IV  
g. Infusion rate/time: 4 mL/min over no less than 25 minutes  
h. Preparation date and time  
 155 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 i. Beyond use date and time: 4 hours after preparation if stored at 
room temperature and within 24 hours if stored under refrigerated conditions  
j. Any additional information required by jurisdiction  
 5.3 Supply, Distribution, and Accountability
 
 
5.3.1 Supply/Distribution  
 
BRII-196 and BRII-198 will be provided by Brii Biosciences and will be available 
through the NIAID Clinical Research Products Management Center (CRPMC).  
 0.9% Sodium Chloride Injection, USP, infusion sets, and any other ancillary supplies will be locally sourced by the site.  
 
5.3.2 Accountability  
 
The site pharmacist is required to maintain complete records of all investigational agents received from the NIAID CRPMC and subsequently dispensed. At US CRSs, all unused investigational agents must be returned to the NIAID CRPMC 
(or as otherwise directed by the sponsor) after the study is completed or 
terminated. At non-US CRSs , the site pharmacist must follow the instructions 
provided by the NIAID CRPMC for the destruction of unused investigational agents.  
 
5.4 Concomitant Medications
 
 
Any pre -medications given will be documented as a concomitant medication. 
 
 
 
 
    
 156 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Evaluations . The schedule of evaluations provided below include all the evaluations in the master protocol and 
additional evaluations for this investigational agent. 
 
Table 6.1-1: Schedule of Evaluations Phase II 
Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Documentation of  
SARS -CoV-2 Infection  X             
COVID -19 Symptom Screen X X            
Medical/Medication History  X X            
Smoking Status   X            
Weight  X             
Physical Exam   X            
Targeted Physical Exam    X X X X  X    X X 
Concomitant Medications    X X X X X X X X X X X 
Assessment for Adverse Events   X X X X X X X X X X X X 
 157 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Collect/Update Secondary Contacts   X X X X X X       
Vital Status Check   If Participant Cannot be Reached per section 6.3.8    
Investigational Agent Administered   X            
Study Kit Dispensed   X            
Participant -Completed Study Diary   Every Day through Day 28         
Study Diary Reminder   Days 1 - 28        
Staff Review of Study Diary   X X X X X      X  
Retrieval of Study Diary       X      X  
Post-Acute COVID -19 Assessment        X X X X X  X 
Household Infection and Linkage 
Report   X    X      X  
Staff-Collected NP Swab   X X X X       X  
Hematology   X X  X X      X  
Chemistry   X X  X X      X  
 158 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Pregnancy Testing  X  Whenever Pregnancy Suspected       
Stored Plasma  X  X  X  X    X X 
Stored Serum   X  X  X  X    X X 
Stored PBMCs (Selected Sites)   X  X  X  X    X  
PK Studies   X   X X X X    X X 
Antidrug Antibodies   X   X X X X    X X 
 
  
 159 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 Table 6.1-2: Sc hedule of Evaluations Phase III  
 
Note that the Brii Phase III schedule of evaluations differs from the phase III schedule of evaluations in the master protocol. For Brii Phase III participants, n o NP swabs will be collected and no hematology, chemistry, stored serum, or stored plasma will  be 
collected at Day 3. Participant self-collected anterior nasal swabs will be collected.  
 
Phase III Evaluation  
Screening  
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week  12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28)  
Premature Study D/C 
(After Day 28)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Documentation of  
SARS -CoV-2 Infection  X             
COVID -19 Symptom Screen X X            
Medical/Medication History  X X            
Smoking Status   X            
Weight  X             
Physical Exam   X            
Targeted Physical Exam    X   X  X    X X 
Concomitant Medications    X X X X X X X X X X X 
Assessment for Adverse Events  X X X X X X X X X X X X X 
 160 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 Phase III Evaluation  
Screening  
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week  12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28)  
Premature Study D/C 
(After Day 28)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Collect/Update Secondary Contacts   X X X X X X       
Vital Status Check   If Participant Cannot be Reached per section 6.3.8    
Investigational Agent Administered   X            
Study Kit Dispensed   X            
Participant -Completed Study Diary   Every Day through Day 28         
Study Diary Reminder   Days 1 - 28        
Staff Review of Study Diary   X X X X X      X  
Retrieval of Study Diary       X      X  
Post-Acute COVID -19 Assessment        X X X X X  X 
Household Infection and Linkage 
Report   X    X      X  
Self-Collected Anterior Nasal Swab   X X X X X      X  
Retrieval of Self -Collected Anterior 
Nasal Swabs    Follow Instructions in MOP    X  
Hematology   X    X      X  
Chemistry   X    X      X  
 161 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 Phase III Evaluation  
Screening  
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week  12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28)  
Premature Study D/C 
(After Day 28)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Pregnancy Testing  X  Whenever Pregnancy Suspected       
Stored Plasma  X    X  X    X X 
Stored Serum   X    X  X    X X 
PK Studies   X    X X X    X X 
Antidrug Antibodies   X    X X X    X X 
 
 
 162 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 6.2 Timing of Evaluations  
 
6.2.1 Screening Evaluations  
 
Screening evaluations must occur prior to the participant starting any study 
medications, treatments, or interventions. 
 
Screening and study entry visit evaluations may be combined. 
 
6.3 Instructions for Evaluations  
 
6.3.9 Investigational Agent Administered 
 
Pre-Medication 
Pre-medication for infusions is not planned. However, if an infusion reaction 
occurs during administration or if the participant has a medical history suggesting a potential benefit from pre-medication, the study investigator(s) should determine the appropriate pre-medication. 
 
Any pre -medications given will be documented as a concomitant medication. 
 
If minor infusion reactions are observed, administration of acetaminophen, 500 mg to 1000 mg, antihistamines, and/or other appropriately indicated medications 
may be given prior to the start of infusions for subsequent participants.  
  
Before the Infusion  
Vital signs (temperature, heart rate, respiratory rate, blood pressure and SpO 2). 
 
During the Infusion  
Vital signs (temperature, heart rate, respiratory rate, blood pressure and SpO 2) 
will be measured every 15 minutes (± 3 minutes)  during the infusion.  
 
After Infusion 
Vital signs (temperature, heart rate, respiratory rate, blood pressure and SpO 2) 
will be measured every 30 minutes  (± 5 minutes) for 2 hours post infusion.  
 
Only vital signs that meet AE reporting requirements will be recorded on an 
eCRF.  
 
6.3.14 Virologic Studies  
 
Participant self-collected anterior nasal swabs will  be collected for Brii phase III 
participants per the Brii phase III SOE (Table 6.1-2). Nasopharyngeal swabs described in the master protocol phase III SOE will not be collected for Brii phase III participants. 
 163 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 6.3.15 Laboratory Evaluations 
 
Hematology  
Participants will have blood drawn for complete blood cell count (CBC) with 
automated differential and platelet count.  
 At Entry/Day 0, blood should be drawn before study drug administration.   
Chemistry  
Participants will have blood drawn for liver function tests (ALT, ALP, AST, total bilirubin, direct bilirubin, and total protein), and renal function tests (albumin, BUN, creatinine, potassium, glucose, and sodium).  
 At Entry/Day 0, blood should be drawn before study drug administration.  
 
Pregnancy Testing  
For participants of reproductive potential: Serum or urine β-HCG. (Urine test 
must have a sensitivity of ≤25 mIU/mL).  
 
Post-screening, pregnancy testing should be done any time pregnancy is 
suspected.  
 In the event of pregnancy occurring during the study, record pregnancy and pregnancy outcome per section 8.3
. 
 
6.3.16 Pharmacokinetics  
 
Serum will be collected and used to measure investigational agent levels.   At Entry/Day 0, serum  should be collected before the dose of investigational 
agent/placebo (up to 10 minutes before the start of infusion) and again 
approximately 30 minutes (± 5 minutes)
 after the flush to clear the line of any 
remaining investigational agent/placebo following the end of the infusion of the second investigational agent/placebo
 (post-end of infusion PK assessment). The 
30-minute post-end of infusion PK draw should be collected from an opposite 
limb and not the IV line/same site as the infusion.  If it is not possible to collect the 
sample from an opposite limb for clinical reasons such as lymphedema or limited or restricted vascular access, the post-end of infusion PK draw should be skipped and the reason for the missed collection noted in site records.  
Post-entry, serum should be collected as per the SOE. Date and time of 
collection should be recorded.   Samples will be analyzed at a laboratory approved by the sponsor and stored at a facility designated by the sponsor. Concentrations of the investigational agents 
 164 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 will be assayed using a validated bioanalytical method. Analyses of samples 
collected from placebo-treated partic ipants are not planned. Samples will be 
retained for up to 2-years after last patient visit. Remaining samples used for PK 
may be pooled and used for exploratory metabolism or bioanalytical method 
experiments as deemed appropriate.  
 
6.3.18 Antidrug Antibodies  
 
Serum will be collected to measure anti -drug antibodies. At Entry/Day 0, serum 
should be collected before the dose of investigational agent/placebo.  
 
Post-entry, serum should be collected as per the SOE (at the same time as serum collection for PK analysis). Date and time of collection should be recorded.  
 
Samples will be analyzed at a laboratory approved by the sponsor and stored at 
a facility designated by the sponsor.  
 7.0 ADVERSE EVENTS AND STUDY MONITORING 
 7.1 Definitions of Adverse Events
 
 
Adverse Events of Special Interest  
The following are AESIs for the agent BRII-196, BRII-198, or placebo for each of the 
investigational agents:  
• Grade ≥1 infusion-related reactions  occurring within 12 hours of investigational 
agent/placebo administration (deemed related to study product as determined by the site investigator)  
• Grade ≥1 allergic/hypersensitivity  reactions  occurring within 12 hours of 
investigational agent/placebo administration (deemed related to study product as 
determined by the site investigator)  
  8.0 CLINICAL MANAGEMENT ISSUES 
 8.2 Management of Side Effects
 
 8.2.1 Overdose 
 
There is no known antidote for BRII-196 or BRII-198 overdose. In the event this occurs, the participant should be closely monitored for AE/SAE and laboratory 
abnormalities, and supportive care provided as indicated.  
 
8.2.2 Infusion-Related Reactions  
 
All participants should be monitored closely, as there is a risk of infusion reaction 
 165 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 (including anaphylaxis) with any biological agent.  
 Symptoms and signs that may occur as part of an infusion reaction include, but are not limited to fever, chills, nausea, headache, bronchospasm, hypotension,  
angioedema, throat irritation, rash including urticaria, pruritus, myalgia, and 
dizziness.  
   
The severity of infusion-related reactions will be assessed and reported using the 
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can 
be found on the DAIDS RSC website at https://rsc.niaid.nih.gov/clinical -research-
sites/daids -adverse-event-grading-tables . 
 The clinical site should have necessary equipment and medications for the 
management of any infusion reaction, which may include but is not limited to 
oxygen, IV fluid, epinephrine, acetaminophen, and antihistamine. 
Investigators should determine the severity of the infusion reaction and manage infusion reactions based on standard of care and their clinical judgment. If an infusion reaction occurs, then supportive care should be provided in accordance with the signs and symptoms. 
 
Dosing can be modified, such as slowing infusion, for mild or moderate reactions (Grade 1 or Grade 2). 
 
8.2.3 Hypersensitivity  
 
Signs and symptoms of infusion-related immediate hypersensitivity reactions may include, but are not limited to anaphylaxis, angioedema, bronchospasm, chills, diarrhea, hypotension, itching, skin rash, shortness of breath, urticaria, tachycardia, and throat irritation or tightness [8].  
 
Participants will be closely monitored for immediate hypersensitivity reactions.  
 
Sites should have appropriately trained medical staff and appropriate medical equipment available when study participants are receiving BRII-196 and BRII-198. It is recommended that participants who experience a systemic 
hypersensitivity reaction be treated per the local standard of care.  
 
Dosing can be modified, such as slowing infusion, for mild or moderate reactions (Grade 1 or Grade 2). 
 8.3 Pregnancy
 
 
Since there are no data regarding the use of BRII-196 and BRII-198 in participants who are pregnant, participants who are pregnant are not eligible for the study.  
 166 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198  
Participants of childbearing potential and participants who may impregnate their partners are required to follow the instructions for prevention of pregnancy provided in the 
protocol.  
 If a participant becomes pregnant during the study (post-entry), study follow up will 
continue for the duration of the study.   At the end of the pregnancy, outcome and adverse events for participant and infant will 
be recorded on the outcome eCRF.  
 
8.4 Breastfeeding
 
 
Since there are no data regarding the use of BRII-196 or BRII-198 in participants who 
are breastfeeding, participants who are breastfeeding are not eligible for the study.  
 
9.0  CRITERIA FOR DISCONTINUATION 
 9.1 Permanent and Premature Treatment Discontinuation
 
 
A participant will stop investigational agent/placebo if a Grade ≥3 event occurs that is deemed  related to the investigational agent/placebo.  
 10.0 STATISTICAL CONSIDERATIONS  
 
10.2 Outcome Measures
 
 
Primary and secondary outcome measures listed below will be addressed in the BRII-
196/BRII-198 specific appendix to the study’s primary Statistical Analysis Plan. 
 
10.2.3 Secondary Outcome Measures 
 
The following secondary outcome measures will also be assessed:   10.2.3.14 Phase II only: New Grade 2 or higher AE through week 72. 
 
10.2.3.15 Phase III only: New Grade 3 or higher AE through week 72. 
 
10.4 Sample Size  
 
The following sample size considerations for phase III are specific to BRII-196/BRII-198: 
 
 167 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 10.4.2 Phase III 
 
The phase III aspect of the study is designed to evaluate the efficacy of BRII-
196/BRII-198 to reduce the proportion of participants hospitalized or dying by 
28 days after starting investigational agent in outpatient adults diagnosed with 
COVID -19 compared to those receiving placebo. The primary analysis will 
focus on comparing the ratio of proportions  because of the uncertainty in 
knowing what the hospitalization/death proportion will be.  
 
A total of approximately 421 participants will be randomized to receive the agent and approximately 421 participants will be concurrently randomized as the placebo control. This sample size includes the enrollment that occurred 
during the phase II evaluation of BRII-196/BRII-198. With 842 participants, the 
study  has 90% power to detect a relative reduction of 50% in the proportion of 
participants hospitalized/dying between the study groups (investigational agent 
versus placebo), using a two-sided Type I error rate of 5%, using the following 
assumptions: 
• Proportion hospitalized/dying in the placebo arm is 15%. This proportion is 
based on that observed in preliminary data in a similar higher risk outpatient 
population in the BLAZE -1 trial [15]. 
• Targeted 50% reduction is plausible based on the observed effect seen in the BLAZE -1 trial for both a single mAb and for a dual combination mAb 
[15]. Three interim analyses and one final analysis, equally spaced, with 
stopping guideline for efficacy of an agent versus placebo determined using 
the Lan-DeMets spending function approach with an O’Brien and Fleming boundary.  
• Non-binding stopping guideline for futility using a moderately aggressive 
Type II error spending function, specifically a Gamma ( -2) spending 
function [15] , implemented using the Lan-DeMets spending function 
approach. Further details about these stopping guidelines are in section 
10.5.  
• Allowance for 5% of participants to be lost-to-follow -up prior to being 
hospitalized or dying.  
 10.5 Data and Safety Monitoring 
 
The following section outlines considerations for phase III monitoring for BRII-196/BRII-
198.  10.5.2 Phase III Trial  
 
A NIAID -appointed DSMB will undertake reviews of interim data from the study to 
help ensure the safety of participants in the study, and to recommend changes to the study including termination or modification for safety reasons or if there is 
 168 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 persuasive evidence of efficacy or lack of efficacy of an investigational agent 
versus placebo in preventing hospitalizations and deaths. It is not intended, however, to terminate evaluation of an agent early for efficacy based on symptom outcome measures. The DSMB may also recommend termination or 
modification of the study if it appears futile on statistical or operational grounds to 
continue the study as designed. The operation of the DSMB is governed by the NIAID DSMB Charter.  
 At each interim review of BRII-196/BRII-198, the DSMB will review summaries of 
data by randomized treatment arm for the primary outcome of 
hospitalization/death, the secondary outcome of death, losses to follow -up, and 
adverse events (including early discontinuation of investigational agent).  
 
Stopping Guideline for Efficacy and Timing of Interim Efficacy Analyses 
Unless otherwise recommended by the DSMB, it is intended that the DSMB 
review three interim analyses of safety and efficacy data for BRII-196/BRII-198 
versus placebo at the following times (corresponding to approximately 25%, 50% 
and 75% of the expected maximal information): 
 
1. The first interim analysis for Phase III will be when 220 participants from the 
two groups combined have been followed for the primary outcome 
assessed at day 28 (this will likely then be the same hospitalization/death 
information as used in the phase II graduation analysis), or when 
approximately 24 participants in the two groups combined have been 
hospitalized or have died; 
2. The earlier of when approximately 421 participants from the two groups 
combined have been followed for the primary outcome assessed at day 28, 
or when approximately 48 participants in the two groups combined have 
been hospitalized or have died; and  
3. The earlier of when approximately 632 participants from the two groups 
combined have been followed for the primary outcome assessed at day 28, 
or when approximately 72 participants in the two groups combined have 
been hospitalized or have died.  
 
Note that the timing of interim analyses based on number of participants who 
have been hospitalized or have died is based on an expected number of 
hospitalizations and deaths across the two arms combined of 95. This number is 
calculated under the assumed design parameters, i.e., assuming a proportion 
hospitalized/dying of 15% in the placebo control group and a relative reduction of 
50% giving a proportion hospitalized/dying for the investigational agent of 7.5%, 
and a sample size of 421 in each group. 
 
As a stopping guideline for greater efficacy of an investigational agent compared 
with placebo, the O’Brien and Fleming boundary will be used. The stopping guideline will be implemented using the Lan-DeMets spending function approach 
 169 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 to allow for the possibility of changes in the timing of interim analyses and/or 
additional (or fewer) interim analyses if recommended by the DSMB. Formal 
detail s of the expected maximal information and calculation of information time 
will be provided in the Statistical Analysis Plan.  
 
In considering possible modifications to the study or termination of the study for efficacy, the DSMB may consider interim results for the secondary outcome of death. For example, the DSMB might make recommendations  based on a high 
level of evidence for a difference between randomized groups in the proportion 
dying. In these contexts, a “high level of evidence” might be based on application 
of the O’Brien and Fleming stopping guideline to the death outcome. In these circumstances, consideration should also be given to the increased risk of a Type I error.  
 
There is the possibility that differences between the treatment groups may be observed early in follow-up. However, the overall goal of the study is to prevent hospitalization and deaths  regardless of the timing, and therefore the focus of the 
treatment group comparisons will be at day 28. 
 
Stopping Enrollment to an Investigational Agent Because of Lack of Effect 
If enrollment to the study is fast, there may be limited opportunity to stop enrollment to a specific investigational agent before the target of 421 participants 
randomized to that agent is complete (because it will take time to achieve follow -
up of participants and additional time to analyze and review results). However, if the rate of enrollment allows for potential discontinuation of randomization to a 
specific investigational agent, then the following provides non-binding guidance 
on how this might be approached:  
• an agent may be discontinued for statistical futility based on evidence of lack of effect or very limited effect compared with placebo. For the purposes of evaluating this, a moderately aggressive Type II error spending function will be used, specifically the Gamma (-2) spending function implemented using the Lan-DeMets spending function approach [16]. 
 
 170 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 Figure 10.5.2-1 illustrates the stopping guidelines for both efficacy and futility 
assuming four equally spaced analyses (noting that the first interim analysis is at 
approximately 26% of maximal information). The left panel shows the stopping guidelines in terms of critical values for a z -test statistic comparing an agent to 
placebo for the four analyses. The right panel shows the stopping guidelines in terms of observed differences  in proportions for the scenario when the observed 
proporti on in the placebo control arm is 0.15 (i.e., 15%). In both panels, greater 
negative values favor greater effects of an investigational agent versus placebo, and values in the blue area suggest stopping for efficacy whereas values in the 
pink area suggest stopping for futility. As an example, focusing on the right-hand 
panel, if the observed proportion for placebo was 0.15 (i.e., 15%) at the first interim analysis, an absolute difference in proportions of 0.025 or larger (i.e., favoring 
placebo by 2.5%) at the first interim analysis would suggest stopping for futility. At the second interim analysis, an absolute difference of -0.011 (i.e., -1.1%) or smaller 
(i.e., negative but closer to zero than -1.1%, or positive hence favoring placebo) 
would suggest stopping for futility.  
 
Figure 10.5.2-1: Stopping Boundaries for Efficacy and Futility  
 
Modifying or Stopping the Study for Operational Futility 
The DSMB will also monitor operational futility. With respect to operational futility, 
the DSMB may recommend modification or termination of the study if the 
proportion hospitalized/dying in the control group is much lower than expected in 
designing the trial. In addition, the DSMB will monitor the loss to follow-up (LTFU) 
rate. As a benchmark, an overall LTFU rate of more than 10% would be cause for concern.  
 

 171 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 11.0 PHARMACOLOGY PLAN  
 
11.1 Pharmacology Objectives   
 
The phase II pharmacology objective is to determine the pharmacokinetics of BRII-196 
and BRII-198 when used in combination. For phases II and III, the pharmacology 
objective is to explore relationships between dose and concentration of BRII-196 and 
BRII-198 with virology, symptoms, and oxygenat ion.  
 
11.2 Pharmacology Study Design Overview   
 
The Schedule of Evaluations shows the collection schedule for Phase II and for Phase 
III. BRII-196 and BRII-198 have a long-elimination half-lives in preclinical animal studies 
and is expected to be between 9-18 weeks in humans; the predicted elimination half-life 
based on the preclinical data and the established population PK model for mAb with YTE mutation is 89.2 days (10
th-90th percentile of 65.2-124 days). Very limited data in 
participants from Phase I studies who received a single dose of 750 mg, 1500 mg, and 
3000 mg indicated PK behavior consistent with PK model predictions. The PK sample 
schedules are based on the long-elimination half-lives of BRII-196 and BRII-198 and are 
designed to meet the phase II objective of determination of the pharmacokinetics of 
these agents and the phase III objective to explore dose/concentration-response 
relationships. By design, the sample collection schedules are different, with the phase II 
schedule being more intense to determine PK behavior, and the phase III schedule more 
sparse to confirm PK behavior and support dose/concentration-response analyses.  
 
11.3 Pharmacology Data Analysis and Modeling  
 
Pharmacokinetic data analysis of phase II data will use conventional and accepted 
approaches such as non -compartmental analysis or compartmental analysis to determine 
the PK characteristics of BRII-196 and BRII-198. Population pharmacokinetic approaches (e.g., nonlinear mix effects modeling such as implemented in NONMEM) may also be 
used. The usual parameters of interest are area under the concentration-time curve 
(AUC), total body clearance (CL), elimination half-life (T 1/2), and maximum and minimum 
concentrations (C max, Cmin). Exploration of relationships between dose and concentration of 
BRII-196 and BRII-198 with virology, symptoms, and oxygenation will be approached 
using conventional and accepted methods for pharmacokinetic/pharmacodynamic (PK/PD) 
data analyses. Such methods will include the E max or sigmoid E max model or structurally 
linked PK/PD models (as could be performed within NONMEM) to explore exposure-
response relationships. Exposure-response relationships will be performed in conjunction 
with the protocol statisticians.  
  
 172 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198  
16.0 REFERENCES  
1. Doherty M, Robertson MJ. Some early trends in immunology. Trends Immunol 2004;25:623 -31. 
2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004;2:695-703. 
3. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody -based therapies for 
microbial diseases. Vaccine 2009;27:G38-G46.  
4. Casadevall A. The case for pathogen-specific therapy. Expert Opin Pharmacother 2009;10:1699-703.  
5. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531-7.  
6. Fan P, Chi X, Liu L, et al. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. MAbs 2020;12(1):1742457.  
7. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS -CoV -2 
infection. Nature 2020. 584: 115-119. 
8. Brii Biosciences, BRII-198 Investigator’s Brochure v1.0, 2020. 
9. Brii Biosciences, BRII-196 Investigator’s Brochure v1.0, 2020. 
10. Walls, AC. Structure, function, and antigenicity of the SARS -CoV -2 spike 
glycoprotein. Cell 2020; 181: 281-292. 
11. Robbie GJ, Criste R, Dall’aqua WF, et al. A novel investigational Fc -modified 
humanized monoclonal antibody, motavizumab-YTE, has an extended half-life I healthy adults. Antimicrob Agents Chemother 2013; 57:6147 -6153. 
12. Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol 2019; 10:1296  
13. Brii Biosciences. Safety, tolerability and pharmacokinetics study of human monoclonal antibody BRII-196. Available from: https://ClinicalTrials.gov/show/[STUDY_ID_REMOVED]. 
14. Brii Biosciences. Safety, tolerability, and pharmacokinetics study of human monoclonal antibody BRII-198. Available from: https://ClinicalTrials.gov/show/[STUDY_ID_REMOVED]. 
15. Baum A, Ajithdoss D, Copin R, et al. REGN -COV2 antibody cocktail prevents and treats 
SARS- CoV-2 infection in rhesus macaques and hamsters. Science 
2020;370(6520):1110-15. 
 173 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX V: INVESTIGATIONAL AGENTS, BRII -196 + BRII 198 16. Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS- CoV-2 neutralizing antibodies 
and protection from disease in a small animal model. Science 2020;469:956-63. 
17. Hershberger E, Sloan S, Narayan K, et al. Safety and efficacy of monoclonal 
antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine 2019;40:574 -82. 
18. Johnson S, Griego SD, Pfarr DS, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J Infect Dis 1999;180:35-40. 
19. Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 2017:9(388):eaaj1928.  
20. Shah DK, Betts AM. Antibody bio distribution coefficients: inferring tissue 
concentrations of monoclonal antibodies based on the plasma concentrations in 
several preclinical species and human. MAbs 2013; 5:297-305. 
21. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, 
transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID -19): A 
review. JAMA 2020;324:782-93. 
22. Certara. COVID -19: Viral kinetic model 2020 [Available from 
https://www.covidpharmacology.com/in-silico -workbench/viral -kinetic -model/. 
23. Hwang IK, Shih WJ, DeCani JS. Group s equential designs u sing a f amily of t ype I 
error p robability spending functions. Stat Med 1990;9:1439-45. 
 
 174 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI: SAMPLE INFORMED C ONSENT FOR STUDY DRUGS BRII -196 
AND BRII -198 APPENDIX VI: SAMPLE INFORMED CONSENT FOR STUDY DRUGS BRII -196 AND BRII-198 
 
No participants will be enrolled in version 7 or later of this protocol for this investigational agent. 
Consents retained for recording purposes.  
 
One of the study drugs that you might be assigned to in this study is the combination of BRII- 196 
and BRII -198 or the placebos for these study drugs .  
 BRII-196 and BRII-198 are both drugs called a monoclonal antibody  (mAb) . Many antibodies 
are naturally made by your body and help fight diseases. BRII-196 and BRII-198 are made in a laboratory. “Monoclonal” means that BRII-196 and BRII-198 are made up of many copies of just two antibodies.  
 Your assignment is random, like the flip of a coin. You will be told about all the study drugs you 
may be assigned to in this study. If only one study drug is available, you will have an equal 
chance of receiving the study drug or placebo. If two study drugs are available, you will have a 2:1 chance of receiving a study drug or placebo. If three study drugs are available, you will have a 3:1 chance of receiving a study drug or placebo, and so forth. You will not be able to choose your group (study drug), and neither you, your study doctor, nor the study staff at your site will 
know whether you are receiving the study drug or placebo. 
 The United States Food and Drug Administration (FDA) has not approved BRII-196 or BRII-198 
for general use by the public. However, we have told the FDA about this study and they have given us permission to conduct this study.  
 
 
ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE BRII -196 and BRII-198 
OR PLACEBO?  
 
Screening Visit  
• At your screening visit, if you can become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample for a pregnancy test. You cannot participate in the study  if you 
are pregnant.  
 
Entry Visit  
• You will have blood drawn. This blood will be used for the following tests:  o routine safety tests (liver and kidney tests and blood counts)  
o levels of antibodies to the drug (your body’s immune response to the drug)  
• You will have the infusion of BRII -196 and BRII-198 or placebos for each. The infusions will be 
given back -to-back  (first one and then the other)  and will be given through a small plastic tube 
that will be placed into a vein in your arm. This is called an intravenous (IV) infusion. The infusions will take approximately 60 minutes. You will be monitored in the clinic for 2 hours 
after the end of the infusions.  
 175 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI: SAMPLE INFORMED C ONSENT FOR STUDY DRUGS BRII-196 
AND BRII -198 • You will have blood drawn to check the levels of drug in your blood. The blood sample will 
be collected before the study infusion and 30 minutes after the study infusion in the opposite 
limb as the study infusion.  
Study Visits  
After the Entry visit, your study visits and evaluations will be different depending on whether you 
are in the first part of the study or the second part of the study.  
  IF YOU ARE IN THE FIRST PART OF THE STUDY:  
 
Study Visits on Days 3, 14, and 28  
• You will have blood drawn. This blood will be used for the following tests:  o routine safety tests (liver and kidney tests and blood counts)  (Day 3, 14, and 28)  
o levels of the drug and levels of antibodies to the drug (your body’s immune response to the drug)  (Day 14 and 28) 
 
Study Visits on Week 12 and Week 24 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
• You will be asked whether you have had any new symptoms or clinical events since your last visit .  
 
Study Visits on Weeks 36, 48, and 72 
• You will be contacted by phone by the study team to assess whether you have had any new symptoms or clinical events since your last visit  
• You will answer questions about any potential COVID -19 related symptoms or conditions 
you have experienced  
  
IF YOU ARE IN THE SECOND PART OF THE STUDY:  
 
Study Visit on Day 28 
• You will have blood drawn. This blood will be used for the following tests:  
o routine safety tests (liver and kidney tests and blood counts)  
o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
 
Study Visits on Week  12 and 24 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
 176 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI: SAMPLE INFORMED C ONSENT FOR STUDY DRUGS BRII-196 
AND BRII -198 • You will be asked whether you have had any new symptoms or clinical events si nce your 
last visit   
 
Study  Visits on Weeks 36, 48, and 72 
• You will be contacted by phone by the study team to assess whether you have had any new 
symptoms or clinical events since your last visit  
• You will answer questions about any potential COVID -19 related symptoms or conditions 
you have experienced.  
 
 
WHAT ARE THE RISKS OF BRII -196 and BRII-198? 
 There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are
 
taken with the study drugs. For your safety, you must  tell the study  doctor  or nurse about all 
medications  you are taking before you start the study.   
 Another risk is that the study drugs used in this
 study  may have side effects, some  of which  are 
listed below.  Additionally,  the study drug tested  in the study  may have unknown side effects  in 
persons  with SARS-CoV -2 infection.  In a research  study, all the risks or side effects  may not be 
known before you start the study.  You need to tell your doctor  or a member  of the study  team  
immediately  if you experience any side effects.  
 Please note that these lists do not include all the side effects  seen with this study drug.
 These 
lists include the more  serious  or common side effects  with a known or possible  relationship to the 
study drug. If you have questions  concerning the additional side effects,  please ask the medical  
staff at your site. 
 
Risks Associated with BRII-196 and BRII-198 
There is limited safety data on BRII -196 and BRII-198 since they have not been given to a lot of 
people. As of August 2020, healthy volunteers in studies of BRII-196 and BRII-198 have not 
reported any infusion-related reactions, allergic reactions, moderate to severe adverse events 
(negative effects), or any adverse events requiring discontinuation of therapy. 
 BRII-196 and BRII-198 are being administered together for the first time to hospitalized persons 
with COVID- 19 in a separate study, but they have not yet been given to persons who have 
tested positive for COVID -19 and are at a high risk  for developing severe COVID -19.  
 Administration of mAbs, such as BRII -196 and BRII-198 can result in allergic reactions. Signs 
and symptoms of these reactions include:  
• chills  
• skin rash  
• itching  
• hives  
 177 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI: SAMPLE INFORMED C ONSENT FOR STUDY DRUGS BRII-196 
AND BRII -198 • swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
• loose stools  
 
Administration of mAbs, such as BRII -196 and BRII-198 may induce release of chemicals called 
cytokines in the body. These chemicals may induce allergic reactions listed above as well as:  
• fever 
• muscle aches  
• nausea  
• vomiting 
• headache  
• dizziness  
 
Some of these reactions may be serious or life-threatening including:  
• skin rash  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
 
You will be monitored closely during administration of study drug.  Medical personnel, 
equipment, and medication will be available to manage these reactions appropriately if they 
occur.  
 Administration of mAbs, such as BRII-196 and BRII-198 can cause the following risks and 
discomforts:  
• development of proteins (antibodies) against BRII-196 and/or BRII-198. This may cause 
your body to get rid of BRII-196 and/or BRII-198 more quickly or c hange the effect of these 
study drugs  on the body. Your blood will be tested to find out whether your body made 
antibodies to BRII-196 and/or BRII-198. The anticipated risk of this is low because BRII-196 
and BRII-198 are fully human antibodies. Therefore, it is less likely to be seen as “foreign” by your body’s immune system  and your body is less likely to form antibodies against them . 
• mixture of antibody and other chemicals in the body that may be deposited in tissues such as blood vessels and kidneys.  
• unexpected increase in virus reproduction in your body. Although this has  been observed 
with some viruses, this has not been observed with COVID -19 or with the use of serum -
 178 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI: SAMPLE INFORMED C ONSENT FOR STUDY DRUGS BRII-196 
AND BRII -198 containing antibodies given to people with COVID -19. This risk of increased viral growth is 
perhaps greater when there are lower levels of antibodies in the blood in the presence of 
virus. To avoid this, BRII-196 and BRII-198 will be given at a dose that is felt to be high 
enough to keep this from occurring. 
 
Effect on Future Vaccination 
The US Centers for Disease Control and Prevention (CDC)  currently recommends that people 
wait at least 90 days after receiving antibody treatment before receiving a COVID -19 vaccine, 
because some antibodies remain in the body for about 90 days, and there is a chance that 
these antibodies could  interfere with how your body responds to the vaccine during those 90 
days. Some  of the antibodies in this study including BRII-196 and BRII-198 are designed to 
remain in the body for longer than 90 days. Although there is no further guidance available, 
there is a chance that these longer -lasting monoclonal antibodies could interfere with how your 
body responds to the vaccine even if you wait at least 90 days for the vaccine.  
  ARE THERE  RISKS RELATED TO PREGNANCY  AND BREASTFEEDING? 
 
Pregnancy  
Since there are no data regarding the use of this study drug in people who are pregnant, you 
cannot participate in the study if you are pregnant.  
 The study drug may  involve risks to you (or to the embryo or fetus, if you or your partner
 become 
pregnant), which  are currently  unforeseen.  
 
If you are engaging in sexual activity that could lead to pregnancy, you must agree to use effective contraception for 24 weeks after the study drugs are administered. This would include 
oral contraceptives, implanted contraceptives, intrauterine devices, and/or barrier methods.  
 If you are engaging in sexual activity that may lead to pregnancy in your partner, you must agree to either remain abstinent or use male contraceptives. You are also advised to inform 
your non-pregnant sexual partners that can become pregnant to use effective contraceptives for 
24 weeks after the study drugs are administered to you. 
 If you have a pregnant partner you should use condoms during vaginal intercourse through 24 weeks after the study drugs  administered. 
 
If applicable, you should refrain from sperm donation for 24 weeks after study drug 
administration.  If at any point during the study you think you may be pregnant, you should let the staff at your site know so that a pregnancy test can be done.  
 
 179 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI: SAMPLE INFORMED C ONSENT FOR STUDY DRUGS BRII-196 
AND BRII -198 Let your doctor know  immediately  if you become  pregnant. If you become pregnant while  on the 
study, you will be asked to continue to have study visits and the study  staff would like to obtain 
information from you about the outcome of the pregnancy  (even if it is after your participation in 
the study  ends). 
 
Breastfeeding 
It is not known if this study drug is safe to use in people who are breastfeeding. You are not 
eligible to receive this study drug if you are breastfeeding. 
 
 180 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 
 APPENDIX VII : INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION  
 
Information/evaluations noted in this agent-specific appendix are IN ADDITION to those presented in the master protocol. Section numbering aligns with the master protocol. 
 
SCHEMA  
 DESIGN:  The design of the phase II evaluation of AZD7442 IV is as described in the master 
protocol. There is no phase III evaluation for this agent.  
  2.0 INTRODUCTION  
 2.2 Rationale
 
 
Monoclonal Antibodies (mAbs)  
Sera obtained from persons or animals who recovered from a particular infection has 
shown prophylactic and therapeutic potential for a variety of infections, and Emil von 
Behring won the Nobel Prize in 1893 for his work on use of immune serum from the 
blood of infected animals to provide immunity to diphtheria [1]. Currently, hyperimmune 
human sera immunoglobulin is still used to treat many viral infections including 
cytomegalovirus (CMV), respiratory syncytial virus (RSV), hepatitis A virus (HAV), 
hepatiti s B virus (HBV), and rabies [2].  
 
Unfortunately, heterologous sera were associated with a variety of complications including 
serum sickness and hypersensitivity, which significantly limited its usefulness clinically [3]. 
Given the long history of use of antibodies for infectious diseases, monoclonal antibodies 
(mAbs) were developed. Improved purification techniques and the ability to engineer 
humanized mAbs allowed for the development of broadly reactive and potent mAbs, which 
helped reduce some of the issues that hampered the utility of heterologous sera [3, 4]. In 
fact, current technology allows mAbs to be produced requiring only tissue culture or 
microbial expression systems, thus the potential toxicity of humanized mAbs is 
comparable to antibiotics [2, 4]. 
 
Engineered humanized and human mAbs have shown considerable efficacy for viral 
infections. The first was palivizumab in 1998, which is used for RSV [5]. Monoclonal 
antibodies have also been quickly developed for emerging infections such as Ebola [6]. 
As a part of the massive scientific effort to stop COVID -19, mAbs have been developed 
for treatment of COVID -19. These agents now need to be evaluated in rigorous 
randomized clinical trials. 
 
The limitations of mAbs continue to be cost and that these antibodies are perishable, 
require refrigeration, and must be administered parenterally [4]; however, their use may 
still be useful in the outpatient setting, as one dose often stays in the therapeutic range 
 181 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION ‘for months [5], potentially allowing an entire treatment course with a single 
administration. 
 
A number of viral infectious diseases have been successfully treated with mAbs, 
including RSV and HIV. Some of these mAbs were derived from persons who were 
infected with these viruses and mounted neutralizing humoral responses.   An investigational agent to be evaluated in this trial will be the mAb AZD7442 delivered by IV infusion and made by AstraZeneca Pharmaceuticals LP for the treatment of early, 
symptomatic SARS -CoV -2 infection .  
 
Investigational Agent  
 Background  
AZD7442 is a combination of two human mAbs, AZD8895 and AZD1061. Both were 
cloned from B -cells isolated from peripheral blood mononuclear cells (PBMCs) obtained 
from COVID -19 convalescent patients. These mAbs bind to unique, non- overlapping 
epitopes at the human angiotensin-converting enzyme 2 (hACE2) interface of the receptor binding domain (RBD) of the Spike (S) protein of SARS -CoV -2, preventing viral 
entry into human cells and its subsequent viral replication. The two antibodies in the 
combination contain modifications in their Fc regions that extend their anticipated half -
life up to 70- 130 days [3- 6] and reduce the risk of antibody dependent enhancement 
(ADE), by limiting binding to cellular Fc gamma receptors [7]. The combination of two 
mAbs with differing binding sites on the RBD is intended to reduce the probability of viral mutations that would confer antibody resistance, and to provide synergy in their virus 
neutralizing activity.  
 
AZD7442 is expected to result in a clinically important decrease of viral replication, 
mitigating the severity of COVID -19 in persons with the infection in whom ongoing viral 
replication is the primary driver of pathophysiology. The potential reduction in viral replication may also decrease a treated person’s extent and duration of viral shedding 
and transmission, thus potentially positively impacting public health.  
 
Non-Clinical Studies: Pharmacokinetics (PK)  
Nonclinical studies of AZD7442 have been performed in mice and non- human primates  
(NHPs). In human Fcn transgenic Tg32 mice, peak serum concentrations at 28 days post intravenous administration of AZD7442 components remained well above the 
EC50s and EC99s determined in cellular infection assays  [8]. The toxicokinetic profile of 
AZD7442 (AZD8895 and AZD1061) following IV or IM administration is being evaluated 
in cynomolgus monkeys as part of a GLP toxicology study. In this GLP toxicology study for AZD7442 high exposures were achieved and were very consistent across animals and between males and females for both AZD8895 and AZD1061, for both the 300 
mg/kg IV dose and the 75 mg/kg IM dose of each antibody  [8]. Based on the data 
available over the first 2 weeks after dosing, the safety exposure margin for the clinical 
 182 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 300 mg IV AZD7442 dose against the IV NOAEL of 600 mg/kg AZD7442 is 103-fold and 
150-fold for AUC (0-4 weeks) and C max, respectively  [8].  
 Non-Clinical Studies: Antiviral Effects  
Murine models of SARS-CoV -2 have been performed to study the prophylactic and post-
exposure antiviral activity of the AZD7442. In these models, the parenteral formulations of AZD7442 components were studied: COV2-2196 and COV2-2130, the respective parental antibodies of AZD8895 and AZD1061. COV2-2196 and COV2-2130 lack the Fc region modifications but are expected to retain antiviral activity. In a mouse-adapted-
SARS- CoV-2 model, BALB/c mice were inoculated via intranasal route with 10
5 
fluorescent focus units (FFU) of MA-SARS- CoV-2 and COV2 -2196 and COV2-2130 (1:1 
cocktail) administered intravenously 12 hours after. Viral burden in the lungs was 
measured 2 days post infection (dpi) after viral challenge using RT-qPCR or plaque 
assay. Mice were monitored daily for body weight change. Administration of the mAbs 
12 hours  post infection in Ad5-hACE2 transduced mice resulted in neutralization of 
infectious virus in the lungs. The mAbs  were also evaluated for in vivo efficacy in an 
immuno -competent model using a mouse-adapted-SARS- CoV-2 virus. In this model 
there was significant viral replication in the lungs but little or no clinical disease [9 ]. 
 
The parental mAb formulations were also assessed in a NHP model [10, 11]. Rhesus 
macaques received one 50 mg/kg dose of COV2-2196 or isotype control antibody 
intravenously 3 days prior to intranasal and intratracheal challenge with a total dose of 10,000 PFU SARS -CoV-2. Virus replication was quantitated by RT-qPCR for viral 
sgmRNA, which measures replicative viral RNA intermediates. Animals that received isotype control antibody showed a median peak of 7.53 log10 sgmRNA copies/swab in 
nasal swab and a median peak of 4.97 log10 sgmRNA copies/mL in bronchoalveolar 
lavage. In contrast, viral sgmRNA was not detected in either nasal or bronchoalveolar lavage samples from animals that received COV2-2196. A PK analysis revealed similar concentrations of circulating human mAbs in animals from both groups.  
 Human Clinical Studies  
The first in-human clinical studies of AZD7442 began enrolling in August 2020. 
([STUDY_ID_REMOVED]). Both IV (300 mg, 1000 mg, and 3000 mg), sequentially and co-
administered, and IM (300 mg) administration have been studied in this phase I, single-dose, dose- escalating trial among healthy adults. As of early December , 50 persons in 
this study have received the product at doses up to 3000 mg IV, and no safety concerns 
have emerged. Specifically, there were no deaths, SAEs or discontinuation of study 
product due to AEs and no laboratory events of concern. Pharmacokinetic data from this 
phase I study also demonstrate the persistence of neutralizing antibody levels at 90 days post-infusion in all participants, with dose-dependent concentrations observed. As described below, pharmacokinetic data have demonstrated relative levels achieved with IV and IM dosing.  
 The proposed adaptive Phase II/III trial is likely to be the first administration in persons with COVID- 19 disease, although pre -exposure and post-exposure prophylaxis studies 
 183 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION have started. These include clinical  studies PROVENT (pre-exposure), STORM 
CHASER (post -exposure) and TACKLE (treatment with 600 mg IM). As of December 8,  
2020, there was a single SAE in a pre-exposure prophylaxis participant who fainted 
following product administration (IM) and required evaluation at the hospital.  
 
Choice of Study Dosing  
Human efficacious doses for AZD7442 were evaluated using in vitro potency data (virus neutralizing activity of AZD7442 against SARS -CoV -2) and PK data. In addition, a 
viral-dynamic model was developed, which allowed for understanding of the 
pharmacodynamic effects of AZD7442 to inhibit a SARS -CoV-2 infection and the 
resulting immune response. The viral -dynamic model indicates that assuming a partition 
ratio ranging between 0.1- 1.0% for lung epithelial lining fluid -to-serum and assuming 
potency with an IC
80 (inhibiting SARS-CoV -2 by 80%) of 40 ng/mL, the estimated 
effective concentration may be as low 4 µg/mL in serum. The dosing in Phase I studies therefore targeted 20-40 µg/m to assure sufficient levels in patients with an active SARS -
CoV-2 infection; 300 mg AZD7442 IV administration before the time of peak viral load 
(on average ~7 days after day of infection is expected to result in reduction of the peak 
viral load and earlier eradication of the viral load. Administration of 300 mg IV AZD7442 after the peak viral load has been reached, is still expected to result in earlier viral load eradication compared to when drug is not present.  
 
Figure 1 shows the preliminary serum AZD7442 concentration through 30 days post dose for the different single doses tested, as well as the predicted concentration time course for a single 600mg IM dose by multiplying the concentrations for the 300 mg IM dose by 2. The median time of maximum drug levels still needs to be defined when more 
data are available but initial data suggests that the T
max can be as late as 30 days post 
dose when administered in the ventrogluteal muscle.  
 
  
   
Figure 1: Observed Mean (SD) Serum AZD7442 concentrations over the first 30 days in 
Adult Healthy Volunteers in the Phase 1 Study  

 184 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  
 
Participants must meet inclusion and exclusion criteria from the master protocol, as well 
as the appropriate inclusion and exclusion criteria for the investigational agent included 
below.  
 4.1 General Eligibility Criteria
 
  
4.1.1 Inclusion Criteria 
 
4.1.1.10 For participants who are of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or laboratory that has a CLIA certification or its equivalent, or by a point of care (POC)/CLIA -waived test.  
 
Reproductive potential is defined as: 
• participants who have reached menarche 
• participants who have not been post -menopausal for at least 12 
consecutive months with follicle-stimulating hormone (FSH) ≥40 IU/mL or 24 consecutive months if an FSH is not available  
• participants who have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy)  
• participants with no other clinical conditions (such as anorexia nervosa) that could induce amenorrhea 
• participants not taking medications such as oral contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs) or chemotherapy that could induce amenorrhea  
• For individuals with permanent infertility due to an alternate medical cause (e.g., Mullerian agenesis, androgen insensitivity), 
investigator discretion should be applied to determining study 
entry.  
 
 4.1.1.11 If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use highly effective contraception for 24 weeks after investigational agent is 
administered. Highly effective contraception includes oral 
contraceptives, implanted contraceptives, and intrauterine de vices.  
 
NOTE: Participants not of reproductive potential are eligible without requiring the use of a contraceptive method. Participant-reported 
history is acceptable documentation of surgical sterilization and 
menopause, including vasectomy in a sole partn er. 
 185 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION  
4.1.1.12 Participants that engage in sexual activity that may lead to pregnancy 
in their partner must agree to either remain abstinent or use male contraceptives. They are also strongly advised to inform their non-
pregnant sexual partners of reproductive potential to use effective 
contraceptives for 24 weeks after investigational agent is administered. 
 
Partici pants with pregnant partners should use condoms during vaginal 
intercourse through 24 weeks after investigational agent 
administration. 
 Partici pants should refrain from sperm donation for 24 weeks after 
investigational agent administration.  
 
4.1.2  Exclusion Criteria  
 
4.1.2.11 Currently pregnant or breastfeeding  
 4.1.2.12  In phase II, meeting the protocol definition of being at “higher” risk of progression to hospitalization or death (see SCHEMA, POPULATION
) 
 
5.0 INVESTIGATIONAL AGENTS  
 5.1 Regimen, Administration, and Duration
 
 
5.1.1 Regimen and Duration 
 
Participants will be randomized to receive one of the following regimens: 
 
Investigational  Agent: AZD7442, 300 mg (AZD8895, 150 mg PLUS  AZD1061, 
150 mg) to be administered intravenously (IV) for one dose at study Entry/Day 0.  
 
OR 
 
Placebo for AZD7442: 0.9% Sodium Chloride Injection, USP, to be administered IV for one dose at study Entry/Day 0  
 
 
5.1.2 Administration 
 
AZD7442/Placebo to be administered IV over approximately 15 minutes at a rate 
of 20 mg/minute. 
 
 186 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION Prior to administration, the infusion solution must be allowed to equilibrate to 
room temperature. An infusion set containing low protein binding 0.2 or 0.22 µm in-line filters must be attached and primed per institutional procedures. The entire 
contents of the IV bag must be infused to the participant. After the entire contents 
of the IV bag have been administered, flush the catheter with 5 mL of 0.9% Sodium Chloride Injection, USP and flush the infusion line as per site requirements to ensure the full dose is administered. Infusion time does not include the final flush time.   
5.2 Formulation, Storage, and Preparation
 
 
5.2.1 Formulation and Storage 
 
AZD7442 consists of two independent drug substances, AZD8895 and AZD1061, 
which are formulated separately. Both AZD8895 and AZD1061 are supplied as a 
100 mg/mL aqueous solution with 150 mg (nominal) of active investigational product in 10R glass vials with a volume of 1.5 mL. The aqueous solutions are 
colorless to slightly yellow, clear to opalescent. AZD8895 and AZD1061 vials must be stored between 2°C to 8°C (refrigerated storage) until use. AZD7442 is described in further detail in AZD7442 Investigator’s  Brochure.  
 Placebo for AZD7442 is 0.9% Sodium Chloride Injection, USP. The product must be locally sourced and stored according to the manufacturer’s recommendation.  
 
5.2.2. Preparation  
 
Pharmacists must follow appropriate aseptic technique and consider sterile preparation procedures/guidance as outlined in USP General Chapter <797> Pharmaceutical Compounding – Sterile Preparations. Pharmacists must also 
follow the requirements of their country, institution, and pharmacy regulatory authority regarding these procedures. The investigational agent and placebo 
should be prepared in a sterile environment, utilizing a biosafety cabinet/isolator. 
If a biosafety cabinet or isolator is not available, a laminar flow hood may be used. Local regulations and s ite institutional policies and procedures for use of 
personal protective equipment, such as gloves, gowns, face masks, and safety glasses, must be followed. 
 
Any unused portion of investigational agent must not be used for another participant. Any empty vials, unused portion of entered vials, or unused solution which contains investigational agent should be discarded in a biohazard containment bag and incinerated or autoclaved in accordance with institutional or pharmacy policy.  
 
 187 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 5.2.2.1 AZD7442 
 
1. Remove one (1) vial of AZD8895 and one (1) vial of AZD1061 from 
the refrigerator, and an appropriately sized IV bag of 0.9% Sodium 
Chloride Injection USP. The target volume of the 0.9% Sodium 
Chloride Injection, USP IV bag is 100 mL, however, a range of 50 to 250 mL volumes can be utilized if a 100 mL IV bag is not available.  
2. Using an appropriately sized syringe and needle, withdraw 1.5 mL of AZD8895 from the AZD8895 vial and inject the contents into the IV 
bag with 0.9% Sodium Chloride Injection, USP. Gently mix th e 
contents until visually uniform. When the stopper of the vial is 
punctured to start preparation, record this time as the investigational agent preparation time. Assign a 4 hour beyond use date and time from the preparation time if stored at room temperature or a 24 hour 
beyond use date and time from the preparation time if stored at 
refrigerated conditions.  
3. Using an appropriately sized syringe and needle, withdraw 1.5 mL of AZD1061 from the AZD1061 vial and inject the contents into the same IV bag with 0.9% Sodium Chloride Injection, USP and AZD8895 prepared in Step 2. Gently mix the contents until visually 
uniform.  
4. Place an opaque cover over the IV bag.  
 
5.2.2.2 Placebo for AZD7442 
 
1. Remove an appropriately sized IV bag of 0.9% Sodium Chloride 
Injection, USP. The target volume of the 0.9% Sodium Chloride Injection, USP IV bag is 100 mL, however, a range of 50 to 250 mL volumes can be utilized if a 100 mL IV bag is not available. The IV bag used must be the same size as the IV bag used for the preparation of the investigational agent. 
2. Remove a second container of 0.9% Sodium Chloride Injection, USP. Using an appropriately sized syringe and needle withdraw 3 mL of 0.9% Sodium Chloride Injection, USP from this container and inject the contents into the IV bag obtained in Step 1.  
3. Assign a 4 hour beyond use date and time from the preparation time 
if stored at room temperature or a 24 hour beyond use date and time 
from the preparation time if stored at refrigerated conditions.  
4. Place an opaque cover over the IV bag.  
 
 
 
 188 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 5.2.3 Labeling of Investigational Agent and Placebo  
 
Label the prepared IV bag with the following information: a. Participant identifier(s)  
b. Protocol number: ACTIV -2/A5401 
c. Investigational agent names: AZD7442 300 mg or Placebo  
d. Total volume: 100 mL (or appropriate size within range of 50 to 250 mL dependent on availability)  
e. Route: IV  
f. Infusion rate/time: 20 mg/minute over approximately 15 minutes  
g. Preparation date and time 
h. Beyond use date and time: 4 hours at room temperature conditions or 24 hours at refrigerated conditions after preparation  
i. Any additional information required by jurisdiction  
 
5.3 Supply, Distribution, and Accountability
 
 
5.3.1 Supply/Distribution  
 
AZD7442 will be manufactured by Catalent for AstraZeneca and will be available 
through the NIAID Clinical Research Products Management Center (CRPMC). 
The site pharmacist will receive ordering instructions for AZD8895 and AZD1061 vials from the NIAID CRPMC.  
 0.9% Sodium Chloride Injection, USP, infusion sets, and any other ancillary 
supplies will be locally sourced by the site.  
 
5.3.2 Accountability  
 
The site pharmacist is required to maintain complete records of all investigational 
agents received from the NIAID CRPMC and subsequently d ispensed. At US 
CRSs, all unused investigational agents must be returned to the NIAID CRPMC (or as otherwise directed by the sponsor) after the study is completed or terminated. At non-US CRSs , the site pharmacist must follow the instructions 
provided by the CRPMC for the destruction of unused investigational agents. 
 
5.4 Concomitant Medications
 
 
Any pre -medications given will be documented as a concomitant medication. There are 
no known or expected drug-drug interactions with the investigational agent and therefore 
there no prohibited medications except as outlined in sectio n 5.4  of the parent protocol. 
 
 
 189 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 6.0 CLIN ICAL AND LABORATORY EVALUATIONS 
 
6.1 Schedule of Evaluations . The schedules of evaluations provided below include additional evaluations for this inv estigational 
agent. 
 
Table 6.1-1: Schedule of Evaluations Phase II 
Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Investigational Agent Administered   X            
Hematology   X X  X X      X  
Chemistry   X X  X X      X  
Pregnancy Testing  X  Whenever Pregnancy Suspected       
PK Studies   X1 X X X X X X    X X 
Antidrug Antibodies   X   X X X X    X X 
1 First PK serum sample to be obtained prior to infusion along with remainder of entry labs. A second PK sample to be obtained at the completion 
of the infusion 
 190 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 6.3 Instructions for Evaluations  
 
6.3.9 Investigational Agent Administered 
 
Pre-Medication 
Pre-medication for infusions is not planned. However, if the participant has a 
medical history suggesting a potential benefit from pre-medication, the study investigator(s) should determine the appropriate pre-medication. 
 
Any pre-medications given will be documented as a concomitant medication. 
 
Before the Infusion  
Vital signs (temperature, heart rate, respiratory rate, blood pressure, and SpO2).  
 
During the Infusion  
As the infusion should run over approximately 15 minutes, vital signs (temperature, heart rate, respiratory rate, blood pressure and SpO
2) will be 
measured at infusion end (± 3 minutes) . 
 
After Infusion 
Vital signs (temperature, heart rate, respiratory rate, blood pressure, and SpO2) will be measured every 30 minutes  (± 5 minutes) for 2 hours post infusion.  
 Only vital signs that meet AE reporting requirements will be recorded on an eCRF.  
 
6.3.15 Laboratory Evaluations 
 
Hematology  
Participants will have blood drawn for complete blood cell count (CBC) with automated differential and platelet count.   
At Entry/Day 0, blood should be drawn before study drug administration.  
 
Chemistry  
Participants will have blood drawn for liver function tests (ALT, ALP, AST, total bilirubin, direct bilirubin, and total protein), and renal function tests (albumin, 
BUN, creatinine, potassium, glucose, and sodium).  
 
At Entry/Day 0, blood should be drawn before study drug administration.  
 
Pregnancy Testing 
For participants of reproductive potential: Serum or urine β-HCG. (Urine test 
must have a sensitivity of ≤25 mIU/mL).  
 
 191 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION Post-screening, pregnancy testing should be done any time pregnancy is 
suspected per the SOE.  
 In the event of pregnancy occurring during the study, record pregnancy and 
pregnancy outcome per section 8.3
. 
 
6.3.16 Pharmacokinetics   
 
Serum will be collected and used to measure investigational agent levels.   
At Entry/Day 0, the first serum sample should be collected along with the remainder of entry labs before the dose of investigational agent/placebo (up to 10 minutes before the start of infusion). A second PK sample should be obtained at the completion of the infusion (up to 15 minutes after completion of infusion) from 
an opposite limb and not the IV line/same site as the infusion.  If it is not possible 
to collect the sample from an opposite limb for clinical reasons such as 
lymphedema or limited or restricted vascular access, the post-end of infusion PK 
draw should be skipped and the reason for the missed collection noted in site records.  
 
Post-entry, serum should be collected as per the SOE for PK measurements. Date and time of collection should be recorded.   Samples will be analyzed at a laboratory approved by the sponsor and stored at a facility designated by the sponsor. Concentrations of the investigational agent 
will be assayed using a validated bioanalytical method. Analyses of samples 
collected from placebo-treated participants  are not planned. Samples will be 
retained for up to 2-years after last patient visit. Remaining samples used for PK 
may be pooled and used for exploratory metabolism or bioanalytical method experiments as deemed appropriate.  
 
6.3.18 Anti-Drug Antibodies  
 
Serum will be collected to measure anti -drug antibodies (ADAs). At Entry/Day 0, 
serum should be collected before the dose of investigational agent/placebo.   
Post-entry, serum should be collected as per the SOE for ADA measurement. 
Date and time of collection should be recorded.   Samples will be analyzed at a laboratory approved by the sponsor and stored at a facility designated by the sponsor.  
 
 192 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 7.0 ADVERSE EVENTS AND STUDY MONITORING 
 
7.1 Definitions of Adverse Events  
 
Adverse Events of Special Interest  
The following are AESIs for the agent AZD7 442 or placebo for AZD7442:  
• ≥ Grade 1 infusion-related reactions  within 12 hours  of investigational  agent/placebo 
administration (deemed related to study product as determined by the site investigator) 
• ≥ Grade 1 allergic/hypersensitivity  reactions  within 12hrs  of investigational  
agent/placebo administration (deemed related to study product as determined by the 
site investigator)  
 
8.0 CLINICAL MANAGEMENT ISSUES 
 
8.2 Management of Side Effects
  
 
8.2.1 Overdose 
 
An overdose is defined as greater than the protocol indicated dose for either component of AZD7442 (>150 mg). There is no known antidote for AZD7442 
overdose. In the event this occurs, the participant should be closely monitored for AE/SAE and laboratory abnormalities, and supportive care provided as indicated. If it is determined that an infusion contains more than the assigned dose, the 
infusion should be stopped immediately on recognition and the estimated dose 
received should be recorded. 
 
8.2.2 Infusion-Related Reactions  
 
All participants should be monitored closely, as there is a risk of infusion reaction (including anaphylaxis) with any biological agent.   Symptoms and signs that may occur as part of an infusion reaction include, but are not limited to fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, and 
dizziness.  
 
The severity of infusion-related reactions will be assessed and reported using the 
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can 
be found on the DAIDS RSC website at https://rsc.niaid.nih.gov/clinical -research-
sites/daids -adverse-event-grading-tables . 
 
The clinical site should have necessary equipment and medications for the management of any infusion reaction, which may include but is not limited to 
 193 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION oxygen, IV fluid, epinephrine, acetaminophen and antihistamine. 
 Investigators should determine the severity of the infusion reaction and manage infusion reactions based on standard of care and their clinical judgment. If an 
infusion reaction occurs, then supportive care should be provided in accordance 
with the signs and symptoms. 
 Dosing can be modified, such as slowing infusion, for mild or moderate reactions (Grade 1 or Grade 2). 
 
8.2.3 Hypersensitivity  
 
Signs and symptoms of infusion-rel ated immediate hypersensitivity reactions 
may include, but are not limited to anaphylaxis, angioedema, bronchospasm, 
chills, diarrhea, hypotension, itching, skin rash, shortness of breath, urticaria, 
tachycardia, and throat irritation or tightness [9 ].  
 Participants will be closely monitored for immediate hypersensitivity reactions.  
 Sites should have appropriately trained medical staff and appropriate medical 
equipment available when study participants are receiving AZD7442. Participants 
who experience a systemic hypersensitivity reaction should be treated per the local standard of care.  
 Dosing can be modified, such as slowing infusion, for mild or moderate reactions 
(Grade 1 or Grade 2). 
 
8.3 Pregnancy
  
 
There are no data regarding the use of AZD7442 in participants who are pregnant, and therefore potential participants who are pregnant are not eligible during screening.  
 If a participant becomes pregnant during the study (post-entry), study follow up will 
continue for the duration of the study.   At the end of the pregnancy, outcome and adverse events for participant and infant will 
be recorded on the outcome eCRF.  
 
8.4 Breastfeeding
 
 
Since there are no data regarding the use of AZD7442 in participants who are breastfeeding, participants who are breastfeeding are not eligible for the study. 
 
 194 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 9.0  CRITERIA FOR DISCONTINUATION 
 
9.1 Permanent and Premature Treatment Discontinuation 
 
A participant will stop investigational agent/placebo if a Grade ≥3 event occurs that is deemed  related to the investigational agent/placebo.  
 
10.0 STATISTICAL CONSIDERATIONS  
 
10.2 Outcome Measures
 
 
Primary and secondary outcome measures listed below will be addressed in the 
AZD7442 IV specific appendix to the study’s primary Statistical Analysis Plan. 
 
10.2.3 Secondary Outcome Measures 
 
The following secondary outcome measures will also be assessed:  
 
10.2.3.14 Phase II only: New Grade 2 or higher AE through week 72. 
 
11.0 PHARMACOLOGY PLAN  
 
11.1 Pharmacology Objectives   
 
The phase II pharmacology objective is to determine the pharmacokinetics of AZD7442. 
For phases II and III, the pharmacology objective is to explore relationships between 
dose and concentration of AZD7442 with virology, symptoms, and oxygenation.  
 
11.2 Pharmacology Study Design Overview   
 
The Schedule of Evaluations shows the collection schedule for Phase II and for Phase 
III. AZD7442 has a long elimination in preclinical animal studies and is expected to be as 
long as 90 days in humans. The PK sample schedules are based on the long-elimination 
half-life of AZD7442 and are designed to meet the phase II objective of determination of 
AZD7442 pharmacokinetics and the phase III objective to explore dose/concentration-
response relationships. By design, the sample collection schedules are different, with the 
phase II schedule being more intense to determine PK behavior, and the phase III 
schedule sparser to confirm PK behavior and support dose/concentration- response 
analyses.  
 
11.3 Pharmacology Data Analysis and Modeling  
 
Pharmacokinetic data analysis of phase II data will use conventional and accepted 
approaches such as non -compartmental analysis or compartmental analysis to 
determine the PK characteristics of AZD7442 and its components. Population 
 195 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION pharmacokinetic approaches (e.g., nonlinear mix effects modeling such as implemented 
in NONMEM) may also be used. The usual parameters of interest are area under the 
concentration-time curve (AUC), total body clearance (CL), elimination half-life (T 1/2), and 
maximum and minimum concentrations (C max, Cmin). Exploration of relationships between 
dose and concentration of AZD7442 components with virology, symptoms, and 
oxygenation will be approached using conventional and accepted methods for 
pharmacokinetic/pharmacodynamic (PK/PD) data analyses. Such methods will include 
the E max or sigmoid E max model or structurally linked PK/PD models (as could be 
performed within NONMEM) to explore exposure-response relationships. Exposure -
response relationships will be performed in conjunction with the protocol statisticians.  
 
  
 196 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VI I: INVESTIGATIONAL AGENT AZD7442 INTRAVENOUS ADMINISTRATION 16.0 REFERENCES 
 
1. Doherty M, Robertson MJ. Some early trends in immunology. Trends Immunol 2004;25:623 -31. 
2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for  infectious 
diseases. Nat Rev Microbiol 2004;2:695-703. 
3. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody -based therapies for 
microbial diseases. Vaccine 2009;27:G38-G46.  
4. Casadevall A. The case for pathogen-specific therapy. Expert Opin Pharm acother 
2009;10:1699-703.  
5. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531-7.  
6. Fan P, Chi X, Liu L, et al. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. MAbs 2020;12:1742457.  
7. Everds NE, Tarrant JM. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicol Pathol 2013;41:280-302. 
8. Investigator’s Brochure, AstraZeneca AZD7442 3.0; 08 December 2020. 
9. Dinnon KH, 3rd, Leist SR, Schafer A, et al. A mouse-adapted model of SARS -CoV-2 
to test COVID -19 countermeasures. Nature 2020 586:560-6. 
10. Chandrashekar  A, Liu J, Martinot AJ, et al. SARS -CoV -2 infection protects against 
rechallenge in rhesus macaques. Science 2020;369:812-17. 
11. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine  protection against SARS -CoV -2 in 
rhesus macaques. Science 2020;369:806-11. 
12. Zuidema J, Pieters  FAJM , Duchateau GSMJE . Release and absorption rate aspects 
of intramuscularly injected pharmaceuticals. Int J P harma 1988;47:1-12. 
13. Scialli AR, Bailey G, Beyer BK , et al. Potential seminal transport of pharmaceuticals 
to the conceptus. Reprod Toxicol  2015;58: 213-21.
 197 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED VIA INTRAVENOUS INFUSION  
 APPENDIX VII I: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED VIA INTRAVENOUS INFUSION  
 
No participants will be enrolled in version 7 or later of this protocol for this investigational agent. 
Consents retained for recording purposes.  
 
One of the study drugs that you might be assigned to in this study is AZD7442 or the placebo for 
AZD7442.  
 
AZD7442 is a type of drug called a monoclonal antibody. Many antibodies are naturally made by 
your body and help fight diseases. AZD7442 is made in a laboratory. It is a combination of two 
monoclonal antibodies, meaning many copies each of two antibodies designed to prevent 
SARS- CoV-2, the virus that causes COVID -19, from entering cells.  
 
Your assignment is random, like the flip of a coin. You will be told about all the study drugs you 
may be assigned to in this study. If only one study drug is available, you will have an equal chance of receiving the study drug or placebo. If two study drugs are available, you will have a 2:1 chance of receiving a study drug or placebo. If three study drugs are available, you will have a 3:1 chance of receiving a study drug or placebo, and so forth. You will not be able to choose your group (study drug), and neither you, your study doctor, nor the study staff at your site will 
know whether you are receiving the study drug or placebo. 
 The United States Food and Drug Administration (FDA) has not approved AZD7442 for general 
use by the public. However, we have told the FDA about this study and they have given us permission to conduct this study.  
  ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE AZD7442 OR 
PLACEBO?  
Screening Visit  
• At your screening visit, if you can become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample for a pregnancy test. You cannot receive AZD7442 or placebo 
if you are pregnant.  
 
Entry Visit  
• You will have blood drawn. This blood may be used for the following tests:  
o routine safety tests (liver and kidney tests and blood counts)  
o levels of the drug in your blood (you will have blood drawn before you receive the study drug and again after)  
o levels  of antibodies to the drug (your body’s immune response to the drug)  
• You will have the infusion of each component of AZD7442 or placebo. The infusion will be 
given through a small plastic tube that will be placed into a vein in your arm. This is called 
 198 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED VIA INTRAVENOUS INFUSION  an intravenous (IV) infusion. The infusion itself will take approximately 15 minutes. You will 
then be monitored for another 2 hours. 
 
Study Visits  
After the Entry visit, your study visits and evaluations will be different depending on whether you are in the first part of the study or the second part of the study.    IF YOU ARE IN THE FIRST PART OF THE STUDY:  
 
Study Visits on Days 3, 7, 14, and 28  
• You will have blood drawn. This blood will be used for the following tests:  o Routine safety tests (liver and kidney tests and blood counts) (days 3, 14, and 28)  
o Levels of the drug and/or levels of antibodies to the drug (your body’s immune response to the drug) (days 3, 7, 14 and 28)  
 
Study Visits on Week 12 and 24 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug and levels of antibodies to the drug (your body’s immune response to the drug)  
• You will be asked whether you have had any new symptoms or clinical events since your last visit .  
 
Study  Visits on Weeks 36, 48, and 72 
• You will be contacted by phone by the study team to assess whether you have had any new symptoms or clinical events since your last visit  
• You will answer questions about any potential COVID -19 related symptoms or conditions 
you have experienced  
 
IF YOU ARE IN THE SECOND PART OF THE STUDY:  
 
Study Visit on Day 28 
• You will have blood drawn. This blood will be used for the following tests:  
o routine safety tests (liver and kidney tests and blood counts)  
o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
 
Study Visit on Weeks 12 and 24 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
• You will be asked whether you have had any new symptoms or clinical events since your last visit .  
 199 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED VIA INTRAVENOUS INFUSION   
Study  Visits on Weeks 36, 48, and 72 
• You will be contacted by phone by the study team to assess whether you have had any new 
symptoms or clinical events since your last visit  
• You will answer questions about any potential COVID -19 related symptoms or conditions 
you have experienced  
 
HOW  LONG  WILL I BE IN THIS  STUDY? 
 
If you are assigned to AZD7442 or placebo for AZD7442, you will be in this study  for 72 weeks.  
  WHAT ARE THE RISKS OF AZD7442? 
 
There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are
 
taken with the study drugs. For your safety, you must  tell the study  doctor  or nurse about all 
medications  you are taking before you start the study.   
 
Another risk is that the study drug used in this study  may have side effects, some  of which  are 
listed below.  Additionally,  the study drug tested  in the study  may have unknown side effects  in 
persons  with SARS-CoV -2 infection.  In a research  study, all of the risks or side effects  may not 
be known before you start the study. You need to tell your doctor  or a member  of the study  team  
immediately  if you experience any side effects.  
Please note that these lists do not include all the side effects  seen with this study drug.  These 
lists include the more  serious  or common side effects  with a known or possible  relationship to the 
study drug. If you have questions  concerning the additional side effects,  please ask the medical  
staff at your site. 
 
Risks Associated with AZD7442 
There is limited safety data on AZD7442 since it has not been given to a lot of people. As of 
December 8, 2020, there have been no serious unexpected effects reported by >100 healthy  
people taking AZD7442 or placebo to date. Most effects after taking AZD7442 or placebo have 
been mild or moderate and have either all gone away or are getting better. This study is likely to 
be the first study where this study drug is given to people with COVID -19 disease.  
 
Administration of AZD7442 may result in allergic reactions. Signs and symptoms of these 
reactions include:  
• chills  
• skin rash  
• itching  
• hives  
• swelling of the face or other soft tissues  
• low blood pressure  
 200 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED VIA INTRAVENOUS INFUSION  • rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
• loose stools  
 
Administration of AZD7442 may induce release of chemicals called cytokines in the body. 
These chemicals may induce allergic reactions listed above as well as: 
• fever  
• muscle aches  
• nausea  
• vomiting 
• headache  
• dizziness  
 
Some of these reactions may be serious or life-threatening including:  
• skin rash  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
 
You will be monitored closely during administration of study drug.  Medical personnel, 
equipment, and medication will be available to manage these reactions appropriately if they occur.  
 Administration of study drug may also cause the following risks and discomforts: 
• development of proteins (antibodies) against AZD7442. This may cause your body to get rid 
of AZD7442 more quickly or change the effect of AZD7442 on the body. Your blood will be 
tested to find out whether your body made antibodies to AZD7442. The anticipated risk of 
this is low because AZD7442 is a fully human antibody. Therefore, it is less likely to be seen 
as “foreign” by your body’s immune system and your body is less likely to form antibodies against AZD7442. 
• mixture of antibody and other chemicals in the body that may be deposited in tissues such as blood vessels and kidneys.  
• unexpected increase in virus reproduction in your body. Although this has been observed 
with some viruses, this has not been observed with COVID -19 or with the use of serum -
containing antibodies given to people with COVID -19. This risk of increased viral growth is 
perhaps greater when there are lower levels of antibodies in the blood in the presence of 
 201 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED VIA INTRAVENOUS INFUSION  virus. To avoid this, AZD7442 will be given at a dose that is felt to be high enough to keep 
this from occurring.  
 
Effect on Future Vaccination 
The US Centers for Disease Control and Prevention (CDC)  currently recommends that people 
wait at least 90 days after receiving antibody treatment before receiving a COVID -19 vaccine, 
because some antibodies remain in the body for about 90 days, and there is a chance that 
these antibodies could  interfere with how your body responds to the vaccine during those 90 
days. Some  of the antibodies in this study including AZD7442 are designed to remain in the 
body for longer than 90 days. Although there is no further guidance available, there is a chance 
that these longer-lasting monoclonal antibodies could interfere with how your body responds to 
the vaccine even if you wait at least 90 days for the vaccine.  
 
 
ARE THERE  RISKS RELATED TO PREGNANCY  AND BREASTFEEDING?  
 
Pregnancy  
Since there are no data regarding the use of this study drug in people who are pregnant, you 
are not eligible to receive this study drug if you are pregnant.  
 The study drug may  involve risks to you (or to the embryo or fetus, if you or your partner
 become 
pregnant), which  are currently  unforeseen.  
If you are engaging in sexual activity that could lead to pregnancy, you must agree to use 
effective contraception for  24 weeks after the study drugs are administered. Effective 
contraception includes oral contraceptives, implanted contraceptives, and intrauterine devices  
 If you are engaging in sexual activity that may lead to pregnancy in your partner, you must agree to either remain abstinent or use male contraceptives. You are also advised to inform 
your non-pregnant sexual partners that can become pregnant to use effective contraceptives for 
24 weeks after the study drugs are administered to you.  
 
If you have a pregnant partner you should use condoms during vaginal intercourse through 24 
weeks after the study drugs administered. 
 
If applicable, you should refrain from sperm donation for 24 weeks after study drug administration. 
 
If at any point during the study you think you may be pregnant, you should let the staff at your site know so that a pregnancy test can be done.  
 Let your doctor know  immediately  if you
 become  pregnant. If you become pregnant while  on the 
study, you will be asked to continue to have study visits and the study  staff would like to obtain 
information from you about the outcome of the pregnancy  (even if it is after your participation in 
the study  ends). 
 202 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED VIA INTRAVENOUS INFUSION   
Breastfeeding 
It is not known if this study drug is safe to use in people who are breastfeeding. You are not 
eligible to receive this study drug if you are breastfeeding.
 203 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION  
 
Information/evaluations noted in this agent-specific appendix are IN ADDITION to those presented in the master protocol. Section numbering aligns with the master protocol. 
 
SCHEMA  
 DESIGN:  The design of the phase II evaluation of AZD7442 IM is as described in the 
master protocol . There is no phase III evaluation for this agent 
  2.0 INTRODUCTION  
 2.2 Rationale
 
 
Monoclonal Antibodies (mAbs)  
Sera obtained from persons or animals who recovered from a particular infection has 
shown prophylactic and therapeutic potential for a variety of infections, and Emil von 
Behring won the Nobel Prize in 1893 for his work on use of immune serum from the 
blood of infected animals to provide immunity to diphtheria [1]. Currently, hyperimmune 
human sera immunoglobulin is still used to treat many viral infections including 
cytomegalovirus (CMV), respiratory syncytial virus (RSV), hepatitis A virus (HAV), 
hepatiti s B virus (HBV), and rabies [2].  
 
Unfortunately, heterologous sera were associated with a variety of complications 
including serum sickness and hypersensitivity, which significantly limited its usefulness 
clinically [3]. Given the long history of use of antibodies for infectious diseases, 
monoclonal antibodies were developed (mAbs). Improved purification techniques and 
the ability to engineer humanized mAbs allowed for the development of broadly reactive 
and potent mAbs, which helped reduce some of the issues that hampered the utility of 
heterologous sera [3, 4]. In fact, current technology allows mAbs to be produced 
requiring only tissue culture or microbial expression systems, thus the potential toxicity 
of humanized mAbs is comparable to antibiotics [2, 4]. 
 
Engineered humanized and human mAbs have shown considerable efficacy for viral 
infections. The first was palivizumab in 1998, which is used for RSV [5]. Monoclonal 
antibodies have also been quickly developed for emerging infections such as Ebola [6]. 
As a part of the massive scientific effort to stop COVID -19, mAbs have been developed 
for treatment of COVID -19. These agents now need to be evaluated in rigorous 
randomized clinical trials. 
 
The limitations of mAbs continue to be cost and that these antibodies are perishable, 
require refrigeration, and must be administered parenterally [4]; however, their use may 
still be useful in the outpatient setting, as one dose often stays in the therapeutic range  
 204 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION for months [5], potentially allowing an entire treatment course with a single 
administration. 
 
A number of viral infectious diseases have been successfully treated with mAbs, 
including RSV and HIV. Some of these mAbs were derived from persons who were 
infected with these viruses and mounted neutralizing humoral responses.   An investigational agent to be evaluated in this trial will be the mAb AZD7442 delivered intramuscularly and made by AstraZeneca Pharmaceuticals LP for the treatment of 
early, symptomatic SARS -CoV -2 infection.  
 
Investigational Agent  
 
Background  
AZD7442 is a combination of two human mAbs, AZD8895 and AZD1061. Both were 
cloned from B -cells isolated from peripheral blood mononuclear cells (PBMCs) obtained 
from COVID -19 convalescent patients. These mAbs bind to unique, non- overlapping 
epitopes at the human angiotensin-converting enzyme 2 (hACE2) interface of the receptor binding domain (RBD of the Spike (S) protein of SARS -CoV -2, preventing viral 
entry into human cells and its subsequent viral replication. The two antibodies in the 
combination contain modifications in their FC regions  that extends their anticipated half-
life up to 70- 130 days [3- 6] and reduces the risk of antibody disease enhancement 
(ADE), by limiting binding to cellular Fc gamma receptor [7]. The combination of two 
mAbs with differing binding sites on the RBD is intended to reduce the probability of viral mutations that would confer antibody resistance, and to provide synergy in their virus 
neutralizing activity.  
 
AZD7442 is expected to result in a clinically important decrease of viral replication, mitigating the severity of COVID -19 in persons with the infection in whom ongoing viral 
replication is the primary driver of pathophysiology. The potential reduction in viral replication may also decrease a treated person’s extent and duration of viral shedding 
and transmission, thus potentially positively impacting public health.  
 
Non-Clinical Studies: Pharmacokinetics (PK)  
Nonclinical studies of AZD7442 have been performed in mice and non- human primates 
(NHPs). In human Fcn transgenic Tg32 mice, peak serum concentrations at 28 days post intravenous administration of AZD7442 components remained well above the 
EC50s and EC99s determined in cellular infection assays  [8]. The toxicokinetic profile of 
AZD7442 (AZD8895 and AZD1061) following IV or IM administration has been evaluated in cynomolgus monkeys as part of a GLP toxicology study. In this GLP toxicology study for AZD7442 high exposures were achieved and were very consistent across animals and between males and females for both AZD8895 and AZD1061, for 
both the 300 mg/kg IV dose and the 75 mg/kg IM dose of each antibody  [8]. Based on 
the data available over the first 4 weeks after dosing, the predicted safety exposure 
margin for the clinical 600 mg IM AZD7442 dose against the IM NOAEL of 150 mg/kg 
 205 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION AZD7442 dose is 21-fold and 28-fold for AUC (0-4 weeks) and C max, respectively  [8]. Neither 
component of AZD7442 cross -reacts with human tissue targets, and neither was found 
to bind to any human reproductive tissues in pre- clinical testing, including the placenta 
[8].  
 
Non-Clinical Studies: Antiviral Effects  
Murine models of SARS-CoV -2 have been performed to study the prophylactic and post-
exposure antiviral activity of the AZD7442. In these models, the parenteral formulations 
of AZD7442 components were studied: COV2-2196 and COV2-2130, the respective 
parental antibodies of AZD8895 and AZD1061. COV2-2196 and COV2-2130 lack the Fc 
region modifications but are expected to retain antiviral activity. In a mouse-adapted-SARS- CoV-2 model, BALB/c mice were inoculated via intranasal route with 10
5 
fluorescent focus units (FFU) of MA-SARS- CoV-2 and COV2 -2196 and COV2-2130 (1:1 
cocktail) administered intravenously 12 hours after. Viral burden in the lungs was 
measured 2 days post infection (dpi) after viral challenge using RT-qPCR o r plaque 
assay. Mice were monitored daily for body weight change. Administration of the mAbs 
12 hours post infection in Ad5-hACE2 transduced mice resulted in neutralization of infectious virus in the lungs. The mAbs  were also evaluated for in vivo efficacy  in an 
immuno -competent model using a mouse-adapted-SARS- CoV-2 virus. In this model 
there was significant viral replication in the lungs but little or no clinical disease [9].  
 The parental mAb formulations were also assessed in a non-human primate (NHP) model [10, 11]. Rhesus macaques received one 50 mg/kg dose of COV2-2196 or 
isotype control antibody intravenously 3 days prior to intranasal and intratracheal challenge with a total dose of 10,000 PFU SARS -CoV -2. Virus replication was 
quantitated by RT-qPCR for viral sgmRNA, which measures replicative viral RNA 
intermediates. Animals that received isotype control antibody showed a median peak of 7.53 log10 sgmRNA copies/swab in nasal swab and a median peak of 4.97 log10 sgmRNA copies/mL in bronchoalveolar lavage. In contrast, viral sgmRNA was not detected in either nasal or bronchoalveolar lavage samples from animals that received COV2 -2196. A PK analysis revealed similar concentrations of circulating human mAbs in 
animals from both groups.  Human Clinical Studies  
The first in-human clinical studies of AZD7442 began enrolling in August 2020. 
([STUDY_ID_REMOVED]). Both IV (300 mg, 1000 mg, and 3000 mg), sequentially and co-
administered, and IM (300 mg) administration have been studied in this phase I, single -
dose, dose- escalating trial among healthy adults. As of early December , >100  persons 
in this study have received the product at doses up to 3000 mg IV, and no safety 
concerns have emerged. Specifically, there were no deaths, SAEs or discontinuation  of 
study product due to AEs and no laboratory events of concern. Pharmacokinetic data from this phase I study also demonstrate the persistence of neutralizing antibody levels 
at 90 days post-infusion in all participants, with dose-dependent concentrations  
observed. As described below, pharmacokinetic data have also demonstrated relative 
levels achieved with IV and IM dosing. 
 206 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION  
The proposed adaptive Phase II/III trial is likely to be the first administration in persons with COVID- 19 disease, although pre -exposure and post-exposure prophylaxis studies 
have started. These include clinical  studies PROVENT (pre-exposure), STORM 
CHASE R (post -exposure) and TACKLE (treatment with 600 mg IM). As of December 8, 
2020, there was a single SAE in a pre-exposure prophylaxis participant who fainted following product administration (IM) and required evaluation at the hospital.  
 Choice of Study D osing  
Human efficacious doses for AZD7442 were evaluated using in vitro potency data (virus neutralizing activity of AZD7442 against SARS -CoV -2) and PK data. In addition, a 
viral-dynamic model was developed, which allowed for understanding of the pharmacodynamic effects of AZD7442 to inhibit a SARS -CoV-2 infection and the 
resulting immune response. The viral -dynamic model indicates that assuming a partition 
ratio ranging between 0.1-1.0% for lung epithelial lining fluid -to-serum and assuming 
potency with an IC
80 (inhibiting SARS-CoV -2 by 80%) of 40 ng/mL, the estimated 
effective concentration may be as low as 4µg/mL in serum. The dosing in Phase I studies therefore targeted 20-40 µg/ml to assure sufficient levels in patients with an active SARS -CoV -2 infection; 600 mg AZD7442 IM administration before the time of 
peak viral load (on average ~7 days after day of infection) is expected to result in 
reduction of the peak viral load and earlier eradication of the viral load. Administration of 
600 mg IM AZD7442 after the peak viral load has been reached is still expected to result in earlier viral load eradication compared to when drug is not present based on this same viral -dynamic model.  
 
Figure 2.2-1
 shows the preliminary serum AZD7442 concentration through 30 days post 
dose for the different single doses tested as well as the predicted concentration time 
course for a single 600 IM dose, estimated by multiplying the concentrations for the 300 mg IM dose by a factor of 2. The median time of maximum drug levels still needs to be defined when more data are available but initial data suggests that the T
max can be as 
late as 30 days post dose when administered in the ventrogluteal muscle. However, the 
crucial therapeutic window is likely to be within three days of administration, which 
means that the fasted possible attainment of target serum concentrations (4-40 µg/mL) 
should be prioritized over the C max for therapeutic uses. Because the 600 mg dose will 
result in serum concentrations in the target range at an earlier time point compared to the 300 mg IM dose, 600 mg IM was selected, also given the maximum volume that can 
be administered intramuscularly with AZD7442 supplied at 100 mg/mL, as two separate 
site injections of 3 mL each.
 As both 300mg IV and 600mg IM are being tested together 
in separate appendices of this same ACTIV -2 protocol, the selection of these two 
separate doses and routes of administration will allow direct comparison of the PK between these groups.  
 207 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION  
  
 
Figure 2.2-1: Observed Mean (SD) Serum AZD7442 concentrations over the first 30 
days in Adult Healthy Volunteers in the Phase 1 Study  
 
Rationale for Administration S ite  
The Phase I study tested 300 mg administered in two gluteal injections at a total 
injection volume of 1.5 mL per side. The dose selected for this trial is 600 mg IM, which 
will be delivered as two thigh injections of 300 mg each with a total volume of 3.0 mL per side (one injection in each thigh). Given the argument above that time to estimated effective concentration range is the most important parameter in treating COVID -19, we 
have chosen to administer IM AZD7442 to the vastus lateralis (lateral thigh). Compared to either dorsal or ventral gluteal sites, the thigh or deltoid have increased rate and 
decreased variability of absorption. The planned volume per injection exceeds that 
administered to the deltoid but falls within the accepted standard of care for the thigh. 
Gluteus medius absorption is slowest and most variable, with variability related to BM I, 
sex, and age, with slowest and impaired absorption in those with higher gluteal fat (Figure 2.2-2, Panel  2A
), especially when administration is into the adipose layer and 
does not reach muscle (Figure 2.2-2 Panel 2B ) [12]. 
    
 
 

 208 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION  
 
   
 
  
Figure 2.2-2 : Panel 2A shows more consistent and rapid absorption of cefradine in women on 
par with men in the vastus lateralis, likely due to differential distribution of gluteal adipose tissue. 
This is further exemplified by Panel 2B, which shows impaired absorption of diazepam when 
administered to the gluteus with a shorter needle, which frequently results in administration to 
the adipose layer rather than a true intramuscular administration [12].  
 4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  
 
Participants must meet inclusion and exclusion criteria from the master protocol, as well as the appropriate inclusion and exclusion criteria for the investigational agent included below.  
 4.1 General Eligibility Criteria
 
  
4.1.1 Inclusion Criteria 
 
All criteria within the master informed consent are applicable with the additional criteria as added below: 
 
4.1.1.9 For participants who are of reproductive potential, negative serum or urine pregnancy test at within 48 hours prior to study entr y by any clinic 
or laboratory that has a CLIA certification or its equivalent, or by a point of care (POC)/CLIA -waived test.  
 
Reproductive potential is defined as: 
• participants who have reached menarche 

 209 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION • participants who have not been post -menopausal for at least 12 
consecutive months with follicle-stimulating hormone (FSH) ≥40 
IU/mL or 24 consecutive months if an FSH is not available  
• participants who have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy)  
• participants with no other clinical conditions (such as anorexia nervosa) that could induce amenorrhea 
• participants not taking medications such as oral contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs) or chemotherapy 
that could induce amenorrhea  
• For individuals with permanent infertility due to an alternate medical 
cause (e.g., Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry. 
 
4.1.1.10  If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use highly 
effective contraception for 24 weeks after investigational agent is 
administered. This would include oral contraceptives, implanted contraceptives, and intrauterine devices.  
 
NOTE: Participants not of reproductive potential are eligible without requiring the use of a contraceptive method. Participant-reported 
history is acceptable documentation of surgical sterilization and 
menopause, including vasectomy in a sole partner. 
 
4.1.1.11 Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male 
contraceptives. They are also strongly advised to inform their non-
pregnant sexual partners of reproductive potential to use effective contraceptives for 24 weeks after investigational agent is administered. 
 
Participants with pregnant partners should use condoms during 
vaginal intercourse through 24 weeks after investigational agent 
administration.  Participants should refrain from sperm donation for 24 weeks after investigational agent administration.  
 
 210 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION 4.1.2  Exclusion Criteria  
 
4.1.2.11 Currently pregnant or breastfeeding  
  
4.1.2.12 Inflammatory skin conditions that compromise the safety of IM   
injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator  
 
4.1.2.13  History of coagulopathy which, in the opinion of the investigator, would 
preclude IM injection, or use of oral or injectable anticoagulants (see prohibited medications, section 5.4
). 
 4.1.2.14  In phase II, meeting the protocol definition of being at “higher” risk of 
progression to hospitalization or death (see SCHEMA, POPULATION
) 
 
5.0 INVESTIGATIONAL AGENTS  
 5.1 Regimen, Administration, and Duration
 
 
5.1.1 Regimen and Duration  
Participants will be randomized to receive one of the following regimens: 
 
Investigational Agent: AZD7442, 600 mg, to be administered intramuscularly (IM), 
as two separate injections (AZD8895, 300 mg, and AZD1061, 300 mg), for one 
dose at study Entry/Day 0.   OR 
 
Placebo for AZD7442: 0.9% Sodium Chloride Injection, USP, to be administered IM, 
as two separate injections, for one dose at study Entry/Day 0. 
 
5.1.2 Administration  
 
AZD8895/Placebo and AZD1061/Placebo to be administered IM as two separate injections, one following the other in this order, with a 22-25 gauge, 1-1.5 inch (25-
38 mm) length needle each. The injections are to be administered using standard IM injection technique. Injections will be given in the lateral thigh (vastus lateralis, VL) site, one injection in each thigh. No pause between the two injections is required. The time and site of each injection will be recorded on the eCRF.  
 
 
 211 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION 5.2 Formulation, Storage, and Preparation  
 
5.2.1 Formulation and Storage 
 
AZD7442 consists of two independent drug substances, AZD8895 and AZD1061, 
which are formulated separately. Both AZD8895 and AZD1061 are supplied as a 100 mg/mL aqueous solution with 150 mg (nominal) of active investigational product in 10R glass vials with a volume of 1.5 mL. The aqueous solutions are 
colorless to slightly yellow, clear to opalescent.  
 AZD8895 and AZD1061 vials must be stored between 2°C to 8°C (refrigerated storage) until use. AZD7442 is described in further detail in AZD7442 Investigator ’s Brochure.  
 
Placebo for AZD7442 will be 0.9% Sodium Chloride Injection, USP. The product 
must be locally sourced and stored according to the manufacturer’s recommendation.  
 
5.2.2  Preparation  
 
Pharmacists must follow appropriate aseptic technique and consider sterile preparation procedures/guidance as outlined in USP General Chapter <797> Pharmaceutical Compounding – Sterile Preparations. Pharmacists must also 
follow the requirements of their country, institution, and pharmacy regulatory authority regarding these procedures. The investigational agent and placebo 
should be prepared in a sterile environment, utilizing a biosafety cabinet/isolator. 
If a biosafety cabinet or isolator is not available, a laminar flow hood may be used. Local regulations and site institutional policies and procedures for use of personal protective equipment, such as gloves, gowns, face masks and safety glasses, must be followed.  
Any unused portion of investigational agent must not be used for another 
participant. Any empty vials, unused portion of entered vials, or unused solution 
which contains investigational agent should be discarded in a biohazard containment bag and incinerated or autoclaved in accordance with institutional or pharmacy policy.  
 
5.2.2.1 AZD7442 
 
1. Remove two (2) vials of AZD8895 and two (2) vials of AZD1061 from the refrigerator. Equilibrate the vials to room temperature prior to use. 
2. Withdraw a total of 3 mL of AZD8895 from the vials obtained in Step 1, using an appropriately sized latex -free disposable syringe made 
of polycarbonate or polypropylene. When the stopper of the vial is 
 212 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION punctured to start preparation, record this time as the investigational 
agent preparation time. Assign a 4 hour beyond use date and time from the preparation time if stored at room temperature or a 24 hour beyond use date and time from the preparation time if stored at 
refrigerated conditions.  
3. Using a new appropriately sized latex -free disposable syringe made 
of polycarbonate or polypropylene, withdraw a total of 3 mL of 
AZD1061 from the vials obtained in Step 1. Assign the same beyond use time given in Step 2. 
4. Apply an overlay to each syringe to ensure blinding is maintained.  
 
5.2.2.2 Placebo for AZD7442  
 
1. Remove 0.9% Sodium Chloride Injection, USP from storage. 
2. Withdraw a total of 3 mL of 0.9% Sodium Chloride Injection, USP, using an appropriately sized latex -free disposable syringe made of 
polycarbonate or  polypropylene. When the stopper of the container 
is punctured to start preparation, record this time as the placebo preparation time. Assign a 4 hour beyond use date and time from the preparation time if stored at room temperature or a 24 hour 
beyond use date and time from the preparation time if stored at 
refrigerated conditions.  
3. Using a new appropriately sized latex-free disposable syringe made of polycarbonate or polypropylene, withdraw a total of 3 mL of 0.9% Sodium Chloride Injection, USP. Assign the same beyond use time 
given in Step 2. 
4. Apply an overlay to each syringe to ensure blinding is maintained.  
 
5.2.3 Labeling of Investigational Agent and Placebo  
 
Label each prepared IM syringe with the following information: a. Participant identifier(s)  
b. Protocol  number: ACTIV -2/A5401 
c. Investigational agent name:  
i. AZD8895 300 mg or placebo 
ii. AZD1061 300 mg or placebo 
d. Describe sequential order of administration (Administer AZD8895/placebo, 
first, followed by AZD1061/placebo)  
e. Total volume: 3 mL  
f. Route: IM  
g. Preparation date and time 
h. Beyond use date and time: 4 hours after preparation if stored at room 
temperature conditions or 24 hours after preparation if stored at refrigerated 
conditions  
i. Any additional information required by jurisdiction  
 213 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION  
 5.3 Supply, Distribution, and Accountability  
 
5.3.1 Supply  and Distribution  
 
AZD8895 and AZD1061 will be manufactured by Catalent for AstraZeneca and 
will be available through the NIAID Clinical Research Products Management Center (CRPMC).  The site pharmacist will receive ordering instructions for 
AZD8895 and AZD1061 vials from the NIAID CRPMC.  
 
0.9% Sodium Chloride Injection, USP, and any other ancillary supplies will be locally sourced by the site.   
5.3.2 Accountability  
 
The site pharmacist is required to maintain complete records of all investigational agents received from the NIAID CRPMC and subsequently dispensed. At US CRSs, all unused investigational agents must be returned to the NIAID CRPMC (or as otherwise directed by the sponsor) after the study is completed or 
terminated. At non-US CRSs , the site pharmacist must follow the instructions 
provided by the CRPMC for the destruction of unused investigational agents. 
 5.4 Concomitant Medications
 
 
Due to the IM route of administration, persons receiving therapeutic anticoagulation 
including warfarin, low-molecular -weight heparins, and Direct Oral Anti -Coagulants are 
excluded.  
 Any pre -medications given will be documented as a concomitant medication. There are 
no known or expected drug-drug interactions with the investigational agent, and there are no additional prohibited medications except as outlined in section 5.4
 of the parent 
protocol.  
 
 214 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION 
 6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Evaluations . The schedules of evaluations provided below include additional evaluations for this investigational 
agent. 
 
Table 6.1-1: Schedule of Evaluations Phase II 
Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 1*  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Investigational Agent Administered   X             
Hematology   X  X  X X      X  
Chemistry   X  X  X X      X  
Pregnancy Testing  X  Whenever pregnancy suspected       
PK Studies   X1 X** X X X X X X    X X 
Anti-Drug Antibodies   X    X X X X    X X 
**For approximately 40 participants at selected sites (s ee MOP and additional site-specific information) 
1 First PK serum sample to be obtained prior to investigational agent/placebo administration along with other entry labs. A second PK 
sample to be obtained 1 hour after IM administration.
 215 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION 
 6.3 Instructions for Evaluations  
 
6.3.9 Investigational Agent Administered 
 
Pre-Medication 
Pre-medication for IM administration is not planned. However, if the participant 
has a medical history suggesting a potential benefit from pre-medication, the study investigator(s) should determine the appropriate pre-medication.  
 
Any pre -medications given will be documented as a concomitant medication. 
 
Before the IM Administration 
Vital signs (temperature, heart rate, respiratory rate, blood pressure, and SpO2).  
 
After IM Administration  
Vital signs (temperature, heart rate, respiratory rate, blood pressure, and SpO2) 
will be measured every 30 minutes (± 5 minutes)  for 2 hours post-administration. 
 Only vital signs that meet AE reporting requirements will be recorded on an eCRF.  
 
6.3.15 Laboratory Evaluations 
 
Hematology  
Participants will have blood drawn for complete blood cell count (CBC) with 
automated differential and platelet count.  
 At Entry/Day 0, blood should be drawn before study drug administration.   
Chemistry  
Participants will have blood drawn for liver function tests (ALT, ALP, AST, total 
bilirubin, direct bilirubin, and total protein), and renal function tests (albumin, 
BUN, c reatinine, potassium, glucose, and sodium).  
 At Entry/Day 0, blood should be drawn before study drug administration.  
 
Pregnancy Testing  
For participants of reproductive potential: Serum or urine β-HCG. (Urine test 
must have a sensitivity of ≤25 mIU/mL).  
 
Post-screening, pregnancy testing should be done any time pregnancy is 
suspected.  
 
 216 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION In the event of pregnancy occurring during the study, record pregnancy and 
pregnancy outcome per section 8.3 . 
 
6.3.16 Pharmacokinetics   
 
Serum will be collected and used to measure investigational agent levels.   At Entry/Day 0, the first serum sample should be collected along with the remainder of entry labs before the dose of investigational agent/placebo (up to 10 
minutes before the start of administration). A second PK sample should be 
obtained one hour (± 10 minutes ) after administration of the IM injection.  
 Post-entry, serum should be collected for PK as per the SOE. Date and time of collection should be recorded.  
 
Day 1 PK (Selected Sites): Approximately 40 Phase II participants at selected US sites will have a sample taken for PK at an additional Day 1 visit. The Day 1 PK is the only procedure performed at that visit for those selected participants; other participants do not have a Day 1 visit. The Day 1 PK sample should be collected 18-30 hours after administration of investigational agent/placebo. If it is not 
possible to collect the Day 1 PK sample due to Day 1 occurring on a weekend or 
holiday, this PK draw should be skipped and the reason for the missed collection noted in site records. See MOPS and additional site-specific information for selection of participants for this additional Day 1 PK sample collection.  
Samples will be analyzed at a laboratory approved by the sponsor and stored at 
a facility designated by the sponsor. Concentrations of the investigational agent 
will be assayed using a validated bioanalytical method. Analyses of samples collected from placebo-treated participants  are not planned. Samples will be 
retained for up to 2 years after last patient visit. Remaining samples used for PK 
may be pooled and used for exploratory metabolism or bioanalytical method 
experiments as deemed appropriate.  
 
6.3.18 Anti-Drug Antibodies  
 
Serum will be collected to measure anti -drug antibodies. At Entry/Day 0, the 
sample should be collected prior to the dose of investigational agent/placebo. 
Post entry, serum should be collected as per the SOE. Date and time of collection should be recorded.  
 Samples will be analyzed at a laboratory approved by the sponsor and stored at a facility designated by the sponsor.  
 
 217 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION 7.0 ADVERSE EVENTS AND STUDY MONITORING 
 
7.1 Definitions of Adverse Events  
 
Adverse Events of Special Interest  
The following are AESIs for the agent AZD7442 or placebo for AZD7442:  
• Grade ≥3 injection-site  reactions  (ISRs)  within 72 hours  of investigational  
agent/placebo administration (deemed related to study  product as determined by the 
site investigator) 
• Grade ≥1 allergic/hypersensitivity  reactions  within  24 hours  of investigational  
agent/placebo administration (deemed related to study  product as determined by the 
site investigator) 
• Grade ≥2 other  systemic reactions, including cytokine  release syndrome, within 24 
hours  of investigational  agent/placebo administration (deemed related to study  
product as determined by the site investigator).  
 
 8.0 CLINICAL MANAGEMENT ISSUES 
 8.1 Toxicity
 
 
The second IM injection should not be administered if the participant experiences a 
Grade 3 or higher AE after the first IM injection. For any other AE, following the first IM 
injection, the participant’s clinical status should be assessed before proceeding with the second IM injection.  
 
8.2 Management of Side Effects 
 
 
8.2.1 Overdose 
 
An overdose is defined as receiving > 300 mg of either of the component 
monoclonal antibodies. There is no known antidote for AZD7442 overdose. In the event this occurs, the participant should be closely monitored for AE/SAE and laboratory abnormalities, and supportive care provided as indicated.  
 
8.2.2 Systemic Reactions Related to Investigational Agent Administration  
 
All participants should be monitored closely, as there is a risk of systemic reaction (including anaphylaxis) with any biological agent.  
 Symptoms and signs that may occur as part of an administration reaction include, but are not limited to fever, chills, nausea, headache, bronchospasm,  
hypotension, angioedema, throat irritation, rash including urticaria, pruritus, 
myalgia, and dizziness.  
   
 218 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION The severity of systemic reactions will be assessed and reported using the 
criteria for infusion-related reactions in the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can be found on the DAIDS RSC website 
at https://rsc.niaid.nih.gov/clinical -research-sites/daids -adverse-event-grading-
tables . 
 
The clinical site should have necessary equipment and medications for the management of any administration reaction, which may include but is not limited 
to oxygen, IV fluid, epinephrine, acetaminophen and antihistamine. 
 Investigators should determine the severity of the reaction and manage reactions based on standard of care and their clinical judgment. If an administration 
reaction occurs, then supportive care should be provided in accordance with the 
signs and symptoms.  
 
8.2.3 Hypersensitivity   
 
Signs and symptoms of administration-related immediate hypersensitivity 
reactions may include, but are not limited to anaphylaxis, angioedema, 
bronchospasm, chills, diarrhea, hypotension, itching, skin rash, shortness of 
breath, urticaria, tachycardia, and throat irritation or tightness [8].  
 Participants will be closely monitored for immediate hypersensitivity reactions.  
 
Sites should have appropriately trained medical staff and appropriate medical 
equipment available when study participants are receiving AZD7442. It is recommended that participants who experience a systemic hypersensitivity reaction be treated per the local standard of care.  
8.2.4 Injection-Site Reactions  
 
Injection-site reactions (ISRs) will be differentiated from the above generalized hypersensitivity reactions by definition as localized pain/tenderness, induration, erythema, and/or formation of an ulceration or infection at the injection site. ISRs will b e graded per the DAIDS AE Grading Table), corrected Version 2.1, July 
2017.  
 8.3  Pregnancy
  
 
There are no data regarding the use of AZD7442 in participants who are pregnant, and therefore potential participants who are pregnant are not eligible during screening.  
 
If a participant becomes pregnant during the study (post-entry), study follow up will 
continue for the duration of the study.  
 219 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION  
At the end of the pregnancy, outcome and adverse events for participant and infant will 
be recorded on the outcome eCRF.  
 
8.4 Breastfeeding  
 
Since there are no data regarding the use of AZD7442 in participants who are 
breastfeeding, participants who are breastfeeding are not eligible for the study. 
 
10.0 STATISTICAL CONSIDERATIONS  
 
10.2 Outcome Measures  
 
Primary and secondary outcome measures listed below will be addressed in the 
AZD7442 IM specific appendix to the study’s primary Statistical Analysis Plan.  
 
10.2.3 Secondary Outcome Measures 
 
The following secondary outcome measures will also be assessed:  
 
10.2.3.14 Phase II only: New Grade 2 or higher AE through week 72. 
 
11.0 PHARMACOLOGY PLAN  
 
11.1 Pharmacology Objectives   
 
The phase II pharmacology objective is to determine the pharmacokinetics of AZD7442 
administered via the intramuscular route. For phase II, the pharmacology objective is to  
explore relationships between dose and concentration of AZD7442 with virology, 
symp toms, and oxygenation. For phase II an additional objective is to define whether 
there is differential time to reach the calculated effective concentration by site of 
injection.  
 
11.2 Pharmacology Study Design Overview   
 
The Schedule of Evaluations shows the collection schedule for Phase II. AZD7442 has a 
long elimination in preclinical animal studies and is expected to be as long as 26 weeks 
in humans. The PK sample schedules are based on the long-elimination half-life of 
AZD7442 and are designed to meet the phase II objective of determination of AZD7442 
pharmacokinetics . Approximately 40 participants (~20 receiving investigational agent) 
will have an additional sample collected on Day 1 (24 hours after dosing) to further 
define time to calculated effective concentration. Participants contributing Day 1 samples 
will be recruited from selected domestic sites and the PK data from these participants 
will be analyzed (see section 6.3.15 ) as soon as the last of these participants completes 
Day 7 on study.  
 220 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION  
11.3 Pharmacology Data Analysis and Modeling  
 
Pharmacokinetic data analysis of phase II data will use conventional and accepted 
approaches such as non -compartmental analysis or compartmental analysis to 
determine the PK characteristics of AZD7442 and its components. Population 
pharmacokinetic approaches (e.g., nonlinear mix effects modeling such as implemented 
in NONMEM) may also be used. The usual parameters of interest are area under the 
concentration-time curve (AUC), total body clearance (CL), elimination half-life (T 1/2), and 
maximum and minimum concentrations (C max, Cmin). PK characteristics from AZD7442 
given intramuscularly  (test) will be compared with those when given intravenously 
(reference) by calculation of geometric mean ratios of primary PK parameters (e.g., C max, 
AUC). Exploration of relationships between dose and concentration of AZD7442 
components with virology, symptoms, and oxygenation will be approached using 
conventional and accepted methods for pharmacokinetic/pharmacodynamic (PK/PD) 
data analyses. Such methods will include the E max or sigmoid E max model or structurally 
linked PK/PD models (as could be performed within NONMEM) to explore exposure-
response relationships. Exposure-response relationships will be performed in 
conjunction with the protocol statisticians .  
 
  
 221 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX IX: INVESTIGATIONAL AGENT AZD7442 INTRAMUSCULAR ADMINISTRATION 16.0 REFERENCES 
 
1. Doherty M, Robertson MJ. Some early trends in immunology. Trends Immunol 2004;25:623 -31. 
2. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004;2:695-703. 
3. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody -based therapies for 
microbial diseases. Vaccine 2009;27:G38-G46.  
4. Casadevall A. The case for pathogen-specific therapy. Expert Opin Pharmacother 2009;10:1699-703.  
5. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531-7.  
6. Fan P, Chi X, Liu L, et al. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. MAbs 2020;12(1):1742457.  
7. Everds NE, Tarrant JM. Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans. Toxicol Pathol 2013;41:280-302.  
8.  Investigator’s Brochure, AstraZeneca AZD7442 3.0; 08 December 2020. 
9.  Dinnon KH, 3rd, Leist SR, Schafer A, et al. A mouse-adapted model of SARS -CoV-2 
to test COVID -19 countermeasures. Nature 2020;586:560-6. 
10. Chandrashekar  A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. 
SARS- CoV-2 infection protects against rechallenge in rhesus macaques. Science 
2020;369(6505):812-17. 
11. Yu J, Tostanoski LH, Peter L, et al. DNA  vaccine protection against SARS -CoV -2 in 
rhesus macaques. Science 2020;369(6505):806-11. 
12. Zuidema J, Pieters FAJM, Duchateau GSMJE. Release and absorption  rate aspects 
of intramuscularly injected pharmaceuticals. Int J Pharm 1988;47:1-3. 
13. Scialli AR, Bailey G, Beyer BK,  et al. Potential  seminal transport of pharmaceuticals 
to the conceptus. Reprod Toxicol  2015;58213-21. 
 
 222 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED AS AN INTRAMUSCULAR INJECTION  APPENDIX X: SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED AS AN INTRAMUSCULAR INJECTION  
 
No participants will be enrolled in version 7 or later of this protocol for this investigational agent. 
Consents retained for recording purposes.  
 
One of the study drugs that you might be assigned to in this study is AZD7442 or the placebo for 
AZD7442.  
 
AZD7442 is a type of drug called a monoclonal antibody. Many antibodies are naturally made by 
your body and help fight diseases. AZD7442 is made in a laboratory. It is a combination of two 
monoclonal antibodies, meaning many copies of two antibodies designed to prevent SARS -
CoV-2, the virus that causes COVID -19, from entering cells.  
 Your assignment is random, like the flip of a coin. You will be told about all the study drugs you 
may be assigned to in this study. If only one study drug is available, you will have an equal chance of receiving the study drug or placebo. If two study drugs are available, you will have a 2:1 chance of receiving a study drug or placebo. If three study drugs are available, you will have a 3:1 chance of receiving a study drug or placebo, and so forth. You will not be able to choose your group (study drug), and neither you, your study doctor, nor the study staff at your site will 
know whether you are receiving the study drug or placebo. 
 The US Food and Drug Administration (FDA) has not approved AZD7442 for general use by the 
public. However, we have told the FDA about this study and they have given us permission to conduct this study.  
 At this time, participants assigned to this study drug will be in the first part of the study (phase 
II), as described in the main consent.  
  ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE AZD7442 OR 
PLACEBO?  
Screening Visit  
• At your screening visit, if you can become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample for a pregnancy test. You cannot receive AZD7442 or placebo 
if you are pregnant.   
Entry Visit  
• You will have blood drawn. This blood will be used for the following tests:  
o routine safety tests (liver and kidney tests and levels of the drug in your blood (you will have blood drawn before you receive the study drug and again 1 hour after)  
o levels of antibodies to the drug (your body’s immune response to the drug)  
 223 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X : SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED AS AN INTRAMUSCULAR INJECTION  • You will receive two intramuscular injections of AZD7442 or placebo. The administration will 
consist of one injection into the outside of the thigh, one in each thigh. You will be monitored 
for 2 hours after the injection.  
 
Study Visits on Days 3, 7, 14, and 28  
• You will have blood drawn. This blood will be used for the following tests:  o routine safety tests (liver and kidney tests and blood counts) (days 3, 14, and 28)  
o levels of the drug and/or levels of antibodies to the drug (your body’s immune response 
to the drug)  
 
Study Visits on Weeks 12 and 24 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug and levels of antibodies to the drug (your body’s immune response to 
the drug)  
• You will be asked whether you have had any new symptoms or clinical events since your last visit  
 
Study  Visits on Weeks 36, 48, and 72 
• You will be contacted by phone by the study team to assess whether you have had any new symptoms or clinical events since your last visit  
• You will answer questions about any potential COVID -19 related symptoms or conditions 
you have experienced  
 
Extra Visits  
Approximately 40 participants will be asked to return about 24 hours (1 day) after the Entry visit for an additional blood draw to test levels of the drug. The site staff will tell you if you may be one 
of these 40 participants.  
 HOW  LONG  WILL I BE IN THIS  STUDY? 
 If you are assigned to AZD7442 or placebo for AZD7442, you will be in this study  for 72 weeks.  
  WHAT ARE THE RISKS OF AZD7442?  There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are
 
taken with the study drugs. For your safety, you must  tell the study  doctor  or nurse about all 
medications  you are taking before you start the study.   
 Another risk is that the study drug used in this
 study  may have side effects, some  of which  are 
listed below.  Additionally,  the study drug tested  in the study  may have unknown side effects  in 
persons  with SARS-CoV -2 infection.  In a research  study, all of the risks or side effects  may not 
 224 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X : SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED AS AN INTRAMUSCULAR INJECTION  be known before you start the study. You need to tell your doctor  or a member  of the study  team  
immediately  if you experience any side effects.  
 
Please note that these lists do not include all the side effects  seen with this study drug.  These 
lists include the more  serious  or common side effects  with a known or possible  relationship to the 
study drug. If you have questions  concerning the additional side effects,  please ask the medical  
staff at your site. 
 
Risks Associated with AZD7442 
There is limited safety data on AZD7442 since it has not been given to a lot of people. As of 08 
December 2020, there have been no serious unexpected effects reported by >100 healthy 
people taking AZD7442 or placebo to date. Most effects after taking AZD7442 or placebo have 
been mild or moderate and have either all gone away or are getting better. This study is likely to be the first study where this study drug is given to people with COVID -19 disease.  
 Administration of AZD7442 may result in allergic reactions. Signs and symptoms of these 
reactions include:  
• chills  
• skin rash  
• itching  
• hives  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
• loose stools  
 
Administration of AZD7442 may induce release of chemicals called cytokines in the body. 
These chemicals may induce allergic reactions listed above as well as: 
• fever 
• muscle aches  
• nausea  
• vomiting 
• headache  
• dizziness  
 
Intramuscular injections of any chemical can cause: 
• Redness, pain, and/or swelling at the injection site 
• Tenderness of the muscle group or soreness with movement  
• Ulceration  
 225 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X : SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED AS AN INTRAMUSCULAR INJECTION  • Infection  
 
Some of these reactions may be serious or life-threatening including:  
• skin rash  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
 
You will be monitored closely during and after administration of study drug.  Medical personnel, 
equipment, and medication will be available to manage these reactions appropriately if they occur.  
 Administration of study drug may also cause the following risks and discomforts: 
• development of proteins (antibodies) against AZD7442. This may cause your body to get rid 
of AZD7442 more quickly or change the effect of AZD7442 on the body. Your blood will be 
tested to find out whether your body made antibodies to AZD7442. The anticipated risk of 
this is low because AZD7442 is a fully human antibody. Therefore, it is less likely to be seen 
as “foreign” by your body’s immune system and your body is less likely to form antibodies 
against AZD7442. 
• mixture of antibody and other chemicals in the body that may be deposited in tissues such 
as blood vessels and kidneys.  
• unexpected increase in virus reproduction in your body. Although this has been observed with some viruses, this has not been observed with COVID -19 or with the use of serum or 
plasma containing antibodies given to people with COVID -19. This risk of increased viral 
grow th is perhaps greater when there is lower levels of antibodies in the blood in the 
presence of virus. To avoid this, AZD7442 will be given at a dose that is felt to be high 
enough to keep this from occurring.  
 
Effect on Future Vaccination 
The US Centers for Disease Control and Prevention (CDC)  currently recommends that people 
wait at least 90 days after receiving antibody treatment before receiving a COVID -19 vaccine, 
because some antibodies remain in the body for about 90 days, and there is a chance that 
these antibodies could  interfere with how your body responds to the vaccine during those 90 
days. Some  of the antibodies in this study including AZD7442 are designed to remain in the 
body for longer than 90 days. Although there is no further guidance available, there is a chance 
that these longer-lasting monoclonal antibodies could interfere with how your body responds to 
the vaccine even if you wait at least 90 days for the vaccine.  
 
 
 226 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X : SAMPLE INFORMED CONSENT FOR STUDY DRUG AZD7442 
ADMINISTERED AS AN INTRAMUSCULAR INJECTION  ARE THERE  RISKS RELATED TO PREGNANCY  AND BREASTFEEDING? 
 
Pregn ancy  
Since there are no data regarding the use of this study drug in people who are pregnant, you 
are not eligible to receive this study drug if you are pregnant.  
 
The study drug may  involve risks to you (or to the embryo or fetus, if you or your partner  become 
pregnant), which  are currently  unforeseen.  
 
If you are engaging in sexual activity that could lead to pregnancy, you must agree to us e 
effective contraception for 24 weeks after the study drugs are administered. This would  
include oral contraceptives, implanted contraceptives, or intrauterine devices . 
 
If you are engaging in sexual activity that may lead to pregnancy in your partner, you must 
agree to either remain abstinent or use male contraceptives. You are also advised to inform 
your non-pregnant sexual partners that can become pregnant to use effective contraceptives for 
24 weeks after the study drugs are administered to you.  
 If you have a pregnant partner you should use condoms during vaginal intercourse through 24 weeks after the study drugs administered. 
 
If applicable, you should refrain from sperm donation for 24 weeks after study drug administration.  If at any point during the study you think you may be pregnant, you should let the staff at your 
site know so that a pregnancy test can be done.  
 
Let your doctor know  immediately  if you
 become  pregnant. If you become pregnant while  on the 
study, you will be asked to continue to have study visits and the study  staff would like to obtain 
information from you about the outcome of the pregnancy  (even if it is after your participation in 
the study  ends). 
 
Breastfeeding 
It is not known if this study drug is safe to use in people who are breastfeeding. You are not 
eligible to receive this study drug if you are breastfeeding.
 227 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X I: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  APPENDIX XI: INVESTIGATIONAL AGENT INHALED I NTERFERON- β1a (SNG001) 
 
NOTE: Phase III evaluation of SNG001 will be initiated under a future protocol version and not protocol Version 8.  
 
Information/evaluations noted in this agent-specific appendix are IN ADDITION to those presented in the master protocol. Section numbering aligns with the master protocol.  SITES PARTICIPATING IN THE STUDY  
 Participation in phase II evaluations of this agent will be restricted to select US sites, due to limited investigational agent/placebo supply.  
 1.0 STUDY OBJECTIVES  
 1.2  Secondary Objectives
 
 
1.2.10 Phase II: To evaluate SNG001 adherence compared to placebo for SNG001 
over the 14- day treatment period.  
 
1.2.11 Phase III: To determine whether SNG001 reduces hospitalization or death 
through study day 28 among individuals in the subgroup who report 
moderate or severe shortness of breath or difficulty breathing at day 0, and in the subgroup who report severe shortness of breath or difficulty breathing at day 0. 
 1.2.12 Phase III: To determine whether SNG001 reduces duration of targeted COVID -19-associated symptoms through study day 28 (as defined in 
section 10.2.1.1
) among individuals in the subgroup who report moderate 
or severe shortness of breath or difficulty breathing at day 0, and in the subgroup who report severe shortness of breath or difficulty breathing at 
day 0. 
 
1.2.13 Phase III: To determine whether SNG001 reduces COVID -19 Severity 
Ranking scale based on COVID -19-associated symptom burden (severity 
and duration) among individuals in the subgroup who report moderate or 
severe shortness of breath or difficulty breathing at day 0, and in the 
subgroup who report severe shortness of breath or difficulty breathing at day 0. 
 1.2.14 Phase III: To determine whether SNG001 reduces progression of one or more COVID-19-associated symptoms to a worse status than recorded in 
the study diary at study entry among individuals in the subgroup who 
report moderate or severe shortness of breath or difficulty breathing at 
 228 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  day 0, and in the subgroup who report severe shortness of breath or 
difficulty breathing at day 0. 
 1.2.15 Phase III: To determine whether SNG001 increases proportion of 
individuals with pulse oximetry measurement of ≥96% through study day 
28 among individuals in the subgroup who report moderate or severe 
shortness of breath or difficulty breathing at day 0, and in the subgroup 
who report severe shortness of breath or difficulty breathing at day 0. 
 
1.2.16 Phase III: To determine whether SNG001 reduces the time to sustained 
symptom resolution through study day 28 (as defined in section 10.2.3.2
) 
among individuals in the subgroup who report moderate or severe shortness of breath or difficulty breathing at day 0, and in the subgroup who report severe shortness of breath or difficulty breathing at day 0. 
 1.2.17  Phase III: To determine whether SNG001 prevents the composite endpoint of either hospitalization due to any cause or death due to any cause through study week 72 among individuals in the subgroup who report moderate or severe shortness of breath or difficulty breathing at day 0, and in the subgroup who report severe shortness of breath or 
difficulty breathing at day 0. 
 
1.2.18 Phase III: To determine whether SNG001 prevents the composite endpoint of hospitalization or death through study day 28, excluding hospitalizations that are determined to be unrelated to COVID-19, among 
individuals in the subgroup who report moderate or severe shortness of 
breath or difficulty breathing at day 0, and in the subgroup who report severe shortness of breath or difficulty breathing at day 0. 
 1.3 Exploratory Objectives
 
 
1.3.13 Phase II and III: To determine whether SNG001 reduces severity of shortness of breath or difficulty breathing through study day 28.  
 1.3.14    Phase II: To determine whether SNG001 reduces a COVID -19 Severity 
Ranking scale based on COVID -19-associated symptom burden (severity and 
duration), hospitalization, and death, through study day 28 among individuals who report moderate to severe shortness of br eath or difficulty breathing at day 
0. 
 2.0 INTRODUCTION  
 
2.2 Rationale
 
 
 229 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  COVID -19 represents one of the most significant infectious threats to global public 
health security in over a century . In the absence of a licensed therapy for ambulatory 
patients with COVID -19 there is a need to assess new treatments which will prevent and 
effecti vely treat upper and severe lower respiratory tract (LRT) illness caused by the 
SARS- CoV-2.  
 
Interferon-beta (IFN-β) is a naturally occurring protein which orchestrates the body’s antiviral responses. Its role has been thoroughly elucidated in innate and adaptive immunity against viral infection. IFN -β binds to and activates IFN receptors on the 
surface of cells, triggering the expression of interferon stimulated genes (ISGs) which will orchestrate and augment the host anti -viral response in the lung [ 1].  
 
IFN-β driven anti -viral responses have been shown to be compromised/deficient in older 
people and those with chronic airways diseases [2 -4]. These and other patient groups 
are at higher risk  of developing severe LRT illness which can be fatal and are major risk 
factors for death in COVID -19. The IFN -β deficiency can be overcome through the 
administration of exogenous IFN -β. This has been shown both in vitro, using cells from 
patients, and in clinical trials using SNG001, a nebulized formulation of IFN -β that has 
been developed as an inhaled treatment of early, symptomatic SARS -CoV -2 infection.  
 
Investigational Agent  
Background  
IFN-β’s role in innate and adaptive immunity against viral infection has been well 
described and acts by binding to and activating IFN receptors on the surface of cells, triggering the expression of interferon stimulated genes (ISGs) which then orchestrate 
and augment the host anti -viral response in the lung [1].  
 
Host defense triggered by IFN -β-1a has been observed in vitro and in vivo during viral 
infection with a range of respiratory viruses including SARS -CoV-2. The anti -viral effect 
of IFN -β-1a was confirmed in in vitro models of rhinovirus (RV) and respiratory syncytial 
virus (RSV) infection, using primary bronchial epithelial cells (pBECs) from individuals with asthma and in pBECs from long term smokers (with and without COPD) [4, 5]. Anti -
viral activity has also been shown in vitro against seasonal influenza infection using a 
human lung alveolar epithelial cell line and in an in vivo model of viral pneumonia, using 2009 pandemic H1N1 influenza in cynomolgus macaques [6, 7].  
 
Host defense via IFN -β-1a has also been demonstrated for coronaviruses. In particular, 
SNG001 has been shown to inhibit viral shedding following MERS -CoV and SARS- CoV-
2 infection in cell -based assays, with a similar potency to that reported in the literature 
and against other virus types [1, 5, 8 -19].  
 
Non-Clinical Studies: Pharmacokinetics (PK)  
The absorption of IFN-β -1a in Cynomolgus monk ey and rat has been studied in vivo  in 
conjunction to pivotal toxicity studies after inhalation administration.  
 
 230 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Based primarily on data obtained in Cynomolgus monkeys, it was concluded that inhaled 
IFN-β-1a was absorbed into systemic circulation and displayed multiphasic plasma 
decay. Maximum plasma concentrations were generally obtained between 2 and 8 hours after end of inhalation, and inhaled IFN -β-1a could be observed in plasma throughout 
the 24-hour dosing interval  [5]. In general, no obvious sex -based difference in exposure 
after inhalation administration of IFN-β -1a was noted [5]. Taken together, there was a 
tendency for an accumulation of IFN -β-1a exposure in terms of both Cmax and AUC 
after repeated dosing, especially at the low doses level, but the increase in exposure was not proportional with the increasing dose [5].  
  Interferons have been reported to reduce the activity of cytochrome P -450 enzymes  [20]. 
The influence of human IFN -β-1a on cytochrome P -450 and monooxygenase reactions 
has been analy zed after dosing rat and guinea pig intraperitoneally (i.p. ) or 
subcutaneously (s.c.) daily for 7 days and measuring liver enzyme activity (in different 
monooxygenase reactions) 24 hours after last administration [5]. In rat, effects wer e 
seen in some monooxygenase reactions after i.p. although no obvious dose-dependent 
effects were seen, and no effects seen after s.c . [5]. In the guinea pig, significant effects 
were seen in some reactions after s.c. and after i.p., a trend towards a reduction in 
activity only in one reaction at a high dose [5]. Due to species differences, extrapolation 
of these results to human is uncertain. 
 
No studies have been performed to investigate the distribution, metabolism, and excretion of IFN -β-1a after inhalation administration or parenteral administration, as it is 
expected that IFN -β-1a will be degraded in vivo  into small peptides and individual amino 
acids, and follow the endogenous processes for natural IFN -β. 
 Toxicology  
As IFN -β-1a for parenteral administration is a marketed product, a limited program of 
toxicology studies has been conducted, specifically to support inhaled administration.   Core battery safety pharmacology assessments of central nervous (modified Irwin 
assessments), cardiovascular (ECG parameters including morphology, RR interval, PR 
interval, QRS duration, QT and QTcR interval) and respiratory systems (respiratory rate and tidal volume) of IFN -β-1a have been performed during repeated dose toxicology 
studies in which IFN -β-1a has been administered via parenteral or pulmonary routes and 
no treatment-related effects were recorded [5].  
 The No Observed Adverse Effect Level (NOAEL) was determined to be present at 8.66 μg/kg/day  [5]. Based on the NOAEL from a 14-day toxicity study in cynomolgus monkey 
of 8.7 μg/kg/day total inhaled dose, which corresponds to 2.2 μg/kg/day lung deposited 
dose and assuming a lung deposition fraction of 25%, the non-clinical data supports a maximum administered dose in humans of 132 μg, assuming a conservative 60 kg 
human body weight. Based on the performed preclinical safety studies it is concluded that there are no toxicological concerns for conducting the planned clinical trials with the proposed inhaled IFN -β-1a formulation. 
 231 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)   
The proposed formulation of inhaled IFN -β-1a for administration in clinical studies 
contains the excipient DL-methionine. DL-methionine has been used as a 
pharmaceutical excipient in parenteral products, but has not, as far as we know, been 
used as an excipient in inhaled formulations. DL-methionine is a naturally occurring 
amino acid and therefore not anticipated to cause concern. DL-methionine was included in the vehicle and test formulations used in the two 14-day inhalation toxicology studies and in the 28-day inhalation local tolerance study  [5]. When compared to air or vehicle 
treated animals, it was determined that there were no adverse effects attributable to the 
vehicle/excipients.  
 
Genotoxicity : For in vitro analysis, the genotoxic potential of IFN -β-1a was  studied in 
tests involving gene mutation in bacteria ( E. coli, S. typhimurium ) and chromosome 
aberrations in human lymphocytes. No indication of genotox icity was observed [5]. No in 
vivo genotoxicity studies have been conducted.  
 
Carcinogenicity : Carcinogenicity studies have not been conducted.  
 
Reproductive and developmental toxicity: No reproductive and developmental studies 
have been conducted in mammalian species.  
 
Embryo-fetal development: Embryotoxicity of IFN-β -1a (HSA-containing formulation) was 
tested in the hatched egg test (HET). The acute embryotoxicity as mid lethal dose 
(LD50) was 8,300 IU/egg when IFN-β -1a was administered on day 1 and 1,850 IU/egg 
when IFN -β-1a was administered on day 5. There was no increased occurrence of 
macroscopic -anatomic anomalies or malformations in chicks which died or hatched in 
comparison with historical data and the control groups  [5]. 
 
Non-Clinical Studies: Antiviral Effects  
The intended primary pharmacodynamic mechanism of action of IFN -β-1a is as an 
augmenter of lung anti -viral defense. Data generated by Synairgen (with SNG001) from 
the in vitro primary pharmacodynamic studies in pBECs  from participants with asthma or 
human alveolar epithelial cells from participants without asthma, support:  
• The up-regulation of anti -viral pathways within cells (CXCL-10, MxA and 2’ -5’ OAS; 
biomarkers of IFN -β related antiviral activity)  
• The reduced percentage of respiratory -virus infected cells  
• The reduced viral load and cell lysis across a broad range of respiratory viruses  
 
The primary pharmacodynamic data provide a good rationale supporting the primary 
pharmacology for the proposed novel use of IFN -β-1a, both in vitro and in-vivo delivered 
via the inhaled route, for the prevention or attenuation of virus -induced exacerbations of 
COPD and the treatment of COVID -19. The safety pharmacology data do not suggest 
any potential for significant adverse events . 
 
 232 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Human IFN -β is highly species -specific in its biological activity. Data from in vitro studies 
using a cell line and whole blood from the cynomolgus macaques support the primary 
mechanism of action and suggest that the cynomolgus macaque is a suitable species for studying the anti -viral activity of human IFN -β in vivo . Inhaled SNG001 up-regulated anti -
viral biomarkers in the lung of cynomolgus macaques. Post -infection treatment reduced 
viral load and pathology in a model of influenza infection, supporting the primary mechanism of action and suggesting potential use of inhaled IFN -β-1a as a treatment for 
patients with established infection.  
 
Efficiency of delivery of nebuli zed SNG001 [36 MIU IFN -β-1a (RB) lot 1001697 and 
1002261] to the lungs of cynomolgus macaques was demonstrated by the induction of lung biomarkers in bronchoalveolar lavage (BAL; MxA and 2'-5' OAS genes, CXCL-10 protein), confirming that biologically active IFN-β -1a had been successfully delivered via 
inhalation to the lungs of cynomolgus macaques, using two different pediatric face 
masks (Philips Respironics, UK, cat. no. HS81110EU -001 and TMI, Canada, cat. no. 
10550394010) (Synairgen study report SR028). There was no evidence for any 
treatment-related effects on IFN-γ, interleukin (IL- )8, IL-6, IL-4 and tumor necrosis factor 
alpha (TNFα) protein levels in these samples, suggesting the absence of toxicity (Study VKS0905)  [5]. 
 
Nebuli zed SNG001 (36 MIU) effectively decreased lung tissue viral load pre- and post-
infection with 2009 pandemic H1N1 influenza as compared to placebo, when measured 
using molecular methods  [6]. Six of nine placebo recipients but none of the animals 
treated with SNG001 experienced a severe fever. Correspondingly, significantly fewer areas of lung tissue stained positively for influenza in pre- and post-infection treatment 
groups compared to placebo (semi -quantitatively scoring of lung tissue sections by 
immuno -histochemistry staining using an antibody directed against the influenza 
nucleoprotein). Macroscopic examination of SNG001-treated animals showed their lungs were less affected, having fewer lesions than placebo-treated animals. Alveolar histopathology scores relating to lung inflammation, hemorrhage, edema, and 
pneumocyte hyperplasia were lower in SNG001-treated animals (Synairgen study report 
SR043) [5].  
 
Clinical Human Studies  
There is extensive experience from individuals who have received parenteral injections of IFN -β-1, as this is has been approved for treatment of multiple sclerosis in the United 
States since 1996. The most common side effects from intravenous injections of IFN -β-1 
are mild and short-lived, including flu-like symptoms such as headache, fever, muscle aches, and chills . Rare side effects that have been reported from intravenous injections 
of IFN -β-1 include anaphylaxis , neutropenia, lymphopenia, acute hepatic injury, acute 
kidney injury, seizures, depression, and suicidal thoughts. These studies are detailed in the investigator brochure. Importantly, since systemic exposure of IFN-β-1 after inhaled 
SNG001 administration is negli gible, systemic side effects seen with intravenous 
injections of IFN -β-1 are not anticipated with inhaled SNG001.  
 
 233 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Five clinical studies (SG004, SG005, D6230C00001, SG015, and SG016) of SNG001 
have been completed in which safety, tolerability, systemic absorption, antiviral biomarkers, and efficacy of inhaled IFN -β-1a were assessed. Approximately 339 
individuals have been dosed with SNG001 as of November  2021, 31% of whom have 
had COVID -19, and 69% of whom have asthma or COPD . Overall, in clinical trials 
(three in asthma and one in COPD) conducted to date, inhaled SNG001 has upregulated 
lung antiviral biomarkers in sputum, confirming successful delivery of biologically active drug to the lungs, demonstrating proof-of-mechanism, safety and tolerability and suppor ting dose selection [5, 21].  
 
In a Phase 1 single and multiple ascending dosing study (Study SG004) conducted in 35 asthma patients, inhaled IFN-β -1a was shown to be well tolerated up to the highest dose 
given (6 MIU once daily for 14 days). Biomarkers of IFN-β related anti -viral activity 
indicated that biologically active IFN-β -1a had been successfully delivered to the lung 
and that anti -viral response had been primed in the lungs of the participants. 
Administration of SNG001 in single or multiple doses as described did not result in any clinically significant changes in spirometry tests [FEV1, forced vital capacity (FVC), 
DLCO] compared to placebo. The majority of adverse events were mild or moderate in intensity, and there was little consistency and no obvious relationship with dose or active treatment. Considering treatment emergent adverse effects (TEAEs) assessed as 
related to study medication (as judged by the Investigator) in the highest dose at the highest frequency (6 MIU single dose and then once daily for 14 days), there was some slight evidence of increased central nervous system ev ents, particularly headache.  
 
In a Phase 2a study (SG005; n=147) 6 MIU inhaled IFN -β-1a, or placebo, was 
administered once daily for 14 days to persons with asthma (Steps 2-5 according to the British Thoracic Society (BTS) guideline) after the onset of symptoms of common cold or influenza [22]. In the subgroup of individuals with difficult-to- treat asthma, that is, BTS 
Steps 4-5 (n=27 on active drug; n=31 placebo), inhaled IFN -β-1a significantly attenuated 
the development of asthma symptoms as measured by change in the 6-item Asthma Control Questionnaire (ACQ) from Baseline to Day 8, compared to placebo. In addition, 
fewer participants required oral steroids or antibiotics in the BTS Steps 4-5 group in the 
active compared to placebo arms. Reported adverse effects were similar across study arms except for cardiac palpitations, which were experienced in five participants on 
inhaled IFN -β-1a and none on placebo. All palpitations were mild and transient and not 
considered clinically signific ant. 
 In a second Phase 2a study (study D6230C00001; n=121) , 6 MIU inhaled IFN -β-1a, or 
placebo, was administered once daily for 14 days to persons with severe asthma (Global Initiative for Asthma Step 4-5) (GINA Report 2014) and with severe exacerbations triggered by an upper respiratory viral infection. Among the 61 participants who were randomi zed to active drug and 60 participants to placebo, safety and adverse event data 
indicate that SNG001 was well tolerated. Biomarker (serum CXCL10) data suggest that treatment with SNG001 induced anti -viral responses in asthmatics during a respiratory 
viral infection. The difference between SNG001 and placebo for the primary endpoint of 
 234 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  the study, the proportion of participants with a severe exacerbation during the 14 days of 
treatment, was not significantly different. Data suggests that SNG001 accelerated recovery in home measured morning Peak Expiratory Flow Rate (PEFR) in participants receiving SNG001 compared to those receiving placebo. No difference between treatment groups 
were observed for reliever medication use, asthma symptom scores or ACQ -6 scores . 
 
In contrast to SG005, cardiac palpitations occurred in only one person in the placebo treatment group. There were four  serious TEAEs during the study, all in the SNG001 
treatment group, and all related to worsening of asthma. Two participants in the SNG001 
group each experienced one serious TEAE, and one person experienced two serious 
TEAEs. These were not considered to be related to study drug by the investigators. In conclusion, SNG001 is generally considered to be well tolerated in persons with asthma with an upper respiratory tract infection.  
A third Phase 2 study (SG015) of SNG001 in COPD patients, with and without a 
confirmed respiratory virus infection, was conducted in two parts. Both parts (Part 1 and 2) were randomi zed, double-blind, placebo-controlled designs to assess safety, anti -viral 
biomarker responses and clinical effects of inhaled SNG001 compared to placebo in male and female COPD patients.  
 
In Part 1 of SG015, the local tolerance and safety of SNG001 was assessed in patients 
with stable COPD. These patients received 6 MIU of SNG001 or placebo once daily for 3 days. Thirteen COPD patients (in a stable state without respiratory infection) were administered at least one dose of SNG001 (6 MIU) or placebo once daily for 3 days. Patients were randomi zed in a 4:1 ratio, respectively. Ten patients completed the 
protocol required dosing regimen with eight patients receiving SNG001 and two patients receiving placebo. Patients were monitored for safety to include changes in lung function, vital signs and AEs and concomitant medications. Sputum samples were also obtained for analysis of biomarkers. Safety was monitored until 4 days post last dose.  
 Results for Part 1 of the study showed that COPD patients inhaling SNG001 had 
significantly increased markers of antiviral activity. Sputum samples were taken before, 
during and after treatment. Gene expression was measured in cells extracted from sputum. Expression of antiviral genes Mx1 and OAS1 were significantly higher at visits 
during the treatment phase (p<0.0001; gene expression was increased approximately 10-fold and 5-fold, respectively). These genes code for proteins that are known to 
interfere wi th viral replication. Other IFNβ -stimulated genes which also have antiviral 
activity (CXCL10 (IP -10), GBP1 and IFT2) were also upregulated.  
 
A Data Safety Monitoring Committee (DSMC) met to review and assess the safety information after the last of the ten patients had completed dosing and follow -up for Part 
1. After this review, the DSMC gave its recommendation to progress to Part 2 of the 
study. Efficacy was not assessed during Part 1 of the study.  
 
 235 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  In Part 2  of SG015, COPD patients with a confirmed respiratory virus infection were 
evaluated to confirm IFNβ driven anti -viral biomarker up-regulation and to assess clinical 
effects following the administration of inhaled SNG001 or placebo. Safety and other 
efficacy endpoints were also assessed. Patients were randomi zed 1:1 to receive 6 MIU 
SNG001 or placebo once daily for 14 days. Doses were delivered at the study site and at home, by a CE marked breath-actuated nebulizer  (I-neb Philips Respironics). The first 
dose of study medication was administered within 48 hours of the onset of respiratory virus symptoms (cold symptoms) and/or deterioration in COPD symptoms (Group A) or the onset of a moderate COPD exacerbation (Group B) and continued for a treatment 
period of 14 days.  
 
Originally, up to 120 patients in total were to be randomi zed during Part 2, however, due 
to the SARS -CoV -19 pandemic in 2020, the study was paused and an interim analysis 
was conducted of all currently available data in order to aid decision making with respect 
to the potential of SNG001 in treating and preventing COVID -19 symptoms. At this time, 
109 (p lacebo, n=52; SNG001, n=57) patients had been randomi zed and following the 
interim analysis a decision was made to close the trial.  
 
Results of the interim analysis of Part 2 of the study indicated that the impact of viral infection on COPD patients was most evident on PEFR and patient-reported symptoms 
assessed using the Breathlessness Cough and Sputum Score (BCSS ) and  was 
particularly apparent in patients with a moderate exacerbation of COPD (i.e., requiring 
treatment with oral corticosteroids and/or antibiotics at the time of randomization). 
Exacerbating patients who received SNG001 had significantly better lung function during the treatment period (difference in change from baseline morning PEFR between 
patients receiving SNG001 and placebo over days 2-15 was 25.5 L/min; p=0.041). 
Although there was no statistically significant difference in total BCSS in this group over the treatment period, there was a trend towards improvement of the br eathlessness 
component of the score, suggesting that patients may have recovered more rapidly if they received SNG001 rather than placebo. Viral infections had less impact on non-exacerbating patients and there were no significant treatment effects. Biomar ker 
analysis showed that in the overall population COPD patients inhaling SNG001 had significantly increased markers of antiviral activity . The safety profile in study SG015 
showed no safety signals of concern. During Part 1 of the study 7 (70%) and 2 (66.7%) of patients experienced treatment emergent adverse events (TEAEs) in the SNG001 and the placebo groups respectively. The number of related events was similar and there 
were no SAEs. During Part 2 of the study, 33 (57.9%) and 29 (55.8%) patients 
experienced TEAEs in the SNG001 and the placebo groups, respectively. The most frequently reported TEAE was exacerbation of chronic obstructive pulmonary disease, which was reported in 11 patients (19.3%) in the SNG001 group and 10 patients (19.2%) in the placebo group. During Part 2, fewer patients experienced treatment-emergent 
serious adverse events (SAEs) in the SNG001 group than the placebo group (SNG001: 
1 patient, placebo: 3 patients). The treatment-emergent SAEs were related to breast 
cancer (2 placebo patients) and exacerbation of COPD (1 placebo patient and 1 
 236 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  SNG001 patient). The events were considered as either unlikely related or unrelated to 
study treatment.   In Part 2 of SN G015 TEAEs related to treatment were more common in the placebo 
group than in the SNG001 group (SNG001: 9 [15.8%] patients, p lacebo: 13 [25%] 
patients); chronic obstructive pulmonary disease, reported by 11 SNG001 patients (19.3%) and 10 placebo patients (19.2%), was the most frequently occurring TEAE. Wheezing was reported by 5 SNG001 patients (8.8%) and no patients in the placebo group. Cough was reported by 4 patients in both SNG001 and placebo groups. Dyspnea 
was reported in similar numbers of patients in both SNG001 and placebo groups with a 
slightly higher proportion in placebo (SNG001, 2 patients [3.5%], placebo 3 patients [5.8%]). Oropharyngeal pain was reported in 2 patients (3.8%) in the placebo group and no patients in SNG001 group. Diarrhea was reported by 3 patients in both SNG001 and 
placebo groups (5.3% and 5.8% respectively). Other events were of low occurrence in 
both SNG001 and placebo groups. During Part 2 there were no fatal TEAEs in either of 
the treatment groups. In summary, the proportion of patients reporting AEs in SG015 were comparable in the inhaled SNG001 and placebo groups.   Most recently, a Phase II double-blinded randomized controlled trial (SG016, a Pilot phase) to evaluate safety and efficacy of inhaled SNG001 (once-a-day dosing x  14 
days) in the treatment of hospitalized and ambulatory patients with confirmed SARS -
CoV-2 infection was completed in the UK. In the hospitalized cohort, treatment was 
initiated a median 10 days after onset of COVID -19 symptoms. Analysis of the 
Ordinal Scale for Clinical Improvement (OSCI) demonstrated patients who received SNG001 were more than twice as likely to recover to Level 1 or better on the scale (no 
limitation of activities) than those who received placebo during the dosing period and a 
trend towards reduced odds of progression towards severe disease or death (5, 24) . 
Analysis of clinical outcomes in the intention to treat population revealed a significant improvement in the symptom of breathlessness (Figure 2.2-1) using the BCSS, in recovery at the end of dosing, and at day 28 as measured by the WHO OSCI (Figure 2.2-2 ). 
 
 237 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)   
Figure 2.2-1. Change in self-reported breathlessness during SG016 using 
Breathlessness, Cough and Spu tum Score (BCSS) assessment. 
  
 
Figure 2.2-2. Analysis of OSCI in the ITT population at the end of SNG001 vs . placebo 
dosing through to day 28 in study SG016. 

 238 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  In the hospitalized SG016 cohort, a total of 26 (54.2%) and 30 (60.0%) patients 
experienced TEAEs in the SNG001 and the placebo groups, respectively. Fewer 
patients experienced serious TEAEs in the SNG001 group than the placebo group (SNG001: 7 [14.6%] patients, placebo: 14 [28.0%] patients) .  
 The most frequently reported TEAE was headache, which was reported in 7 patients (14.6%) in the SNG001 group and 5 patients (10.0%) in the placebo group. Treatment-emergent adverse events related to treatment were more common in the SNG001 group than the placebo group (SNG001: 7 [14.6%] patients, placebo: 2 [4.0%] patients); cough, 
reported by 2 patients (4.2%), was the most frequently occurring treatment-related TEAE 
in the SNG001 group. The most common serious TEAEs were related to COVID -19: 
respiratory failure (SNG001: 4 [8.3%] patients, placebo: 6 [12.0%] patients) and COVID -
19 pneumonia (3 [6.3%] patients in the SNG001 and 3 in the placebo group [6.0%]).  
 
Other TEAEs related to SNG001, each occurring in 1 patient, included: decreased 
oxygen saturation, diarrhea, dry throat, oral pain, night sweats and tremor. Three TEAEs led to study withdrawal in 3 (6.0%) patients in the placebo group: nausea, multiple organ dysfunction syndrome (fatal) and pulmonary embolism (fatal); none was considered treatment related. In addition to the fatal TEAEs above, a third patient died in the placebo group where cause of death was recorded as COVID -19 pneumonia 
(considered unrel ated to study treatment). 
 Given the positive results from the pilot phase in hospitalized patients, a pivotal phase (Phase 3) trial was initiated in January of 2021. On March 15
th, 2021, a 
suspected unexpected serious adverse reaction report (SUSAR) was submitted 
regarding a participant in the pivotal phase inpatient trial (1 SUSAR out of 74 
hospitalized patients randomized and treated at that time). In this SUSAR, a hospitalized 
study participant was discharged home after receiving three daily doses of 
investigational drug (SNG001 or placebo). One day after discharge, the patient took the study drug at home. That same evening, the participant experienced worsening 
shortness of breath, cough, and fever, and was readmitted the following day for 
worsening COVID-19. On the second day of readmission, the participant was dosed with 
the investigational drug by nebulizer, and shortly thereafter developed bronchospasm leading to significant oxygen desaturation. Study drug was permanently discontinued due to this bronchospasm event. This bronchospasm event was considered an unexpected serious adverse reaction, probably related to study drug.  
 
In the pilot  ambulatory (home) SG016 cohort, 114 participants were randomized to 
inhaled SNG001 (n=56) versus p lacebo (n=58). Treatment was initiated a median 6 
days after onset of COVID -19 symptoms, with a median age of 61 years and 
predominantly white (94.7%) study population. There was no significant difference 
between treatment groups in recovery, improvement or worsening assessed on 
the OSCI scale or the number of days with an OSCI score ≥2 (limitation of 
activities and above). Only two  patients were hospitalized due to COVID -19 during 
treatment, both received placebo. Secondary analysis of symptoms did not reveal 
 239 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  any difference between SNG001 and placebo treatment groups. There was a 
suggestion from post hoc analyses that patients who were more short of breath at baseline (breathlessness score ≥ 2 or ≥ 3) were more likely to recover with SNG001 
treatment than with placebo, but this analysis was limited to a small number of 
patients.  
 In the ambulatory cohort, the incidence of all reported TEAEs during the study was slightly higher in the placebo group (46 [79.3%]) than in the SNG001 group (38 [67.9%]). The most frequently reported TEAEs were diarrhea (9 [16.1%] patients in 
the SNG001 group vs. 4 [6.9%] in the placebo group) and nausea (9 [16.1%] in the 
SNG001 group vs. 8 [13.8%] in the placebo group). The majority of TEAEs were 
considered unrelated to study treatment. The most frequent TEAEs considered related to study treatment were cough (3 [5.4%] for SNG001 vs. 5 [8.6%] for placebo, dizz iness (2 [3.6%] for SNG001 vs. 2 [3.4%] for plac ebo), and nausea ( 5 
[8.5%] for SNG001 vs. 2 [3.4%] for placebo). Other TEAEs considered related to study treatment in the SNG001 group included paresthesia, dry throat, diarrhea, chapped lips, musculoskeletal chest pain, arthralgia, procedural dizziness, procedural nausea; all of these TEAEs were reported in one patient each in the 
SNG001 group except for diarrhe a which was reported in two  patients. In total, 
four (7.1%) patients in the SNG001 group experienced a total of five serious 
TEAEs compared with 2 (3.4%) patients in the placebo group who experienced a total of two  serious TEAEs. The serious TEAEs reported in the SNG001 group 
were urinary tract infection, cardiac failure, and asthma reported in one patient 
each, and COVID -19 pneumonia reported in two  patients. The serious TEAEs 
reported in one patient each in the placebo group were COVID -19 and LRT 
infection. No serious TEAEs were considered to be related to study treatment.  In conclusion, based on the studies SG004, SG005, SG015, SG016, and D6230C 00001, 
safety parameters including spirometry, DLCO, vital signs and blood markers showed no obvious difference between the SNG001 and the placebo groups. The number of TEAEs was generally evenly distributed between the inhaled IFN -β-1a and placebo groups, with 
the exception of cardiac palpitations in study SG005, described above. Based on the experience from performed clinical trials in healthy volunteers and individuals with asthma, inhaled IFN -β-1a is generally safe and well tolerated in multiple doses of up to 6 
MIU daily for 14 days. D ata in patients with COVID -19 also demonstrate an overall  
favorable safety profile and improvement in clinical outcomes  among hospitalized 
patients. There has been one serious adverse event reported (bronchospasm) that was 
temporally associated with blinded study drug administration. 
 
Choice of Study Dosing  
Pharmacokinetic data from the Phase I study (SG004) demonstrated that levels of IFN -β 
remained below the Limit of Detection (LOD; 5 IU/mL) at all time points  in the serum 
samples collected from participants with asthma receiving doses of up to  
6 MIU inhaled IFN -β-1a single dose and then once daily for 14 days. Biomarker data 
from the Phase I study (SG004) suggest that biologically active SNG001 was 
 240 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  successfully delivered to the lung and that anti -viral responses had been primed in the 
lungs of partici pants with asthma following inhaled delivery of SNG001 (primary 
pharmacodynamic activity). Lung (sputum) anti -viral biomarker responses were 
increased post dose in a dose dependent manner with 1.5 and 6 MIU SNG001 doses 
evoking near equivalent responses. Biomark er responses in the lung were maintained 
by once-a-day but not once-every -three-day dosing regimen supporting once daily 
administration. 
 In the Phase 2 study (SG005) , pharmacokinetic data demonstrated that levels of 
Interferon beta remained below the Limit of Quantification (LOQ; 1.2 pg/m L-0.4 IU/mL) in 
serum samples from most subjects tested (25/27). Low concentrations of IFN -β (1.69 
and 3.73 pg/mL) were detected in serum samples from two participants on one occasion. In summary, the systemic absorption following single and repeated 6 MIU 
doses of IFN -β-1a administered via the inhaled route is low.  
 Based on an integrated assessment of all available non-clinical data, as well as the extensive experience of parenteral administration of IFN -β-1a, inhaled IFN -β-1a  is 
considered safe to administer to adult humans in controlled clinical trials of up to 14 days duration. Although reproductive toxicology studies have not been conducted with inhaled IFN-β-1a, available data from marketed parenteral IFN -β-1a indicates that there may be 
an increased risk of spontaneous abortion and initiation of treatment is contraindicated during pregnancy.  
 In prior studies SNG001 has been delivered using the Philips -I neb device which has an 
efficiency of approximately 60% delivery to the lung based on scintigraphy studies  [23]. 
As a result, a single syringe of 12 MIU/m L SNG001 (0.65 mL ) is estimated to deliver 3.8 
MIU after taking into account emitted dose and delivery efficiency to the lung (
Table 2.2-
1). In the current study SNG001 will be delivered using the Aerogen Ultra device, which 
has an efficiency of approximately 35% drug delivery to the lung [ 24]. Using the Aerogen 
Ultra device, a single syringe of 12 MIU/m L SNG001 (0.65 mL ) is estimated to deliver a 
dose of 2.3 MIU to the lungs after accounting for emitted dose and delivery efficiency to 
the lung. In this study, two syringes (1.3 mL total) will be used, similar to the Phase II UK 
study of SNG001, and will be expected to deliver a dose of 5 MIU to the lungs after 
accounting for emitted dose and delivery efficiency to the lung.  
 
 241 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Table 2.2-1. SNG001 D ose and Drug Delivery to the L ung [23, 24] 
 
 
Study Drug Duration SNG001 will be dosed daily for 14 days as this was the duration of dosing in Phase I and 
II studies. With this dosing schedule data from the SG016 study in which hospitalized 
patients with confirmed COVID -19 were randomized to either SNG001 or placebo 
revealed an increased likelihood to recover to “no limitation of symptoms ” over the 
treatment period and at day 28 as defined by a post-baseline WHO OSCI of 0 or 1 (Figure 2.2-3
). This effect was most pronounced after 9 days of dosing, with dosing 
having commenced a mean of 9 days after first developing COVID -19 symptoms. 
Importantly, in this study the median duration of hospitalization was approximately 7 days , and thus participants continued to self-administer study product at home post 
discharge, with continued clinical improvement.  
 

 242 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)    
 
  
 
    
 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  
 
Participants must meet inclusion and exclusion criteria from the master protocol, as well as the appropriate inclusion and exclusion criteria for the investigational agent included below.  
 4.1 General Eligibility Criteria
 
  
4.1.1 Inclusion  Criteria 
 
4.1.1.9 For participants who are of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or laboratory that has a CLIA certification or its equivalent, or by a point of care (POC)/CLIA-waived test.  
 
NOTE: Reproductive potential is defined as:  
• participants who have reached menarche 
• participants who have not been post -menopausal for at least 12 
consecutive months with follicle-stimulating hormone (FSH) ≥40 
IU/mL or 24 consecutive months if an FSH is not available  
Figure 2.2 -3. In patients with more severe disease at time of hospital admission 
(requiring treatment with supplemental oxygen), patients treated with SNG001 
were more than twice as likely to have recovered by the end of the treatment period (HR 2.60 [95% CI 0.95-7.07]; p=0.062) and had greater odds of recovery at day 28 (OR 3.86 [95% CI 1.27-11.75]; p=0.017). Recovery is defined as a post 
baseline OSCI score of 0 or 1 which does not rise above 1 at any subsequent 
visit. 
 
 243 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  • participants who have not undergone surgical sterilization (e.g., 
hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy)   
• participants with no other clinical conditions (such as anorexia nervosa) that could induce amenorrhea 
• participants not taking medications such as oral contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs) or chemotherapy that could induce amenorrhea  
• For individuals with permanent infertility due to an alternate medical cause (e.g., Mullerian agenesis, androgen insensitivity), 
investigator discretion should be applied to determining study 
entry.  
 
4.1.1.10 If participating in sexual activity  that could lead to pregnancy, 
participants who are of reproductive potential  must agree to use 
effective contraception for 30 days after  investigational agent is 
administered. This would include oral contraceptives, implanted 
contraceptives, intrauterine devices, and barrier methods. 
 
NOTE: Participants not of reproductive potential are eligible without requiring the use of a contraceptive method. Participant-reported 
history is acceptable documentation of surgical sterilization and 
menopause. 
 
4.1.1.11 Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives for 30 days after investigational agent administration. 
They are also strongly advised to inform their non-pregnant sexual 
partners of reproductive potential to use effective contraceptives for 30 days after investigational agent is administered to the participant. 
 
Participants with pregnant partners should use condoms during vaginal 
intercourse through 30 days after  last dose of investigational agent 
administration. 
 
Participants should refrain from sperm donation for 30 days after 
investigational agent administration.  
 
4.1.1.12  In phase III, meeting the protocol definition of being at “higher” risk of progression to hospitalization or death (see SCHEMA, POPULATION
 
for definition of “higher” risk ). 
 
 244 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  4.1.2  Exclusion Criteria  
 
4.1.2.11 Use of or need for chronic supplemental oxygen  
 
4.1.2.12 Currently pregnant or breastfeeding  
 
4.1.2.13  In phase II, meeting the protocol definition of being at “higher” risk of progression to hospitalization or death (see SCHEMA, POPULA TION
 
for definition of “higher” risk ) 
 
5.0 INVESTIGATIONAL AGENTS  
 5.1 Regimen, Administration, and Duration
 
 
5.1.1 Regimen and Duration 
 
Participants will be randomized to receive one of the following regimens:  Investigational Agent: Interferon-β1a (SNG001) nebulizer solution two syringes (1.3 mL; 15.6 MIU) inhaled once daily for 14 days  
 OR 
 Placebo for Interferon-β1a (SNG001) nebulizer solution two syringes (1.3 mL) inhaled once daily for 14 days, for Phase II participants only. 
 
5.1.2 Administration 
 
Interferon-β1a (SNG001) nebulizer solution and Placebo for Interferon-β1a (SNG001) will be self-administered as a single nebulized dose via the Aerogen Ultra Nebulizer device once a day for 14 days. Participants will be trained by 
study staff on use of the Aerogen Ultra device and Interferon-β1a ( SNG001) or 
placebo administration on Day 0. The first dose should be taken on the same of day of training (Day 0) and may be taken at the clinic or at home. Study participants will take all subsequent doses of the investigational agent or placebo at home. Interferon-β1a (SNG001) or placebo should be taken at about the same 
time every day.  
 
Two syringes of Interferon-β1 a (SNG001) or Placebo for Interferon-β1 a 
(SNG001) should be removed from the refrigerator 15 minutes before 
administration and administered within 8 hours. After each dose, the device will be cleaned with nebulized 0.9% Sodium Chloride, USP.  
 Dosing should be stopped at the end of the 14-day treatment period (i .e., any 
missed doses at the end of 14 days should not be taken).  
 245 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)   
5.2 Formulation, Storage, and Preparation  
 
5.2.1 Formulation and Storage 
 
5.2.1.1 Interferon-β1 a (SNG001) 
 
Interferon-β1a (SNG001) is a sterile, clear and colorless, ready -to-use 
aqueous nebulizer solution presented in disposable pre-filled glass 
syringes. Each pre -filled syringe contains 0.65 mL of interferon-β1a 
(SNG001) at a concentration of 12 MIU/mL. Interferon-β1a (SNG001) 
pre-filled syringes will be packaged in wallets containing seven syringes per wallet. Interferon-β1a (SNG001) should be stored at 2-8°C. Do not freeze.  
 Once delivered to enrolled study participants, Interferon-β1a (SNG001) should be stored in a refrigerator until use. Do not freeze.  
 Interferon-β1 a (SNG001) is described in further detail in the Interferon-
β1a (SNG001) Investigator’s Brochure. 
 
5.2.1.2 Placebo for Interferon-β1 a (SNG001)  
 
The composition of the placebo for Interferon-β1a (SNG001) is trisodium citrate dihydrate, di -sodium hydrogen-phosphate, sodium dihydrogen-
phosphate dihydrate, racemic methionine (DL-methionine), and water. Placebo for Interferon-β1a (SNG001) is presented in pre-filled syringes containing 0.65 mL of solution. Placebo for Interferon-β1a (SNG001) pre-filled syringes will be packed in wallets containing seven syringes per wallet. Placebo for Interferon-β1a (SNG001) should be stored at 2-8°C. Do not freeze.  
 Once delivered to enrolled study participants, placebo for Interferon-β1a (SNG001) should be stored in a refrigerator until use. Do not freeze.  
 Placebo for Interferon-β1a (SNG001) is described in further detail in the 
Interferon-β1a (SNG001) Investigator’s Brochure. 
 
5.2.2 Dose Preparation 
 
Interferon-β1 a (SNG001) will be prepared from two Interferon-β1 a (SNG001) pre-
filled syringes.  
 
Placebo for Interferon-β1 a (SNG001) will be prepared from two Placebo for 
Interferon-β1 a (SNG001) pre -filled syringes. (Phase II Participants Only)  
 246 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Four wallets of Interferon-β1 a (SNG001) or Placebo for Interferon-β1 a (SNG001) 
will be dispensed to each study participant for a total of 28 pre-filled syringes. 
 
5.2.3 Labeling of Investigational Agent and Placebo  
 
Interferon-β1a (SNG001) and Placebo for Interferon-β1a (SNG001) will be provided with customary two-part labels which include a tear -off portion 
containing the un-blinded product identification [i.e., Interferon-β1a (SNG001) or Placebo for Interferon-β1a (SNG001)]. 
 
Prior to dispensing, the un-blinded portion of the tear -off label must be removed 
and attached to the participant-specific pharmacy record such as participant prescription or participant-specific study product accountability record. The permanently affixed section of the label will remain on the original wallets. Four 
wallets will be dispensed per participant.  A participant -specific label must be affixed to the Interferon-β1a (SNG001) or 
Placebo for Interferon-β1a (SNG001) wallets prior to dispensing to the participant.  
 
Label each wallet with the following information: 
a. Participant identifier(s)  
b. Protocol number: ACTIV -2/A5401 
c. Investigational agent name  
Phase II: 
Interferon-β1a (SNG001) or Placebo  
 
d. Total volume: 1.3 mL 
e. Route: Inhale as directed using the Aerogen Ultra nebulizer device  
f. Frequency and duration: once daily for 14 days  
g. Date of dispensing  
h. Expiration date 
i. Storage information: store refrigerated (2-8°C). Do not freeze.  
j. Disposal instructions: empty syringes will be kept in a sharps container and 
returned to clinic  
k. Any additional  information required by jurisdiction  
  5.3 Supply, Distribution, and Accountability
 
 
5.3.1 Supply  and Distribution  
 
Interferon-β1a (SNG001) and Placebo for Interferon-β1a (SNG001) will be 
provided by Synairgen and will be available through the NIAID Clinical Research 
Products Management Center (CRPMC).  
 
 247 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Nebulizer devices will be provided by Aerogen and will be available through the 
NIAID Clinical Research Products Management Center (CRPMC).  
 
5.3.2 Accountability  
 
The site pharmacist is required to maintain complete records of all investigational agents received from the NIAID CRPMC and subsequently dispensed. At US CRSs, all unused investigational agents must be returned to the NIAID CRPMC (or as otherwise directed by the sponsor) after the study is completed or 
terminated. At non-US CRSs , the site pharmacist must follow the instructions 
provided by the NIAID CRPMC for the destruction of unused investigational agents.  
 5.4 Concomitant Medicati ons
 
 
Any pre -medications given will be documented as a concomitant medication. There are 
no known or expected drug-drug interactions with the investigational Interferon-β1a (SNG001) agent and therefore there are no prohibited medications except as outlined in 
section 5.4
 of the parent protocol.  
 
 248 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X I: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Evaluations   
 
The schedule of evaluations provided below include additional evaluations for this investigational agent.  Table 6.1-1: Schedule of Evaluations Phase II  
Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Investigational Agent Self -
Administered   Days 0 -13         
Participant -Completed Adherence 
Assessment   Days 0-13          
Staff Review of Adherence    X X X         
Retrieval of Adherence Log      X         
Hematology   X  X  X      X  
Chemistry   X  X  X      X  
 249 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Pregnancy Testing  X Whenever pregnancy suspected       
 
  
 250 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Table 6.1-2: Schedule of Evaluations Phase III  
 
Phase III Evaluation  
Screening  
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week  12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C 
(Before Day 28)  
Premature Study D/C 
(After Day 28)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Investigational Agent Self-
Administered   Days 0 -13         
Stored Plasma  X X   X  X    X X 
Stored Serum   X X   X  X    X X 
 
 
 251 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X I: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  6.3 Instructions for Evaluations  
 
6.3.9 Investigational Agent Administered 
 
On Day 0, site staff will train the participant on use of the Aerogen Ultra de vice. 
 All doses of Interferon-β1a (SNG001) or placebo, including the Day 0 dose, will 
be self-administered by the participant. Interferon-β1a (SNG001) or placebo should be taken at about the same time every day. 
 
6.3.10 Study Kit Dispensed  
 
In addition to the kit contents described in the master protocol, the study kit will include:  
• Investigational agent/placebo wallets   
• Assembled Aerogen Ultra device  
• Normal saline packet  
• Sharps containers  
• Nose clip  
• Study medication adherence assessment log (see below)  
• Biohazard bag for returning supplies  
 
Additional specifics of study kit dispensation/retrieval are detailed in the MOPS. 
 
6.3.15 Laboratory Evaluations 
 
Hematology  
Participants will have blood drawn for complete blood cell count (CBC) with 
automated differential and platelet count.  
 At Entry/Day 0, blood should be drawn before study drug administration.   
Chemistry  
Participants will have blood drawn for liver function tests (ALT, ALP, AST, total bilirubin, direct bilirubin, and total protein), and renal function tests (albumin, BUN, c reatinine, potassium, glucose, and sodium).  
 At Entry/Day 0, blood should be drawn before study drug administration.  
 
Pregnancy Testing  
For participants of reproductive potential: Serum or urine β-HCG. (Urine test 
must have a sensitivity of ≤25 mIU/mL.) 
 
 252 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  Post-screening, pregnancy testing should be done any time pregnancy is 
suspected.  
 In the event of pregnancy occurring during the study, record pregnancy and 
pregnancy outcome per section 8.3
. 
 
6.3.16 Pharmacokinetics  
 
PK analyses will be conducted on select stored samples .  
 
6.3.17 Stored Samples  
 
In addition to the assays described in the master protocol, stored plasma and 
serum will be collected at time points per the SOE for the following testing:  
 
Stored Plasma (Day s 0, 7, and 28 in Phase II and Days 0 and 28 in Phase III)) 
• Auto-anti -Interferon antibodies including, but not limited to, IFN -α2, IFN -ω, and 
IFN-β 
 
Stored Serum (Days 0, 7, 14, and 28 in Phase II and Days 0 and 28 in Phase III)  
• Assessment of anti -drug antibodies  
 
All Entry/Day 0 samples should be collected prior to first dose of investigational agent/placebo.  
 
6.3.18 Participant-C ompleted Adherence Assessment and Staff Review of Adherence  
 Treatment adherence will be assessed by an adherence questionnaire (study medication log) completed by the participant on Days 0-13.   
The study medication log will be reviewed by study staff in person or remotely 
with each participant as per the SOE. The data will be recorded on an eCRF and log retrieved as described in the MOPS .  
 7.0 ADVERSE EVENTS AND STUDY MONITORING 
 
7.1 Definitions of Adverse Events
 
 
Adverse Events of Special Interest  
The following are AESIs for the agent SNG001or Placebo for SNG001:  
• Grade ≥2 palpitations  during the dosing period and up to 24 hours  after the last dose.  
 253 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  • Grade ≥3 bronchospasm  within 4 hours  of investigational  agent/placebo 
administration (symptoms  causing inability  to perform  usual  social  and functional  
activities  and deemed related to study  product as determined by the site 
investigator).  
 
8.0 CLINICAL MANAGEMENT ISSUES 
 8.2 Management of Side Effects
  
 
8.2.1 Overdose 
 
There is no case of overdosage reported in the previous trials with inhaled IFN -β-
1a and there is no known antidote to IFN -β-1a. Any dose above the investigated 
dose should be considered as an overdose. In cases of known or suspected overdose, symptomatic treatment and monitoring of vital functions should be performed according to routine clinical practice.  
 
8.3 Pregnancy
  
 
Given the limited data on the use of SNG001 in participants who are pregnant, participants who are pregnant are not eligible for the study. Participants of reproductive 
potential and participants who may impregnate their partners are required to follow the 
instructions for prevention of pregnancy provided in the protocol.  
 
If a participant becomes pregnant during the study (post-entry), administration of 
SNG001 or placebo will be stopped, the participant will remain on study through the 
end of the study, and the pregnancy will be followed through completion.   
 
At the end of the pregnancy, outcome and adverse events for participant and infant will be recorded on the outcome eCRF.  
 8.4 Breastfeeding
 
 
Since there are no data regarding the use of SNG001 in participants who are breastfeeding, participants who are breastfeeding are not eligible for the study. 
 10.0  STATISTICAL CONSIDERATIONS  
 
10.2 Outcome Measures
 
 
10.2.3 Secondary Outcome Measures 
 
10.2.3.14 Phase II only: Number of missed doses of SNG001 or placebo for SNG001.  
 
 254 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  10.2.3.15  Phase II only:  Percentage of the 14 doses of SNG001 or placebo for 
SNG001 that are missed, defined as the number of missed doses divided by 14. 
 
10.2.4 Other Outcome Measures  
 
10.2.4.12 Phase II and III: Area under the curve of shortness of breath or 
difficulty breathing symptom severity over time from the participant’s 
study diary from day 0 to day 28. For participants who are alive at 28 
days and not previously hospitalized, symptom severity on a given 
day is defined as the individual symptom score for shortness of breath or difficulty breathing in the participant’s study diary (each 
individual symptom is scored from 0 to 3). Participants who are hospitalized or who die during follow -up through 28 days will be 
ranked as worse than those alive and never hospitalized as follows (in worsening rank order): alive and not hospitalized at 28 days; hospitalized but alive at 28 days; and died at or before 28 days. 
 10.6 Analyses
 
 
10.6.3  Secondary Outcomes  
 
10.6.3.7 Adherence 
 
Analyses of adherence will be restricted to those randomized to 
SNG001 or placebo for SNG001 and will not include other pooled 
placebos as adherence is only assessed in those who took SNG001 or the matching placebo.  
 Adherence will be evaluated by estimating the proportion of partic ipants who missed at least one dose of SNG001 or placebo for 
SNG001 and will be compared between arms using binary regression. 
The percentage of missed dosed will be compared between study arms using a two-sided Wilcoxon test with 5% Type I error rate.  Additional details are provided in the SNG001 SAP.  
 
10.6.3.8 Analyses in Subgroups Defined by Shortness of Breath Severity 
at Day 0 
 
The secondary objectives concerning analyses of the primary outcome and the secondary clinical outcomes in the subgroup 
who report moderate or severe shortness of breath or difficulty 
breathing at day 0, and in the subgroup who report severe shortness of breath or difficulty breathing at day 0, will be 
 255 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  undertaken using the same methods as for analyses of these 
outcomes in the overall study population. 
 16.0 REFERENCES 
 
1. Liu SY, Sanchez DJ, Cheng G. New developments in the induction and anti viral 
effectors of type I interferon. Curr Opin Immunol 2011;23:57-64.  
2. Agrawal A. Mechanisms and implications of age-associated impaired innate 
interferon secretion by dendritic cells: a mini -review. Gerontology 2013;59:421-6. 
3. Singanayagam A, Loo SL, Calderazzo M, et al . Antiviral immunity is impaired in 
COPD patients with frequent exacerbations. Am J Physiol Lung Cell Mol Physiol 2019;317:L893-L903.  
4. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells  have a 
deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201:937-47.  
5. Synairgen. Investigators Brochure version 12 23, April 2020.  
6. Herfst S, van den Brand JM, Schrauwen EJ, et al. Pandemic 2009 H1N1 influenza virus causes diffuse alveolar damage in cynomolgus macaques. Vet Pathol 2010;47:1040-7.  
7. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS -CoV -2 infection. Antiviral Res 2020;179:104811.  
8. Chan JF, Chan KH, Kao RY, et al . Broad-spectrum antivirals for the emerging Middle 
East respiratory syndrome coronavirus. J Infect 2013;67:606 -16.  
9. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS 
coronavirus to selected antiviral compounds. J C lin Virol 2004;31:69-75.  
10. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 2003;362(9380):293-4.  
11. Dahl H, Linde A, Strannegard O. In vitro inhibition of SARS virus replication by human interferons. Scand J Infect Dis. 2004;36(11-12):829-31.  
12. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci Rep 2013;3:1686.  
13. Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell -based 
assays. J Gen Virol 2014;95(Pt 3):571-7.  
14. Hensley LE, Fritz LE, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis 2004;10:317-1 9.  
15. Lau SKP, Lau CCY, Chan KH, et al. Delayed induction of proinflammatory cytokines 
and suppression of innate antiviral response by the novel Middle East respiratory 
syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 
 256 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX  XI: INVESTIGATIONAL AGENT INHALED INTERFERON-β1a (SNG001)  2013;94(Pt 12):2679-90.  
16. Scagnolari C, Vicenzi E, Bellomi F, et al . Increased sensitivity of SARS -coronavirus 
to a combination of human type I and type II interferons. Antivir Ther 2004;9:1003-
11. 
17. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of 
remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS -
CoV. Nat Commun 2020;11:222. 
18. Spiegel M, Pichlmair A, Muhlberger E, Haller O, Weber F. The antiviral effect of 
interferon-beta against SARS -coronavirus is not mediated by MxA protein. J Clin 
Virol 2004;30:211-1 3.  
19. Zheng B, He ML, Wong KL, et al. Potent inhibition of SARS- associated coronavirus 
(SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN -gamma). J Interferon Cytokine Res 2004;24:388-90.  
20. Rembecki RM, Bennett M, Kumar V, Potter TA. Expression of hemopoietic histocompatibility antigens on H -2-loss variants of F1 hybrid lymphoma cells: 
evidence consistent with trans gene regulation. J Immunol 1987;138:2734 -8. 
21. Djukanovic R, Harrison T, Johnston SL, et al; INTERCIA Study Group. The effect of 
inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 2014;190:145-54.  
22. BTS/SIGN British Guideline on the Management of Asthma 2014  [cited 2020 October 15,]; 2014:[Available from: https://www.brit-thoracic.org.uk/quality -
improvement/guidelines/asthma/. 
23. Nikander K, Prince I, Coughlin S, Warren S, Taylor G. Mode of breathing -tidal or slow 
and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc -DTPA. J Aerosol Med Pulm Drug Deliv. 2010;23( Suppl 1):S37-
S43.  
24. Dugernier J, Hesse M, Vanbever R, et al . SPECT-CT comparison of l ung deposition 
using a s ystem combining a v ibrating-mesh nebulizer with a valved holding chamber 
and a c onventional jet nebuliz er: a r andomized csoss -over Study. Pharm Res 
2017;34:290 -300.  
 257 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X II: SAMPLE INFORMED CONSENT FOR STUDY DRUG SNG001  
 APPENDIX XII : SAMPLE INFORMED CONSENT FOR STUDY DRUG SNG001  
 
One of the study drugs that you might be assigned to in this study is SNG001 or the placebo for 
SNG001.  
 
SNG001 is an inhalational form of interferon beta-1a ( IFN-β-1a). IFN -b1a is a class of drug 
called an immunomodulator. IFN-b1a are naturally made by your body and help fight diseases. 
SNG001 is made in a laboratory. It is designed to stimulate an immune response against SARS -
CoV-2, the virus that causes COVID -19.  
 The United States Food and Drug Administration (FDA) has not approved SNG001 for general 
use by the public. However, we have told the FDA about this study and they have given us permission to conduct this study.  
 
 
ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I AM ASSIGNED TO SNG001?  
Screening 
If you can become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample for a pregnancy test. You cannot participate in the study if you are pregnant.  
 
After the Screening visit, your study visits and evaluations will be different depending on whether you are in the first part of the study or the second part of the study.   IF YOU ARE IN THE FIRST PART OF THE STUDY (PHASE II, COMPARISON TO PLACEBO)  
 
Entry Visit (Day 0)  
• Site staff will show you how to administer SNG001 or placebo to yourself using the Aerogen nebulizer .  
 
Study Events and Evaluations Days 0-13 
• You will administer SNG001 or placebo to yourself by inhalation using a nebulizer once a 
day for 14 days . The site staff will discuss with you if the first dose may be taken in the 
clinic.  Each nebulizer treatment will take approximately 2 minutes. You should administer 
your SNG001  or placebo at about the same time every day.  
• You will record whether or not you gave yourself inhaled SNG001 or placebo each day for 
14 days.  
 
Study Visits on Day 7, 14, 28  
• You will have blood drawn. This blood will be used for the following tests:  o routine safety tests (liver and kidney tests and blood counts) (Day 7, 28)  
 
 258 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XII: SAMPLE INFORMED CONSENT FOR STUDY DRUG SNG001  Study Visit on Day 14 
• You will return the controller cable, wall charger, and sharps container to the study clinic.  
 
IF YOU ARE IN THE SECOND PART OF THE STUDY  (PHASE III): 
 
Entry Visit (Day 0)  
• Site staff will show you how to administer SNG001 to yourself at home using the Aerogen 
nebulizer.  
 
Study Events and Evaluations Days 0-13 
• You will administer SNG001 to yourself by inhalation using a nebulizer once a day for 14 
days. The site staff will discuss with you if the first dose may be taken in the clinic.  Each 
nebulizer treatment will take approximately 2 minutes. You should administer your SNG001 at about the same time every day.  
• Yo u will record whether or not you gave yourself inhaled SNG001 each day for 14 days.  
 
Study Visit on Day 28 
• You will return the controller cable, wall charger, and sharps container to the study clinic. 
  WHAT ARE THE RISKS OF SNG001?  
 There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are
 
taken with the study drugs. For your safety, you must  tell the study  doctor  or nurse about all 
medications  you are taking before you start the study.   
 Another risk is that the study drug used in this
 study  may have side effects, some  of which  are 
listed below.  Additionally,  the study drug tested  in the study  may have unknown side effects  in 
persons  with SARS-CoV -2 infection.  In a research  study, all of the risks or side effects  may not 
be known before you start the study. You need to tell your doctor  or a member  of the study  team  
immediately  if you experience any side effects.  
 Please note that these lists do not include all the side effects  seen with this study drug.
 These 
lists include the more  serious  or common side effects  with a known or possible  relationship to the 
study drug. If you have questions  concerning the additional side effects,  please ask the medical  
staff at your site. 
 
Risks Associated with Inhaled SNG001  
There is limited safety data on inhaled SNG001 since it has not been given to a lot of people. 
This study will be one of the first studies to give inhaled SNG001 to non-hospitalized patients with COVID- 19. A study of inhaled SNG001 in COVID-19 outpatients was recently started in the 
UK. As of November  24, 2021, there have been no serious unwanted effects reported by >300 
healthy people and patients with asthma, as well as ≥ 150 non-hospitalized COVID -19 patients, 
 259 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XII: SAMPLE INFORMED CONSENT FOR STUDY DRUG SNG001  taking inhaled SNG001. There has been one report of bronchospasm (narrowing and 
obstruction of breathing) following administration of either SNG001 or placebo in a hospitalized patient with COVID-19. Most effects after taking inhaled SNG001 or placebo for SNG001 have 
been mild or moderate and have either all gone away or are getting better.  
  Based on previous trials, administration of inhaled SNG001 may result in  
• Fast heart rate 
• Coughing 
• Wheezing  
• Narrowing of airways which can cause shortness of breath 
• Dry throat 
• Hoarseness of voice  
• Sneezing  
• Tremors  
• Headache 
• Diarrhea  
• Dizziness  
• Nausea 
 
There is extensive experience from individuals who have received intravenous injections of IFN -
β-1, as this is has been approved for treatment of multiple sclerosis in the United States since 
1996. The most common side effects from intravenous injections of IFN-β -1 are mild and short-
lived, including flu-like symptoms such as headache, fever, muscle aches, and chills . Rare side 
effects that have been reported from intravenous injections of IFN -β-1 include severe allergic 
reactions, low white blood cell counts, liver injury, kidney injury, seizures, depression, and suicidal thoughts . Importantly, since inhaled SNG001 does not result in elevated levels of IFN -β-
1 in the blood, systemic side effects seen with intravenous injections of IFN -β-1 are not 
anticipated with inhaled SNG001.  
  ARE THERE  RISKS RELATED TO PREGNANCY  AND BREASTFEEDING? 
 
Pregnancy  
There is limited information regarding the use of this study drug in people who are pregnant. 
More than 1,000 pregnancy outcomes have been reported from individuals who received injections of IFN-β-1 suggest there are no increased risk to you or the embryo or fetus during 
the first trimester of pregnancy . Experience in the second and third trimester is very limited. 
Based on information from animal studies, there is possibly an increased risk for loss of pregnancy. You cannot participate in the study if you are pregnant. 
 The study drug may  involve risks to you (or to the embryo or fetus, if you or your partner
 become 
pregnant), which  are currently  unforeseen.  
 
 260 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XII: SAMPLE INFORMED CONSENT FOR STUDY DRUG SNG001  If you are engaging in sexual activity that could lead to pregnancy, you must agree to use 
effective contraception for 30 days after taking the study drug. This would include oral contraceptives, implanted contraceptives, intrauterine devices, and/or barrier methods.  
If you are engaging in sexual activity that may lead to pregnancy in your partner, you must 
agree to either remain abstinent or use male contraceptives. You are also advised to inform your non-pregnant sexual partners that can become pregnant to use effective contraceptives for 30 days after you take the study drug . 
 
If you have a pregnant partner you should use condoms during vaginal intercourse through 30 
days after taking the last dose of study drug.  
 
If applicable, you should refrain from sperm donation for 30 days after taking the study drug.  
 
If at any point during the study you think you may be pregnant, you should let the staff at your 
site know so that a pregnancy test can be done.  
 Let your doctor know  immediately  if you
 become  pregnant. If you become pregnant while  on the 
study, we will ask you to continue through the end of the study.  The study  staff would like to 
obtain information from you about the outcome of the pregnancy  (even if it is after your 
participation  in the study  ends). 
 
Breastfeeding 
It is not known if this study drug is safe to use in people who are breastfeeding. You are not 
eligible to receive this study drug if you are breastfeeding.
 261 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XI II: INVESTIGATIONAL AGENT CAMOSTAT  APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  
 
Information/evaluations noted in this agent-specific appendix are IN ADDITION to those presented in the master protocol. Section numbering aligns with the master protocol.  
 
No participants will be enrolled in version 7 or later of this protocol for this investigational agent. Appendix retained for recording purposes.  
 1.0 STUDY OBJECTIVES  
 1.2 Secondary Objectives
 
 
1.2.9  Phase II:  To evaluate camostat adherence compared with placebo for camostat over the 7-day treatment period.  
 1.3  Exploratory Objectives
 
 
1.3.13 Phase II: To explore relationship between camostat adherence and study outcomes. 
 
2.0 INTRODUCTION  
 
2.2 Rationale
 
 
SARS- CoV-2 Entry  
Hofmann et al. identified the angiotensin-converting enzyme 2 (ACE2) as the entry receptor 
for SARS- CoV-2 [1]. Another host cell surface molecule, transmembrane protease serine 
subtype 2 (TMPRSS2), cleaves the viral spike protein which is a required step for viral entry  
and a mechanism that it shares with SARS- CoV. TMPRSS2 is a known host cell factor for 
infections with several viruses, including influenza A viruses and coronaviruses. Hence, 
TMPRSS2 appears an attractive target for inhibition as it was found dispensable in 
development and homeostasis [2].  
 
The biological function of TMPRSS2, with its gene located on chromosome 21, is hitherto unknown. So far, no specific consequence of trisomy 21 has been specifically ascribed to TMPRSS2 expression. Other serine proteases  are involved in relevant 
physiologic functions with tightly regulated action (e.g., trypsin, chymotrypsin, and elastase) that play a role in digestion, and plasmin and thrombin, important serine proteases of the coagulation cascade.   SARS- CoV-2 entry into lung cells is blocked by camostat, an inhibitor of TMPRSS2 and 
other serine proteases.  
 
 262 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  Investigational Agent  
Camostat (synonyms: FOY -305, camostat mesilate or camostat mesylate), is a protease 
inhibitor that is orally administered and inactivates TMPRSS2 and other serine proteases 
(e.g., trypsin, plasma kallikrein, plasmin, thrombin, C1r and C1 esterase) but not α-
chymotrypsin, pepsin, or pancreatin. Camostat has been approved for clinical use in 
Japan since 1985 for acute flares of chronic pancreatitis and was also approved for postoperative reflux esophagitis. Subsequent post-marketing surveillance has not revealed significant safety problems [3]. A clinical trial using camostat for chronic pancreatitis is currently ongoing in the United States ([STUDY_ID_REMOVED]).  
 Camostat is a biologically plausible candidate to prevent the infection of SARS -CoV -2 or 
stop the progression of COVID-19 once a person is infected. In vitro studies have shown 
that camostat inhibits SARS -CoV -1 and SARS- CoV-2 infection of both lung cell lines and 
primary human lung cells [1]. Widespread clinical use of camostat in Japan and Korea, a 
favorable safety profile, oral administration, and ongoing experience in clinical trials 
make camostat an attractive candidate for a drug repurposing strategy in the current COVID -19 pandemic. This could substantially facilitate clinical use if trial results 
confirmed therapeutic efficacy.  
 
Nonclinical Studies  
Nume rous nonclinical studies have been performed to evaluate safety of camostat. 
Camostat has been studied in rats, mice, dogs, rabbits, hamster cells (hERG gene), and various bacteria (Ames mutation test). Nonclinical studies, including in- vitro and in-vivo 
pharmacology; PK including administration, distribution, metabolism, and excretion; 
safety pharmacology; toxicology and toxicokinetic evaluations; genotoxicity; tolerance 
studies; and reproduction and development studies have all been completed. 
Camostat’s effect on general symptoms, central nervous system, autonomic nervous 
system, cardiorespiratory system, reproduction, and urinary system as well as local irritation and antigenicity have all been evaluated. The test methods and results of these studies can be found in the current version of the Investigator’s Brochure.  
 
Clinical Studies  
Camostat, or Foipan [4], has been approved in Japan since 1985 for the remission of 
acute symptoms of chronic pancreatitis and postoperative reflux esophagitis. Many of the 
results and data in this section are from clinical studies presented as part of the Japanese 
drug approval process. FOY -251 and GBA were found to be the primary metabolites of 
camostat when administered to normal, healthy subjects. FOY -251, the active meta bolite, 
has a half-life in blood of approximately 75 minutes. Plasma kallikrein was suppressed for 
2 to 4 hours following administration of camostat. Nine studies using camostat enrolling a 
total population of 216 subjects with acute, chronic, or postoperative pancreatitis were 
conducted, with the majority of subjects dosed at 200 mg TID. The duration of dosing 
ranged from 2 weeks to more than 13 weeks. Few adverse events (AEs) were reported 
and no serious adverse events (SAEs) were documented from these studies. These 
studies did not have formal statistical tests but  did show a decrease in serum and urinary 
 263 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  amylase levels throughout the treatment period [5-13]. Two studies by Hirayama et al. 
were conducted on subjects with pancreatitis [6, 14]. In both of these studies, camostat 
was dosed at 200 mg TID. Both studies showed that camostat significantly reduced serum 
and urine amylase levels. Only one AE was reported in the camostat group compared with 
none in the placebo arm. 
 
A PK and safety Phase 1/2 study ( NI03 -001) is currently being conducted in the United 
States, Russia and Ukraine with two phases [15]. In the first phase, a single dose of 
camostat at doses of 100 mg, 200 mg, and 300 mg were administered to 18 subjects 
with chronic pancreatitis. At all doses, camostat displayed markedly lower exposure 
(maximum serum concentration [C max] and area under the curve [AUC]) than the two 
metabolites. 4-GBA exposure appeared to be two to three times higher than that of FOY -
251. The area under the curve (AUC) for camostat levels did not increase with 
increasing doses, which is likely attributable to its rapid metabolism  FOY-251 exposure 
increased as the doses of camostat increased from 100 mg to the 200 mg, but not from 
the 200 mg to the 300 mg. 4-GBA exposure (both Cmax and AUC) increased as the 
doses of camostat increased from 100 mg to the 200 mg, but only the AUC slightly 
increased from the 200 mg to the 300 mg. There were no deaths or SAEs, and 3 out of 
18 subjects reported four treatment-emergent adverse events  (TEAEs). Two TEAEs 
were mild and two were moderate in severity, with both of the mild TEAEs considered by 
the investigator to be possibly related to camostat. They occurred in the same subject 
and were an episode of dizziness and one episode of hot flashes after a single dose of 
100 mg dose. Three of the TEAEs were reported following a dose of 100 mg camostat 
and the fourth TEAE was reported following a dose of 300 mg camostat. Laboratory 
hematology and clinical chemistry data showed no trends following camostat 
administration and there were no individual clinically significant abnormalities. Camostat 
had no significant effect on heart rate or blood pressure at any dose tested. The data 
from the first phase of this study suggested that the camostat is safe to administer to 
subjects with chronic pancreatitis as a single dose up to and including 300 mg.  
 
The second phase of Study NI03-001 is a randomized, double-blind, placebo-controlled 
study of three doses of camostat (100 mg, 200 mg, and 300 mg) administered TID for 28 
days for the treatment of chronic pancreatitis associated pain. This study is still ongoing 
and data remain blinded. Six SAEs (nephrolithiasis, diabetic ketoacidosis, abdominal 
pain [two events], pancreatitis, pancreatitis acute) have been reported from three 
subjects. All events required hospitalization and each event resolved. All events  were 
considered by the investigator as not related to study drug. All but one event occurred in 
the 28-day follow -up period after the last treatment. Two studies done as far back as 
1980 in subjects with pancreatitis reported that adverse effects were rar e (<3%), mostly 
mild, such as such as pruritus, increased thirst and appetite, and lightheadedness [7, 
16]. Camostat was given to six COVID patients requiring ICU level care and clinical 
outcomes were compared to five COVID patients requiring ICU level care who received 
hydroxychloroquine showing improvement of clinical status (Sepsis -related Organ 
Failure Assessment score and oxygenation) in the camostat treated but not the 
 264 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  hydroxychloroquine treated patients [17], [Camostat Investigator Brochure; June 11, 
2020]. Based on clinical experience to date, there are no expected safety concerns for 
camostat. The safety profile of this class of drugs is favorable. 
 
Several trials of camostat in COVID -19 are being conducted, for example, a multicenter 
study in Denmark: Subjects in this trial will receive two 100 mg pills of camostat or 
placebo three times daily (TID) for 5 days ([STUDY_ID_REMOVED]) . CAMELOT ( CAM ostat 
Efficacy vs. p Lacebo for Outpatient Treatment of COVID -19) is an ongoing multicenter, 
randomized, double-bli nd, placebo-controlled trial of the efficacy of camostat for the 
treatment of confirmed COVID -19 in outpatients at increased risk for severe illness 
comparing camostat to placebo four times daily (QID) for 14 days ( [STUDY_ID_REMOVED]).  
 
Rationale for 200 mg Q6H Dosing – Human PK/PD Studies and Safety Considerations  
Hoffmann et al. demonstrate that ACE -2 and TMPRSS2 are host factors for SARS- CoV-
2 entry and that camostat functions as an entry inhibitor [1]. The ED 50 for TMPRSS2 
inhibition is currently not know n. Continuous camostat levels in the blood may be 
necessary for the most effective antiviral activity and might be preferred as long as they 
are safe. Camostat is unstable in plasma and rapidly hydrolyzed to its primary metabolite FOY-251 and then to GBA, an inactive metabolite. 
 
Pharmacokinetic Studies  
There are two studies describing PK after oral administration and one after IV 
administration in humans: Hiraku et al. gave 200 mg or 600 mg camostat to 10 healthy 
males (n=5 per group) [18] ( Figures 2.1-2  and 2.1-3)
. Plasma levels were measured by 
HPLC and enzymatic (kallikrein) inhibition methods. Standard curves constructed for 
enzymatic inhibition showed similar activity between camostat and FOY -251. However 
only FOY -251 was detected in both dose groups. The T max for both doses was at 40 
minutes with a C max of 84 ng/mL and 393 ng/mL, respectively. After 600 mg, the half-life 
according to HPLC was estimated to be 73 minutes and enzymatic inhibition of kallikrein 
was suppressed to up 5 hours post dose, although as the figure below shows it was minimal at this time. It should be noted the enzyme inhibition method was established to 
estimate low levels of FOY -251. Midgley et al. reported data from their study where a 
dose of 40 mg camostat was administered intravenously over 12 hours to healthy volunteers [19]. The terminal half-life of FOY -251 was shown to decline rapidly and be 
biexponential with a half -life of 0.75- 1.4 hours, which agrees with the valu es reported by 
Hiraku et al.  [18]. 
 A second PK study was conducted in subjects with chronic pancreatitis. This was a single blind evaluation using oral doses of 100 mg, 200 mg, or 300 mg camostat and was carried out as the first phase of the TACTIC study ([STUDY_ID_REMOVED]). The three tables below show summary PK statistics for the parent compound and its two metabolites at the three doses of camostat administered to subjects with chronic 
pancreatitis.  
 
 265 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT   
Figure 2.1-2: Time course of plasma kallikrein inhibition after oral administration of camostat. 
 
Figure 2.1-3: Plasma levels of metabolite FOY -251 after oral administration of Camostat in 
healthy subjects (Dose: 600 mg per person, n = 5). 
 

 266 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  Table 2.1-1: Summary Pharmacokinetics for Camostat (NI-03) Administered as a Single Dose to 
Subjects with Chronic Pancreatitis  
 Table 2.1-2: Summary Pharmacokinetics for FOY -251 Following a Single Dose of 
Camostat Administered to Subjects with Chronic  Pancreatitis  
 
Table 2.1-3: Summary Pharmacokinetics for GBA Following a Single Dose of 
Camostat Administered to Subjects with Chronic  Pancreatitis  
 In general, the possible reasons for a decrease in Cmax and AUC at higher doses may include, but are not limited to, the drug's formulation and solubility limited absorption (saturated solubility 
of the drug in the GIT fluid), saturable transport system , saturation of protein-binding, or delay of gastric emptying due to nauseating effects at high doses. Because of limited data it is not possible to suggest an accurate half- life of FOY -251 at any dose from this study.  
 It is well accepted that after five half- lives there is no, or negligible amounts, of drug left in the 
blood stream. The measurable half- life of camostat is approximately 75 minutes  (based on 
Hiraku et al. [18]) and therefore five half-lives would be 6.25 hours. The approved dose of 
Camostat in Japan is 200 mg TID but taking that dose in the treatment of COVID -19 would only 
provide coverage for approximately 18-19 hours and not sustained 24 hours coverage. Since camostat has its active effects on host cells, interrupted levels are not expected to produce viral 
mutations and, based on the work from Hiraku et al ., it appears that enzymatic inhibition persists 
longer than there are measurable drug levels [18]. Nevertheless, troughs would represent a 

 267 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  period of reduced anti -viral activity. Therefore, a dose of 200 mg every 6 hours appears 
reasonable for optimal antiviral therapy. 
 Safety Data 
Given the proposed dose of 200 mg Q6H is 33% higher than the approved dose in Japan, 
there are several points to consider: In the TACTIC study, 25% of subjects are randomized to 300 mg TID. In a blinded  review of safety data after 100 subjects had completed the 28-day 
study, the Medical Monitor and the Principal Investigator both concluded there were no concerning trends in any of the groups (placebo, 100 mg, 200 mg, or 300 mg all given TID) 
and all the TEAEs were consistent with the pathology of chronic pancreatitis ( Figure 2.1-3
). In 
post-marketing safety data from Japan and blinded safety analysis of 100 subjects in TACTIC, there were no safety signals in persons with known renal or liver disease prior to enrollment. These data provide supportive evidence the drug is safe to administer up to 900 mg/day for up to 28 days. 
 
6 
5 
4 
3 
2 
1 
0 
Group A      Group B           Group C   Group D  
Nausea Vomiting  Abdominal  pain Pyrexia  Headache  Appetite loss 
Figure 2.1-4: Distribution of treatment emergent adverse events from a blinded safety 
analysis  of n=100 subjects with chronic pancreatitis enrolled in the NI-003 (TACTIC) 
randomized, controlled  trial. 
 
Data from pre-clinical studies show the Human Equivalent no- observed-adverse-effect- level 
(NOAEL) dose to be 780 mg/day. Based on data from rats, the equivalent NOAEL dose in 
humans is 1.7 g/day for a 70 kg individual. Ohkoshi et al. administered camostat to nine 
subjects for the prevention or recurrence of carcinoma of the mouth and treatment of 
terminal carcinoma [20]. The dose started at 600 mg/day and was increased up to 7.2 g/day, in some cases for up to 6 months. In only one case was the range of normal 
laboratory values exceeded, these abnormalities were attributed to reduced oral intake. The only other events noted were facial itching (n=1), facial impetigo (n=1), and slight alopecia 
(n=1 after 8 months of therapy). 
          
     
          
           
   
       
 
 268 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  In summary, based on existing pharmacokinetic data, we decided on an oral dose of 200 mg 
orally every 6 hours for investigations into the antiviral efficacy of camostat, to provide more steady drug levels. There is no anticipated increase in risk profile, since there are safety data from higher daily doses for longer periods of time (i.e., ≥28 days).  
 4.0 SELECTION AND ENROLLMENT OF PARTIC IPANTS 
 
Participants must meet inclusion and exclusion criteria from the master protocol, as well as the appropriate inclusion and exclusion criteria for the investigational agent included 
below.  
 
4.1 General Eligibility Criteria
 
 
4.1.1 Inclusion Criteria 
 
4.1.1.9 For participants who are of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or laboratory that has a CLIA certification or its equivalent, or by a point of care (POC)/CLIA-waived test.  
 
NOTE: Reproductive potential is defined as:  
• participants who have reached menarche 
• participants who have not been post -menopausal for at least 12 
consecutive months with follicle-stimulating hormone (FSH) ≥40 
IU/mL or 24 consecutive months if an FSH is not available  
• participants who have not undergone surgical sterilization (e.g., 
hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy)  
• participants with no other clinical conditions (such as anorexia nervosa) that could induce amenorrhea 
• participants not taking medications such as oral contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs) or chemotherapy that could induce amenorrhea  
• For individuals with permanent infertility due to an alternate medical cause (e.g., Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry. 
 
4.1.1.10  If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use effective contraception from study entry through 90 days after the last dose of treatment. This would include oral contraceptives, implanted 
contraceptives, intrauterine devices, and barrier methods. 
 269 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  NOTE: Participants not of reproductive potential are eligible without 
requiring the use of a contraceptive method. Participant-reported history is acceptable documentation of surgical sterilization and menopause.  
 
4.1.1.11 Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives. They are also strongly advised to inform their non-pregnant sexual partners of reproductive potential to use effective contraceptives from study entry through 90 days after study treatment. 
 
Participants with pregnant partners should use condoms during vaginal intercourse from study entry through 90 days after the last dose of the study treatment.  
Participants should refrain from sperm donation from study entry 
through 90 days after the last dose of study treatment. 
 
4.1.2 Exclusion Criteria  
 
4.1.2.11 Currently pregnant or breastfeeding  
 
4.1.2.12 Known severe liver disease prior to enrollment (defined as ALT or AST >5 times upper limit of normal or end stage liver disease with Child-Pugh Class C or Child-Pugh-Turcotte score ≥10)  
 
4.1.2.13 Known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m
2 or on renal -
replacement therapy such as peritoneal dialysis or hemodialysis)  
 
4.1.2.14  In phase II, meeting the protocol definition of being at “higher” risk of progression to hospitalization or death (see SCHEMA, POPULATION)
 
 5.0 INVESTIGATIONAL AGENT  
 5.1 Regimen, Administration, and Duration
 
 
5.1.1 Regimen and Duration 
 
Participants will be randomized to receive one of the following regimens:  Investigational Agent: Camostat, 200 mg orally every 6 hours for 7 days  
 
 270 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  OR 
 
Placebo for Camostat orally every 6 hours for 7 days only.  
 
5.1.2 Administration 
 
Camostat will be administered as two 100 mg tablets orally every 6 hours for 7 days.  
 
Placebo for camostat will be administered as two placebo tablets orally every 6 
hours for 7 days.  
 
Camostat and Placebo for camostat can be taken with a meal or a snack but this is not required. Doses of camostat and Placebo for camostat should be 
separated by 6 hours, ideally. If a dose is delayed, it should be taken as soon as 
possible, but no later than 4 hours after this dose was originally scheduled, and with a minimum of 2 hours between doses. If it is not possible to give a dose within 4 hours after the originally scheduled time, this dose should be omitted and recorded as such, and the next dose should be taken per schedule. Dosing should be stopped at the end of the 7 -day treatment period (i.e., any missed 
doses and remaining tablets at the end of 7 days should not be taken).  
 5.2 Formulation, Storage, and Preparation
 
 
5.2.1 Formulation and Storage 
 
5.2.1.1 Camostat  
 
Camostat is presented as a film -coated tablet. Each tablet contains 100 
mg of camostat. Tablets  will be packaged in high density polyethylene 
bottles containing 56 tablets per bottle. Camostat should be stored at 
controlled room temperature (15°C to 30°C, 59°F to 86°F). Avoid 
contact with moisture.  
 Camostat is described in further detail in the Investigator’s Brochure.  
 
5.2.1.2 Placebo for Camostat  
 
Placebo for camostat is identical in appearance to camostat. Placebo for camostat will be packaged in bottles containing 56 tablets per bottle. 
Placebo for camostat should be stored at controlled room temperature (15°C to 30°C, 59°F to 86°F) . Avoid contact with moisture. 
  
 271 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  5.2.2 Preparation 
 
One bottle of camostat or placebo for camostat will be dispensed to each study 
participant.  
 
5.2.3  Labeling of Investigational Agent and Placebo  
 A participant -specific label must be affixed on the camostat or placebo for 
camostat bottle prior to dispensing to the participant. 
 
Label each bottle with the following information: a. Participant identifier(s)  
b. Protocol number: ACTIV -2/A5401 
c. Investigational agent name and strength: Camostat 100 mg tablets or 
Placebo  
d. Total number of tablets dispensed: 56 tablets 
e. Dose, route, frequency, and duration: Take two tablets by mouth every 6 
hours for 7 days  
f. Date of dispensing  
g. Expiration date 
h. Storage information: Store at controlled room temperature, avoid contact with moisture 
i. Any additional information required by jurisdiction  
 5.3 Supply, Distribution, and Accountability
 
 
5.3.1 Supply  and Distribution  
 
Camostat and placebo for camostat will be provided by Sagent Pharmaceuticals, Inc. and will be available through the NIAID Clinical Research Products Management Center (CRPMC).  
 
5.3.2 Accountability  
 
The site pharmacist is required to maintain complete records of all investigational agents received from the NIAID CRPMC and subsequently dispensed. At US 
CRSs, all unused investigational agents must be returned to the NIAID CRPMC 
(or as otherwise directed by the sponsor) after the study is completed or terminated. At non-US CRSs , the site pharmacist must follow the instructions 
provided by the NIAID CRPMC for the destruction of unused investigational agents.  
 
 272 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  5.4 Concomitant Medications  
 
There are no known or expected drug-drug interactions with camostat and therefore 
there are no prohibited medications except as outlined in section 5.4  of the master 
protocol.  
 273 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XI II: INVESTIGATIONAL AGENT CAMOSTAT  6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Evaluations 
 
The schedule of evaluations provided below include all the evaluations in the master protocol and additional evaluations for this investigational agent. 
 
Table 6.1-1: Schedule of Evaluations Phase II  
Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Investigational Agent Administered   Days when doses 
taken           
Participant -Completed Adherence 
Assessment   Days 0 -7          
Staff Review of Adherence    X X          
Retrieval of Adherence Assessment     X          
Hematology   X  X  X  X    X  
Chemistry   X  X  X  X    X  
 274 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Pregnancy Testing  X  Whenever pregnancy suspected       
 275 ACTIV -2/A5401 
  FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XI II: INVESTIGATIONAL AGENT CAMOSTAT  6.3 Instructions for Evaluations  
 
6.3.9 Investigational Agent Administered  
The full course of camostat/placebo tablets (56 tablets) will be dispensed to the 
participant at the Day 0/Entry visit. The first dose of camostat/placebo (2 tablets) should be taken by mouth by the participant during the Day 0/Entry visit, with a sip of water, if preferred.   
Site staff should provide counseling to participants on the dosing 
requirements/schedule. Camostat should be taken per instructions in sect ion 5.0
. 
 
6.3.15 Laboratory Evaluations 
 
Hematology  
Participants will have blood drawn for complete blood cell count (CBC) with automated differential and platelet count.   At Entry/Day 0, blood should be drawn before study drug administration.   
Chemistry  
Participants will have blood drawn for liver function tests (ALT, ALP, AST, total bilirubin, direct bilirubin, and total protein), and renal function tests (albumin, BUN, creatinine, potassium, glucose, and sodium).  
 
At Entry/Day 0, blood should be drawn before study drug administration.  
 
Pregnancy Testing 
For participants of reproductive potential: Serum or urine β-HCG. (Urine test 
must have a sensitivity of ≤25 mIU/mL).  
 
Post-screening, pregnancy testing should be done any time pregnancy is 
suspected.  
 In the event of pregnancy occurring during the study, record pregnancy and 
pregnancy outcome per section 8.3
. 
 
6.3.18   Participant-Completed Adherence Assessment, Staff Review of Adherence, and 
Retrieval of Adherence Assessment  
 
Treatment adherence will be assessed by an adherence questionnaire (study 
medication log) completed by the participant on days when doses are ta ken.  
 
 276 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  The study medication log will be reviewed by study staff in person or remotely 
with each participant as per the SOE. The data will be recorded on an eCRF and log retrieved as described in the MOPS.  
 8.0 CLINICAL MANAGEMENT ISSUES 
 8.2 Management of Side Effects
 
 Camostat is expected to be well tolerated. Dose modification of camostat/placebo for camostat are not allowed. In the event of any treatment-related toxicity, the site 
investigator has the option to discontinue study treatment at their discretion, with 
reporting of premature treatment discontinuation as per section 8.1
.  
 
8.2.1 Overdose 
 
There is no known antidote for camostat overdose. In the event this occurs, the participant should be monitored for AE/SAE and laboratory abnormalities, and supportive care provided as indicated.  
8.3 Pregnancy
  
 
Since there are insufficient data regarding the use of camostat in participants who are pregnant, participants who are pregnant are not eligible for the study. Partic ipants of 
childbearing potential and participants who may impregnate their partners are required to follow the instructions for prevention of pregnancy provided in the protocol.  
 
If a participant becomes pregnant during the study (post-entry), camostat/placebo should 
be discontinued; study follow up will continue for the duration of the study.  
 At the end of the pregnancy, outcome and adverse events for participant and infant will be recorded on the outcome eCRF.  
8.4 Breastfeeding
 
 
Since there are insufficient data regarding the use of camostat in participants who are breastfeeding, participants who are breastfeeding are not eligible for the study.  
10.0  STATISTICAL CONSIDERATIONS  
 10.2 Outcome Measures
 
 
10.2.3 Secondary Outcome Measures 
 
10.2.3.13  Phase II: Percentage of the 28 doses of camostat or placebo for camostat that are missed, defined as the number of missed doses 
 277 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  divided by 28. 
 
10.2.3.14 Phase II: Number of missed doses of camostat or placebo for camostat.  
 
10.6 Analyses
 
 
10.6.3 Secondary Outcomes  
 
10.6.3.7 Adherence 
 
Analyses of adherence will be restricted to those randomized to 
camostat or placebo for camostat and will not include other pooled placebos as adherence is only assessed in those who took camostat or the matching placebo.  
 
Adherence will be evaluated by estimating the proportion of participants who missed at least four doses of camostat or placebo for camostat. In phase II, the camostat and placebo arms will be compared using binary regression. The percentage of missed dosed will be compared between study arms using a two-sided Wilcoxon test 
with 5% Type I error rate. 
 Additional details are provided in the camostat SAP.  
   
 278 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  16.0 REFERENCES 
 
1. Hofmann M, Kleine-Weber H, Schroeder S, et al. SARS -CoV-2 cell entry depends on 
ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:1-10. 
2. Kim TS, Heinlein C, Hackman RC, Nelson PS. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol 2006;26:965-75. 
3. Breining P, Frolund AL, Hojen JF, et al. Camostat mesylate against SARS -CoV -2 and 
COVID -19-Rationale, dosing and safety. Basic Clin Pharmacol Toxicol 2021;128:204 -12. 
doi: 10.1111/bcpt.13533.  
4. Foipan® package insert. Oral protease inhibitor FOIPAN Tablets 100 mg <Camostat mesilate tables>. Revised August 2009. http://www.shijiebiaopin.net/upload/product/201272318373223.PDF. Accessed 28 April 
2020. 
5. Kinami Y, Takita Y, Shinmura K, et al. Clinical effect of FOY -305 on pancreatitis. New 
Horiz Med 1980;12:108.  
6. Hirayama A, Izumiyama S, Itagaki Y, et al. Clinical investigation of FOY-305 against 
pancreatitis. New Horiz Med 1980a;12:245. 
7. Abe M, Hara Y, Kuwano K, et al. Use of FOY -305 for the treatment of pain attacks 
associated with chronic pancreatitis. New Horiz Med 1980;12:233. 
8. Fujiwara S, Iwamoto K, Miyazaki A. Clinical experience with oral FOY -305 for 
pancreatitis. New Horiz Med 1980;12:104. 
9. Hayawaka T, Noda T, Kondo T, et al. Effect of oral administration of FOY -305 on 
pancreatitis. New Horiz Med 1980;12:236. 
10. H irono T. Clinical Experience with oral anti -enzyme agent FOY -305 for pancreatitis. New 
Horiz Med 1980;12:215.  
11. Horiguchi Y, Nakajima S, Ito M. Clinical experience with FOY -305 for pancreatitis. New 
Horiz Med 1980;12:27. 
12. Kubota Y, Meada S. Experience with FO Y-305 in patients with pancreatitis. New Horiz 
Med 1980;12:211. 
13. Tanaka N, Tsuchiya R. Clinical efficacy of FOY-305 in pancreatitis. New Horiz Med 1980;12:223. 
14. Hirayama A, Izumiyama S, Itagaki Y, et al. Clinical analysis of FOY -305 for pancreatitis - 
a small double-blind clinical trial. New Horiz Med 1980b;12:253. 
15. Ramsey ML, Nuttall J, Hart PA, et al.; TACTIC Investigative Team. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC). Trials 2019;20(1):501. 
16. Ishii K, et al. Evaluation of the efficacy of FOY -305 in pancreatitis: multicenter, double-
blind study. New Horiz Med 1980;12:261. 
 279 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
APPENDIX XIII: INVESTIGATIONAL AGENT CAMOSTAT  17. Hofmann-Winkler H, Moerer O, Alt-Epping S, et al. Camostat mesylate may reduce 
severity of coronavirus disease 2019 sepsis: a first observation. Crit Care Explor 2020;2(11):e0284. PMID: 33225308. 
18. Hiraku S, Muryobayashi K, Ito H, et al. Absorption and excretion of camostat orally administered to male rabbit and healthy subject. Iyakuhin Kenkyu 1982;13:756-65. 
19. Midgley I, Hood AJ, Proctor P, et al. Metabolic fate of 14C -camostat mesylate in man, rat 
and dog after intravenous administration. Xenobiotica 1994;24:79-92. 
20. Ohkoshi M, Oka T. Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy) -phenylacetate] methanesulfate for 
prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma. J Maxillofac Surg 1984;12:148-52.  
 
 280 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIV: SAMPLE INFORMED CONSENT FOR STUDY DRUG CAMOSTAT  
 APPENDIX XIV:  SAMPLE INFORMED CONSENT FOR STUDY DRUG CAMOSTAT 
 
No participants will be enrolled in version 7 or later of this protocol for this investigational agent. 
Consent retained for recording purposes.  
 One of the study drugs that you might be assigned to in this study is camostat for 7 days or the placebo for camostat for 7 days.   Camostat is a type of drug called a protease inhibitor. It blocks certain enzymes, including an 
enzyme (called TMPRSS2) that sits on human cells and that the novel coronavirus that causes 
COVID -19 uses to enter the cells. We want to see if camostat will prevent coronavirus from 
entering cells and thereby reduce the risk of progression to serious disease and death.  
 Camostat is made in a laboratory.  
 Your assignment is random, like the flip of a coin. You will be told about all the study drugs you may be assigned to in this study. If only one study drug is available, you will have an equal chance of receiving the study drug or placebo. If two study drugs are available, you will have a 2:1 chance of receiving a study drug or placebo. If three study drugs are available, you will have a 3:1 chance of receiving a study drug or placebo, and so forth. You will not be able to choose 
your group (study drug)., and neither you, your study doctor, nor the study staff at your s ite will 
know whether you are receiving the study drug or placebo. 
 The United States Food and Drug Administration (FDA) has not approved camostat for general 
use by the public. However, it has been approved in other countries and has been used there 
for decades for other diseases. We have told the FDA about this study and they have given us 
permission to conduct this study.  
 At this time, only the first  part of this study (as described in the main consent) is enrolling 
participants  
 
ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE CAMOSTAT OR 
PLACEBO?  
Screening 
• If you can become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample for a pregnancy test. You cannot receive camostat or placebo if you are pregnant. 
 
Entry Vis it  
• You will take the first dose of camostat /placebo. Camostat/placebo is in the form of tablets. 
Each dose consists of 2 tablets taken at the same time. After the visit, you will continue to take 2 tablets every 6 hours, by mouth, on your own. 
 
 281 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIV: SAMPLE INFORMED CONSENT FOR STUDY DRUG CAMOSTAT  Study Drug Dosing and Requirements Days 0-6 
• You will take camostat/placebo every 6 hours for 7 days. Camostat/placebo can be taken 
with food but this is not required. The doses must be separated by at least 2 hours. The site staff will discuss the timing of doses in detail with you. 
 
• You will record whether or not you took all doses of the study drug (camostat/placebo) each 
day for 7 days in a Study Medication Log.  
• The staff will review your Study Medication Log with you.  
 
Study Visit Day 3 
• The staff will review your Study Medication Log with you.  
 
Study Visits on Days 7 and 28  
• You will have blood drawn. This blood will be used for the following tests:  
o routine safety tests (liver and kidney tests and blood counts)  
• The staff will review your Study Medication Log with you and collect the log (Day 7)  
 
Study Visits on Weeks 12 and 24 
You will be asked whether you have had any new symptoms or clinical events since your last 
visit  
 
Study Visits on Weeks 36, 48, and 72 
• You will be contacted by phone by the study team to assess whether you have had any new symptoms or clinical events since your last visit  
• You will answer questions about any potential COVID -19 related symptoms or conditions 
you have experienced  
  HOW  LONG  WILL I BE IN THIS  STUDY? 
 If you are assigned to camostat or placebo for camostat, you will be in this study  for 72 weeks  
 
 
WHAT ARE THE RISKS OF CAMOSTAT?  
 It is not known if this study drug will help your disease or if it will make it worse. We do not know all the possible risks from treatment with camostat. Camostat is an approved drug for 
pancreatitis and postoperative reflux esophagitis in Japan and is generally considered safe for 
these indications. The dosage of camostat for COVID-19 is higher than that used for pancreatitis (800 mg per day for COVID-19 compared to 600 mg per day for pancreatitis and 
300 mg per day for postoperative reflux disease). In another study, a daily dose of 900 mg of camostat was well -tolerated. 
 
Common side effects  (reported in 1 -4 per 1000 patients)  include: 
• rash 
 282 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIV: SAMPLE INFORMED CONSENT FOR STUDY DRUG CAMOSTAT  • itching  
• nausea  
• abdominal (stomach) bloating  
• abdominal discomfort 
• diarrhea 
• abnormal liver function tests  
• headache  
 
While rare side effects include:  
• allergic reactions  
• decreased platelets (a component of blood that helps with clotting)  
• increas ed potassium levels in blood  
 Although data from studies in animals suggest that camostat could be beneficial for patients with COVID- 19, the risks and potential benefits to these patients are unknown. 
 There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are
 
taken with the study drugs. For your safety, you must  tell the study  doctor  or nurse about all 
medications  you are taking before you start the study.   
 
 
ARE THERE  RISKS RELATED TO PREGNANCY  AND BREASTFEEDING? 
 
Pregnancy  
Since there are no data regarding the use of this study drug in people who are pregnant, you 
are not eligible to receive this study drug if you are pregnant.  
 The study drug may  involve risks to you (or to the embryo or fetus, if you or your partner
 become 
pregnant), which  are currently  unforeseen.  
 If you are engaging in sexual activity that could lead to pregnancy, you must agree to use effective contraception from the time you start the study through 90 days after the study drugs are last taken. This would include oral contraceptives, implanted contraceptives, intrauterine devices, and/or barrier methods. 
 
If you are engaging in sexual activity that may lead to pregnancy in your partner, you must agree to either remain abstinent or use male contraceptives. You are also advised to inform 
your non-pregnant sexual partners that can become pregnant to use effective contraceptives from the time you start the study through 90 days after you last take the study drug.  
 If you have a pregnant partner you should use condoms during vaginal intercourse from the time you start the study through 90 days after you last take the study drug.  
 283 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XIV: SAMPLE INFORMED CONSENT FOR STUDY DRUG CAMOSTAT  If applicable, you should refrain from sperm donation from the time you start the study through 
90 days after you last take the study drug.  If at any point during the study you think you may be pregnant, you should let the staff at your 
site know so that a pregnancy test can be done.  
 
Let your doctor know immediately if you become pregnant. If you become pregnant while on the study, you will be asked to stop the study drug, but you will continue to have study visits and the study staff would like to obtain information from you about the outcome of the pregnancy (even 
if it is after your participation in the study ends).  
 
Breastfeeding 
It is not known if this study drug is safe to use in people who are breastfeeding. You are not 
eligible to receive this study drug if you are breastfeeding.
 284 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS  
(TC BOVINE -DERIVED)  
APPENDIX XV: SAB-185 ANTI-SARS-COV-2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE-DERIVED) 
 
Information/evaluations noted in this agent-specific appendix are IN ADDITION to those 
presented in the master protocol. Section numbering aligns with the master protocol. 
  2.0 INTRODUCTION  
  
2.2 
Rationale 
 
Antibodies as Therapies  
Sera obtained from persons or animals who recovered from a particular infection has 
shown prophylactic and therapeutic potential for a variety of infections, and Emil von 
Behring won the Nobel Prize in 1893 for his work on use of immune serum from the 
blood of infected animals to provide immunity to diphtheria [1]. Currently, hyperimmune 
human sera immunoglobulin is still used to treat many viral infections including 
cytomegalovirus (CMV), respiratory syncytial virus (RSV), hepatitis A virus (HAV), 
hepatiti s B virus (HBV), and rabies [2] . Unfortunately, heterologous sera from infected 
animals was associated with a variety of complications including serum sickness and 
hypersensitivity, which significantly limited its usefulness clinically [3]. 
 
The limitations of polyclonal antibodies continue to be cost and that these antibodies are 
perishable, require refrigeration, and must be administered parenterally; however, their 
use may still be useful in the outpatient setting, as one dose often stays in the 
therapeutic range for months, potentially allowing an entire treatment course with a 
single administration.  
 
Investigational Agent  
Transchromosomic (Tc) bovines may be useful in the production of fully human polyclonal IgG antibodies to fight SARS-CoV -2 infection. The genome of Tc bovines 
contains a human artificial chromosome (HAC), which comprises the entire human Ig gene repertoire (human Ig heavy chain [IgH] and human kappa light chain) that reside on two different human chromosomes (i.e., the IgH locus from human chromosome 14 
and the immunoglobulin kappa locus from human chromosome 2). This system in the Tc bovine uses the genetic information in the HAC provided by the immunoglobulin gene 
repertoires to generate diverse fully human polyclonal antibodies (pAbs). The collected 
plasma with Tc pAbs are passed through an affinity chromatography column, first using 
an anti -human IgG kappa affinity column, which captures Tc pAbs and removes residual 
non-hIgG and bovine plasma proteins . 
 Through this process, SAB has generated a number of useful human pAbs that can be 
used as therapy for infectious agents, like SARS -CoV -2. Antibody products developed 
through this method have demonstrated in vivo  efficacy against a range of viral infections, 
 285 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) including, Middle Eastern Respiratory Syndrome virus (MERS -CoV),  Ebola, Zika, and 
influenza in a variety of animal models including rodents, ferrets , and non-human 
primates. For SARS -CoV-2, SAB has developed SAB-185, which will use an antigen 
production system that is non-mammalian and non-egg based that has been shown to be 
safe and used in previous clinical trials of SAB -301 and SAB -136. Enzyme linked 
immunosorbent assay indicates that SAB -185 neutralizes not only the RBD but also the 
full-length spike protein. Specifically, SAB -185 is a human polyclonal antibody 
preparation consisting of purified human immunoglobulin (hIgG) molecules targeted 
against SARS-CoV -2 spike protein. This full human pAbs (hIgG/hIgκ) was produced in Tc 
bovines after vaccination with suitable viral antigens. This vaccination schedule was conducted with a pDNA vaccine that expressed wild-type SARS -CoV -2 spike protein, 
followed by additional immunizations with a recombinant spike protein from SARS -CoV-2 
produced in insect cells.  
 
After hyperimmunization with pDNA and purified protein, SAB-185 was purified from the 
vaccinated Tc bovines, which can produce up to 15 g/L of IgG antibodies in their plasma (similar to humans which have 7-16 g/L IgG). Tc bovine plasma is then collected via 
plasmapheresis. After collection plasma is pooled, fractionated by caprylic acid and clarified by depth filtration in the presence of filter aid. The collected plasma with Tc pAbs are passed through an affinity chromatography, first using an anti -human IgG  
kappa affinity column, which captures Tc pAbs and remove residual non- hIgG and 
bovine plasma proteins. To further remove residual IgG molecules that contain a bovine heavy chain, the next purification is conducted by passing the plasma through an anti -
bovine IgG heavy chain specific affinity column. The Tc pAb fraction is then subjected to 
a Q Sepharose chromatography to further reduce impurities. This purification process is 
similar to other IVIG products in that there is no specific purification for target specific antibodies. The purified plasma had extremely high Plaque Reduction Neutralization 
Test (PRNT) titers against SARS -CoV -2.  
 
There are several advantages to bovine production of antibodies. First is the size of the animals, which enables collection at least 30 liters of plasma each month from the 
animals used to produce SAB-185. Being ruminants, these animals have robust immune systems that can produce 10-20 grams of IgG per liter of plasma. Finally, SAB is able to hyperimmunize these animals as many as 12 times which optimizes antibody expression and potency. SAB maintains a supplemental herd of mature and non-immunized animals 
that could be immediately used to produce antibodies
. Additionally, SAB is proactively 
and continually replenishing the herd f or future needs.  
 
As described below and in the investigational brochure, SAB -185 was tested both in vitro 
and in vivo to evaluate its potency and safety for clinical trials. Further, nonclinical 
studies were performed including a pharmacology study in ham sters and two safety 
studies (tissue cross reactivity study in normal human tissues and a ferret study). 
Additional nonclinical studies for efficacy are underway. SAB Biotherapeutics has submitted a general information update to Investigational New Drug (IND ) #023187 on 
 286 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 24 November, 2020 that includes clinical summary of Phase I study results of single 
infusion doses of SAB-185 given to healthy volunteers ( study SAB-185-101). Of the data 
available as of 13 November, 2020, there have been no serious adverse events (SAEs) recorded to date. An analysis of treatment emergent adverse events (TEAEs) showed 
that most events were not related and were mild or moderate in severity. There were no 
clinically meaningful changes in any laboratory safety parameter and no c linically 
meaningful changes in vital signs. Single infusion doses of SAB -185 of up to 25 mg/kg 
appear to be safe and well tolerated in healthy participants. Multiple doses of 25 mg/kg and single doses of 50 mg/kg were also studied but were not included in  the interim 
analysis.  
 Toxicity  
Tissue Cross -Reactivity : To evaluate potential cross reactivity of biotinylated SAB-185 to 
human tissue, cryosections from a full panel of cryosections of normal human tissues (at 
least 3 donors per tissue) were conducted after perfusion with biotinylated SAB -185 
(SAB-185-Bio) at two concentrations (35 and 20 µg/mL). Additionally, as an antibody 
control, the SAB-185 was substituted with a biotinylated polyclonal human IgG antibody, 
which has a different antigenic specificity  from that of the SAB -185. Also, assay controls 
were produced by omission of the test or control articles from the assay.  
 
These experiments found SAB -185- Bio produced weak to strong staining of the positive 
control material (SARS- CoV-2 RBD- His UV -resin spot slides [spotted at 50 μg/mL]) at 
both staining concentrations tested, but the SAB -185-Bio did not react with the negative 
control material (human hypercalcemia of malignancy peptide, amino acid residues 1-34 
UV-resin spot slides [spotted at 50 μg/mL]) at either staining concentration. Overall, 
staining with SAB -185-Bio in the panel was restricted to the cytoplasm of rare to very 
rare islet cells in the pancreas, and this staining reactivity was cytoplasmic. Generally, 
antibody binding  to cytop lasmic sites in tissue cross-reactivity studies is considered of 
little to no toxicologic significance because of the limited ability of antibody drugs to 
access the cytoplasmic compartment in vivo [4, 5]. The control antibody did not react 
with either the positive or negative control materials, and there was no staining of the 
assay control slides.  
 
Antibody Dependent Enhancement (ADE): ADE occurs when a viral infection can 
become more severe or lethal after vaccination or after administration of antibodies 
against the virus. This phenomena is well documented in dengue and RSV. It seems unlikely to occur in SARS -CoV -2 infection but the process remains poorly understood 
[6]. To this end, the UPITT investigated the potential  of SAB-185 to cause severe 
disease in their ferret model  of mild disease after infection with SARS-CoV-2. Four 
cohort groups  of (N=3)  were  infused with 1.1, 0.6 and 0.1 mg/kg of SAB-185 (one log 
difference in dose) or normal  saline 15 hours  before infection  with low-passage of the 
Munich s train of SARS- CoV-2 and then followed for 14 days. These doses  were   
 287 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) selected to estimate non-neutralizing SAB-185 antibody  concentrations  that would occur  
after multiple half-lives  after a human received 5 to 20 mg/kg of SAB-185. 
 
Compared to control  ferrets, these treatments  of the WT ferrets  did not cause  acute 
toxicity,  any mortality  or significantly  enhanced disease over the 14-day  follow -up 
regardless  of dose. All animals  exhibited mild disease with no statistically  significant 
increase in any clinical or virological  parameter  measured, though individual  animals  
demonstrated considerable variance  in measured parameters. There was a non-
significant trend for increased fever duration in the 0.6 and 1.1 mg/kg dosed groups, but 
this was only one degree of fever response and likely  detected only because of the high 
sensitivity  of the instrumentation used  and the continuous  nature of the monitoring. It 
should be noted, however, that animal  models  cannot absolutely  predict  human 
experience for the potential  for ADE after antibody  treatment, like SAB-185. 
 
There were no test article-related effects noted on clinical signs, body weights, body 
weight gains, food consumption, ophthalmology, gross necropsy findings, organ weights, or histopathologic examinations. There were also no test article-related unscheduled deaths. However, leukocytes were down to 0.82X: lymphocytes (0.74X), monocytes (0.61X), eosinophils (0.50X), basophils (0.57X), and large unstained cells (0.73X), as well as increased neutrophils (1.2X) were noted in test article -treated female ferrets  on 
Day 1 when compared to concurrent controls. These differences  improved, but most  
were  still present on Day 3 of the study, but by Day 50, these values  were  similar  to that 
of concurrent controls. Further, d ecreased activated partial  thromboplastin time (0.76X 
and 0.80X) was observed in test article-treated females  on Day 3 and Day 50 when 
compared to concurrent controls  and globulin was increased 1.59X  with associated 
decreased albumin to globulin ratio was noted in test article -treated males  and females  
on Day 3 when compared to concurrent controls.  These differences  were  also not noted 
on Day 50. 
 
In vi
vo Activity and Justification for Dose of SAB -185 
Hamsters : To evaluate in vivo efficacy, SAB -185 (from Lot #PD2001144SP, which was 
also used in the Phase 1 and 1b studies) was initially evaluated to treat hamsters infected with SARS -CoV-2 at the University of Pittsburgh (UPITT). COVID -19 from 
SARS- CoV-2 infection in the UPITT WT hamster model is rapidly progressive, non-
lethal, but with moderate to severe symptoms and is characterized by weight loss, fever, pneumonia, variable qRT-PCR viral load in the oropharynx and observable signs and 
symptoms of disease measured by clinical scoring (hunching, sneezing, etc.). 
Measurement of physiological status used inserted temperature probes, plethysmography, frequent SARS -CoV -2 qRT-PCR of oropharyngeal samples and 
tissues at euthanasia, and clinical scoring of symptoms over a 14-day period to capture acute and mid-term disease in the UPITT hamster model. Four cohorts of hamsters (n = 8 or 9) were treated with 100 mg/kg or 50 mg/kg of SAB-185, 50 mg/kg of negative 
control Tc bovine immunoglobulin, or an equivalent volume of PBS. Of note, the dose 
100 mg/kg is twice the dose contemplated for the phase 1 clinical trial, and the human 
 288 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) equivalent dose (HED) of 100 mg/kg and 50 mg/kg corresponds to approximately 13.5 
mg/kg and 6.75 mg/kg in a human recipient according to standard body surface area adjustments [7]. 
 
The study found that treatment with 100 mg/kg of SAB -185 prevented weight loss with 
minimal illness as compared to PBS control, 50 mg/kg of SAB -185, and Tc bovine 
immunoglobulin. Also, treatment with 50 mg/kg of SAB -185 reduced weight loss and  
clinical illness as compared to control with PBS. The treatment of the hamsters with 50 mg/kg of Tc bovine immunoglobulin also reduced weight loss and clinical illness as 
compared to the PBS control cohort (see Figure 2.2-1
). It is felt that this effect may be 
due to the ability of non- specific IgG to supplement the host’s immune system. In 
summary, this study indicates that SAB -185 treatment reduces the severity of COVID -19 
disease in a dose dependent manner, and 50 mg/kg dose in hamsters represents a HED 
of 6.76 mg/kg and a 100 mg/kg dose represents a HED of 13.51 mg/kg. 
 
Figure 2.2-1 . Hamster Challenge Weight Loss  
 Recently, SAB -185 was evaluated in an additional non-clinical efficacy study using the 
same lot of drug product (Lot #PD2005220SP) proposed for use in the ACTIV -2 trial. 
This study, titled “Evaluate the Therapeutic Efficacy of Operation Warp Speed (OWS) 
SARS- CoV-2 Specific Antibody Therapeutics in Golden Syrian Hamsters,” was  
performed at Integrated Research Facility at the National Institute of Allergy and Infectious Disease (IRF NIAID).  
 

 289 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) SAB-185 was investigated in hamsters, which were treated with 10mg/kg and 50mg/kg 
24 hours prior to intranasal exposure to SARS- CoV-2. There were indicators of efficacy 
in both groups. Hamsters treated with 10mg/kg and 50mg/kg demonstrated reduced disease burden; less efficacy was observed in the lower dose of treatment as 
determined by evaluation of weight loss and pathology of the lungs when compared to 
other infected groups. Viral load from lungs and nasopharyngeal swabs are pending.  
 Based on this non-clinical data (using the same lot of product proposed for use in the ACTIV -2 study) in hamsters and using a body surface area (BSA) calculation, the 
estimated efficacious dose in humans would be to 1.35mg/kg to 6.76mg/kg. If no BSA calculation is used, the estimated efficacious dose would be between 10mg/kg to 50mg/kg.  
Rabbits : Multiple in vivo  studies have been conducted for agents manufactured in the 
same platform as SAB-185, which is proposed for use in ACTIV-2. Although different target viral antigens were used in the upstream process of the hyperimmunization of the animals, these products were made in the same way as SAB -185. An anti -Influenza 
Human Immunoglobulin, SAB -176, was used in a single dose study in rabbits to 
determine the potential toxicity for influenza treatment (IND# 19714). This study found that administration of SAB -176 once by IV infusion was well tolerated in rabbits at levels 
of 362.65 and 725.30 mg/kg/day. Administration of SAB -176 as a single IV dose (0, 
362.65, or 725.30 mg/kg) did not result in any attributable mortality, macroscopic or microscopic changes at Day 3 or Day 50. Further, no target organ impairment was observed. Based on these results, the no observed adverse effect level was considered to be 725.30 mg/kg/day or higher. Thus, based on body surface area calculations, the 
725.30 mg/kg/day in rabbits is a human equivalent dose of approximately 235 mg/kg, 
and using a five times safety factor, the maximum recommended starting dose would be 
approximately 47 mg/kg. Further, the proposed starting doses for SAB -185 are 3,840 
Units/kg and 10,240 Units/kg, which correspond to a protein dose of 7.5 mg/kg and 20 mg/kg, respectively. This represents a 31.3 times safety factor for the 3,840 Units/kg 
dose and an 11.75 times safety factor for the 10,240 Units/kg  dose from the human 
equivalent dose, which was well tolerated in this study.  
 
Humans: SAB-185 is currently being evaluated in two clinical studies, a Phase 1 study of 
28 healthy volunteers and a Phase 1b study of 21 patients positive for COVID -19. To 
date 20 healthy volunteers and 15 patients positive for COVID -19 have received 
infusions of SAB-185. There have been no reports in either study of serious drug-related reactions or any adverse events requiring discontinuation of therapy.  
 An interim analysis was conducted for study SAB -185-101, “A Phase 1, Randomized, 
Doubl e-Blind, Placebo- Controlled, Single and Multiple Ascending Dose Study of SAB -
185 in healthy subjects.” This analysis evaluated 28 subjects for 14-day safety, 
immunogenicity (currently by rheumatoid factor), and 8-day pharmacokinetic (PK) data 
following the  final dose time point.  In summary, there have been no SAEs recorded to 
 290 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) date. An analysis of TEAEs showed that most events were not related and were mild or 
moderate in severity. There were no clinically meaningful changes in any laboratory safety parameter and no clinically meaningful changes in vital signs. Single infusion 
doses of SAB -185 of up to 25 mg/kg appear to be safe and well tolerated in healthy 
participants.  
 Other SAB Platform Products  
A Phase 1 clinical study was conducted in healthy participants with a product produced in the same platform as SAB -185, SAB -301 (an anti -MERS -CoV Human Immunoglobulin 
[8]. It is believed that SAB -185 will have a similar safety and PK profile as SAB -301. This 
trial was a Phase 1 double-blind, placebo-controlled, single dose escalation study conducted in six cohorts of 3-10 participants. Cohorts received 1, 2.5, 5, 10, 20, and 50 mg/kg of SAB -301 or placebo on Day 0, and were followed by clinical, laboratory, and 
pharmacokinetic assessments on days 1, 3, 7, 21, 42 and 90 ([STUDY_ID_REMOVED]). Ninety -
seven AEs were reported: 64 AEs occurred in 23 of 28 participants (82%) receiving SAB-301 (mean 2.3 AEs per participant), and 33 AEs occurred in 10 of 10 participants 
(100%) receiving placebo (mean 3.3 AEs per participant). The most common AEs were 
headache, albuminuria, elevated creatine kinase, and common cold, and occurred in similar proportions as placebo.  
 
Pharmacokinetics : While PK data from SAB -185 is still blinded/being analyzed, 
preliminary data indicates similari ty to SAB-301 PK. Pharmacokinetic  analysis  of SAB-
301 found nearly  linear, but slightly  less than dose -proportional  increases  in PK 
parameters  of Cmax  and AUCinf  over the 20-fold range of doses  from 2.5 to 50 mg/kg. 
Concentrations  after infusion followed a bi-exponential  decline and best fit a two-
compartmental  PK model. Average terminal  elimination half-life  (T½) was ~ 28 days, 
which  is within  the range of a typical  antibody  in humans, across  all dose  cohorts, except 
the 1.0 mg/kg cohort. Specifi cally,  PK data from the 1 mg/kg cohort was not utilized as a 
terminal  phase because multiple concentrations  were  below  the limit of assay detection 
(15.625 µg/mL). Limited  preliminary  data from the ongoing Phase 1b study  of SAB-185 
(N=3  available from cohort 1) indicates  a T½ of 25.3 days, Cmax  of 371.0 µg/mL  
(40.7%), and AUCinf  of 8779.6 µg*day/mL. The estimated volume of distribution is 40.9 
(77.3%) mL/kg with a clearance of 1.1 (95.3%) mL/day/kg.  
 
Based on the PK and PK/PD assessment and the available nonclinical and clinical safety profile detailed above, the doses of SAB-185 chosen for study in ACTIV -2 are 
3,840 Units/kg and 10,240 Units/kg. The 10,240 Units/kg dose was selected to minimize potential risk of underdosing and thus failing to detect an efficacy signal. Further, there are no significant safety concerns about using the proposed dose, as side effects in antibody therapy are not generally dose dependent.  
 291 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 3.0 STUDY DESIGN  
 
3.2. Overview of Study Design for Graduation from Phase II to Phase III  
 
Since there will be two doses  of the same  agent (SAB-185 3,840 Units/kg and 10,240 
Units/kg), an interim  graduation analysis  will be conducted using the same  criteria 
outlined in section 3.2 of the master protocol  when  50% of participants  receiving each  
dose (~55 participants  for each dose)  plus shared placebo have completed 7 days  of 
follow -up and have the required data available in the database. In this analysis,  the 
DSMB  will assess whether the doses  have met the graduation  criteria.  
 
If either dose of SAB-185 meets  the pre-specified antiviral  or clinical  efficacy  graduation 
criteria and the safety  criteria at the interim  analysis  of ~55 participants, a small,  fire-
walled group from the SAB company  will review  the unblinded results  of phase II that 
were  reviewed by the DSMB. Based  on this review  and the needs  of the company, the 
group may recommend to the TOC  that a dose that met graduation criteria move  into 
phase III. If the  lower dose is chosen  to graduate  into phase III, then no more  
participants  will be enrolled into phase II. This  is because if the lower dose of SAB-185 
graduates  to phase III, then 110 participants  will have already  received  that dose of 
SAB-185 or higher. If the  higher  dose  of SAB-185  is chosen to graduate to phase III, 
enrollment into the low dose group will stop, but enrollment to the higher  dose in phase II 
will be completed (to approximately  110 participants  on the higher dose and a similar  
number in the placebo control  group). The DSMB  and/or  TOC  may also recommend that 
both doses  complete enrollment prior to selecting a dose for graduation to phase III. If 
this occurs, the DSMB  will review  complete phase II safety  data through day 28 to 
ensure an acceptable safety  profile before enrollment in phase I II may  begin. If 
graduation of a dose is determined at any time, further efficacy  evaluations  for 
graduation may not be pursued.  
 
If neither dose of SAB -185 meets the graduation criteria based on the interim graduation 
analysis, then enrollment will continue for both doses, and a final graduation analysis will 
be conducted when 220 participants assigned to each dose or concurrent placebo have 
completed their Day 7 evaluations and have the required data available in the database. If more than one dose has met graduation criteria to phase III after full enrollment, a similar review process involving the firewalled SAB company group and TOC will occur.  
3.4 Study Design Considerations Specific to the Phase III Evaluation of SAB -185 
 Phase III evaluation of SAB -185 was initiated under protocol version 7 in a non -
inferiority comparison of SAB -185 to an active control of casirivimab plus 
imdevimab. While enrollment was ongoing, the Omicron variant of SAR -CoV -2 
became highly prevalent. In vitro data suggested that c asirivimab plus imdevimab 
would be ineffective against this variant, and FDA authorization for emergency 
use of this regimen for treatment of COVID -19 due to non-susceptible SARS-C oV-2 
 292 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) variants (such as Omicron)  was withdrawn. Because of this, enrollment into the 
study was paused pending development of this version of the protocol, w hich 
replaces the non-inferiority evaluation of investigational agents compared with 
casirivimab plus imdevimab with a placebo-controlled superiority design allowing 
for the additional use of SOC treatments, if available, in both arms.  
 
Over 700 participants were enrolled under protocol version 7 and randomized to 
SAB-185 or c asirivimab plus imdevimab. These participants can be divided into 
two subpopulations: (1) participants who are definitely or very likely infected with 
the Omicron SAR S-CoV-2 variant (“Omicron subpopulation” ); and (2) participants 
who are definitely not, or likely not infected with the O micron variant (“non-
Omicron subpopulation” ). These two subpopulations are defined in more detail in 
section 10.1.1  of this appendix.  
 
Based on the in vitro data, in the Omicron subpopulation, the combination of 
casirivimab plus imdevimab is thought to have no effect and so is considered 
functionally to be a placebo. Therefore, for the purposes of evaluating SAB -185 
under this version of the protocol, the Anal ysis Population will comprise the 
Omicron subpopulation enrolled under protocol version 7 as well as the 
population enrolled under this version of the protocol that is randomized to SAB -
185 or its appropriate placebo control group (in both, restricted to those who 
receive study product) . The planned enrollment for this Analysis Population 
combining the O micron subpopulation enrolled under protocol version 7 and 
enrollment under this version of the protocol is 1200 participants. 
 
Follow -up of the non-O micron population enrolled under protocol version 7 will 
continue. In this subpopulation, the combination of c asirivimab plus imdevimab is 
expected to be effective. Analysis of outcomes from that subpopulation will be 
undertaken separately following the plans laid out in protocol version 7. It is 
recognized that there will be limited power to assess non-inferiority with respect 
to the hospitalization/death primary outcome measure. 
 4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  
 4.1 General Eligibility Criteria
 
 
4.1.1 Inclusion Criteria 
 
 [subsequent numbering was not updated] 
 
4.1.1.10 For participants of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or 
laboratory that has a CLIA certification or its equivalent, or by a point of 
care (POC)/CLIA-waived test.  
 293 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED)  
Reproductive potential is defined as: 
• participants who have reached menarche 
• participants who have not been post -menopausal for at least 12 
consecutive months with follicle-stimulating hormone (FSH) ≥40 IU/mL or 24 consecutive months if an FSH is not available  
• participants who have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy)  
• participants with no other clinical conditions (such as anorexia nervosa) that could induce amenorrhea 
• participants not taking medications such as oral contraceptives, hormones, gonadotropin -releasi ng hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs) or chemotherapy 
that could induce amenorrhea 
• For individuals with permanent infertility due to an alternate 
medical cause (e.g., Mullerian agenesis, androgen insensitivity), investi gator discretion should be applied to determining study 
entry.  
 
4.1.1.11 If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use effective contraception for 24 weeks after investigational agent is administered. This would include oral contraceptives, implanted contraceptives, intrauterine devices, and barrier methods. 
 
NOTE: Participants not of reproductive potential are eligible without requiring the use of a contraceptive method. Participant-reported history is acceptable documentation of surgical sterilization and menopause.  
4.1.1.12 Participants that engage in sexual activity that may lead to pregnancy 
in their partner must agree to either remain abstinent or use male 
contraceptives. They are also strongly advised to inform their non-
pregnant sexual partners of reproductive potential to use effective contraceptives for 24 weeks after investigational agent is administered. 
 
Participants with pregnant partners  should use condoms during vaginal 
intercourse through 24 weeks after investigational agent administration.  Participants should refrain from sperm donation for 24 weeks after 
investigational agent administration.  
 
 294 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 4.1.1.13  In phase III, meeting the protocol definition of being at “higher” risk of 
progression to hospitalization or death (see SCHEMA, POPULATION  
for definition of “higher” risk ). 
 
4.1.2 Exclusion Criteria  
 
4.1.2.11 Currently pregnant or breastfeeding  
 4.1.2.12  In phase II, meeting the protocol definition of being at “higher” risk of 
progression to hospitalization or death (see SCHEMA, POPULATION
) 
 
5.0 INVESTIGATIONAL AGENT  
 5.1 Regimen, Administration, and Duration
 
 
Two doses of SAB-185 will be studied in this study. Each dose is considered separately, as its own agent group. 
 
Participants may be randomized to receive either SAB -185 (3,840 Units/kg)/Placebo or 
SAB-185 (10,240 Units/kg)/Pl acebo.  
 
5.1.1 Regimen and Duration 
 
5.1.1.1 SAB-185, 3,840 Units/kg or Placebo (Phase II and Phase III)  
 
Investigational Agent: SAB-185, 3,840 Units/kg, to be administered 
intravenously (IV) for one dose at study Entry/Day 0.  
 OR 
 Placebo for SAB-185: 0.9% Sodium Chloride Injection, USP, to be 
administered IV for one dose at study Entry/Day 0. 
 
5.1.1.2 SAB-185, 10,240 Units/kg or Placebo (Phase II only)  
 
Investigational Agent: SAB-185, 10,240 Units/kg, to be administered IV 
for one dose at study Entry/Day 0.  
 
OR 
 Placebo for SAB-185: 0.9% Sodium Chloride Injection, USP, to be administered IV for one dose at study Entry/Day 0. 
 
 295 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 5.1.2 Administration 
 
Prior to administration, attach an infusion set containing a low protein binding 0.2 
or 0.22 µm in-line filter and prime the infusion set per institutional procedures. 
 
SAB-185/placebo is to be administered as an intravenous infusion at a r ate ≤2 
mL/min . After the entire contents of the IV bag have been administered, flush the 
infusion line as per site requirements or with approximately 25 mL of 0.9% Sodium Chloride Injection, USP, and administer the flush volume to the 
participant to ensure delivery of the required dose. 
 The infusion of SAB -185/placebo must be done in a way to obscure the contents 
(as SAB-185 may develop bubbles if agitated). The IV bag and the drip chamber of the infusion set must be covered for blinding purposes.  
 
Administer investigational agents/placebo immediately after preparation. If 
immediate administration is not possible, the investigational agents/placebo should be used within 24 hours if stored at room temperature, including flush of line.  Participants will be monitored for signs and symptoms of infusion reaction per 
section 6.3.9 
and the infusion rate may be slowed, paused, or stopped, 
lengthening the duration of infusion as deemed necessary if an infusion reaction 
is observed (sections 8.2.2 and 8.2.3) . 
 
5.2 Formulation, Storage, and Preparation  
 
5.2.1 Formulation and Storage 
 
SAB-185 is a clear, colorless sterile liquid for intravenous use and is stored at 2-8º C. SAB -185 is packaged in 10 mL glass vials with a draw volume of 10.3 mL. 
SAB-185 is a polyclonal product, and there will be small differences in the protein 
concentration and potency of each lot. The concentration and potency will be 
included on the label. Once SAB -185 is removed from 2-8º C storage and diluted 
into the 0.9% Sodium Chloride Injection, USP IV bag, it is stable at room 
temperature for 24 hours.  
Placebo for SAB-185 will be 0.9% Sodium Chloride Injection, USP. The product must 
be locally sourced and stored according to the manufacturer’s recommendation.  
 
5.2.2 Preparation 
 
Pharmacists must follow appropriate aseptic technique and consider sterile 
preparation procedures/guidance as outlined in USP General Chapter <797> 
Pharmaceutical Compounding – Sterile Preparations. Pharmacists must also 
 296 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) follow the requirements of their country, institution, and pharmacy regulatory 
authority regarding these procedures. The investigational agents and placebo should be prepared in a sterile environment, utilizing a pharmacy biosafety cabinet/isolator. If a biosafety cabinet or isolator is not available, a laminar flow 
hood may be used. Local regulations and site institutional policies and procedures for use of personal protective equipment, such as gloves, gowns, face masks and safety glasses, must be followed.  Any unused portion of investigational agent must not be used for another 
participant. Any empty vials, unused portion of entered vials, or unused solution 
which contains investigational agent should be discarded in a biohazard containment bag and incinerated or autoclaved in accordance with institutional or pharmacy policy.  
 
5.2.2.1 SAB-185, 3,840 Units/kg  
 
1. Using the participant’s body weight (kg) and Table 5.2.2-1 calculate the following volumes:  
• SAB-185  
• 0.9% Sodium Chloride Injection, USP  
• SAB-185 + 0.9% Sodium Chloride Injection, USP  
  
Multiply the participant’s body weight (kg) by the applicable number 
in Table 5.2.2-1 to determine each volume. Round each volume to the nearest tenth of a decimal point. Calculations will vary based on the potency (Units/mL) of each lot. See example calculations 
below for Lot # P100264357:  
 
Example #1: Participant with weight of 70 kg: 
SAB-185: 70 kg x 0.099 mL/kg = 6.9 mL  
0.9% Sodium Chloride Injection, USP: 70 kg x 0.901 mL/kg = 63.1 mL SAB-185 + 0.9% Sodium Chloride Injection, USP: 70 kg x 1 mL/kg 
= 70 mL  
 
Example #2: Participant with weight of 97.3 kg: 
SAB-185: 97.3 kg x 0.099 mL/kg= 9.6 mL 
0.9% Sodium Chloride Injection, USP: 97.3 kg x 0.901 mL/kg = 
87.7 mL SAB-185 + 0.9% Sodium Chloride Injection, USP: 97.3 kg x 1 mL/kg = 97.3 mL  
  
 297 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED)  
 
Table 5.2.2-1 . Dilution of SAB -185 for 3,840 Units/kg Dose  
A B C D 
(B ÷ C)  E 
(1 mL – D) F 
(1 mL total volume 
per kg)  
SAB- 185 Lot 
Number  SAB-185 
Dose 
Level 
(Units/kg)  Potency 
(Units/mL)  SAB- 185  
(mL/kg)   0.9% Sodium Chloride 
Injection, USP  
(mL/kg)  SAB-185 + 0.9% 
Sodium Chloride 
Injection, USP  
(Total mL/kg)  
P100264357  
3840  38753  0.099  0.901  1 
P100285179  38026  0.101  0.899  1 
P100294909  25451  0.151  0.849  1 
For Future 
Lots Not 
Listed  Based on 
vial label  SAB- 185 needed 
per kg = dose 
level ÷ potency  0.9% Sodium Chloride 
needed per kg = 1 mL 
minus volume of SAB -
185 needed per kg  1 
 
2. Based on the calculated volumes in Step 1, remove an appropriate 
number of SAB -185 vial(s) from the refrigerator, an appropriately 
sized container(s) of 0.9% Sodium Chloride Injection, USP from 
storage, and an appropriately sized empty, sterile IV bag from storage. When the vial(s) of SAB-185 is removed from the refrigerator, record this time as the investigational agent 
preparation time. Assign a 24-hour beyond use date and time from 
the preparation time. 
3. Gently invert the SAB -185 vial(s) to ensure homogeneity of the 
contents. Do not shake or vigorously agitate the vial(s). Visually inspect the vial(s) for the presence of any visible particulate matter. If visible particulate matter is observed, appropriately discard the 
vial(s), obtain a new vial(s), and restart the preparation.  
4. Using an appropriately sized syringe(s) fitted with ≤22-gauge 
needle, withdraw the calculated volume of 0.9% Sodium Chloride Injection, USP from the container(s) of 0.9% Sodium Chloride Injection, USP and inject into the empty, sterile IV bag.  
5. Using an appropriately sized syringe(s) fitted with ≤22-gauge needle, withdraw the calculated volume of SAB -185 from the SAB-
185 vial(s) and inject into the IV bag with 0.9% Sodium Chloride Injection, USP prepared in Step 4.  
6. Gently invert the prepared IV bag by hand to ensure homogeneity 
of the contents. Do not shake or vigorously agitate the prepared 
bag. Avoid foaming. Visually inspect the bag after preparation. The 
 298 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) contents of the bag should be free of any visible particulate matter. 
Obtain a new vial(s) and re-prepare the dose if visible particulate matter is observed.  
7. Encase the IV bag and the drip chamber of the infusion set in a 
cover that will obscure the appearance of the product. 
 
The investigational agent should be stored at room temperature and administered within 24 hours of preparation (refer to the assigned beyond use time in Step 2 above).  
 
5.2.2.2 Placebo for SAB-185, 3,840 Units/kg  
 
1. Using the participant’s body weight (kg), calculate the volume of 0.9% Sodium Chloride Injection, USP required using 1 mL volume 
per kg of the participant’s body weight. For example, the volume of 
0.9% Sodium Chloride Injection, USP for a participant with a weight of 70 kg would be 70 mL. 
2. Based on the calculated volume in Step 1, remove an appropriately sized container(s) of 0.9% Sodium Chloride Injection, USP and an appropriately sized empty, sterile IV bag from storage. When the 
container(s) of 0.9% Sodium Chloride Injection, USP is removed from storage, record this as the placebo preparation time. Assign a 24-hour beyond use date and time from the preparation time.  
3. Using an appropriately si zed syringe(s) fitted with ≤22-ga needle, 
withdraw the calculated volume of 0.9% Sodium Chloride Injection, 
USP from the container(s) obtained in Step 2 and inject into the 
empty, sterile IV bag.  
4. Visually inspect the bag after preparation. The contents of the bag 
should be free of any visible particulate matter. Obtain a new container(s) of 0.9% Sodium Chloride Injection, USP and re-prepare the dose if visible particulate matter is observed in the bag. 
5. Encase the IV bag and the drip chamber of the infusion set in a 
cover that will obscure the appearance of the product. 
 
The placebo should be stored at room temperature and administered within 24 hours of preparation (refer to the assigned beyond use time 
in Step 2 above). 
 
5.2.2.3 SAB-185, 10,240 Units/kg 
 
1. Using the participant’s body weight (kg)  Table 5.2.2-2
, calculate 
the following volumes: 
• SAB-185  
• 0.9% Sodium Chloride Injection, USP  
 299 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) • SAB-185 + 0.9% Sodium Chloride Injection, USP  
 
Multiply the participant’s body weight (kg) by the applicable number 
in Table 5.2.2-2  to determine each volume. Round each volume to 
the nearest tenth of a decimal point. Calculations will vary based on the potency (Units/mL) of each lot. See example calculations 
below for Lot # P100264357: 
 
Example #1: Participant with weight of 70 kg: 
SAB-185: 70 kg x 0.264 mL/kg = 18.5 mL  
0.9% Sodium Chloride Injection, USP: 70 kg x 0.736 mL/kg = 51.5 mL SAB-185 + 0.9% Sodium Chloride Injection, USP: 70 kg x 1 
mL/kg= 70 mL  
 
Example #2: Participant with weight of 97.3 kg: 
SAB-185: 97.3 kg x 0.264 mL/kg = 25.7 mL 
0.9% Sodium Chloride Injection, USP: 97.3 kg x 0.736 mL/kg= 71.6 mL 
SAB-185 + 0.9% Sodium Chloride Injection, USP: 97.3 kg x 1 mL/kg= 97.3 mL  
 Table 5.2.2-2 . Dilution of SAB -185 for 10,240 Units/kg Dose  
A B C D 
(B ÷ C) E 
(1 mL – D) F 
(1 mL total volume 
per kg)  
SAB- 185 Lot 
Number  SAB-185 
Dose 
Level 
(Units/kg)  Potency 
(Units/mL)  SAB- 185  
(mL/kg)   0.9% Sodium Chloride 
Injection, USP  
(mL/kg)  SAB-185 + 0.9% 
Sodium Chloride 
Injection, USP  
(Total mL/kg)  
P100264357  
10240  38753  0.264  0.736  1 
P100285179  38026  0.269  0.731  1 
P100294909  25451  0.402  0.598  1 
For Future 
Lots Not 
Listed  Based on 
vial label  SAB- 185 needed 
per kg = dose 
level ÷ potency  0.9% Sodium Chloride 
needed per kg = 1 mL 
minus volume of SAB -
185 needed per kg  1 
 
2. Based on the calculated volumes in Step 1, remove an appropriate number of SAB -185 vial(s) from the refrigerator, an appropriately 
sized container(s) of 0.9% Sodium Chloride Injection, USP from storage, and an appropriately sized empty, sterile IV bag from  
storage. When the vial(s) of SAB-185 is removed from the 
refrigerator, record this time as the investigational agent 
 300 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) preparation time. Assign a 24-hour beyond use date and time from 
the preparation time. 
3. Gently invert the SAB -185 vial(s) to ensure homogeneity of the 
contents. Do not shake or vigorously agitate the vial(s). Visually 
inspect the vial(s) for the presence of any visible particulate matter. 
If visible particulate matter is observed, appropriately discard the vial(s), obtain new vial(s), and restart the preparation.  
4. Using an appropriately sized syringe(s) fitted with ≤22-gauge needle, withdraw the calculated volume of 0.9% Sodium Chloride 
Injection, USP from the container(s) of 0.9% Sodium Chloride 
Injection, USP and inject into the empty, sterile IV bag.  
5. Using an appropriately sized syringe(s) fitted with ≤22-gauge needle, withdraw the calculated volume of SAB -185 from the SAB-
185 vial(s) and inject into the IV bag with 0.9% Sodium Chloride 
Injection, USP prepared in Step 4.  
6. Gently invert the prepared IV bag by hand to ensure homogeneity 
of the contents. Do not shake or vigorously agitate the prepared bag. Avoid foaming. Visually inspect the bag after preparation. The contents of the bag should be free of any visible particulate matter. Obtain a new vial(s) and re-prepare the dose if visible particulate 
matter is observed.  
7. Encase the IV bag and the drip chamber of the infusion set in a 
cover that will obscure the appearance of the product. 
 
The investigational agent should be stored at room temperature and 
administered within 24 hours of preparation (refer to the assigned 
beyond use time in Step 2 above).  
 
5.2.2.4 Placebo for SAB-185, 10,240 Units/kg  
 
1. Using the participant’s body weight, calculate the volume of 0.9% 
Sodium Chloride Injection, USP required using 1 mL volume per kg 
of the participant’s body weight. For example, the volume of 0.9% Sodium Chloride Injection, USP for a participant with a weight of 70 kg would be 70 mL. 
2. Based on the calculated volume in Step 1, remove an appropr iately 
sized container(s) of 0.9% Sodium Chloride Injection, USP and an appropriately sized empty, sterile IV bag from storage. When the container(s) of 0.9% Sodium Chloride Injection, USP is removed from storage, record this as the placebo preparation time. Assign a 24-hour beyond use date and time from the preparation time.  
3. Using an appropriately sized syringe(s) fitted with ≤22-ga needle, 
withdraw the calculated volume of 0.9% Sodium Chloride Injection, 
 301 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) USP from the container obtained in Step 2 and inject it into the 
empty, sterile IV bag. 
4. Visually inspect the bag after preparation. The contents of the bag should be free of any visible particulate matter. Obtain a new 
container of 0.9% Sodium Chloride Injection, USP and re-prepare 
the dose if visible particulate matter is observed in the bag.  
5. Encase the IV bag and the drip chamber of the infusion set in a 
cover that will obscure the appearance of the product. 
 
The placebo should be stored at room temperature and administered within 24 hours of preparation (refer to the assigned beyond use time 
in Step 2 above). 
 5.2.2.5  Labeling of Investigational Agent and Placebo  
 
Label the prepared IV bag with the following information: a. Participant identifier(s)  
b. Protocol number: ACTIV -2/A5401 
c. Investigational agent name:  
i. SAB-185 3,840 Units/kg  or placebo  
ii. SAB-185 10,240 Units/kg or placebo  
d. Total volume: Calculated using 1 mL per kg of participant body weight  
e. Route: IV  
f. Infusion rate/time: ≤ 2 mL/min 
g. Preparation date and time 
h. Beyond use date and time: 24 hours after preparation if stored at room temperature  
i. Any additional information required by jurisdiction  
 5.3 Supply, Distribution, and Accountability
 
 
5.3.1 Acquisition  and Distribution 
 
SAB-185 will be provided by SAB Biotherapeutics and will be available through the NIAID Clinical Research Products Management Center (CRPMC).  
 
0.9% Sodium Chloride Injection, USP, infusion sets, and any other ancillary 
supplies will be locally sourced by the site.  
 
5.3.2 Accountability  
 
The site pharmacist is required to maintain complete records of all investigational 
agents received from the NIAID CRPMC and subsequently dispensed. At US 
CRSs, all unused investigational agents must be returned to the NIA ID CRPMC 
 302 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) (or as otherwise directed by the sponsor) after the study is completed or 
terminated. At non-US CRSs , the site pharmacist must follow the instructions 
provided by the NIAID CRPMC for the destruction of unused investigational agents.  
 
5.4 Concomitant Medications
 
 
Any pre -medications given will be documented as a concomitant medication.
 303 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS (TC BOVINE -DERIVED)  
 6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Evaluations 
 
The schedules of evaluations provided below include evaluations for this investigational agent to be performed in addition 
to evaluations specified in the master protocol (master protocol T able 6.1-1  and Table 6.1-2 ). 
 Table 6.1-1: Schedule of Evaluations Phase II  
Phase II Evaluation  
Screening 
Study Entry/Day 0  
Day 1 
Day 3 
Day 7 
Day 14 
Day 28 
Day 45 
Week 12  
Week  24  
Week 36  
Week 48  
Week 72  
Premature Study D/C  
(Before Day 28 Visit)  
Premature Study D/C 
(After Day 28 Visit)  
Visit Window   +/-1 
day +/-2 days  0/+4 
days  +/-7 
days  -7/+14 days    
Investigational Agent Administered   X              
Hematology   X  X  X X       X  
Chemistry   X  X  X X       X  
Pregnancy Testing  X Whenever Pregnancy Suspected       
PK Studies   X X* X X X X X X X    X X 
Antidrug Antibodies   X  X X X X X X X    X X 
Neutralizing Antibodies   X  X X X X X X X    X X 
 304 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS (TC BOVINE -DERIVED)  *For approximately 28 participants  per SAB- 185 dose group at selected sites (see MOP and additional site -specific information).  
NOTE : First PK serum sample to be obtained prior to investigational agent/placebo administration along with other entry labs. A second sample to 
be obtained 1 hour after the end of infusion and line flush of the investigational agent.  
  
 305 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS (TC BOVINE -DERIVED)  Table 6.1-2: Schedule of Evaluations Phase III  
 
All evaluations apply to all participants randomized to open -label SAB- 185 under protocol Version 7 and all participants 
enrolled to SAB-185 or placebo for SAB-185 under protocol Version 8. See also master protocol Table 6.1-2 for 
additional master protocol evaluations that apply to all participants.     
Phase III Evaluation  
Screening 
Study Entry/Day 0  
Day 3 
Day 7 
Day 14 
Day 28 
Week  12  
Week 24  
Week 36  
Week 48  
Week 72  
Premature Study D/C 
(Before Day 28)  
Premature Study D/C 
(After Day 28)  
Visit Window    +/-1 
day +/-2 days  0/+4 
days  -7/+14 days    
Investigational Agent Administered   X            
PK Studies   X    X  X    X X 
Antidrug Antibodies   X    X  X    X X 
Neutralizing Antibodies   X    X  X    X X 
 
 306 ACTIV -2/A5401 
FINAL Version 8.0 
25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 
 6.3 Instructions for Evaluations  
 
6.3.9 Investigational Agent Administered 
 
Pre-Medication 
Pre-medication for infusions is not planned. However, if an infusion 
reaction occurs during administration or if the participant has a medical history suggesting a potential benefit from pre-medication, the study investigator(s) should determine the appropriate pre-medication. 
 
Any pre -medications given will be documented as a concomitant 
medication.  
 
If minor infusion reactions are observed, administration of 
acetaminophen, 500 mg to 1000 mg, antihistamines, and/or other 
appropriately indicated medications may be given prior to the start of infusions for subsequent  participants. 
  
Before the Infusion  
Vital signs (temperature, heart rate, respiratory rate, blood pressure and 
SpO 2). 
 
During the Infusion  
Vital signs (temperature, heart rate, respiratory rate, blood pressure and 
SpO 2) will be measured every 15 (± 3 minu tes) minutes during the 
infusion.  
 
After Infusion 
Vital signs (temperature, heart rate, respiratory rate, blood pressure and SpO
2) will be measured every 30 minutes  (± 5 minutes)  for 2 hours post 
infusion.  
 Only vital signs that meet AE reporting requirements will be recorded on an eCRF.  
 
6.3.15 Laboratory Evaluations 
 
Hematology  
Participants will have blood drawn for complete blood cell count (CBC) with automated differential and platelet count.  
 At Entry/Day 0, blood should be drawn before study drug administration.  
 307 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) Chemistry  
Participants will have blood drawn for liver function tests (ALT, ALP, AST, 
total bilirubin, direct bilirubin, and total protein), and renal function tests (albumin, BUN, creatinine, potassium, glucose, and sodium).  
 
At Entry/Day 0, blood should be drawn before study drug administration.  
 
Pregnancy Testing  
For participants of reproductive potential: Serum or urine β-HCG. (Urine 
test must have a sensitivity of ≤25 mIU/mL).  
 
Post-screening, pregnancy testing should be done any time pregnancy is 
suspected.  
 In the event of pregnancy occurring during the study, record pregnancy and pregnancy outcome per section 8.3
. 
 
6.3.16 Pharmacokinetics  
 
Serum will be collected and used to measure investigational agent levels.   At Entry/Day 0, serum should be collected before the dose of investigational agent/placebo (any time prior to the start of infusion) and 
again 1 hour (± 10 minutes)  after the flush to clear the line of any 
remaining investigational agent/placebo following the end of the infusion (post-end of infusion (EOI) PK assessment). The 1-hour  post-EOI PK 
draw should be collected from an opposite limb and not the IV line/same site as the infusion. If it is not possible to collect the sample from an 
opposite limb for clinical reasons such as lymphedema or limited or restricted vascular access, the post- EOI PK draw should be skipped and 
the reason for the missed collection noted in site records.  
 Post-entry, serum should be collected as per the SOE. Date and time of collection should be recorded.   
Phase II Day 1 PK (Selected Sites): Approximately 28 participants 
assigned to each SAB- 185 dose  group in Phase  II at selected US sites 
will have a sample taken for PK at an additional Day 1 visit. The Day 1 PK 
is the only procedure performed at that visit for those selected 
participants; other participants do not have a Day 1 visit. The Day 1 PK 
sample should be collected 18-30 hours after administration of 
investigational agent/placebo. If it is not possible to collect the Day 1 PK 
sample due to Day 1 occurring on a weekend or holiday, this PK draw 
should be skipped and the reason for the missed collection noted in site 
 308 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) records.  See MOPS and additional site-specific information for selection 
of participants for this additional Day 1 PK sample collection.  
 
Samples will be analyzed at a laboratory approved by the sponsor and 
stored at a facility designated by the sponsor. Concentrations of the 
investigational agents will be assayed using a validated bioanalytical method. Samples will be retained for up to 2 years after last patient visit. 
Remaining samples used for PK may be pooled and used for exploratory metabolism or bioanalytical method experiments as deemed appropriate.  
 
6.3.18 Antidrug Antibodies  
 
Serum will be collected to measure anti -drug antibodies.  
 
At Entry/Day 0, serum should be collected before the dose of 
investigational agent/placebo.  
 Post-entry, serum should be collected as per the SOE. Date and time of 
collection should be recorded.   
Samples will be analyzed at a laboratory approved by the sponsor and 
stored at a facility designated by the sponsor.  
 
6.3.19 Neutralizing Antibodies  
 
Serum will be collected and stored for neutralizing antibody  
assays either by microneutralization or ACE -2 ligand  
electrochemiluminescence (MSD) assay.  
 At Entry/Day 0, serum should be collected before the dose of investigational agent/placebo.  
 Post-entry, serum should be collected as per the SOE. Date and time of collection should be recorded.   Samples will be analyzed at a laboratory approved by the sponsor and 
stored at a facility designated by the sponsor.  
 
  
 309 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 7.0 ADVERSE EVENTS AND STUDY MONITORING 
 
7.1 Definitions of Adverse Events  
 
Adverse Events of Special Interest  
The following are AESIs for the agent SAB-185 3,840 Units/kg dose, SAB -185 10,240 
Units/kg dose, or placebo for each of the investigational agents:  
• Grade ≥1 infusion-related reactions  within 12 hours  of investigational  agent/placebo 
administration (deemed related to study  product as determined by the site 
investigator) 
• Grade ≥1 allergic/hypersensitivity  reactions  within  12 hours  of investigational  
agent/placebo administration (deemed related to study  product as determined by the 
site investigator) 
 8.0 CLINICAL MANAGEMENT ISSUES 
 8.2 Management of Side Effects 
 
 
8.2.1 Overdose 
 
There is no known antidote for SAB -185 overdose. In the event this occurs, the 
participant should be closely monitored for AE/SAE and laboratory abnormalities, and supportive care provided as indicated. 
 
8.2.2 Infusion-Related Reactions  
 
All participants should be monitored closely, as there is a risk of infusion reaction (including anaphylaxis) with any biological agent.   
Symptoms and signs that may occur as part of an infusion reaction include, but 
are not limited to fever, chills, nausea, headache, bronchospasm, hypotension, 
angioedema, throat irritation, rash including urticaria, pruritus, myalgia, and dizziness.  
   
The severity of infusion-related reactions will be assessed and reported using the 
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can be found on the DAIDS RSC website at https://rsc.niaid.nih.gov/clinical -research-
sites/daids -adverse-event-grading-tables . 
 
The clinical site should have necessary equipment and medications for the 
management of any infusion reaction, which may include but is not limited to oxygen, IV fluid, epinephrine, acetaminophen and antihistamine.  
 310 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) Investigators should determine the severity of the infusion reaction and manage 
infusion reactions based on standard of care and their clinical judgment. If an 
infusion reaction occurs, then supportive care should be provided in accordance with the signs and symptoms. 
 
A participant will stop study product infusion if a Grade ≥3 event occurs that is 
deemed  possibly, probably, or definitely  related  to the study product.  
 
Dosing can be modified, such as slowing infusion, for mild or moderate reactions 
(Grade 1 or Grade 2). 
  
8.2.3 Hypersensitivity  
 
Signs and symptoms of infusion-related immediate hypersensitivity reactions 
may include, but are not limited to anaphylaxis, angioedema, bronchospasm, 
chills, diarrhea, hypotension, itching, skin rash, shortness of breath, urticaria, tachycardia, and throat irritation or tightness [9].  
 Participants will be closely monitored for immediate hypersensitivity reactions.  
A participant will stop study product infusion if a Grade ≥3 event occurs.  
 
Dosing can be modified, such as slowing infusion, for mild or moderate reactions 
(Grade 1 or Grade 2). 
 
Sites should have appropriately trained medical staff and appropriate medical 
equipment available when study participants are receiving SAB -185. It is 
recommended that participants who experience a systemic hypersensitivity 
reaction be treated per the local standard of care.  
 8.3  Pregnancy
  
 
Since there are no data regarding the use of SAB -185 in participants who are pregnant, 
participants who are pregnant are not eligible for the study. Participants of childbearing potential and participants who may impregnate their partners are required to follow the instructions for prevention of pregnancy provided in the protocol.  
 
If a participant becomes pregnant during the study (post-entry), the participant will 
remain on study through the end of the study, and the pregnancy will be followed 
through completion.  
 At the end of the pregnancy, outcome and adverse events for participant and infant will be recorded on the outcome eCRF.  
 
 311 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 8.4 Breastfeeding  
 
Since there are no data regarding the use of SAB -185 in participants who are 
breastfeeding, participants who are breastfeeding are not eligible for the study. 
 
10.0  STATISTICAL CONSIDERATIONS  
 
10.1.1 Analysis Population 
 
As noted above in section 3.4 of this appendix, the Analysis Population for evaluating SAB -185 versus placebo (with SOC treatment allowed in both 
arms, if available) includes enrollment under this version of the protocol 
combined with the “ Omicron subpopulation” enrolled under protocol 
Version 7. Participants in this O micron subpopulation who were 
randomized to casirivimab plus imdevimab are considered functionally to have received a placebo. This Analysis Population will be restricted to 
those who received study product .  
 The “ Omicron subpopulation” enrolled under protocol Version 7 is defined 
as (1) all participants randomized under protocol Version 7 who are 
infected with the O micron variant as identified o n sequencing of an NP 
sample obtained on day 0, plus (2) all participants randomized under protocol Version 7 on or after December 26, 2021, who do not have variant 
information available from a sample obtained on day 0. The second of 
these two groups of participants are assumed very likely to be infected 
with the O micron variant on the basis that prevalence of the Omicron 
variant in the U.S. was estimated by the CDC to be 89.2% for the week ending January 1, 2022 (and starting December 26, 2021), 95.2% for the week ending January 8, 2022, 97.9% for the week ending January 15, 2022, 
and 98.9% for the week ending January 22, 2022, during which enrollment 
under protocol Version 7 was stopped [10]. 
 The “non-O micron subpopulation” enrolled under protocol Version 7 is 
defined as all participants enrolled under protocol Version 7 excluding 
those in the “O micron subpopulation.” 
   
10.3 Randomization and Stratification
 
 
As outlined above, two doses of SAB -185 will be evaluated as part of this platform trial 
(3,840 Units/kg and 10,240 Units/kg); the master protocol notes up to two dose levels of 
the same agent may be assessed.  
 
Each dose of SAB -185 will be considered as a separate Agent Group in the study and in 
the randomization. In phase II, participants will be first randomized to Agent Group, and 
 312 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) if eligible, will have equal probability of being assigned to the 3,840 Units/kg dose group 
or the 10,240 Units/kg dose group. The second randomization will be to active vs 
placebo for 3,840 Units/kg unit dose, and to active vs placebo for the 10,240 Units/kg  
dose; the randomization ratio in the second randomization depends on the number of 
agents the participants was eligible to receive in the first randomization. The SAB -185 
dose of 3,840 Units/kg was selected for evaluation in phase III. Randomization in 
phase III will be as defined in the master protocol ( section 3.3 and section 10.3 ). 
 
10.5 Data and Safety Monitoring 
 
10.5.2 Phase III 
 
In addition to the details regarding data and safety monitoring laid out in the Master Protocol, the DSMB may consider results from the 
“non-O micron subpopulation” enrolled under protocol Version 7 to 
guide their recommendations, particularly regarding any safety 
issues or possible early termination of the placebo-controlled evaluation of SAB -185 based on lack of sufficient efficacy. For 
example, data suggesting that SAB-185 may be less effective than casirivimab plus imdevimab in the “non-O micron subpopulation” 
might support a finding of lack of sufficient efficacy of SAB -185 
versus placebo in the “ Omicron subpopulation” . Note, however, that 
a recommendation to terminate randomization to SAB -185 under this 
version of the protocol based on a finding of superiority of SAB -185 
versus placebo should, in general, be based only on results from the 
Analysis Population for this comparison defined in section 10.1.1
 of 
this appendix.  
 
10.6 Analyses 
 
Data from the Analysis Population defined in section 10.1.1  of this 
appendix will be used to evaluate the efficacy and safety of SAB -185 versus 
placebo (with possible SOC treatment added in both arms, if available) . 
These analyses will follow section 10.6 of the Master Protocol. Analyses of 
the “non-O micron subpopulation” will follow section 10.6 of the Master  
Protocol in protocol Version 7 (including any letters of amendment to 
Version 7).  
 
In addition, safety analyses will be presented for the following mutually exclusive subgroups: (1) the “ Omicron subpopulation” enrolled under 
protocol Version 7, as the control group received casirivimab plus 
imdevimab; (2) participants enrolled under this version of the protocol who 
did not receive SOC treatment; and (3) participants enrolled under this 
version of the protocol who received SOC treatment. It is recognized that 
 313 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) the comparisons in subgroups (2) and (3) may not be pure randomized 
comparisons because receipt of SOC treatment may be influenced by the clinical status of a participant after randomization. 
 
Efficacy analyses for the primary outcome (hospitalization/death), the virologic outcomes (proportion with SARS -CoV-2 RNA <LLOQ and 
quantitative levels of RNA), and the main sympto m duration outcome may 
also be presented separately for the “ Omicron subpopulation” enrolled 
under protocol Version 7 and the population enrolled under protocol 
Version 8. The possibility of heterogeneity in the effect of SAB -185 versus 
casirivimab plus imdevimab in the “ Omicron subpopulation” (considered 
functionally to be a placebo in this population) versus the effect of SAB-185 versus placebo (with the possibility of SOC treatment, if available) among participants enrolled under this version of the protocol may also be 
evaluated to assess the possible impact on interpretation of results.  
 11.0 PHARMACOLOGY PLAN  
 11.1 Pharmacology Objectives   
 
The phase II pharmacology objective is to determine the pharmacokinetics of SAB-185. 
For phases II and III, the pharmacology objective is to explore relationships between 
dose and concentration of SAB-185 with virology, symptoms, and oxygenation.  
 
11.2 Pharmacology Study Design Overview   
 
The Schedule of Evaluations shows the collection schedule for Phase II and for Phase 
III. SAB-185 have a long -elimination half-lives in preclinical animal studies and is 
expected to be approximately 28.5 days in healthy humans. Limited data in participants 
from Phase I studies who received a single dose of 10 mg/kg, 25 mg/kg and 50 mg/kg 
indicated PK behavior consistent with PK model predictions. The PK sample schedules 
are based on the long-elimination half-life of SAB-185 and are designed to meet the 
phase II objective of determination of the pharmacokinetics of these agents and the 
phase III objective to explore dose/concentration -response relationships.  
 
Approximately 28 participants assigned to each SAB-185  dose  group (~14  or more  
receiving investigational  agent  at each  dose) will have an additional sample collected 
on Day 1 to further define time to calculated effective concentration. Participants 
contributing Day 1 samples will be recruited from selected domestic sites and the PK 
data from these participants will be analyzed (see section 6.3.15 ). By design, the sample 
collection schedules are different, with the phase II schedule being more intense to 
determine PK behavior, and the phase III schedule more sparse to confirm PK behavior 
and support dose/concentration-response analyses.  
 
 314 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 11.3 Pharmac ology Data Analysis and Modeling  
 
Pharmacokinetic data analysis of phase II data will use conventional and accepted 
approaches such as non -compartmental analysis or compartmental analysis to 
determine the PK characteristics of SAB -185. Population pharmacokinetic approaches 
(e.g., nonlinear mix effects modeling such as implemented in NONMEM) may also be 
used. The usual parameters of interest are area under the concentration-time curve 
(AUC), total body clearance (CL), elimination half-life (T 1/2), and maximum and minimum 
concentrations (C max, Cmin). Exploration of relationships between dose and concentration 
of SAB-185 with virology, symptoms, and oxygenation will be approached using 
conventional and accepted methods for pharmacokinetic/pharmacodynamic (PK/PD ) 
data analyses. Such methods will include the E max or sigmoid E max model or structurally 
linked PK/PD models (as could be performed within NONMEM) to explore exposure-
response relationships. Exposure-response relationships will be performed in 
conjunction with the protocol statisticians.  
 
  
 315 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X V: SAB-185 ANTI -SARS -COV -2 HUMAN IMMUNOGLOBULIN INTRAVENOUS 
(TC BOVINE -DERIVED) 16.0 REFERENCES 
 
1. Doherty  M, Robertson MJ. Some early Trends in Immunology. Trends Immunol 
2004;25: 623-31. 
2. Casadevall  A, Dadachova E, Pirofski LA, Passive antibody therapy for infectious 
diseases. Nat Rev Microbiol 2004;2: 695-703. 
3. Saylor C , Dadachova E, Casadevall  A, Monoclonal antibody -based therapies for 
microbial diseases. Vaccine 2009;27( Suppl 6): G38-46. 
4. Hall WC, Price -Schiavi  SA, Wicks J , Rojko JL.In: Preclinical Safety Evaluation of 
Biopharmaceuticals. John Wiley & Sons, Inc., 2008, pp. 208- 240. 
5. Leach M W, Halpern WG, Johnson CW, et al. Use of tissue cross -reactivity studies in 
the development of antibody -based biopharmaceuticals: history, experience, 
methodology, and future dir ections. Toxicol Pathol  2010;38: 1138-66. 
6. Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody -dependent 
enhancement of SARS -CoV-2. Nature 2020;584: 353-63. 
7. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and 
human. J Basic Clin Pharm 2016;7: 27-31. 
8. Beigel  JH, Voell J, Kumar P, et al . Safety and tolerability of a novel, polyclonal 
human anti -MERS coronavirus antibody produced from transchromosomic cattle: a 
phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 
2018;18:410 -18. 
9. Everds NE, Tarrant JM Unexpected hematologic effects of biotherapeutics in 
nonclinical species and in humans. Toxicol Pathol 2013;41: 280-302. 
10. CDC COVID Data Tracker. Variant Proportions. Updated February 15, 2022. Available at: https://covid.cdc.gov/covid-data-tracker/#variant -proportions. 
 
 
 316 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI : SAMPLE INFORMED CONSENT FOR STUDY DRUG SAB -185 APPENDIX XVI : SAMPLE INFORMED CONSENT FOR STUDY DRUG SAB -185 
 
A study drug that you might be assigned to in this study is one of two doses of the SAB-185 or 
the placebo. Each dose of SAB- 185 is considered a separate study drug in the trial.  
 
SAB-185 is a type of drug called a polyclonal antibody. Many antibodies are naturally made by your body and help fight diseases. SAB -185 is  made by  cows that are genetically engineered to 
make human antibodies. Blood is collected from these cows and the antibodies are separated out and purified so they can be given to humans. “Polyclonal” means that SAB -185 is made up 
of several different antibodies.  
 The United States Food and Drug Administration (FDA) has not approved SAB -185 for general 
use by the public. However, we have told the FDA about this study and they have given us permission to conduct this study.  
 
Screening Visit  
• At your screening visit, if you can become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample for a pregnancy test. You cannot participate in the study  if you 
are pregnant.  
 After the Screening Visit, your study visits and evaluations will be different depending on whether you are in the first part of the study or the second part of the study.  
 
IF YOU ARE IN THE FIRST PART OF THE STUDY (PHASE II, COMPARISON TO PLACEBO)  
 
Entry  Visit  
• You will have blood drawn. This blood will be used for the following tests:  o routine safety tests (liver and kidney tests and blood counts)  
o levels of the drug in your blood  
o levels of antibodies to the drug (your body’s immune response to the drug)  
• You will have the infusion of SAB-185 or placebo for SAB-185. The infusion will be given through a small plastic tube that will be placed into a vein in your arm. This is called an intravenous (IV) infusion. The infusions will take approximately 50 minutes. You will be monitored in the clinic for 2 hours after the end of the infusions. 
 
Extra Visits  
Approximately 56 participants (28 per dose group) will be asked to return about 24 hours (1 day) after the Entry visit for an additional blood draw to test levels of the drug. The site staff will tell you if you may be one of these 56 participants.  
 
Study Visits on Days 3, 7, 14, 28, and 45, Week 12, and Week 24  
• You will have blood drawn. This blood will be used for the following tests:  o routine safety tests (liver and kidney tests and blood counts)  (Day 3, 14, and 28)  
 317 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI : SAMPLE INFORMED CONSENT FOR STUDY DRUG SAB -185 o levels of the drug 
o levels of antibodies  (your body’s immune response to the drug)  
 
 
IF YOU ARE IN THE SECOND PART OF THE STUDY (PHASE III, COMPARISON TO 
PLACEBO):  
Entry Visit  
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug in your blood  
o levels of antibodies to the drug (your body’s immune response to the drug)  
• You will have the infusion of SAB-185. The infusion will be given through a small plastic tube that will be placed into a vein in your arm. This is called an intravenous (IV) infusion. The 
infusions will take approximately 50 minutes. You will be monitored in the clinic for 2 hours 
after the end of the infusions.  
 
Study Visit on Day 28 
• You will have blood drawn. This blood will be used for the following tests:  o levels of the drug  
o levels of antibodies to the drug (your body’s immune response to the drug)  
  WHAT ARE THE RISKS OF SAB-185?  There is a risk of serious  and/or  life-threatening side effects  when non-study  medications  are
 
taken with the study drugs. For your safety, you must  tell the study  doctor  or nurse about all 
medications  you are taking before you start the study.   
 Another risk is that the study drugs used in this
 study  may have side effects, some  of which  are 
listed below.  Additionally,  the study drug tested  in the study  may have unknown side effects  in 
persons  with SARS-CoV -2 infection.  In a research  study, all of the risks or side effects  may not 
be known before you start the study. You need to tell your doctor  or a member  of the study  team  
immediately  if you experience any side effects.  
 Please note that these lists do not include all the side effects  seen with this study drug.
 These 
lists include the more  serious  or common side effects  with a known or possible  relationship to the 
study drug. If you have questions  concerning the additional side effects,  please ask the medical  
staff at your site. 
 
 318 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI : SAMPLE INFORMED CONSENT FOR STUDY DRUG SAB -185 Risks Associated with SAB -185 
There is limited safety data on SAB- 185 since it has not been given to a lot of people. As of 
January 2022 , 28 healthy volunteers  (people without COVID -19) and more than 5 00 people 
with COVID -19 have received infusions of SAB -185. Most of the possible side effects from 
SAB-185 have been mild to moderate in severity, including some people experiencing 
bruising, redness, and pain in the area of the skin that the drug was given through a vein. 
One person (a volunteer without COVID -19) had a severe decrease in the amount of 
blood lymphocytes (a form of immune cells) and two people (both with COVID -19) had a 
possible hypersensitivity (allergic) reaction -- one person had chest tightness after 
receiving SAB -185 with rash a few days later, and another person developed hives 
(raised itchy rash) while receiving SAB-185 that led to stopping the drug. There has been 
one report of a person with COVID -19 who had hives and  angioedema (a possible 
allergic reaction with facial swelling) and was hospitalized for a short period (24-48 
hours). 
 
SAB-185 is produced in the same way as another product known as SAB -301. It is believed that 
SAB-185 and SAB -301 will have a similar safety profile. In a study of SAB -301, the most 
common adverse events were headache, increased levels of albumin in urine (may be a sign of kidney damage), increased levels of creatine kinase in blood (may be a sign of muscle damage), and common cold. These adverse events were reported at approximately the same 
frequency in persons who received SAB -301 as in persons who received a placebo. 
 
Administration of antibodies, such as SAB-185 can result in allergic reactions. Signs and 
symptoms of these reactions include:  
• chills  
• skin rash  
• itching  
• hives  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
• loose stools  
 
Administration of antibodies, such as SAB-185 may induce release of chemicals called 
cytokines in the body. These chemicals may induce allergic reactions listed above as well as:  
• fever 
• muscle aches  
• nausea  
• vomiting 
• headache  
• dizziness  
 319 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI : SAMPLE INFORMED CONSENT FOR STUDY DRUG SAB -185 Some of these reactions may be serious or life-threatening including:  
• skin rash  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
 
You will be monitored closely during administration of study drug.  Medical personnel, 
equipment, and medication will be available to manage these reactions appropriately if they occur.  
 Administration of antibodies, such as SAB-185 can cause the following risks and discomforts: 
• development of proteins (antibodies) against SAB -185. This may cause your body to get rid 
of SAB-185 more quickly or change the effect of these agents on the body. Your blood will 
be tested to find out whether your body made antibodies to SAB -185. The anticipated risk of 
this is low because SAB-185 is a fully human antibody. Therefore, it is less likely to be seen as “foreign” by your body’s immune system and your body is less likely  to form antibodies 
against them . 
• mixture of antibody and other chemicals in the body that may be deposited in tissues such as blood vessels and kidneys.  
• unexpected increase in virus reproduction in your body. Although this has been observed with some viruses, this has not been observed with COVID -19 or with the use of serum -
containing antibodies given to people with COVID -19. This risk of increased viral growth is 
perhaps greater when there are lower levels of antibodies in the blood in the presence of virus. To avoid this, SAB -185 will be given at a dose that is felt to be high enough to keep 
this from occurring.  
 
Effect on Future Vaccination 
The US Centers for Disease Control and Prevention (CDC)  recently changed their guidance 
(as of February 11, 2022) to say that people who have received antibody treatment for 
COVID -19 can receive a COVID -19 vaccine at any time, and do not have to wait for a 
period after receiving the antibody treatment. It is possible that the levels of antibodies 
generated by vaccination may be lower in people who received an antibody treatment 
before vaccination than in people who did not receive an antibody treatment before 
vaccination, but it is not known if this means you will not be as protected from future 
COVID -19, and the CDC recommends proceeding with vaccination. SAB-185 is an 
experimental antibody treatment and it is not known if receiving SAB-185 affects how 
you will respond to COVID -19 vaccines.    
  
 320 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI : SAMPLE INFORMED CONSENT FOR STUDY DRUG SAB -185 ARE THERE  RISKS RELATED TO PREGNANCY  AND BREASTFEEDING? 
 
Pregnancy  
Since there are no data regarding the use of this study drug in people who are pregnant, you 
cannot participate in the study if you are pregnant.  
 
The study drug may  involve risks to you (or to the embryo or fetus, if you or your partner  become 
pregnant), which  are currently  unforeseen.  
 
If you are engaging in sexual activity that could lead to pregnancy, you must agree to use 
effective contraception for 24 weeks after the study drugs are administered. This would include oral contraceptives, implanted contraceptives, intrauterine devices, and/or barrier methods.  
 If you are engaging in sexual activity that may lead to pregnancy in your partner, you must 
agree to either remain abstinent or use male contraceptives. You are also advised to inform 
your non-pregnant sexual partners that can become pregnant to use effective contraceptives for 24 weeks after the study drugs are administered to you.  
 If you have a pregnant partner you should use condoms during vaginal intercourse through 24 weeks after the study drugs are administered.  
 If applicable, you should refrain from sperm donation for 24 weeks after study drug administration.   If at any point during the study you think you may be pregnant, you should let the staff at your 
site know so that a pregnancy test can be done.  
 
Let your doctor know  immediately  if you
 become  pregnant. If you become pregnant while  on the 
study, we will ask you to continue through the end of the study.  The study  staff would like to 
obtain information from you about the outcome of the pregnancy  (even if it is after your 
participation  in the study  ends). 
 
Breastfeeding 
It is not known if this study drug is safe to use in people who are breastfeeding. You are not 
eligible to receive this study drug if you are breastfeeding.  
 321 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS) 
 
Information/evaluations noted in this  agent-specific appendix are IN ADDITION to those 
presented in the master protocol. Section numbering aligns with the master protocol. 
 
 
2.0 INTRODUCTION  
 
2.2 Rationale  
 
Monoclonal  Antibodies  (mAbs)  
Passive transfer of antibodies from individuals who recovered from a particular  
infection has shown prophylactic and therapeutic potential for a variety of 
infections. Coronavirus Disease 2019 (COVID -19) antibody therapy in the form of 
polyclonal plasma from convalescent individuals is currently being explored as a therapeutic option and was granted emergency use authorization (EUA) by the 
FDA on August 23, 2020. Highly potent neutralizing monoclonal antibodies (mAbs)  
against SARS-CoV -2 have several advantages compared to convalescent plasma: 
they can be titrated to concentrations of known neutralizing activity, they have less 
potential for off-target binding and subsequent immune pathology (i.e., transfusion-
related acute lung injury (TRALI)), and they show less of the  therapeutic  variability 
that is inherent to polyclonal remedies. 
 
There are close to 100 FDA -approved monoclonal antibodies (mAbs) for treatment 
or prevention of cancer, autoimmune diseases, infectious diseases and other  
conditions. Palivizumab, for example, a humanized monoclonal antibody (IgG)  
directed against the fusion protein of respiratory syncytial virus (RSV), was the first 
monoclonal  antibody approved for clinical  use against an infectious  pathogen and 
it is indicat ed for the prevention of serious lower respiratory tract disease caused 
by RSV in children. Another example that illustrates the utility of mAbs against 
viruses,  particularly the possibility  for rapid development in the face of an emerging 
infection, is the 2014-2016 Ebola epidemic. While an initial  trial of a triple mAb 
cocktail, ZMapp, did not meet its efficacy endpoints (1), a subsequent RCT showed 
superior results for Day 28 mortality for Inmazeb/REGN- EB3 (another triple mAb 
cocktail), leading to approval by the FDA in October 2020 for treatment of Ebola. 
The use of broadly neutralizing mAbs against HIV is yet another example 
illustrating the clinical translation of mAbs to treat or prevent infectious disease (2). 
These anti -HIV-1 antibodies were further modified to include amino acid mutations 
in the Fc region to extend biological half-lives (“LS” mutations). Studies  to date 
demonstrate that the modified antibodies  demonstrate similar safety profiles to the 
unmodified variants (3, 4) and [STUDY_ID_REMOVED],     [STUDY_ID_REMOVED]). 
 
 322 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  Taken together, passive administration of neutralizing antibodies holds great clinical 
promise for the prevention and treatment of COVID -19. Monoclonal  antibodies may 
prove to be particularly useful in preventing SARS -CoV -2 infection in populations 
who may not mount protective immune responses to vaccination (e.g., advanced 
age, immunocompromised) and as therapy in individuals at high risk to develop 
severe COVID -19. Several anti -SARS-CoV-2 mAbs have been isolated by multiple 
groups and have initiated clinical testing, including progression to efficacy  Phase 
II/III  studies  for both prevention and therapy  (5,6). 
 
While some monoclonal antibody combinations given by infusion have received EUA for treatment of early COVID -19 in ambulatory persons with COVID -19 (7), 
monoclonal antibodies administered in an easier and more acceptable way, such as through subcutaneous injection, may improve clinical utility and patient uptake.  
 
Investigational  Agent 
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) are recombinant, fully 
human mAbs of the IgG1κ and λ isotype, respectively, that specifically bind SARS -
CoV-2 spike protein receptor binding domain (RBD). BMS-986414 (C135-LS) and 
BMS -986413 (C144-LS) were identified and cloned at the Rockefeller University  
from two individuals  who recovered from COVID -19 (8). 
 
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) differ from the original 
molecules by two one-amino acid substitutions in the Fc domain: methionine to 
leucine at Fc position 428 (M428L), and asparagine to serine at Fc position 434 
(M428L/N434S). These substitutions were made to the original molecules for the 
purpose of extending their biological half-lives  in humans  (9). Additional details can 
be found in the Investigator’s  Brochure (15). 
 
In vitro neutralization assays were performed to characterize the potency of BMS - 
986414 (C135-LS) and BMS -986413 (C144-LS) . Both antibodies showed 
exceptional neutralizing  potency against authentic SARS -CoV -2 with IC50s of 3.0 
and 2.6 ng/mL and IC90s of 10.43 ng/mL and 21.68 ng/mL, respectively. BMS -
986414 (C135-LS) and BMS -986413 (C144-LS) showed binding patterns 
consistent with recognition of two non-overlapping sites  of the SARS- CoV-2 S 
protein RBD  (8, 10). 
 
The RBD of SARS -CoV-2 displays steric flexibility. The RBD can present in an “up” 
conformation enabling it to bind to angiotensin-converting enzyme 2 (ACE2, an 
identified cell surface receptor for SARS-CoV -2), or in a “down” conformation, in 
which  the closed, pre-fusion S trimer  cannot interact with ACE2. BMS-986413 
(C144-LS) is a Class 2 antibody using the VH3-53 heavy chain gene with a 
relatively long complementarity -determining region 3 (CDRH3). It can bind to the 
RBDs of an S  trimer in both the “up” and “down” confirmation, thus conferring the 
 323 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  ability to  attach to the spike of SARS -CoV -2 in various steric configurations. 
Moreover, the exact epitope of BMS -986413 (C144-LS) has been shown to 
overlap with the binding site for  ACE2. This direct competition with ACE2 could 
partially explain its potency in neutralizing SARS-CoV -2. An additional aspect 
contributing to the exceptional  neutralizing capacity  of BMS -986413 (C144-LS) is 
the aforementioned length of its CDRH3, which enables it to bridge between 
adjacent “down” configured RBDs, thus  locking the S trimer in a closed, pre-fusion 
conformation that is unable to engage ACE2. BMS-986414 (C135-LS) is a class 3 
antibody with a binding mechanism distinct from  BMS -98641 3 (C144-LS) . BMS -
986414 (C135-LS) recognizes a glycopeptide epitope on a region of the RBD near 
the N343RBD glycan and non-overlapping with the ACE2 binding site.  Importantly, 
there is also no steric competition for binding to monomeric RBD  between BMS -
986413 (C144-LS) and BMS-986414, suggesting that both antibodies can bind to 
and neutralize SARS-CoV -2 when given in combination (10, 11). 
 
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) maintain the binding 
properties and neutralizing activity of the original unmodified antibodies. BMS -
986414 (C135-LS) and BMS -986413 (C144-LS) have preserved Fc effector 
functions, which  are required for in vivo activity ( 12). 
 
In vitro experiments have shown that viral escape variants emerge under single 
antibody pressure. BMS -986413 (C144-LS) selects for E484K and Q493R 
mutations and BMS- 986414 for R346S and N440K. These mutations abrogate 
neutralizing activi ty and correspond to key residues  for binding to the RBD by the 
respective antibodies. However, the selection of escape variants can be overcome 
by the combination of BMS -986413 (C144-LS) and BMS -986414 (C135-LS) (13). 
 
It has been recently shown that serum neutralizing activity following immunization with the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines against the emerging SARS- CoV-2 variants encoding E484K or N501Y or the 
K417N:E484K:N501Y combination mutations was reduced by a small but 
significant margin. Vaccine-elicited monoclonal mAbs potently neutralize SARS - 
CoV-2, targeting a number of different RBD epitopes in common with mAbs  
isolated from infected donors. However, neutralization by 14 of the 17 most potent 
mAbs tested was reduced or abolished by either K417N, or E484K, or N501Y  
mutations (14). However, neutralizing activities of the BMS -986414 (C135-LS) and 
BMS - 986413 (C144-LS) antibody combination are maintained against these 
variants (Figure 1
). 
 
 324 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)   
 
Figure 1: Neutralizing activity of BMS -986414 (C135-LS) and BMS -986413 (C144-
LS) against SARS -CoV-2 variants  by a SARS- CoV-2 pseudovirus  neutralization 
assay.  IC50 values  for 2 different m onoclonal antibodies, alone or in their clinically 
designated combinations, for  neutralization of wild type and the indicated mutant 
SARS- CoV-2 pseudotyped viruses. Antibodies with IC50 values above 1000 
ng/mL were plotted at 1000 ng/mL. Data are the mean of 2 independent 
experiments. Color gradient indicates  IC50 values  ranging from 0      (white)  to 1000 
ng/mL (red). 
 
In vivo Preclinical  Studies  
BMS -986414 (C135-LS) and BMS -986413 (C144-LS), administered in combination 
at an equivalent dose of 2.75 mg/kg of each antibody, protected mice from infection 
by a mouse-adapted strain of SARS -CoV-2. Also, the combination of BMS -986414 
(C135-LS) and BMS -986413 (C144-LS) was administered intraperitoneally to 
hamsters 24 hours prior (prophylaxis) or  12 hours after (treatment) the animals were 
challenged intranasally with the WA1- 2020 isolate of SARS -CoV -2. Three groups of 
four hamsters each received doses  of 2, 6 or 20 mg/kg of the antibody combination 
for prophylaxis (i.e., 1, 3, and 10 mg/kg each mAb) and 4, 12, or 40 mg/kg of the 
antibody combination for treatment  (i.e., 2, 6, and 20 mg/kg each mAb), respectively. 
SARS- CoV-2 lung titers were determined by plaque assay three days after viral 
challenge. While all animals in the control group showed high levels of viral infe ction 
(plaque-forming units [PFU] approximately 106 per 100 mg of lung tissue), hamsters 
in prophylactic and therapeutic mid- and high- dose antibody combination groups 
showed complete absence of viral infection with one exception in the therapeutic 20 
mg/kg dose group. In the prophylaxis low dose group (2 mg/kg) 3 out of 4 animals 
achieved protection, and in the therapy low dose group (4 mg/kg of each antibody) 
all animals  had undetectable or  very low virus titers ( 12, 15). 
 
The combination of BMS -986414 (C135-LS) and BMS -986413 (C144-LS) was 
also administered intravenously (IV) to 3 Indian origin rhesus macaques at a dose 
of 20 mg/kg of total antibody (i.e., 10 mg/kg each mAb). The average antibody 
concentration in plasma on Day 40 after administration was 120 µ g/mL, which is 
about 2,000 times  higher than the IC90 neutralization titer for the BMS -986414 

 325 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  (C135-LS) and BMS -986413 (C144-LS) combination against SARS -CoV -2 
pseudovirus (IC90 61.02 ng/mL). In rhesus  macaques, the estimated average 
half-life of the BMS -986414 (C135-LS) plus BMS -986413 (C144-LS) combination 
was approximately 46 days. The 3 animals were subsequently  challenged by 
intranasal, intratracheal,  and intraocular  routes  with 2 x 106 PFU of SARS-CoV-2 
69 days after mAb administration. BMS -986414 (C135-LS) plus BMS -986413 
(C144-LS) protected animals  from SARS -CoV -2 in contrast to 2 control animals  
(15). 
 
In another prevention experiment, the combination of BMS -986414 (C135-LS) and 
BMS -986413 (C144-LS) was administered IV to rhesus macaques 24 hours prior to 
combined intranasal, intratracheal and intraocular challenge with SARS -CoV -2. Three 
groups  of 4 animals each received doses of 2, 6, or 20 mg/kg of total antibody (i.e., 1, 
3, and 10 mg/kg of each mAb). SARS -CoV -2 subgenomic viral copies were 
determined from sequential nasopharyngeal swabs over the course of seven days  
after viral challenge. All animals  in the control  group showed high levels  of viral copies 
(around 105 copies/swab), whereas all but two macaques in the lowest  dose group (2 
mg/kg of total antibody) showed sterilizing protection and absence of productive viral 
infection as determined by subgenomic  viral copies  (15). 
 
The combination of BMS -986414 (C135-LS) and BMS -986413 (C144-LS) was a lso 
evaluated in rhesus  macaques 24 hours after combined intranasal, intratracheal and 
intraocular  challenge with SARS- CoV-2. Three groups of 4 animals each were 
administered intravenously either placebo, low dose (12 mg/kg) or high dose (40 
mg/kg) of the antibody combination (i.e., 6 or 20 mg/kg of each mAb). The animals 
were  euthanized at 7 days after infection. Microscopic lung sections were assessed 
by two independent blinded pathologists for different grades of pneumonitis (using an 
ordinal scale of 0-4). While the placebo control group showed high grades of 
pneumonitis, the animals that received the antibody combination showed significantly 
lower grades of pneumonitis with the high dose group (40 mg/kg of total antibody) 
demonstrating the lowest grades  (average grade around 1) (15). 
 The serum half-lives of BMS -986414 (C135-LS) and BMS -986413 (C144-LS) were 
approximately 4.3 and 8.2 days, respectively, in mice expressing human FcRn. The 
estimated half-lives of the BMS -986414 (C135-LS) plus BMS -986413 (C144-LS) 
combination in rhesus macaques, measured by serum neutralizing activity, was 
approximately 46 days ( 15). 
 Toxicology Studies  
The tissue cross -reactivity studies showed cytoplasmic binding to isolated tissues in 
both rat and human tissue panels. Since BMS -986414 (C135-LS) and BMS -986413 
(C144-LS) are antibodies to a foreign, infectious disease antigen, no on-target binding 
in these tissue panels was expected. As such, observed binding was concluded to be 
 326 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  off target but was limited to binding in the cytoplasmic space. Monoclonal antibody 
binding to cytoplasmic sites in tissue cross -reactivity studies is generally considered of 
little to no toxicologic significance due to the limited ability of antibody therapeutics to 
access the cytoplasmic compartment in vivo ( 15). 
 
The combination of BMS -986414 (C135-LS) and BMS -986413 (C144-LS) was 
administered to Sprague Dawley rats (N=380) intravenously twice weekly at doses ranging from 6 to 120 mg/kg or subcutaneously (SC) at 30 mg/kg for 4 weeks (total of 
8 doses) to evaluate systemic toxicity, local tolerability, toxicokinetics, immunogenicity 
and to assess the reversibility or persistence of effects following a 47-day recovery period.  Nine infusion reactions occurred, four of which were fatal. The cause of death was not determined. There were no gross or microscopic findings related to BMS -986414 
(C135-LS) and BMS -986413 (C144-LS) in the four early deaths, however tissue 
congestion was a common microscopic finding (often to occur in multiple tissues ), 
which is considered a non-specific finding. In 5 animals, infusion reactions occurred across all intravenous dose groups and in 1 animal in the control group; the animals fully recovered and these clinical observations did not recur following subsequent 
doses.  
 
These abnormal clinical observations occurred when the test articles were administered as a bolus IV injection over approximately 1 minute and did not show dose dependency. No infusion reactions were seen in animals receiving the test 
articles subcutaneously but a non-fatal reaction was noted in one animal in the control 
group. Importantly, the anatomic pathology report of main group animals did not identify target organs related to administration of BMS -986414 (C135-LS) and BMS -
986413 (C144-LS). 
 The infusion reactions may have been related to the delivery rate of the bolus 
administration as only one transient non-fatal infusion reaction was observed when 
the injection delivery was extended to approximately 3 minutes; the infusion reactions could also have been related to test species. As such these findings may not be predictive of the safety profile of these fully human monoclonal antibodies in humans. Of note, these events were not observed in the ongoing first-in -human study 
(described below) ( 15). 
 Human Safety Data An ongoing first-in -human, single dose, dose-escalation study (Protocol RUCOV1, 
[STUDY_ID_REMOVED]) is evaluating the safety and pharmacokinetics (PK) of BMS -986414 
(C135-LS) in combination with BMS-986413 (C144-LS) in healthy volunteers after SC 
or IV administration; BMS -986414 (C135-LS) and BMS -986413 (C144-LS) were 
 327 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  administered at 100 and 200 mg of each mAb SC and at doses ranging from 1.5 to 15 
mg/kg IV. Enrollment began on 13 January and completed on 03 March 2021. As of 19 March 2021, 23 participants have been dosed in groups S1 (100 mg of each 
antibody SC, n=3), S2 (200 mg of each antibody SC, n=3), S3 (200 mg of each 
antibody or placebo, ratio 3:1, SC, n=8), V1 (1.5 mg/kg of each antibody, IV, n=3), V2 (5 mg/kg of each antibody, IV, n=3), and V3 (15 mg/kg of each antibody, IV, n=3). 
Following antibody administration, participants remain as inpatients for 24 hours for multiple safety and serum PK assessments. As of 12 March 2021, there were no 
deaths or serious adverse events reported. Eight participants (34.8%) reported 
adverse events (1 participant each in the S1, S2, V1, and V2 treatment groups and 2 participants each in the S3 and V3 treatment groups), all were Grade 1 in severity. Four adverse events were considered possibly related to the investigational products (headache, pruritus at injection site, lightheadedness, and transient paresthesia during antibody infusion). No clinically significant laboratory abnormalities and no 
dose limiting toxicities have been reported to date. 
 Dose Selection Preliminary data from the ongoing first-in -human trial, suggest that SC administration 
of BMS -986414 (C135-LS) and BMS -986413 (C144-LS), at 200 mg of each antibody, 
rapidly achieves serum concentrations >1000-fold above the established in vitro 
IC50s for the mAbs by 9 hours post- dose with little decline over 56 days. Peak serum 
concentrations (Cmax) were ~3000 x IC50 (25-26 µg /mL) with no observed safety 
liability. The predicted t1/2 of BMS -986414 (C135-LS) and BMS -986413 (C144-LS) is 
~73-103 days.  
 Taken together, a 200mg dose of each mAb, BMS-986414 (C135-LS) and BMS -
986413 (C144-LS), was chosen for this study based on in vitro and in vivo preclinical 
data from  mice, hamsters and non-human primates  that demonstrated the neutralizing 
potency of BMS -986414 (C135-LS) and BMS -986413 (C144-LS)  and safety and PK 
data from the ongoing first-in -human study in healthy volunteers; the 200 -mg dose 
was safe and well tolerated and rapidly achieved serum concentrations  above the 
target concentration that are likely to be sustained for a prolonged period.  
 3.0 STUDY DESIGN  
 3.2. Overview of Study Design for Graduation from Phase II to Phase III  
 
An interim  graduation analysis,  using  the same  criteria as outlined in section  3.2 of the 
master protocol, will be conducted when 50% of participants  (~55 participants) plus 
shared placebo have completed 7 days  of follow -up and have the necessary  data in the 
database. Regardless  of the results  on this interim  analysis, enrollment will be 
completed in phase II. The  Day 7 graduation analysis  with the full phase II complement 
 328 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  of participants  will not be necessary  if one or more  graduation criteria are met in the 
interim  analysis.  
 
4.0 SELECTION AND ENROLLMENT  OF PARTICIPANTS 
 
Participants must meet inclusion and exclusion criteria from the master protocol, as well 
as the appropriate inclusion and exclusion criteria for the investigational  agent included 
below. 
 
4.1 General  Eligibility  Criteria  
 
4.1.1 Inclusion Criteria 
 
4.1.1.9 For participants  who are of reproductive potential, negative serum  
or urine pregnancy  test within 48 hours  prior to study  entry by any 
clinic or laboratory that has a CLIA certification or its  equivalent, or 
by a point of  care (POC)/CLIA -waived test.  
 
Reproductive potential  is defined as: 
• participant who has reached menarche 
• participant who has not been post- menopausal for at least 12 
consecutive months with follicle-stimulating hormone (FSH)  level 
≥40 IU/mL or 24 consecutive months if an FSH result is  not 
available participant who has not undergone surgical sterilization 
(e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy)
 
• participant with no other clinical conditions (such as anorexia nervosa)  that could induce amenorrhea 
• participant not taking medications such as oral  contraceptives, 
hormones, gonadotropin -releasing hormone, anti-estrogens, 
selective estrogen receptor modulators  (SERMs) or 
chemotherapy  that could induce amenorrhea 
• participant with permanent infertility due to an alternate medical 
cause (e.g., Mullerian agenesis, androgen insensi tivity),  as per  
investigator  assessment  
 
4.1.1.10 If engaging in sexual activity that could lead to pregnancy, a 
participant who is of reproductive potential must agree to use highly 
effective contraception for at least 48 weeks after the 
investigational agent is administered. This includes oral  
contraceptives, implanted contraceptives and intrauterine devices.  
 
 329 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  NOTE: Participants not of reproductive potential are eligible  
without requiring the use of a contraceptive method. Participant- 
reported history is acceptable documentation of surgical  
sterilization and menopause. 
 
4.1.1.11  In phase III, meeting the protocol definition of being at “higher” risk of progression to hospitalization or death (see 
SCHEMA, 
POPU LATION  for definition of “higher” risk ). 
 
4.1.2 Exclusion  Criteria 
 
4.1.2.10 In Phase II, meeting the protocol definition of being at “higher” risk of progression to hospitalization or death (see SCHEMA,  
POPULATION). 
 
4.1.2.11 Current pregnancy  or breastfeeding.  
 
4.1.2.12 Inflammatory skin conditions that compromise the safety of SC injections, or other overlying skin conditions or tattoos that would 
preclude the assessment of inj ection site reactions, per  discretion 
of the investigator. 
 5.0 INVESTIGATIONAL AGENT  
 
BMS -986414 and BMS -986413 will be referred to throughout this section as C135-LS 
and C144-LS, respectively.  
 5.1 Regimen, Administration, and Duration
 
 
5.1.1 Regimen and Duration 
 
Participants will be randomized to receive one of the following regimens:   Investigational Agent: C135-LS 200 mg and C144-LS 200 mg to be administered subcutaneously (SC) for one dose at study Entry/Day 0.  
 OR 
 Placebo for C135-LS/C144-LS to be administered SC for one dose at study Entry/Day 0, for Phase II participants only.  
 
 330 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  5.1.2 Administration 
 
C135-LS, C144-LS, and Placebo for C135-LS/C144-LS will be administered with 
a 3mL syringe attached to a 23-27G needle suitable for subcutaneous injection, 
using standard subcutaneous injection technique.   If C135-LS and C144-LS are prepared using the 50 mg/mL concentration vials, two syringes will be labeled “C135-LS 200 mg or placebo” and two syringes will 
be labeled “C144-LS 200 mg or placebo” ( section 5.2.2.4
). The four injections 
should be administered at separate sites in the abdomen, upper arms, and/or 
thighs. The two injections of “C135-LS 200 mg or placebo” should be administered on the left side of the participant’s body, and the two injections of “C144-LS 200 mg or placebo” should be administered on the right side of the participant’s body. Injections may be administered immediately one following the 
other, in no particular order, without a required period of monitoring in between 
injections. The time and site of each injection will be recorded on the eCRF.  
 If C135-LS and C144-LS are prepared using the 100 mg/mL concentration vials, one syringe will be labeled “C135-LS 200 mg or placebo” and one syringe will 
be labeled “C144-LS 200 mg or placebo” ( section 5.2.2.4
). The two injections 
should be administered at separate sites in the abdomen, upper arms, and/or 
thighs. The “C135-LS 200 mg or placebo” should be administered on the left side of the participant’s body, and the “C144-LS 200 mg or placebo” should be administered on the right side of the participant’s body. Injections may be 
administered immediately one following the other, in no particular order, without 
a required period of monitoring in between injections. The time and site of each injection will be recorded on the eCR F.  
 Each injection should be administered carefully to avoid inadvertent deposition into muscular tissue or leakage after needle removal. If leakage occurs, it should 
be noted in the study records. 
 Participants should be monitored at the study site for 2 hours  after injection. 
 
5.2 Formulation, Storage, and Preparation 
 
5.2.1 Formulation and Storage 
 
C135-LS and C144-LS are supplied as 300 mg/vial (50 mg/mL) and 200 mg/vial (100 mg/mL), clear to opalescent, colorless to yellow or colorless to brownish-yellow or colorless to brown liquid, which are essentially free from visible 
particulates. The drug products are sterile, nonpyrogenic, single-use, 
 331 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  preservative -free, isotonic aqueous solutions for subcutaneous administration. 
Each vial includes a 0.5 -mL overfill. Store at 2°C to 8°C. Protect from light. Do 
not freeze.  
 
C135-LS and C144-LS are described in further detail in the C135-LS/C144-LS 
Investigator’s Brochure.  
 Placebo for C135-LS/C144-LS is supplied in 6-mL glass vials with a 2 mL or 2.5 
mL fill volume. The placebo is a clear, colorless liquid, essentially free from 
particulates. Store at 2°C to 8°C. Protect from light. Do not freeze.  
 
5.2.2 Preparation 
 
Pharmacists must follow appropriate aseptic technique and consider sterile 
preparation procedures/guidance as outlined in USP General Chapter <797> 
Pharmaceutical Compounding – Sterile Preparations. Pharmacists must also 
follow the requirements of their country, institution, and pharmacy regulatory authority regarding these procedures. The investigational agents and placebo should be prepared in a sterile environment, utilizing a pharmacy biosafety  
cabinet/isolator. If a biosafety cabinet or isolator is not available, a laminar flow hood may be used. Local regulations and site institutional policies and procedures for use of personal protective equipment, such as gloves, gowns, face masks and safety  glasses, must be followed.  
 
Any unused portion of investigational agent or placebo must not be used for 
another participant. Any empty vials, unused portion of entered vials, or unused solution which contains investigational agent should be discarded in a biohazard containment bag and incinerated or autoclaved in accordance with institutional or pharmacy policy.  
 
5.2.2.1 Preparation of C135-LS 200 mg and C144-LS 200 mg  
 
Preparation of C135-LS 200 mg:  
1. Remove one (1) vial of C135-LS from the refrigerator. Inspect the 
vial for particulate matter and discoloration. Discard if cloudy, discolored, or contains particulate matter. Do not shake. When the 
vial is removed from the refrigerator, record this time as the investigational agent preparation time. Assign a 4 hour beyond use date and time from the preparation time if stored at room temperature or a 24 hour beyond use date and time from the preparation time if stored at refrigerated conditions. 
 332 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  2. Using a 3-mL syringe with an 18G or 20G needle attached, 
withdraw 2 mL of C135- LS into the syringe. Remove the used 
needle from the syringe and either cap the syringe or replace with 
a needle suitable for subcutaneous injection administration, per 
institutional procedure.  
3. If the concentration of the C135-LS vial used for preparation is 50 mg/mL , repeat Step #2 to make a total of two syringes that each 
contain 2 mL of C135-LS. If the concentration of the C135-LS vial 
used for preparation is 100 mg/mL, only one syringe that contains 2 mL of C135-LS is needed. 
4. Apply an overlay to each syringe to ensure blinding is maintained.  
 
Preparation of C144-LS 200 mg: 
1. Remove one (1) vial of C144-LS from the refrigerator. Inspect the 
vial for particulate matter and discoloration. Discard if cloudy, 
discolored, or contains particulate matter. Do not shake. When the vial is removed from the refrigerator, record this time as the investigational agent preparation time. Assign a 4 hour beyond use date and time from the preparation time if stored at room 
temperature or a 24 hour beyond use date and time from the 
preparation time if stored at refrigerated conditions. 
2. Using a 3-mL syringe with an 18G or 20G needle attached, withdraw 2 mL of C144- LS into the syringe. Remove the used 
needle from the syringe and either cap the syringe or replace with 
a needle suitable for subcutaneous injection administration, per 
institutional procedure.  
3. If the concentration of the C144-LS vial used for preparation is 50 mg/mL, repeat Step #2 to make a total of two syringes that each 
contain 2 mL of C144-LS. If the concentration of the C144-LS vial 
used for preparation is 100 mg/mL, only one syringe that contains 
2 mL of C144-LS is needed. 
4. Apply an overlay to each syringe to ensure blinding is maintained.  
 
5.2.2.2 Placebo for C135-LS 200 mg and Placebo for C144-LS 200 mg 
(Phase II Participants Only)  
 
1. Remove either four (4) or two (2) vials of Placebo for C135-
LS/C144-LS from the refrigerator (NOTE: 4 vials are needed for 
the placebo to match the C135-LS/C144-LS preparation using the 50 mg/mL vials and 2 vials are needed for the placebo to match the C135-LS/C144-LS preparation using the 100 mg/mL 
vials). Inspect the vials for particulate matter and discoloration. 
 333 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  Discard if cloudy, discolored, or contains particulate matter. Do 
not shake. When the vials are removed from the refrigerator, record this time as the investigational agent preparation time. 
Assign a 4 hour beyond use date and time from the preparation 
time if stored at room temperature or a 24 hour  beyond use date 
and time from the preparation time if stored at refrigerated conditions.  
2. Using a 3-mL syringe with an 18G or 20G needle attached, 
withdraw 2 mL of Placebo for C135-LS/C144-LS into the syringe. 
Remove the used needle from the syringe and either cap the syringe or replace with a needle suitable for subcutaneous injection administration, per institutional procedure.  
3. If the placebo should match the C135-LS/C144-LS preparation using the 50 mg/mL, repeat Step #2 three times to make a total of 
four syringes that each contain 2 mL of Placebo for C135-
LS/C144-LS. If the placebo should match the C135-LS/C144-LS 
preparation using the 100 mg/mL, repeat Step #2 once to make a total of two syringes that each contain 2 mL of Placebo for C135-LS/C144-LS. 
4. Apply an overlay to each syringe to ensure blinding is maintained.  
 
5.2.2.3  Labeling of Investigational Agent and Placebo  
  
Label prepared syringes with the following information: 
1. Participant identifier(s)  
2. Protocol number: ACTIV -2/A5401 
3. Investigational agent name:  
 Phase II:  
 
C135-LS 200 mg or placebo:  
i. If prepared using the 50 mg/mL concentration vials, there will be 2 syringes, each containing 100 mg C135-LS  or placebo.  
ii. If prepared using the 100 mg/mL concentration vials, there will be 1 syringe containing 200 mg C135-LS  or placebo  
 
C144-LS 200 mg or placebo: 
i. If prepared using the 50 mg/mL concentration vials, there will be 2 syringes, each containing 100 mg C144-LS  or place 
ii. If prepared using the 100 mg/mL concentration vials, there will be 1 syringe containing 200 mg C144-LS or placebo 
 334 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
  
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  5.3 Supply, Distribution, and Accountability  
 
5.3.1 Supply  and Distribution  
 
C135-LS, C144-LS, and Placebo for C135-LS/C144-LS will be provided by 
Bristol Myers Squibb (BMS) and will be available through the N IAID Clinical 
Research Products Management Center (CRPMC). The site pharmacist will receive ordering instructions for C135-LS, C144-LS, and Placebo for C135-
LS/C144-LS vials from the NIAID CRPMC.  
 
Ancillary supplies will be locally sourced by the site. 
 
5.3.2 Accountability  
 
The site pharmacist is required to maintain complete records of all 
investigational agents received from the NIAID CRPMC and subsequently dispensed. At US clinical research sites (CRS), all unused investigational agents must be returned to the NIAID CRPMC (or as otherwise directed 
by the sponsor) after the study is completed or terminated. At non-US 
CRSs, the site pharmacist must follow the instructions provided by the 
NIAID CRPMC for the destruction of unused investigational agents.
 
   
 335 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 (C144-LS) 6.0 CLINICAL  AND LABORATORY  EVALUATIONS 
 
6.1 Schedule of Evaluations  
 
The schedule of evaluations provided below includes additional  procedures specific for BMS -886414 (C135-LS) and BMS -
986413 (C144-LS). 
 Table 6.1-1: Schedule of Evaluations  Phase II 
Phase II Evaluation  
Screening 
Study Entry/  Day 0 
Day 1 
Day 3 
Day 7 
Day 14 
Day 28 
Week  12 
Week  24 
Week  36 
Week  48 
Week  72 
Premature Study D/C  
(Before  Day 28 Visit)  
Premature Study D/C   
 (After  Day 28 Visit)  
Visit Window     +/-1 
days  +/-2 days  0/+4 
days  -7/+14  days    
Investigational  Agent  Administered   X             
Hematology   X  X  X X      X  
Chemistry   X  X  X X      X  
Pregnancy  Testing  X  Whenever  Pregnancy  Suspected    
PK Studies   X Xa X X X X X X  X X X X 
Antidrug  Antibodies   X  X X X X X X  X X X X 
a A subset of approximately 40 participants in Phase II at select sites will have an additional sample collected on Day 1 for PK  analysis  (see MOP 
and additi onal site -specific information)
 336 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  6.2 Timing of Evaluations  
 
6.2.1 Screening Evaluations  
 
Screening evaluations must occur prior to the participant starting any  study  
medications, treatments, or interventions. 
 
Screening and Study  Entry visit evaluations  may be combined. 
 
6.3 Instructions for Evaluations  
 
6.3.9 Investigational  Agent Administered 
 
Pre-Medication 
Pre-medication for SC injections is not planned. However, if the participant has a 
medical history suggesting a potential benefit from pre- medication, the study 
investigator(s) should determine the appropriate pre-medication. 
 
Any pre -medic ations given should be documented as a concomitant medication.  
 
Before the Injections  
Vital signs  (temperature, heart rate, respiratory  rate, blood pressure and SpO2) 
should be measured.  
 
After  the Injections  
Vital signs (temperature, heart rate, respiratory rate, blood pressure and   SpO2) 
should be measured every 30 minutes (+/-5 minutes) for two hours after the 
injections.  
 
Only vital signs that meet AE reporting requirements will be recorded on the AE 
eCRF.  
 
6.3.15 Laboratory  Evaluations   
 
Hematology  
Participants will have blood drawn for complete blood cell count (CBC)   with 
automated differential and platelet count. 
 
At Entry/Day  0, blood should be drawn before study  drug administration  
 
Chemistry  
Participants will have blood drawn for liver function tests (ALT, ALP, AST, total 
bilirubin, direct bilirubin, and total protein), and renal function tests  (albumin,  
BUN, creatinine, potassium, glucose, and sodium).  
 337 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)   
At Entry/Day 0, blood should be drawn before study drug admini stration.  
 
Pregnancy  Testing  
For participants  of reproductive potential: serum  or urine β-HCG  (urine test must  
have a sensitivity  of ≤25 mIU/mL).  
 
Post screening, pregnancy  testing should be performed any time pregnancy  is 
suspected.  
 
In the event of a pregnancy occurring during the study, the pregnancy  and 
pregnancy  outcome should be recorded per section 8.3 . 
 
6.3.16  Pharmacokinetics (PK)  
 
Samples will be collected from all participants and used to measure 
investigational agent levels.  
 
At Entry/Day 0, the first PK sample should be collected before the dose of investigational agent/placebo (any time before administration).  
Post-entry, samples should be collected as per the SOE. The date and time of all 
samp le collections should be recorded. 
 
In Phase II, a  subset of approximately 40 participants at select sites will have an additional  sample collected on Day 1 to assess PK. The Day 1  sample collection for PK is the only procedure performed at that visit and should be 
collected 19 -29 hours after the time of investigational agent/placebo 
administration on Day 0. Refer to the MOPs for details on selection of sites and 
participants for the additional Day 1 sample collections.  Samples will be analyzed for BMS -986414 (C135-LS) and BMS -986413 (C144-
LS)  at a laboratory approved by the sponsor and stored at a facility designated 
by the sponsor. Concentrations of the investigational agent will be assayed using a validated bioanalytical method. Analyses of samples collected from placebo-treated participants are not planned.  
 Samples will be retained for up to 2-years after last patient visit. Remaining 
samples used for PK may be pooled and used for analyses as deemed 
appropriate.  
 
Samples designated for PK may also be used for immunogenicity analyses if required (e.g., insufficient volume for complete immunogenicity assessment or to 
follow upon a suspected immunogenicity related AE). The samples for the PK 
 338 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  and immunogenicity analyses should be collected at the same time, except on 
Day1 when only   a PK sample is collected.  
 
6.3.18 Antidrug Antibodies  
 
Samples will be collected to measure antidrug antibodies. At Entry/Day 0, a 
sample should be collected before the administration of study drug. 
 Post-entry, samples should be collected as per the SOE. The samples should be 
collected at the same time as the sample collection for PK except on Day1 when 
only a PK sample is collected. Date and time of collection should be recorded. 
 
Samples will be analyzed at a laboratory approved by the sponsor and stored at a facility designated by the sponsor. The samples will be analyzed for anti -BMS -
986414 (C135-LS) and anti -BMS -986413 (C144-LS) antibodies by a validated 
immunogenicity assay. Immunogenicity samples may also be analyzed for neutralizing antibodies by a validated method and by an exploratory method that 
measures anti -drug antibodies for technology exploration purposes; exploratory 
results may not be reported. Samples designated for PK  may also be used for 
immunogenicity analyses if required.  
 
7.0 ADVERSE EVENTS AND STUDY MONITORING  
 7.1 Definitions of Adverse Events
 
 
Adverse Events  of Special  Interest (AESI) 
The following are AESIs for the investigational  agents  administered in this study:  
• ≥ Grade 1 allergic/hypersensitivity reactions within 24 hours of investigational  
agent/placebo administration (deemed related to study product as determined by the 
site investigator)  
• ≥ Grade 3 Injection-related reactions within 72 hours of investigational  agent/placebo 
administration (deemed related to study product as determined by the site 
investigator) 
 
8.0 CLINICAL  MANAGEMENT ISSUES 
 8.1 Toxicity
 
 
If a participant experiences a Grade 3 or higher AE after any SC injection, subsequent 
SC injections  should not be administered. For any other AE, following each SC injection, 
the participant’s clinical status should be assessed before proceeding with subsequent 
SC injections. 
 
 339 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  8.2 Management of Side Effects  
 
All participants should be monitored closely for 60 minutes following treatment 
administration, as there is a risk of injection-related reactions and hypersensitivity  
(including anaphylaxis) with any biological agent. 
 
8.2.1 Overdose 
 
There is no known antidote for an overdose of BMS -986414 (C135-LS) or BMS-
986413 (C144-LS). In the event an overdose occurs, the participant should be 
closely  monitored for AE/SAEs and laboratory abnormalities; supportive care 
should be provided as indicated (s ection 8.2.1  of the m aster p rotocol).  
 
8.2.2 Injection-Related Reactions  
 
Symptoms and signs that may occur as part of an injection-related reaction include, but are not limited to acute allergic reaction, injection site pain or tenderness, injection site erythema or redness, and injection site induration or swelling, and injection site pruritus.  
 
The severity of injection- related reactions will be assessed and reported using 
the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017, which can be found on the DAIDS RSC website at https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. 
 Investigators should determine the severity of the injection-related reaction and manage reactions based on standard of care and their clinical judgment. 
 
8.2.3 Hypersensitivity  
 
Signs and symptoms of immediate hypersensitivity reactions may include, but are not limited to anaphylaxis, angioedema, bronchospasm, chills, diarrhea, hypotension, itching, skin rash, shortness of breath, urticaria, tachycardia, and throat irritation or tightness [8].  
 
Participants will be closely monitored for immediate hypersensitivity reactions. 
 Sites should have appropriately trained medical staff and appropriate medical equipment available when study participants are receiving study treatment. It is recommended that participants who experience a systemic hypersensitivity reaction be treated per the local standard of care. 
 340 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  8.3 Pregnancy  
 
Participants who are pregnant are not eligible for the study; there are no data regarding 
the use of BMS -986414 (C135-LS) or BMS-986413 (C144-LS) in participants  who are 
pregnant. 
 
Participants  of reproductive potential  are required to follow  the instructions  for prevention 
of pregnancy  provided in section 4.1.1.10  of this appendix.  
 
If a participant becomes pregnant during the study (post-treatment administration), the 
participant will remain on study through the end of the study and the pregnancy 
will be followed through completion. The pregnancy outcome and adverse events  
reported for the participant and infant will be recorded on the outcome eCRF.  
 
8.4 Breastfeeding  
 
Participants  who are breastfeeding are not eligible for the study; there are no data 
regarding the use of BMS -986414 (C135-LS) or BMS -986413 (C144-LS) in participants 
who are breastfeeding.  
 10.0 STATISTICAL CONSIDERATIONS  
 
10.1 General  Design  Issues
 
 
The company may elect to not have the Day 28 unblinded data provided to a small    
group of people from the company. 
 10.2 Outcome Measures
 
 
Primary and secondary  outcome measures  listed  below  will be addressed in the         
BMS -986414 (C135-LS)/ BMS -986413 (C144-LS) specific appendix to the study’s 
primary Statistical  Analysis  Plan.  
 
10.2.3 Secondary  Outcome Measures  
 
10.2.3.32 Phase II only: New Grade 2 or higher  AE through week  72. 
 
11.0 PHARMACOLOGY  PLAN 
 11.1 Pharmacology  Objectives  
 
The Phase II pharmacology  objectives  are the following:  
1. To determine the PK of BMS -986414 (C135-LS) and BMS -986413 (C144-LS) when 
used in combination, including the effects of covariates relevant to a COVID -19 
 341 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  patient population.  
2. To assess relationships  between peripheral  exposures  of BMS-986414 (C135-LS) 
and  BMS -986413 (C144-LS) with primary efficacy endpoints as well as select safety  
endpoints.  
3. To explore the concentrations of BMS -986414 (C135-LS) and BMS -986413 (C144-
LS) at the site of action.  
 
11.2 Pharmacology  Study  Design  Overview  
 
PK data, to date, from a Phase I study of healthy participants who received a single 200 
mg dose each of BMS -986414 (C135- LS) and BMS -986413 (C144- LS) confirms the 
expected long t1/2 for both BMS -986414 (C135- LS) and BMS -986413 (C144 -LS), , longer 
than what is typical for other mAbs. Rapid absorption of both mAbs was observed, 
reaching 1000- fold of IC50 within 9 hours of administration.  
 The PK sample collection schedule is designed to characterize the rapid absorption and the long- elimination half -lives of BMS -986414 (C135- LS) and BMS -986413 (C144- LS) and  
to meet the Phase II objective of determination of the PK of these agents.  
11.3 Pharmacology Data Analys es  
Intensive PK data analyses will undergo non- compartmental analysis to determine the PK 
characteristics of BMS -986414 (C135- LS) and BMS -98641 3 (C144 -LS). Population PK 
analyses (e.g., nonlinear mix effects modeling such as implemented in NONMEM) based 
on pooled studies may also be conducted, and the results may be reported in a separate 
report. The usual parameters of interest are area under the concentration- time curve 
(AUC), total body clearance (CL), elimination half -life (T1/2), and maximum and minimum 
concentrations (Cmax, Cmin), as appropriate. Assessment of relationships between 
exposures of BMS -986414 (C135- LS) and BMS -986413 (C144- LS) with primary efficacy 
endpoints, as well as select safety endpoints, will be conducted.  
Exposure -response relationships may be assessed in conjunction with the protocol 
statisticians. Physiologically based p harmacokinetics (PBPK) approach may also be used 
to explore the exposures at the sites of action, such as within lung.  
 
  
 342 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  16.0 REFERENCES 
 
1. PREVAIL II Writing Group; Multi -National PREVAIL II Study Team; Davey RT, Jr., Dodd 
L, Proschan MA, et al. A randomized, controlled trial of ZMapp for  Ebola virus infection. 
N Engl J Med 2016;375:1448-56. 
2. Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing anti -HIV-1 monoclonal  
antibodies in the clinic. Nat Med 2019;25:547-53. 
3. Gaudinski MR, Coates EE, Houser KV, et al.; VRC 606 Study Team. Safety and pharmacokinetics of the Fc -modified HIV-1 human monoclonal antibody VRC01LS: A 
Phase 1 open-label clinical trial in healthy adults. PLoS Med 2018;15(1):e1002493.  
4. Gaudinski MR, Houser KV, Doria-Rose NA, et al.; VRC 605 Study Team. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07- 523LS in 
healthy adults: a Phase 1 dose-escalation clinical trial. Lancet HIV  2019;6:e667-e679. 
5. Chen P, Nirula A, Heller B, et al.; BLAZE -1  Investigators. SARS-CoV-2 neutralizing 
antibody LY -CoV555 in outpatients  with Covid-19. N Engl J Med 2021;384:229-37. 
6. Weinreich DM, Sivapalasingam S, Norton T, et al.; Trial Investigators. REGN -COV2, a 
neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021;384:238-51. 
7. Regeneron. Fact Sheet for Health Care Providers. Emergency Use Authorization (EUA) of REGEN -COV
TM (casirivimab with imdevimab). Revised 5/2021. Regeneron 
Pharmaceuticals, Inc. Tarrytown, NY. Available from: https://www.regeneron.com/downloads/treatment-covid19-eua -fact-sheet -for-hcp.pdf  
8. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS -
CoV-2 in convalescent individuals. Nature 2020;584(7821):437-42. 
9. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half- life improves in 
vivo activity. Nat Biotechnol 2010;28:157-9. 
10. Barnes CO, Jette CA, Abernathy ME, et al. SARS -CoV -2 neutralizing antibody structures 
inform therapeutic strategies. Nature 2020;588:682-7. 
11. Barnes CO, West AP, Jr., Huey -Tubman KE, et al. Structures of human antibodies  
bound to SARS-CoV -2 spike reveal common epitopes and recurrent features  of 
antibodies. Cell 2020;182:828-42. 
12. Schafer A, Muecksch F, Lorenzi JCC, et al. Antibody potency, effector function, and combinations in protection and therapy for SARS - CoV-2 infection in vivo. J Exp Med 
2021;218(3):e20201993. 
13. Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS -
CoV-2 spike protein variants. eLife 2020;9:e61312. 
14. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS -CoV-
2 and circulating variants. Nature 2021;592:616-22. 
 343 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX XVI I: INVESTIGATIONAL AGENT BMS -986414 (C135-LS) and BMS -986413 
(C144-LS)  15. Investigator’s Brochure, Rockefeller University C135-LS/C144-LS 1.2; 04 February, 
2021 and Investigator’s Brochure Addendum No. 1, 19 March 2021
 344 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUGS  
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) APPENDIX XVIII : SAMPLE INFORMED CONSENT FOR STUDY DRUGS  
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) 
 
No participants will be enrolled in Version 7 or later of this protocol for this 
investigational agent. Consents retained for recording purposes. 
 
A study drug that you might be assigned to in this study is called BMS- 986414 (C135-LS) 
combined with BMS -986413 (C144 -LS).  
 
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) are both a type of drug called a 
monoclonal antibody (mAb). Many antibodies are naturally made by your body and help fight diseases. BMS -986414 (C135-LS) and BMS -986413 (C144-LS) are made in a laboratory. 
“Monoclonal” means that BMS -986414 (C135-LS) and BMS -986413 (C144-LS) are each made 
up of many copies of each of these antibodies .  
 The United States Food and Drug Administration (FDA) has not approved BMS -986414 (C135-
LS) and BMS-986413 (C144-LS) for general use by the public. However, we have told the FDA 
about this study and they have given us permission to conduct this study.  ARE THERE ANY ADDITIONAL STUDY PROCEDURES IF I RECEIVE BMS -986414 (C135-
LS) and BMS-986413 (C144-LS) OR PLACEBO?  
 
Screening Visit  
At your screening visit, if you are able to become pregnant, you will be asked to give blood (1 teaspoon) or a urine sample for a pregnancy test. You cannot participate in the study  if you are 
pregnant.  After the Screening Visit, your study visits and evaluations will be different depending on whether you are in the first part of the study or the second part of the study.   IF YOU A RE IN THE FIRST PART OF THE STUDY (PHASE II, COMPARISON TO PLACEBO)  
 
Entry Visit  
• You will have blood drawn that will be used for:  
• routine safety tests (liver and kidney tests and blood counts) 
• measurement of the levels of study drug in your blood 
• measurement of the levels of antibodies to the drug (your body’s immune response to the drug) 
• Your vital signs (temperature, heart rate, respiratory rate, blood pressure and oxygen level in your blood) will be measured before you receive your study drug  
• The study drug will be administered as either 4 injections or 2 injections that will be given 
subcutaneously  (under the skin), one right after the other, at separate sites in either your 
 345 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUGS  
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) abdomen, thigh, or upper arms. You will  be monitored in the clinic ever y 30 minutes for two 
hours after you receive the injections. 
 
Study Visit on Day 1 
If you are one of the approximately 40 participants who will have an additional blood sample 
collected, you will have blood drawn to measure the level of study drug in your blood.  
 
Study Visits  on Days 3, 7, 14, and 28, Week 12, Week 24, Week 48, and Week 72  
• You will have blood drawn: 
o For routine safety tests (liver and kidney tests and blood counts)  (Days 3, 14, and 28)  
o To measure the levels of the study drug and levels of antibodies to the drug (your body’s 
immune response to the  drug) 
 
 
IF YOU ARE IN THE SECOND PART OF THE STUDY (PHASE III, COMPARISON TO CASIRIVIMAB PLUS IMDEVIMAB) AND ARE ASSIGNED TO BMS-986414 (C135-LS) AND 
BMS -986413 (C144-LS): 
 
Entry Visit  
• You will have blood drawn that will be used for:  
• measurement of the levels of study drug in your blood 
• measurement of the levels of antibodies to the drug (your body’s immune response to the drug) 
• The study drug will be administered as either 4 injections or 2 injections that will be given subcutaneously (under the skin), one right after the other, at separate sites in either your abdomen, thigh, or upper arms. You will be monitored in the clinic every 30 minutes for two hours after you receive the injections. 
 
Study Visits  on Days 3, Day 28, Week 24  
• You will have blood drawn that will be used for:  
• measurement of the levels of study drug in your blood 
• measurement of the levels of antibodies to the drug (your body’s immune response to 
the drug) 
  
WHAT ARE THE RISKS OF BMS -986414 (C135-LS) and BMS-986413 (C144-LS)? 
 
There is a risk of serious  and/or  life-threatening side effects  when non-study  medications are 
taken with the study drugs. For your safety, you must tell the study doctor or nurse about all 
medications  you are taking before you start the study. 
 
Another risk is that the study drugs used in this study may have side effects, some of which are 
listed below. Additionally, the study  drug tested in the study  may have unknown side effects in 
 346 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUGS  
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) persons with SARS- CoV-2 infection. In a research study, all of the risks or side effects may not 
be known before you start the study. You need to tell your doctor or a member  of the study  team  
immediately  if you experience any side effects.  
 
Please note that these lists do not include all the side effects seen with this study drug. These 
lists include the more serious or common side effects with a known or possible relationship to the study drug. If you have questions concerning the additional side effects, please ask the medical staff at your site.  
Risks Associated with BMS -986414 (C135-LS) and BMS -986413 (C144-LS) 
There is limited safety data on BMS -986414 (C135-LS) and BMS -986413 (C144-LS) since they 
have not been given to a lot of people. As of March 19, 2021, 23 healthy volunteers have received injections or infusions of BMS -986414 (C135-LS) and BMS -986413 (C144-LS) in 
studies.  
 As of 12 March 2021, eight volunteers in these studies have reported mild adverse events (negative symptoms): itching at the injection site, lightheadedness, and temporary tingling or “pins and needles” sensation during infusion of the mAbs. No abnormal lab values have been noted and none of these events required discontinuation of therapy.  
Administration of mAbs such as BMS -986414 (C135-LS) and BMS -986413 (C144-LS) can 
result in allergic reactions. Signs and symptoms of these reactions include: 
• chills  
• skin rash  
• itching  
• hives  
• flushing (reddening) of the skin  
• swelling of the face or other soft tissues  
• low blood pressure  
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath 
• loose stools  
 
Administration of mAbs such as BMS -986414 (C135-LS) and BMS -986413 (C144-LS) may 
theoretically induce release of chemicals called cytokines in the body. The release of these 
chemicals has not been observed in laboratory studies of BMS -986414 (C135-LS) and BMS -
986413 (C144-LS). These chemicals may induce allergic reactions listed above, as well as:  
• fever  
• muscle aches  
• nausea 
• vomiting  
 347 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUGS  
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) • headache  
• dizziness  
 
Some of these reactions may be serious or life-threatening, including:  
• skin rash 
• swelling of the face or other soft tissues  
• low blood pressure 
• rapid heart rate 
• throat irritation or tightness  
• tightening of the muscles that line the airways  
• shortness of breath  
 
You will be monitored closely during administration of study drug. Medical personnel, equipment, and medication will be available to manage these reactions appropriately if they occur.  
 
Administration of mAbs, such as BMS -986414 (C135-LS) and BMS -986413 (C144-LS) can also 
cause the following risks and discomforts:  
• Development of proteins (antibodies) against BMS -986414 (C135- LS) and BMS -986413 
(C144- LS). This may cause your body to get rid of BMS -986414 (C135- LS) and BMS -
986413 (C144- LS) more quickly or change the effect of these study drugs on the body. Your 
blood will be tested to find out whether your body made antibodies to BMS -986414 (C135-
LS) and BMS -986413 (C144- LS). The anticipated risk of this is low because BMS -986414 
(C135- LS) and BMS -986413 (C144- LS) are fully human antibodies. Therefore, it is less 
likely to be seen as “foreign” by your body’s immune system and your body is less likely to 
form antibodies against them.  
• Binding of mAbs to other chemicals in the body that may be deposited in tissues such as blood vessels or organs such as kidneys. In the kidneys, this could lead to inflammation and 
kidney disease.  
• An unexpected increase in SARS -CoV- 2 virus reproduction in your body. Increases in virus 
reproduction have been observed with some other viruses when people have antibodies to 
these viruses. However, increases in SARS -CoV-2 virus reproduction are not known to 
occur in people given mAbs or serum -containing antibodies for COVID -19. The theoretical 
risk of increased virus reproduction is perhaps greater when there are lower levels of 
antibodies in the blood in the presence of virus. To avoid this, BMS- 986414 ( C135 -LS) and 
BMS- 986413 (C144 -LS) will be given at a dose that is felt to be high enough to keep this 
from occurring. 
 
Effect on Future Vaccination 
The US Centers for Disease Control and Prevention (CDC) currently recommends that people wait 
at least 90 days after receiving antibody treatment before receiving a COVID - 19 vaccine, because 
some antibodies remain in the body for about 90 days, and there is a chance that these antibodies 
 348 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X VIII: SAMPLE INFORMED CONSENT FOR STUDY DRUGS  
BMS -986414 (C135-LS) and BMS -986413 (C144-LS) could interfere with how your body responds to the vaccine during those 90 days. Some of the 
antibodies in this study including BMS -986413 (C144-LS) and BMS -986414 (C135-LS) are 
designed to remain in the body for longer than 90 days. Although there is no further guidance available, there is a chance that these longer -lasting monoclonal antibodies could interfere with 
how your body responds to the vaccine even if you wait at least 90 days for the vaccine. 
 
 
ARE THERE RISKS RELATED TO PREGNANCY AND BREASTFEEDING?  
 
Pregnancy  
You cannot participate in the study if you are pregnant because there are no data regarding the 
use of this study drug in people who are pregnant. 
 
The study drug may involve risks to you (or to the embryo or fetus ) if you become pregnant. 
These risks are currently unforeseen.  
 If you are reproductive potential, and if you engage in sexual activity that could lead to pregnancy, 
you must agree to use highly effective contraception for 48  weeks after the study drugs are 
administered. This includes oral contraceptives, implanted contraceptives, and intrauterine devices. 
 If at any point during the study you think you may be pregnant, you should let the staff at your study site know so that a pregnancy test can be done.  
Let your doctor know immediately if you become pregnant. If you become pregnant while on the 
study, you will be asked to continue to have study visits and the study staff would like to obtain information from you about the outcome of the pregnancy (even if it is after your participation in the study ends). 
 
Breastfeeding 
You are not eligible to receive this study drug if you are breastfeeding because it is not known if 
this study drug is safe to use in people who are breastfeeding . 
 
 349 ACTIV -2/A5401 
FINAL Version 8.0 
  25Feb2022 
 
 
APPENDIX X IX SIGNATURE  PAGE – STUDY DRUGS  
 APPENDIX XIX: SIGNATURE  PAGE – STUDY DRUGS  
 
Consent forms for the following study drugs were reviewed (initial if reviewed with you):  
_____ (initials) BAMLANIVIMAB INTRAVENOUS ADMINISTRATION  
 
_____ (initials) BRII-196 and BRII-198 INTRAVENOUS ADMINISTRATION  
 _____ (initials) AZD7442 INTRAVENOUS ADMINISTRATION  
 _____ (initials) AZD7442 INTRAMUSCULAR ADMINISTRATION  
 _____ (initials) SNG001 INHALATION ADMINISTRATION  
 
_____ (initials) CAMOSTAT ORAL ADMINISTRATION  
 
_____ (initials) SAB-185 INTRAVENOUS  ADMINISTRATION  
 _____ (initials) BMS -986414 (C135-LS) and BMS -986413 (C144-LS) SUBCUTANEOUS  
ADMINISTRATION  
 [Sites should mark agents that do not apply to a participant with an “N/A” before the page is 
given to the participant to sign]  
 If you have  read this consent  form (or had it explained to you),  all your questions  have been
 
answered and you agree to take part in this study,  please sign your name below. 
 ______________________________________ ___________________________________ 
Participant’s  Name  (print)  Participant’s  Signature and Date 
  
____________________________________  ___________________________________ 
Participant’s  Legally  Authorized Representative  Legally  Authorized Representative (print) 
(As appropriate)      Signature and Date  
 
______________________________________ ___________________________________ 
Study  Staff Conducting   Study  Staff’s  Signature and Date
 Consent 
Discussion  (print)  
 ________________________________  ___________________________________ 
Witness’s Name (print)  Witness’s Signature and Date  
(As appropriate)  